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Abstract 
The neonatal Fe receptor (FeRn) binds the Fe portion of immunoglobulin G (IgG) 
at the acidic pH of endosomes or the gut and releases IgG at the alkaline pH of blood. 
FeRn is responsible for the maternofetal transfer of IgG and for rescuing endocytosed 
lgG from a default degradative pathway. We investigated how FeRn interacts with IgG 
by constructing a heterodimeric form of the Fe (hdFc) that contains one FeRn binding 
site. This molecule was used to characterize the interaction between one FeRn molecule 
and one Fe and to determine under what conditions FeRn forms a dimer. The hdFc binds 
one FeRn molecule at pH 6.0 with a K! of 80 nM. In solution and with FeRn anchored to 
solid supports, the heterodimeric Fe does not induce a dimer of FeRn molecules. FcRn-
hdFc complex crystals were obtained and the complex structure was solved to 2.8 A 
resolution. Analysis of this structure refined the understanding of the mechanism of the 
pH-dependent binding, shed light on the role played by carbohydrates in the Fe binding, 
and provided insights on how to design therapeutic IgG antibodies with longer serum 
half-lives. The FcRn-hdFc complex in the crystal did not contain the FeRn dimer. To 
characterize the tendency of FeRn to form a dimer in a membrane we analyzed the 
tendency of the hdFc to induce cross-phosphorylation of FeRn-tyrosine kinase chimeras. 
We also constructed FeRn-cyan and FeRn-yellow fluorescent proteins and have analyzed 
the tendency of these molecules to exhibit fluorescence resonance energy transfer. As of 
now, neither of these analyses have lead to conclusive results. In the process of acquiring 
the context to appreciate the structure of the FcRn-hdFc interface, we developed a study 
of 171 other nonobligate protein-protein interfaces that includes an original principal 
component analysis of the quantifiable aspects of these interfaces. 
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Protein-Protein Recognition: Areview of the analyses of collections of crystal 
structures 
It is difficult to overstate the importance of the formation of protein-protein 
complexes in biological processes. To determine whether a cell in the body has been 
vi rally infected, a T -cell receptor on a cytotoxic T -cell must bind a major 
histocompatibility complex (MHC) class I molecule on the infected cell (Garboczi et al. , 
1998). In order to couple A TP hydrolysis with the electron transfer necessary to fix 
atmospheric nitrogen, the nitrogenase iron protein must bind the nitrogenase 
molybdenum-iron protein (Schindelin et al. , 1997). In order to activate T-helper cells, a 
central step in adaptive immune responses, the nuclear factor of activated T -cells, NF AT, 
must bind the complex of Fos and Jun proteins to activate the expression of many 
immune response genes (Chen et al., 1998). To rearrange the actin cytoskeleton, 
necessary for cellular motility, the small G-proteins of the Rho family, Rho A and 
RhoGAP form a complex and instigate a phosphorylation cascade by enhancing the rate 
of GTP hydrolysis (Rittinger et al. , 1997). To rescue serum immunoglobulin gamma, 
(IgG) from a default degradation pathway, enhancing the role of these antibodies in 
fighting disease, the neonatal Fe receptor (FeRn) binds IgG in cellular endosomes and 
releases IgG at the cell surface (Martin et al. , 200 I). The formation of protein-protein 
complexes occurs in every organelle, every cell , every tissue, and every organism. 
Understanding how these complexes form and determining their structures is sufficently 
complicated that the complexes are usually studied one at a time, as in this thesis. 
However, some aspects of protein-protein complexes are studied collectively. 
3 
The current understanding of protein-protein recognition stems in part from the 
analyses of collections of crystal structures (Stites, 1997). To provide context for 
understanding the interaction between FeRn and IgG, the last chapter of this thesis is 
such an analysis. This introduction reviews related analyses of protein crystal structures. 
This introduction is an effort to show how analyzing collections of crystal structures has 
improved our understanding of how proteins are folded, oligomer subunits associate, 
protein structure is related to function, different groups of proteins may be distinguished, 
and what different aspects of a protein may be assessed quantitatively. 
Multiple crystal structure analyses: Learning how proteins fold 
Analyses of protein crystal structures have been undertaken to compare the data 
with existing theories on how proteins are folded . Before the existence of large amounts 
of protein structure data, studies of protein structure and theories of protein folding 
emphasized different aspects of a protein's fold. Pauling anticipated the importance of 
hydrogen bonding to secondary structure by predicting the formation of a-helices and ~­
sheets in polypeptide chains (Pauling eta!., 1951 ; Pauling and Corey, 1951 ). Kauzmann 
predicted there would be entropic contributions to folding as proteins folded to shield 
large amounts of their hydrophobic surface area from the aqueous solvent (Kauzmann, 
1959). Examination of the structure of myoglobin reported in 1960 appeared to confirm 
the relevance of both hypotheses, the structure is dominated by a-helices, while the 
nonpolar aliphatic and aromatic residues were primarily buried in the interior while the 
polar residues were exposed to solvent (Perutz eta!. , 1965). 
To quantitatively verify this qualitative observation of hydrophobic burial made 
by Perutz, an algorithm was developed to measure the amount of protein surface 
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accessible to solvent on an atom-by-atom basis (Lee and Richards, 1971 ). This method 
generates a solvent accessible surface by building spheres centered on each crystal 
structure coordinate with radii equal to the sum of the van der Waal radii of the chemical 
group centered on that atom and the radius of water. This atom-by-atom analysis classed 
the protein atoms observed in crystal structures into three groups: all carbon atoms were 
considered nonpolar, all oxygen, nitrogen, and sulfur atoms were considered polar, 
except the carboxylate oxygens and the amino and guanadinium nitrogen atoms that were 
considered charged. With this algorithm Lee and Richards examined the structures of 
myoglobin, lysozyme, and ribonuclease and found that a large fraction of the surface was 
nonpolar and a large fraction of the interior surface was polar (Lee and Richards, 1971 ). 
This quantitative review of a qualitative observation produced a somewhat unexpected 
result. 
Resolving this apparent paradox of the preference of nonpolar residues for the 
protein interior and the presence in the interior of proteins of large amounts of polar 
surface area required a refinement in the way we describe how proteins fold (Chothia, 
1976). Chothia observed that the formation of secondary structure buries large amounts 
of polar surface area. This burial of polar surface area is energetically offset by the 
formation of a large number of hydrogen bonds, and the formation of the hydrogen bonds 
diminishes the polar, hydrophilic, character of the surfaces involved. In contrast, the 
formation of tertiary structure buries almost exclusively nonpolar surface area. This 
hydrophobic surface area buried is largely associated with amino acid side chains, and is 
driven by the hydrophobic effect. 
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Much as the measuring the surface area was understanding the hydrophobic effect 
measuring the volumes occupied by atoms, or how well the atoms are packed, was 
helpful to understanding the importance of the van der Waals forces . Computational 
efforts to assess packing have employed Voronoi polyhedra to measure the volumes of 
atoms (Chothia, 1975; Harpaz et al. , 1994). A Voronoi polyhedron is generated around 
an atom in a protein in two steps. First, lines from that atom to each of its neighbors are 
drawn and second planes normal to these lines are placed according to the van der Waals 
radii of the two atoms. Each plane extends until it intersects another. This method is 
useful for judging atom density because, except for a vertex error due to differences in 
atom radii, it includes all the space around the atoms in the calculation (Gerstein et al., 
1995). 
Previous investigations into the volumes of amino acids in proteins (Chothia, 
1975) were extended more recently in an analysis of 108 high resolution (1.0 A - 1.9 A) 
crystal structures (Harpaz et al. , 1994 ). This study found that hydrophobic residues 
undergo a reduction in volume as a protein folds, which is somewhat offset by the 
increase in the volume of polar and charged residues. This is consistent with the small 
overall change in protein volume that occurs when proteins fold . Further calculations in 
this study show that amino acids in protein interiors occupy 4% less volume than in 
amino acid crystals. When compared with the 15% reduction in volume exhibited when 
organic solvents solidify, these results suggest that organic solvent molecules are 
significantly less well packed than a protein interior. This suggests that approximating 
protein folding as the transfer of a polypeptide chain from aquaeous buffer to organic 
solvent may under estimate the importance of van der Waals forces in protein folding. 
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These results support the proposition that protein stability is more accurately modeled by 
dissolving crystalline cyclic dipeptides in water (Murphy and Gill, 1991). 
Multiple crystal structure analyses: Learning how oligomer subunits associate 
The preference of nonpolar molecules for a nonaquaeous environment predicted 
by Kauzmann to be important for protein folding was also proposed as the driving force 
in protein-protein recognition (Janin and Chothia 1975). If this hydrophobic effect was to 
be considered the predominant source of energy for the interactions between polypeptide 
chains, then their association would less likely to be dominated by the formation of 
extensive hydrogen bond as seen in secondary structure or salt bridge networks. A study 
of 23 oligomers counted the number of hydrogen bonds formed between the polypeptide 
chains and found between none and 1 hydrogen bond per 200 A2 and 78% of these 
hydrogen bonds were formed by interaction between side-chains (Janin et al., 1988). 
This dearth of hydrogen bonds, especially those derived from contact between main-
chain atoms, was consistent in oligomeric interfaces ranging from 700 A 2 to 10,000 A 2 in 
size. This confirmed the importance of the hydrophobic effect for the interactions 
between the polypeptide chains of protein oligomers. 
More recent studies reveal that there is greater diversity here than was originally 
noticed. There are some structures such as in the interchain contacts in the platform of an 
MHC class II molecule (Reinherz et al. , 1999), where each chain contributes one strand 
at the interface between two different four strand 13-sheets to form one 8-strand 13-sheet. 
The association of these chains may be enthalpy driven. A recent examination of 136 
homodimeric proteins corroborated the predominance of nonpolar surface but noted that 
many homo-oligomer subunit interfaces have important hydrophillic aspects (Larsen et 
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al. , 1998). In particular, they found that for homodimers of compact subunits with 
extended oligomeric interfaces the relative importance of hydrogen bonds, ordered waters 
and polar surface area to the interfaces was broadly sampled. 
Multiple crystal structure analyses: Learning how proteins function 
The need to distinguish homo-oligomeric proteins, permanent heterocomplexes, 
and more transient "non-obligatory" complexes was made explicit in an analysis of 
protein crystal structures (Jones and Thornton, 1996). Proteins that exist in their 
biological context physically independent of other proteins may form nonobligate 
protein-protein complexes by associating with other such proteins (Jones and Thornton, 
1996). For example, FeRn in its biological context exists in a form physically 
independent of other proteins. IgG does also. When these proteins associate their 
complex is non-obligatory. In contrast, the heavy chain of FeRn does not exist in its 
biological context in a form independent of the light chain, 132 microglobulin . Even 
though the light chain exists alone in biological systems the complex of the heavy and 
light chains of FeRn is obligate because a nonobligate complex requires both 
participants ' independent existence. The paramount reason we consider nonobligate 
complexes distinct is the structures of nonobligate protein-protein complexes are 
necessarily informative about the function of a protein in a way that the structures of 
obligate, permanent protein complexes need not be. 
Because the crystal structures of nonobligate protein-protein complexes are 
inherently informative about the function of a protein, analyses of these structures have 
been helpful in understanding other systematic structure-function studies . The 
understanding of stoichiometry analyses, binding studies, and the results of site-directed 
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mutageneses for a given set of molecules are all enhanced when couched in the context of 
a crystal structure (see for example, Martin and Bjorkman, 1999; Chapter 2). This is true 
at the scale of multiple sample analyses as well. Analyses of site-directed mutagenesis 
studies show the fraction of tryptophan to alanine mutations that cause a ~ 2 kcallmol 
reduction in binding affinity over the total number of tryptophan mutations is four times 
greater than the average of the ratio for all mutants (Bogan and Thorn, 1998). Analyses 
of the structures of nonobligate protein-protein complexes reveal that tryptophan 
contributes 3.5 times as much to the surfaces of interfaces as it does to the surfaces of 
proteins as a whole (Lo Conte et al. , 1999). It may be that the large size of the effect of 
the mutation on the binding constant is due to the large steric alteration induced by the 
mutation. The crystal structure reviews reveal that tryptophans occur in interfaces with a 
greater frequency than they do on the surface (Lo Conte et al. , 1999), which means that 
size of the effect seen in the mutation studies is not likely the result of undersampling this 
residue. 
The comparison of the review of nonobligate protein-protein complexes and the 
reviews of mutagenesis studies deepens the understanding of another phenomenon. 
Mutagenesis studies revealed that alanine substitutions at only 25% of the total number of 
positions, usually at the center of an interface, generate a sizable reduction in the affinity 
of the interaction (Cunningham and Wells, 1993; Clackson and Wells, 1995; Bogan and 
Thorn, 1998). The studies of nonobligate protein-protein complex stuctures reveal 
several reasons for this. First, because mutageneses fail to affect main-chain atoms they 
fail to affect one-fifth of the interface surface area that provides two-thirds of the 
interface hydrogen bonds. Second, three-quarters of the interface area comes from 
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atoms, almost always those on the interface perimeter, that remain accessible to solvent. 
The affect of mutations at these residues may be ameliorated by the incorporation of 
more ordered water molecules (LoConte et al., 1999). 
Nonobligate complexes allow us to examine the shape of protein surfaces that are 
functionally significant. One might imagine that rough surfaces are more likely to form 
specific intimate associations with other rough surfaces. This is the case with the 
associations between small molecule ligands with proteins. Lewis and Rees developed a 
metric for the degree of roughness of a protein surface called the fractal dimension 
(Lewis and Rees, 1985). This is the sensitivity of the size of the surface to the size of the 
probe used to measure it. Pettit and Bowie, assaying the surface of a protein by its fractal 
dimension, found that sites involved in binding small molecule ligands were very rough 
compared to the surface as a whole (Petit and Bowie, 1999). To determine if the interface 
surface is more or less flat than the surface of a protein generally, it is necessary to 
extract samples of the rest of the surface. Jones and Thornton first attempted this on a 
data set including 31 heterocomplexes with a patch-wise analysis of the surface (Jones 
and Thornton, 1997). Their patch size depended per protein on the size of that protein' s 
interface. They found that in contrast to small molecules, the surfaces of proteins most 
likely to interact with other proteins are more flat than the surface of proteins are 
generally. 
Another reason to distinguish between obligate and nonobligate protein-protein 
complexes is that there may be different selection pressures applied to the protein 
surfaces involved. The protein surfaces involved in nonobligate complexes must be 
adapted to two environments: aqueous buffer and the interface of the complex. The 
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surfaces of obligate complexes must be adapted only to the latter. An analysis of a 
collection of crystal structures has provided a structural insight into this functional 
question . In a review of 15 protease-protease inhibitor complexes and four antibody-
antigen complexes, the interfaces between these proteins contained an average of I 0 
hydrogen bonds, greater than 1 per 100 A 2 of buried surface area (Janin and Chothia, 
1990). This is more than double the density seen between the subunits of oligomers 
(Janin et al. , 1988), indicating that these interfaces rely to a greater extent on hydrogen 
bond formation and less on the hydrophobic effect than do the interfaces between 
subunits of oligomers. A higher density of hydrogen bonds per unit surface area in 
nonobligate complexes was confirmed in later studies (Jones and Thornton, 1996). This 
difference is consistent with the proposition that the surfaces involved in the interfaces of 
nonobligate protein-protein complexes are subjected to selection based on their ability to 
spend indefinite amounts of time exposed to aqueous buffer and cannot be completely 
hydrophobic. 
In contrast to the differences in the use of hydrogen bonds, the packing of atoms 
in nonobligate complexes is similar to that found in cores of proteins (Lo Conte et al., 
1999). Therefore, while the hydrogen bond formation may be more important to 
nonobligate complex formation than to the association of oligomer subunits, the 
importance of van der Waals forces is the similar in both. 
The analyses reviewed in the sections above have confirmed the importance of the 
burial of hydrophobic surface area to the formation of tertiary structure and the 
association of oligomer subunits (Lee and Richards, 1971 ; Chothia, 1976). They have 
also demonstrated the comparatively larger role played by hydrogen bonding in the 
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formation of nonobligate complexes as compared to permanent obligate complexes (Janin 
eta!., 1988; Janin and Chothia, 1990; Jones and Thornton, 1996) though there are homo 
oligomers that are exceptions to this rule (Larsen et a!. , 1988). Multiple crystal structure 
analyses have indicated that van der Waals interactions are an important (if somewhat 
under-appreciated) and consistently employed force in protein folding, and oligomer 
subunit and nonobligate complex formation (Harpaz et a!, 1994; LoConte et a!., 1999). 
They have shown that the flat sections of a protein surface are somewhat more likely to 
bind proteins while rough protein surfaces are more likely to bind small molecule ligands 
(Jones and Thornton, 1996; Petit and Bowie, 1999). When used in conjunction with 
analyses of multiple alanine-scanning mutageneses experiments, crystal structure reviews 
have demonstrated that all residues do not contribute equally to nonobligate protein-
protein interactions (Bogan and Thorn, 1998; LoConte eta!., 1999). We now review how 
other analyses aided in finding what characteristics of proteins are common between 
groups of proteins and what characteristics of proteins may be used to distinguish 
different groups. 
Multiple crystal structure analyses: Distinguishing groups of proteins 
Analyses of multiple crystal structures revealed a relationship between the mass 
of a protein and its surface area that is common to both monomers and oligomers. The 
algorithm that measures the solvent accessible surface area by Lee and Richards was 
improved (Shrake and Rupley, 1973) and used to measure the surface area of 46 small 
monomeric proteins (Janin et a!. , 1987). This study found that the surface area of these 
small proteins was related, with some exceptions, to the molecular weight of the proteins 
by a simple power law. It was proposed that the surface area of oligomeric proteins 
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would not be related to the mass (Sprang et al., 1979). This proposition was refuted in a 
study of 23 oligomeric proteins that found the surface area of the protein as well as the 
area buried between oligomers was a function of the molecular weight of the protein 
(Miller et al. , 1987b ). The relationship between the molecular weight and the surface area 
of the whole oligomeric protein was confirmed in a study of 24 oligomeric proteins 
(Argos, 1988). However, the relationship between the molecular weight and the amount 
of surface area buried between oligomers was not found in this study to be a function of 
the protein ' s mass. Despite this discrepancy, both studies found that for proteins with the 
same molecular weight, the surface area of the subunits depended on the number of 
subunits (Argos, 1988). 
Other studies have revealed what else is consistent between groups and what is 
different. Oligomers and monomers were found to share the same proportions of 
nonpolar, polar and charged surface area both on their solvent accessible surfaces (57% 
nonpolar, 23% polar, and 20% charged) and in their cores (58% nonpolar, 33% polar, and 
9% charged) (Janin et al. , 1988). The surfaces buried between oligomer subunits and 
those buried in nonobligate protein-protein complexes have amino acid compositions that 
are more enriched in aromatic amino acids than like the surfaces of proteins generally 
(Argos, 1988; Janin and Chothia, 1990; Jones and Thornton, 1996; LoConte et al., 1999). 
As noted above, the nonobligate surfaces make more hydrogen bond contacts than occur 
between the surfaces of subunits in oligomers (Janin and Chothia, 1990; Jones and 
Thornton, 1996). 
As more structures have become available for analyses, it has become possible to 
distinguish between groups that were previously considered collectively. The initial 
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studies of homo oligomers treated them as one group of proteins (Janin et al., 1988; Janin 
and Chothia, 1990; Jones and Thornton, 1996) . The more recent work divides 
homodimers into three classes, the first, largest, class is made of compact subunits with 
extended interfaces. The relative importance of hydrogen bonds, ordered waters and 
polar surface area to the homo oligomer interfaces is broadly sampled within this class. 
The other two classes, compact subunits with compact interfaces and a class made up of 
intertwined interfaces rely on hydrophobic cores and extensive hydrophobic surface area, 
respectively (Larsen et al. , 1998). Early studies of nonobligate protein-protein complexes 
found the complexed proteins underwent little conformational change when binding each 
other (Janin and Chothia, 1990; Jones and Thornton, 1996). These older, smaller studies 
saw little movement of the proteins upon complex formation and that result was 
confirmed in a larger study, for small proteins. A recent review of 75 nonobligate 
protein-protein complexes (Lo Conte et al. , 1999) noticed that for larger proteins with 
interfaces burying between 2000-4 700 A 2 total this is not always the case. Among 
others, the binding of Gi~y with phosducin, the binding of Gia to transducin and CDK2 
binding to cyclin A are all accompanied by large changes in the structure. These 
structural changes are of three general types, disorder to order transitions, large main-
chain movements (primarily alterations in loop structure), and changes in the positions of 
the domains relative to each other (Lo Conte et al., 1999). 
It has been shown that the core of a monomer is more like the core of an oligomer 
than it is like the surface of a monomer (Janin et al. , 1988). Oligomers and monomers 
also share a general relationship between the mass of a protein and its surface area 
(Miller et al., 1987b; Janin et al. , 1988; Argos, 1988). While nonobligate complexes have 
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more hydrogen bonds between the interface surfaces than occur in obligate complexes, 
they share a similar propensity for aromatic amino acids as well as efficient packing 
(Janin et al., 1988; Argos, 1988). The distinction between permanent, obligate 
complexes and transient, nonobligate ones as well the difference between small, more 
elastic, nonobligate complexes, and larger inelastic ones was formalized in these analyses 
(Jones and Thornton, 1996; LoConte et al. , 1999). To conclude the review of multiple 
crystal structure analyses, we will examine the tools that have made these analyses 
possible. 
Multiple crystal structure analyses: Tools for quantifying aspects of structures 
We have observed above the importance of the algorithms for calculating the 
basic physical properties of surface area and volume to analyzing collections of crystal 
structures. We have seen how the output of these algorithms may be partitioned in a 
variety of ways to tell us much about the character of the examined proteins. There are 
aspects of nonobligate protein-protein complexes in particular that are captured best by 
algorithms that measure more subtle aspects of a protein's shape. 
The shape of the interface of a nonobligate protein-protein complex has been 
described quantitatively by two numbers in a analyses of multiple crystal structures. In a 
review of 32 homo-oligomers, 4 obligate hetero-oligomers, 10 enzyme-inhibitor 
complexes, 4 antibody-antigen complexes and 7 other nonobligate complexes, the 
planarity and the circularity of both interface surfaces were measured (Jones and 
Thornton, 1996). The atoms that bury surface area to form the interface were used to 
define the absolute shape of an interface. These atoms are dispersed in three dimensions 
such that they do not form any regular, easily defined shape. To describe this shape, the 
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best-fit plane through the dispersion of atoms is found. Jones and Thornton employ this 
method and describe the way the dispersion fits a plane with two values, the planarity and 
the circularity. The planarity is the root mean squared deviation away from the plane, the 
smaller this value the more planar the dispersion. The circularity is the ratio of what may 
be thought of as the two axes of the plane. If this ratio is equal to 1.0, the dispersion of 
atoms that make up the interface will appear circular if one views the interface from a 
perspective normal to the best-fit plane. The smaller this ratio, the more oblong the 
interface. Using this tool to compare the interfaces of obligate and nonobligate 
complexes revealed that nonobligate interfaces were more planar than but similarly 
circular to obligate complexes. 
Jones and Thornton also measured the degree to which the shape of one interface 
surface matched the other, or how well the proteins "fit together." They did this by 
measuring the void volume between the complexed proteins. Larger volumes 
corresponded to poorer fits. Obligate complexes and enzyme-inhibitor complexes fit 
together well, while antibody-antigen complexes fit together less well (Jones and 
Thornton, 1996). This confirmed the results arrived at by a different algorithm that 
measures the degree to which proteins fit in a different way (Lawrence and Colman, 
1993). To assess the shape complementarity of two proteins in complex, this algorithm 
measures both the distance between the surfaces of atoms as well as the angle between 
the normals extending from the surface. Perfectly complementary surfaces have a shape 
complementarity of 1.0, while completely unlike surfaces register 0.0 shape 
complementarity. When this algorithm was applied to the structures of four protease-
protease inhibitor complexes, five obligate complexes, and six antibody antigen 
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complexes, the first two groups were found to have a higher degree of shape 
complementarity than the latter. 
The shape of each of the surfaces in the interface of a nonobligate protein-protein 
complex has been measured as well as the degree of fit between them. These values have 
been found useful in describing differences between the biologically distinguishable 
types of nonobligate protein-protein complexes (Jones and Thornton, 1996; Lawrence 
and Colman, 1993). 
Conclusions 
Analyses of collections protein crystal structures have provided original insights 
into protein folding. Analyses of the types of protein surface buried illuminated the role 
of hydrogen bond dominated secondary structure formation and hydrophobic surface 
burial dominated tertiary structure formation (Lee and Richard, 1971; Chothia, 1976). 
Analysis of the volumes of atoms in cores of proteins in high-resolution crystal structures 
elucidated the importance of van der Waals forces on the packing of atoms in a folded 
protein (Harpaz et a!., 1994 ). This result implies that the solution-transfer model, which 
correctly captures the hydrophobic effect, does not fully account for the role of atom 
packing in protein folding (Kauzmann, 1987; Harpaz et a!. , 1994). The indication of 
these studies is that dissolution of cyclic dipeptides crystals in water may be a better 
model for protein folding than the broadly applied solution transfer model. 
Analyses of multiple crystal structures help us understand how separate 
polypeptide chains associate. The low number of hydrogen bonds between the subunits 
of oligomers and the high density of the participating amino acids suggest that the roles 
of hydrogen bonding, van der Waals forces, and the hydrophobic effect in the formation 
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of quaternary structure are similar to those found in forming tertiary structure (Janin et 
al. , 1988; Harpaz et al. , 1994). The greater number of hydrogen bonds and similar amino 
acid densities at the interfaces of nonobligate protein-protein complexes indicates that 
these complexes require the tight packing of protein cores but rely less on the 
hydrophobic effect and more on enthalpic contributions than do more permanent 
associations (Janin and Chothia, 1990; LoConte et al. , 1999). These studies also reveal a 
prominent role played by aromatic amino acids at interfaces (Argos, 1988; LoConte et al. , 
1999). 
The analyses of multiple crystal structures helped define how we group protein 
crystal structures and demonstrated how the different groups are distinct and how they 
are similar. Analyses of monomeric and oligomeric proteins revealed that in most 
respects measurable in collective studies these proteins are similar (Miller et al., 1987b; 
Janin et al. , 1988). In contrast, studies of nonobligate protein-protein complexes have 
found that within this category there are differences between the extent conformational 
change induced by binding and in the degree of fit between the complexed proteins 
(Lawrence and Colman, 1993; Jones and Thornton, 1996; LoConte et al. , 1999). These 
distinctions indicate that this class may need to be subdivided further. 
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Chapter 2: 
Characterization of the 2:1 Complex between the Class 
I MHC-Related Fe Receptor and Its Fe Ligand in 
Solution 
This chapter describes the generation of the heterodimeric Fe molecule and the 
characterization of its interaction with FeRn. 
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Characterization of the 2 :1 Complex between the C lass I MHC-Related Fe Receptor 
and Its Fe Ligand in Solution" 
W . Lance Martin and Pamela J . Bjorkman * 
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AIJSTIV\CJ: T he neonatal Fe receptor (FeRn) fac il i tate~ the transfer of maternal immunoglobulin G ( l gG) 
to offspring and prolongs the half- life o f serum l gG. FeRn bind~ IgG in ac idic intrace llular vesicles and 
releases l gG upon exposure to the basic pH o f the bloodstream. The crystal structure o f an FcRn/Fc 
complex revealed FeRn dimers bridged by homodimeric Fe mo lecules to neate an o ligomeric array w ith 
two recepto rs per Fe I Burmeister et al. ( 1994) Nature 372. 379-3831. consistent w ith the 2: I FcRn :Fc 
sto ichiometry ob~erved in so lution I Huber et al. ( 1993) ./. M ol. Bioi. 230. 1077 - 1083: Sanchez et al. 
( 1999) Bioche111istry 38. 9471 -94761 . Two distinct 2: I FcRn/Fc complexes were present in the cocrystal 
structure: a complex contain ing an FeRn dimer interacting w ith an Fe and a complex in w hich single 
FeRn molecules are hound to both sides o f the Fe homodimer. To determine w hich of the two possi ble 
2: I FcRn/Fc complexes ex ists in solution. we generated recombinant Fe molec ule~ wi th zero. one. and 
two FeRn bindinl! sites and studied their interaction~ w ith a soluble form of rat FeRn. The w ild-type Fe 
w ith two FeRn bi~1din g sites binds two FeRn molecule~ under all assay conditions. and the nonbinding Fe 
w ith no FeRn binding sites show s no specific binding. The heterodimeric Fe w ith one FeRn binding site 
binds one FeRn mo lecule. suggest ing that the 2: I FeRn/w ild- type Fe complex formed in solution con~ i s t~ 
of single FeRn molecule~ binding to bo th side~ of Fe rather than an FeRn dimer binding to a single site 
on Fe. 
The neonatal Fe receptor ( FcRn)1 transport~ immuno-
globulin G ( lgGJ acro~s epithelial cell hamer~. FeRn wa~ 
onginally di~covcrcd in the Intestine of newborn rodent~ 
(reviewed in ref' I ). where 11 transfer~ mate mal immuno-
globulin in mgcstcd milk to the bloodstream of' the newborn. 
thereby allowing pas~ivc immunization of' the neonate to 
antigens encountered by the mother. Mon: recent ly. FeRn 
has been characterized in adul t animab. FeRn in human 
placenta i~ thought to tran~port matemal lgG to the f'etu~. 
and recent evidence suggest~ that FeRn funcllons throughout 
life to rescue serum lgG from degradation (rcvJcwed in refs 
1-3). In all of' its functions. FeRn bind~ lgG at ac1dic pH 
(.S 6.5) in intracel lular transport vesicle~ and release~ lgG at 
the basic pH of the blood (pH ~7.4 >. 
FeRn is a type I membrane glycoprotem consisting of an 
extracellular domain that resemble~ class I M HC molecule~ 
and a short (43 residue) cytoplasmic tail (4 ). Most biochemi-
cal and structural analyse~ of the FcRn/Fc mtcracllon have 
been done u~1ng a soluble form of the extracellular poruon 
of rat or mou~c FeRn. which i~ compo~cd of the heavy cham 
extracellular domains (a I. a2. and a:l ) bound to (12-
' Supponed hy a C'ami lie and Henry Drcyfu" Teacher Scholar 
Award (P.J.l!.i. a cranl from the IH (A t/GM.ti23<J Jo P.J.B.I. and an 
N l H predoctoral ,;~unmg gran! (5 T32 GM07(11 () to W.L.M.J. 
* COITesrondmg author. Phone: 626 395-8350. l-ax: <•26 792-J<•X3. 
1:-mail : hjor~man (alcco.callcch.cdu. 
1 Ahhrcvtation" C'HO. Chinese ham~lcr ovary: f'c. Fe fragmen1 from 
tmmunoglohulin G: FeRn. Fe rcccplor, neonalal : hdFe. hclerodimer 
Fe: lgG. immunoglohultn G: Ko. equi librium dtssoctal ion consl:lnl : 
nbFc. nonbmdmg Fe: RU. resonance unil" w1Fc. wild-1ypc l'e. 
microglobul in. The crystal >tructurcs of soluble FeRn alone 
(5) and of an FcRn/Fc complex (o) revealed a dimenc 
arrangement of receptor>. Binding ~ludic~ uwolving FeRn 
mutant> wi th alteratiOn> at the dimcr interface demonstrated 
that receptor dimeri1.ation is required for high-aflinity binding 
of lgG ( 7. 8>. We there fore suggested that the cry~tallo­
graphically observed dimer~ represent dimcrs induced hy 
ligand h1nding when FeRn i ~ tethered to a membrane (9). In 
the cocry~tab . the FeRn dimers arc bridged by Fe molecule~ 
such that each of the two potential FeRn binding sites on Fe 
interac t ~ with one of the FeRn molecules in the receptor 
dimcr. resulting in a long "ol igomeric ribbon" in which there 
arc two receptor~ for every Fe dimer (6). A t micromolar 
com:e ntration~ 111 ~ol ution . there i> no detectable formation 
of the oligomeric ribbon (10). l n~tcad. purified FcRn/Fc 
complexc> consist of three molecules: two receptor~ and one 
Fe. wh1ch presumably represent a portion o f the 2n:n r ibbon 
found 111 the cry~tab ( 10, II). There arc two di~t1nct 2: I 
complcxc~ in the cocrystal ' truc turc that cou ld account for 
the FcRn/Fc complex that fonm in solution (Figure I ). In 
one. Fe hinds to an FeRn dimer using one of its two potential 
FeRn hind111g site' (lcl't shaded portion). and in the other. 
~mg lc FeRn molecule' hind to both ~ides of Fe ( nght shaded 
pot1JOll). Computational studic~ ~uggcsted that Fe bound to 
FeRn is bent so a~ to more optimally contact the FeRn dimcr 
( / 2). A hem. rather than ~y mmctrical. strucwrc of Fe bound 
to FeRn i' compatible w ith the l ow-rc~olution cocrystal 
structure ~ince the hinge-proximal portion~ of' the C112 
domain were disordered (6). If Fe b di~torted when bound 
10.1021/bi9913505 CCC: $18.00 <D 1999 A merican Chemical Society 
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2 :1 FcRn/ Fc complex 
with FeRn d imer 
Martin and Bjorkman 
2:1 FcRn/ Fc complex 
w ith bridging Fe 
FIGURE I : Fc Rn/Fc complexes in the 2n:n o ligomeric ribbon observed in the FcRn/ Fc cocrystals. FeRn dimers are bridged by homodimeric 
Fe's. The shaded portions represent the two different 2: I FcRn/ Fc complexes that can be extracted from the ribbon (see text) . A lthough the 
Fe is depicted as being 2-fold symmetric, the low-resolution FcRn/Fc cocrystal structure did not give information about the location of the 
hinge-proximal portions o f the CH2 domains since these were disordered (6). Computational studies suggest that Fe bends in response to 
contacting an FeRn dimer (12): thus either o f the depicted 2: I FcRn/Fc complexes is a possibility for the 2: I complex that forms in 
solution. If the oligomeric ribbon network forms under physio logica l conditions, each FeRn dimer would be associated with a membrane 
parallel to the plane of the paper: the left-most dimcr i s associated with a membrane below the plane of the paper. the central dimer is 
associated w ith a membrane above the paper. and the right-most dimer is again associated with the membrane below the plane of the paper. 
to an FeRn dimer. a second FeRn might be prevented from 
binding to the other Fe polypeptide chain in solution. Thus 
either of the 2: I FcRn/Fc complexes shown in Figure I are 
a possibility for the complex that forms in solution. To 
distinguish which 2: I complex forms in solution, we 
constructed Fe proteins. similar to those previously expressed 
by W ard and colleagues (2, 13- 18), that contain zero, one, 
or two functional FeRn binding sites and studied their binding 
to soluble FeRn. 
MATEniALS AND METHODS 
Constmction of Fe Expression Vectors. A rat lgG2a eDNA 
(kind gift of M ark Agil a, Uni ve rsity of California. Davis) 
was modi fi ed to encode a secreted Fe fragment as follows: 
the DNA encoding the VH and C11 1 domains was removed 
using loop-out mutagenesis (19) to generate an in-frame 
fusion between the secretion signal sequence and the hinge 
region. The complete construct encodes the signal sequence 
fused to IgG2a residues 223 - 447 (EU numbering; 20), which 
corresponds to the hinge, C,2. and C113 domains of w ild-
type Fe (wtFc). The nonbinding Fe (nbFc) construct was 
generated from the wtFc construct by introducing mutations 
at the codons for some of the amino acids previously shown 
to he critical for FeRn binding (2. 9. 13- 18, 21) to make 
the following substi tutions: Thr252 to G ly. llc253 to Gly. 
Th r254 to Gly. His310 to Glu. His433 to Glu. and His435 
to Glu. PC R was used to add a factor Xa cleavage site and 
6 x -His tag to the 3' end of the nbFc construct (added 
sequence encodes the following residues C-term inal to 
residue 447: G ly- llc-Glu-Gly-Arg-G ly-Scr-Scr-His-His-His-
ll is- ll is-His). The w tFc and nbFc constructs were subcloncd 
afte r sequencing illlo the mammalian cell expression pBJ5-
GS (22). which carries the glutamine synthetase gene as a 
means of selection and amplifi cation in the presence of the 
drug methionine sulfoximine (23) . 
Expression of Fe Proteins . Chinese hamster ovary (C I-10) 
cells were colransfected w ith the wtFc and nbFc expression 
vectors, and selection and amplification of stable cell lines 
using methioni ne sulfoximine were carried out as descri bed 
(22, 24). Successfu lly transfected cell s shou ld secrete a 
mix ture of w tFc and nbFc homodimcrs and heterodimeric 
Fe (hdFc) composed of one wtFc and one nbFc polypeptide 
chain. Cell lines secreting w tFc and hdFc were idcmified 
by preci pi tation at pH 6.0 of [35S !methionine/cysteine ( ICN 
Pharmaceuticals. Inc.) metabolicall y labe led supernatants 
using soluble FeRn coupled to CNBr-acti vated Sepharose 
beads (Gibco-BRL) ( I/). Bound Fe was eluted from the 
FeRn-coupled beads by ra ising the pH to 8.0 and loaded onto 
a I 0% SDS-PAGE gel run under reducing conditions. Bands 
migrating w ith apparent molecular masses of 30 and 3 1 kDa 
were v isualized using a Phosphorl mager screen (Molecular 
Dynamics) (data not shown). The lower band was identified 
as wtFc by comparison with the Fe protein expressed in cells 
transfccted wi th the wtFc vector alone (see below). The upper 
band corresponds to nbFc, which migrates more slowly than 
wtFc due to addi tion of the factor X a site and 6 x -His tag to 
its C-terminus. T he majority of the labeled protein migrated 
as the 30 kDa band. indicating that the FeRn-coupled beads 
precipitated wtFc homodimcrs and hdFc. After addition of 
glycerol to 10%. NaCI to 300 mM, and imidazole to 10 mM, 
labeled supernatants were also precipitated with Ni -NT A 
supernow agarose beads (Qiagen). Bound proteins were 
eluted from the Ni- NTA beads by addition of I M imidazole 
and reducing sample buffer and visual ized after SDS- PAGE 
as described above. T he 30 and 3 1 k Da bands were again 
present, wi th the 3 1 kDa band in excess in this instance, 
indicating that the nickel beads precipitated His-tagged nbFc 
homodimers and hdFc. 
CHO cell s were al so transfected w ith the wtFc expression 
vector alone. After selection and ampli fi cation. cells express-
ing wtFc homodimers were identified using FeRn-coupled 
beads as described above. 
Purification of rc Proteins. Secreted wtFc homodimcrs 
were isolated from supernatants of CHO ce lls transfected 
w ith on ly the w tFc expression vector using a modification 
or a previously described functional puri fi cation involving 
Hetcrodimcr Fe Charactcrizallon 
pH-dependent binding 10 FeRn immobilized on Sepharosc 
head~ ( I I). The pH of the harvested growth media wa~ 
adjusted to 5.8 with I M sodium cacodylate. pH 5.5. (~so 
mUSOO mL harvest) then pas~ed over a 10 mL FcRn-
Sepharose column at 0 .5 mUmin . A fler washing with 200 
mL of 50 mM sodium cacodylate. pH 5.5. ISO mM aCI. 
wtFc was eluted with 50 mM Tris-CI. pH 8.0. 150 mM NaCI. 
then concentrated. and exchanged imo 50 mM Tris-CI. 50 
mM h1~-Tris-propanc-CI. pH 8.0. wtFc was loaded on!O a 
Uno-Q I anion-exchange column ( Bio-Rad ) mounted on a 
Biocad 700E perfusion chromatography ~ystem (Perkin-
Elmer) at 5 mUmin. The Uno-QI column \Va~ equilibrated 
with the FeRn loading buffer and then subjected \o a pH 
gradient from 7.5 to 6.0. Under these condiuons. wtFc 
(calculated pi = 7.1) (25) doc~ not hind to the column. 
allowmg it to he separated from contaminants that hind. wtFc 
wa~ concentrated. then purified. and exchanged into 20 mM 
sod1um pho~phatc. pH 6.0. 150 mM aCI hy flowing it over 
a Supcrdcx 200 HR 10/30 gel filtration column (Pharmacia) 
at 0.3 mUmin. 
hdFc and nhFc were purified from CHO cells secreting a 
m1xturc of wtFc. hdFc. and nbFc. S1ncc only the nhFc 
polypeptide chain carries a 6 x- His tag. hdFc and nhFc hind 
to a nickel column. whereas wtFc flow~ through. hdFc and 
nhFc can then he scpara<ed from each other using the FeRn 
affinity column. which hinds hdFc hut not nbFc. Harvc~t 
media were dialyzed twice using 6000-8000 Da Spectral 
Por membranes (Spectrum) against I 0 volume~ of 20 mM 
Tri~-CI. pH 8.0. ISO mM NaCI. and 0.05'/f NaN, to remove 
a med1a component that stripped nickel from the Ni-NTA 
column. The harvest media were then supplemented with 
glycerol to IO'h. NaCi to 300 mM. and imidazole to 10 mM . 
The media were pa~scd over a 20 mL i-NTA superflow 
agarosc column at 0 .5 mUmin and washed with 200 mL of 
50 mM Tris-CI. pH 8.0. I O'h glycerol. 300 mM NaCI. I 0 
mM imidazole. 0.05'/f NaN,. Nickel binding protein~ (hdFc 
and nbFc) were eluted from the column wllh 50 mM Tri~­
CI. pH 8.0. 10% glycerol. 300 mM NaCI. 250 mM imiduolc. 
O.OS'h NaN,. The eluent wa~ conce ntrated and exchanged 
into 20 mM ~odium cacodylate. pH 5.5. ISO mM aCI and 
pa~~cd over an FcRn-Scpharosc column. which wa~ eluted 
hy raising the pH to 8.0. To avoid potential contamination 
of the hdFc with wtFc. different FcRn-Scpharo~c columns 
were used for purifying wtFc and hdFc. After passing the 
flow-through over the FcRn-Scpharo~c column again. the 
flow-through (nbFc) and the eluent (hdFc) were each loaded 
onto the Uno-Q I an1on-exchangc column a~ dc~crihcd for 
wtFc. The hdFc (calcu lated pi = 6.9) (25) hind~ to the 
co lumn and clute~ at pH 7.4. 6 mL after the wtFc peak. The 
nhFc (calculated pi = 6.7) (25) hind~ to th1 ~ colu mn and 
clute~ at pH 7.1. I 0 mL after the hdFc peak . In addition to 
enhancing purity of the ~ample~. th1s chromatography 
facilitate~ evaluation of the degree 10 which each Fe i~ free 
of other contaminating Fe.: specie~. Following anion exchange. 
nhFc and hdFc were conccmratcd and further purified hy 
gel filtration on a Supcrdcx 200 HR 10/30 column as 
described for wtFc 
Final yie lds for the purified Fe.: protc111~ ranged from 3 to 
7 mg/ L of harvest. 
Erpression and Purification of Solu/JI(• Fcl?n . The FeRn 
used for these studies was the prcviou~ly dc~crihcd soluble 
form of the rat FeRn extracel lular rcg1on (rc~iducs 1-269 
27 
Biochemistry, Vol. 38. No. 39, 1999 12641 
of the mature FeRn heavy chain hound to rat (12-micro-
glohulin) produced in C HO cclb (22). FeRn was isolated 
from harvested growth media using a funcl!onal purification 
involving pH-dependent binding to an lgG affinity column 
(22). The protein wa~ further purified on Uno-Q I anion-
exchange and Supcrdex 200 H R I 0/30 gel filtration columm 
and exchanged into assay butTer as described for wtFc. 
Determination of Protein Concentrations. FeRn and Fe 
concentrations were determined spcctrophotometrically using 
extinction coefficients at 280 nm of 84 900 M- 1 em 1 (FeRn) 
and 60 900 M 1 em 1 (wtFc. hdFc. and nhFc). Extincllon 
coefficients that arc val id for denatured protein were fiN 
calcu lated from the protein sequences a-, described (26); then 
1\!Ro measurements for a fixed amount of each protein were 
compared in 6.0 M Gui-ICI and aqueous solutions. and the 
coefficient was adj usted if necessary. 
Coprt•cipirarion of FeRn and Fe. Fe proteins were analyzed 
for their ability to hind ~imultaneou~ly to more than one FeRn 
using u modification of a previously described column 
hmding assay ( II ). For each reaction. 20 ,uL of FcRn -
Scpharo~e bead~ was washed and resuspended in SO 11L of 
~odium phosphate. pH 6.0. 150 mM NaCI in a 1.7 mL 
Eppcndorftuhc und then incubated with 20 II!! of wtFc. nbFc. 
or hdFc in ~s 11L or wi th 5 pL of buffer. After wa~hing 
twice. the heads were resuspended in 50 ,uL of the same 
buffer including 20 I'!! of ~olublc FeRn. After two subsequent 
washes. the protein~ hound to the heads were eluted with 
16 ,uL of I M Tri~-CI. pH 8.0. Eluted proteins were run on 
a I or;, SDS- PAGE gel under reducing conditions and 
stained with Coomassic brilliant blue. 
Nonequilibrium Gel Filtration. The stoichiometry of Fc.:Rn/ 
Fe complexes was determined using conventional gel filtra-
tion chromatography under nonequilibriurn conditions a~ 
described (10). FeRn wa~ incubated with the variou~ Fe·~ at 
molar ratio~ between 3: I and I : I in 20 mM sodium 
phosphate. pH 6.0. ISO mM NaCI. keeping the concentration 
of Fe fixed at 10 11M. After 20 min at room temperature. 25 
,uL w~ injected onto a Superdcx 200 PC 3.2/30 gel filtration 
column (Pharmacia) equilibrated in the sodi um phosphate 
huller. which wa~ run at 0.1 mUmin using a SMART 
micropuritication system (Pharmacia). The absorbance of the 
el uent was monitored at 280 nm. and fraction~ were analyzed 
by SDS- PAGE (data not ~hown). 
l:'quilibrium Gel Filtration. The equilibrium column chro-
matography method of Hummel and Dreyer (27) and a 
SMART mieropurification system were used to analyze the 
association of FeRn with the Fe proteins at equilibrium as 
previously described (/0). A Supcrdex 200 PC 3.2/30 gel 
filtration column was equilibrated with and run in 20 mM 
sodium phosphate. pH 6 .0. ISO mM NaCI containing 2 ,uM 
FeRn (equilibration huller) at 0 . 1 mUmin. Samples (20 11L) 
including a 2 ,uM amount of one of the Fe's and variou~ 
concc!llrations of FeRn were incubated for 20 min at room 
tcmpcr:.nure in equilihration butTer that contained 2 ,uM FeRn. 
Sample~ were injected onto the col umn. and the absorbance 
of the clucm wa~ monitored at 280 nm. 
Biosensor 1\ssavs. A BIAcorc 2000 biosensor system 
( Pharmac1a. LK B Biotechnology) wa~ u~cd to assay the 
interacllon of FeRn with the Fe molecules. This system 
includes a biosensor chip with a dextran-coated gold surface 
to w hich one protein (refciTed to a~ the "ligand") is covalently 
immohiliLcd. Binding of an injected protein (the "analytc") 
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to the immobilized protc111 results in changes that arc directl y 
proportional to the amount of bound protein and read out in 
real time as resonance units (RU) (28, 29). FeRn or one of 
the Fe's was cova lently immobilized to three of the four now 
cells on a C M S biosensor chip (Pharmacia) using standard 
primary amine coupling chemistry (BIAcorc manual). Each 
protein was coupled at three different densities (~200. ~400. 
and ~ 1500 RU). and the fourth !low cell was mock coupled 
us1ng buffer to serve as a blank. For deri v ing kinet ic 
constants, we used binding experiments conducted for short 
times (30 s) using fast flow rates ( 100 ,uUmin) over flow 
cells coupled at low density (~200 or ~400 RU) . These 
conditions were chosen to min11nizc mass transport effects 
upon the kinetics of binding reactions (30). Kinetic constants 
were derived from the scnsorgram data using BIAcvaluation 
version 3.0, wh1ch simultaneously fits the association and 
dissociation phases of the scnsorgrams and globall y fits all 
curves in the working set. Scnsorgrams were lit to models 
>upp/ied by the B l Ac valuation 3.0 package: the "Langmuir 
b1nding" mode/ (a single class of noninteracting binding sites 
111 a I : I binding interaction). the ''heterogenenous ligand .. 
model (two or more populations of non intcracting binding 
sites). and the "bivalent ana/ytc'' mode/ (the injected protein 
can bind to two immobilized proteins) (sec Figure 5 legend). 
The appropriate model was chosen on the basis of the qual ity 
of the fit to the data, the robustness of the lit under different 
experimental conditions. and consistency between the binding 
model and structural information regarding the binding 
mcchalllsm. Equilibrium dissociation constants (K 0 · s) were 
dcnved from the ratios of rate constants (Ko = k.,lk.,. where 
k., and 1..., arc the association and di~sociation rate constants. 
respecuvc/y). For some of the binding interactions. we also 
derived KD's using an equi librium-based approach that is not 
affected by mass transport effects. In these experiments. 
binding reactions were allowed to closely approach or to 
reach equilibrium. Kn's were derived by nonlinear regression 
ana/ys1s of plots of 1?,,1 (the equilibrium binding response) 
versus the log of the analyte concentration . The lit of data 
to binding models assuming a bi valent analyte (A . P. West. 
unpublished results) or to one or more classes of nonintcr-
acting bmding sites on the ligand was examined. and the 
appropriate mode/ wa> chosen as described (31 ). For each 
ana/ys1s. the bulk refractive index parameter was set to zero 
for every concentration. 
RESULTS 
ll'tFc and hdFc, b111 NornbFc, /Jind ro FeRn . In prev1ous 
>tud ics by Ward and colleagues, recombinant versions of 
v.i/d-typc (two FeRn b1nding si tes). nonbind1ng (lcro FeRn 
bmd ing Sites). and hctcrodimcric (one FeRn binding si te) 
mouse Fe were produced in bacteria ( 13- 15). Thc~c proteinS 
were used for 111 vivo catabolic and transcytos1s ~tudics. as 
well as for biochem1ca/ analyses o f binding to soluble mow,e 
FeRn (1.1 - 15. 17. 18. 32, 33). The hcterod1mcnc Fe was 
shov.n to hmd mouse FeRn (33). but 1t was not protected 
from serum dcgradauon or transported across the mouse 
1ntcsunc as efliCICillly as wild-type Fe ( /3. I.J). We expressed 
analogous versiOns or ra t Fe 111 stabl y transfected C'HO cell s 
111 order to generate milligram quanuucs of g/ycosy/atcd Fe 
fragments that could be used for crystallographic and 
hlochemlca/ studies involv ing 'olub/c FeRn. 
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FIGURE 2: SDS-PAGE analysis of Fe proteins. Samples were run 
under reducing or nonreducing conditions on a 10% SDS-PAGE 
gel. 
CHO cells were cotransfccted with expression vectors 
encoding a secretion signal sequence followed by the hinge, 
C112, and C 113 domains of wtFc and nbFc derived from a rat 
/gG2a gene. The nbFc construct was generated from the wtFc 
construct by introduction of a C-termina/ 6 x -His tag 
sequence and incorporation of substi tutions identified previ-
ously that reduce or eliminate binding of Fe to FeRn (2. 9. 
13-18, 21). FeRn- and nickel-based precipitation methods 
were used to identify transfected cells that secrete a mixture 
of wtFc homodimcrs, nbFc homodimcrs, and hdFc molecules 
(data not shown). 
The purification procedures used to isolate the Fe's requ1re 
that wtFc and hdFc hind to FeRn at pH 6 but not pH 8, as 
observed for lgG (3-1 ). and that nbFc be unable to bind to 
FeRn. hdFc and nbFc were purifi ed from the harvested 
growth media of stably cotransfectcd cells using a combina-
tion of nickel and FcRn-Scpharosc chromatography. Su-
pernatants were first passed over a Ni-NTA column. wh ich 
binds nbFc and hdFc. The eluted proteins were then run over 
an FcRn-Scpharm,e column at pH 6 to separate nbFc and 
hdFc. nbFc was further purified from the !low-through of 
this column. whereas hdFc was purified after elution at pH 
8 from the FcRn - Scpharose column. To obtain large 
quamitics of wtFc. thi s protein was purified from the 
harvested growth media of cells transfcctcd with the wtFc 
expression vector only. using pH-dependent binding to the 
f cRn - Scpharosc column. SDS-PAGE analysis of the 
purified Fe's under reducing conditions revealed single bands 
at the expected molecular weights for nbFc and wtFc and 
two hands C01Tcspond1ng to the nbFc and wtFc polypeptide 
chaim for the hdFc (Figure 2). Under nonreducing condi-
tions. each protein migrates as a dimcr. demonstrating that 
the hmgc rcg1on 111lcrcha111 disulfide bonds had formed 
correctl y (F1gure 2). N-Tcrminal sequence analysis of 
purified hdFc revealed a single amino acid sequence (Vai-
Pro-Arg-G iu-X-Asn-Pro-X-Giy-X. where X corresponds to 
cysteine. which was not determined using this protocol) (data 
not shown). This sc4ucncc corresponds to re~1ducs 223-
2:12 of Fe. demonstrating that the secretion signa / sequence 
had been properly cleaved from the wtFc and nbFc polypep-
tide chams. 
II'! Fe and hdFc Sholl' Dijferenr Properties When Binding 
ro lmmobili;ed FeRn. We previously u~cd a column binding 
assay to show that more than one FeRn molecule can bind 
to purified rat Fe(/ 1). In this experiment, soluble rat FeRn 
Heterodimer Fe Characterization 
kDa 2 3 4 5 6 7 
wtFc hdFc Stds wtFe hdFe nbFe FeRn 
200 & ~ & & & elute 
116 FeRn ~ FeRn FeRn FeRn 97 elute elute elute 
66 -
45 - -FeRn 
31 - -hdFc -wiFe 
21 -
14 - - rJ2m -
FIGURE 3: SDS- PAGE analysis of proteins eluted from im-
mobilized FeRn. Samples were run under reducing conditions on 
a 10% SDS-PAGE gel. Lanes I and 2: 5 11g of each of the 
indicated proteins. Lanes 4- 7: Proteins eluted from FcRn-
Sepharose when incubated with the following proteins (20 Jl.g 
each): wtFc and FeRn (lane 4), hdFc and FeRn (lane 5), nbFc and 
FeRn (lane 6), and Fe Rn (lane 7). Only wtFc is able to bind 
simultaneously to immobilized FeRn and added soluble FeRn (lane 
4). hdFc bound to immobilized FeRn does not bind additional FeRn 
molecules (lane 5). nbFc and FeRn (lane 6) or FeRn alone (lane 7) 
does not bind to immobilized FeRn. 
was covalently coupled to Scpharosc beads and used to bind 
Fe at pi I 6.0 . When addiuonal FeRn was passed over the 
co lum n. i t bound to the FcRn/ Fc complex. indicating that 
more than one FeRn molecu le could b ind to a sing le Fe (I I ). 
In the present '>tudy. we per formed a precipitatiOn-based 
vcrs ton o f this experiment using w tFc and hdFc. A s 
demonstrated previously (1/). w tFc i s capable o f binding 
simul taneously to tmmobili;.ed FeRn o n the beads and to 
sol ub le FeRn. but no detectabl e soluble FeRn bmds to 
i mmobili /cd FeRn in the absence o f added Fe ( Figure 3). 
By contrast, hdFc h inds to immo bilized FeRn but does not 
bind addn tonal soluble FeRn. suggesting that hdFc can only 
bmd to a sing le FeRn under the conditions o f th is cxperimem. 
As expected, no detectable nbFc bound to the immobili zed 
FeRn ( Figure 3) . 
Gel Filnwion Analyses Demons/rare Oifferenr Sroichio-
lnerrie.ljor 11"11-'c and hcW c Bindi11g ro FeRn. W e previously 
described noncqui librium and equi l ibrium gel liltrati on assays 
to detennme the stoichio metry o f rat and mouse FeRn 
complexes with Fe ( / 0). In the presen t study, we compared 
the propert ies o r w tFc. hdFc. and nbFc in these assays. In 
the nonequilibrium-based experiments. various ratios or FeRn 
and one or the Fe's were incubated at pH 6.0, and the FeRn/ 
Fe complex was separated from the free pro te tns on a gel 
filtrauon colu mn. There was no detectable complex fonned 
w hen m ix tures of nbFc and FeRn were chro matographcd 
together on the colum n (data no t shown). For w tFc. we 
obtatned resu lts '>nni lar to those prcvtously repo rted ( 10). 
such that v irtuall y all of the protem chro matographs as the 
co mplex at a 2: I molar ratio or FeRn to Fe ( Figure 4A). 
W hen the mput rat to o f FeRn to w tFc 1s greater than 2: I , 
there IS an addt llonal peak correspondtng 10 free FeRn : w hen 
the input ratiO o r FeRn to w tFc i s less than 2: I ' there IS an 
addttional peal- corresponding to free w tFc (vcn ficd by 
SDS- PAGE: data not shown). By contrast. for hdFc. the 
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FIGURE 4: Gel filtration ana lyses of FcRn/Fc complexes. (A) 
Nonequi librium gel filtration. FeRn and wtFc or hdFc were 
incubated at pH 6.0 at the indica ted molar ratios and then passed 
over a gel filtration column run under nonequilibrium conditions 
to separate FcRn!Fc complexes from the free proteins. The identities 
of the proteins in each peak were confirmed by SDS- PAGE (data 
not shown). A single peak corresponding to an FcRn/Fc complex 
is formed at a 2: I stoichiometry for FcRn/wtFc and a I : I 
stoichiometry for FcRnlhdFc. (B) Equilibrium gel filtration. FeRn 
was incubated with 2 ,ttM wtFc or 21tM hdFc at the indicated FeRn/ 
Fe ratios in buffer containi ng 2 11M FeRn (equilibration buffer). 
Samples were injected onto a column equilibrated in the equilibra-
tion buffer. The peak that elutes first corresponds to an FcRn/Fc 
complex in equilibrium with free Fe; thus the concentration o f 
bound Fe in the complex is lower than 2 Ji.M. The second peak or 
trough is at the elution volume of free FeRn. Under equili brium 
conditions, the stoichiometry of the solution complex can be 
determined from the chromatogram with a nat baseline by rounding 
up the ratio of injected proteins to the nearest integral value. Thus 
FeRn binds to wtFc with 2: I stoichiometry and to hdFc wi th I : I 
stoichiometry under these conditions. 
pro tei ns chro matograph as a complex at a I : I mo lar ratio 
( Ftgurc -+A). 
Sto1ch iom etnes detcrmmed u~tng conventto nal ge l fil tra-
tion arc not defini ti ve because the pro te in - protein complex 
IS bc1 ng assayed under noncquilibrium conditions. Thus if 
some o r the complexes d issoctate dunng the expcnment. thc1r 
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con~titucnt~ can fail to rebind because they arc being 
separated from each other dunng the chromatograph ic 
procedure. For example. htgh manno~c carhohydratc-contain-
tng forms of mouse FeRn can form I : I complexes with Fe 
whe n assayed under noncquilihrium conditions (10. 33) hut 
form 2: I complexes when evaluated under equilibrium 
condlliom. ( /0). We therefore used the equilibrium gel 
filtration method of Hummel and Dreyer (27) to investigate 
the tntcractions of wtFc and hdFc with FeRn . As prcviow,ly 
described ( /0). we equilibrated a gel filtration column with 
hufrer containing a uniform concentration of FeRn. Prc-
cquilihratcd complexes of FeRn plus Fl· in different ratio~ 
were then inJected over the gel liltrallon column. If the 
amount of addi!ional FeRn injected wl!h Fe is greater than 
or less than the amoulll required for formation of the FeRn/ 
Fe complex. there is a peak (in the case of too much FeRn) 
or a trough (m the case of too liulc FeRn) at the position 
where free FeRn migrates. When the amount of addittonal 
FeRn tnjected with Fe is equal to the amount required for 
forming the FcRn/Fc complex. there is a flat baseline at the 
position where free FeRn migrate~. Unless the protein 
concentrations greatly exceed the Kn of the interaction. 
however. the rauo of the conccntrauon of added FeRn to 
the concentration of Fe will he a nonintcgral value. from 
which the integral value con-c~ponding to the sto ichiometry 
generally can he derived hy rounding up to the next integer. 
Thts is because the peak corresponding to the complex 
contatns stgnlficant amount~ of free Fe in cqui lhrium wl!h 
the hound form. unlcs~ the ex peri men! ts conducted at 
concentrations that exceed the Kn hy greater than I 0 -fold. 
which is usually not posstbl e due to limiting amounts of 
pun ficd protem. 
We cquilthratcd a small (2.4 ml total volume) gel liltrallon 
column with 2 pM FeRn. Samples contaming 2 pM wtFc 
or hdFc were incubated with various amounts of FeRn and 
chromatographed tn the equi libration huller con taining FeRn. 
As shown in Figure 4B. a flat baseline is observed at the 
positwn where free FeRn migrates when 3.6 pM additional 
FeRn is mjcctcd with 2 ,uM wtFc: thus the stoichiometry of 
the FeRn/wtFc Interaction is 2: I under equil ibrium condi-
tions. By comrasl. a llat baseline is observed when 1.6jtM 
hdFc is injected wi th 2 ,11M hdFc: thu~ at concell!rations up 
to 2 ,11M. hdFc interacts with only one FeRn molecule (Figure 
~B ). The nhFc shows no specific Interaction wnh FeRn (data 
not shown). 
Compari~on of il'tFc and hdFc Binding to FeRn Using 
Stuface Plastt/Ott l<e.\·onwtct' 1\.I~O\'s. FeRn was covalemly 
umnobilizcd onto the surface of a biosensor chtp. and hindmg 
of the Fe protems was monnorcd in rcalttmc ustng a ~urfacc 
plasmon re~onancc-hascd htndmg assay. a~ prcvwusly de-
scribed (7, 8. 21. 31. 35). We first analyzed the abilny of 
nhFc to hind FeRn to check for residual binding at htgh 
conccmrations. We found that nhFc docs not generate a net 
hmding response unless I! is injected at concentrations 
exceeding 5 ,uM. At these conccntrallom. the responses arc 
tndcpcndcnt of concentration and arc not rcproducihlc from 
flow cell to flow cell or from chip to chip and thus represen t 
nonspecific interactions with the biosensor chip (data not 
shown). For wtFc. the hindtng data were lit to a simple I: I 
tnteraction mode l and to a more complex model that assumes 
the response is due to two independent classes of nonilllcr-
acllng binding si tes (heterogeneous ligand model) (Figure 
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)A). The heterogeneous ligand model lit the data hcncr. as 
found tn previous h10scnsor-hascd studies ustng tntact lgG 
or Fe fragments (3 /) . Using the hctcrogcncow, ligand model. 
we derive a Kn of 1-6 nM for the htgh-aflinny population. 
representing ::;::;r;, of the binding site~. and a KD of 14:1 -
218 nM for the low-affinity population. representing 45"/r 
of the htndtng sue~ . By contrasl. the hdFc binding data tit 
the stmplc I : I tntcraction model quite well with a derived 
Kn of 75-96 nM (Ftgurc SA). 
Because the hdFc/FcRn htnding data fit the simple I: I 
interanion model. we inferred that the complex binding data 
observed tn the wtrc/FcRn interaction result primarily from 
the prc\cncc of two potcmial FeRn binding ~i tc~ on wtFc 
rather than from two populations of FeRn molecules on the 
chip surface. We therefore modeled the interaction of FeRn 
and wtFc a~ one Stdc of wtFc binding the coupled FeRn 
followed hy the wtFc/FcRn complex hinding another FeRn 
using the 'ccond FeRn binding site on wtFc (bivalent analytc 
model). Using this model. a Kn is derived for each binding 
even!. ne ither of whtch represents the affinity of wtFc being 
hound on both side~ hy FeRn; t.c .. hoth KD's represent 
disttnct micro,copic btndtng events. When the wtFc binding 
data arc anal y1.cd using thi ~ model. the Kn for the first 
binding event is in the range of 68-116 nM. and the second 
KD is 3 17-487 nM (Figure )A). Thus the Ku for the binding 
of FeRn 10 one site on wtFc is comparable 10 the 75-96 
nM Kn derived for the binding of FeRn 10 hdFc. From these 
results. we concl ude that the complex response exh ibited hy 
the tnteraction of FeRn wi th Fe or lgG on a biosensor chip 
is primari ly the result of FeRn binding lgG or Fe at both 
FeRn binding si tes. 
We previOusly noted that the affinities of FcRn/ lgG 
complexes arc htghcr when FeRn. rather than lgG. is 
immobilized on the biosensor ch tp (3/J. All lgG subtype~ 
tested showed a systematic coupling-dependent affinity 
dil'fcrcncc. ~uch that the high-artinity KD when FeRn was 
tmmohiltzcd (dctcnmncd using a two-site heterogeneous 
ligand model ) ranged between 15 and 9:1 nM . whereas the 
high-aiTinuy KD when lgG was immobilized ranged between 
7~ and 740 nM (30). To determine if hdFc exhibited a similar 
coup I i ng-dcpcndcnl affinity di ffcrcncc. we compared the 
hindtng of FeRn 10 wtFc and hdFc when each was im-
moht llled to a biosensor chip. In both cases. the binding 
data could he fit to the simple I: I interaction model. and 
the derived Kn wa' 4)0- 500 nM (Figure )BJ. Thus both 
hdFc and wtFc hind to FeRn with lower artinity when they 
arc tmmohilizcd than when they arc injected over im-
mohilllcd FeRn. 
DISCUSSION 
FeRn functtons in the transport of lgG across epithelia 
and in the protection of lgG from catabolism in the serum 
(reviewed in ref' / -3). Crystals of a complex between rat 
FeRn and the Fe fragment of lgG reveal an extended 
oligomeric ribbon of FeRn dimers bridged hy homodimcric 
Fe's (o) (Figure I). We have suggested that th is rihhon forms 
under physiological conditions. such as the inside of an acidic 
transport vesicle. and that ribbon formation could serve as a 
component of a trafficking signal for directing vesicles 
contami ng bound lgG to their correct destination (9). To 
investigate this hypothesis. we have in itiated a systematic 
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FtGl1RE 5 B1osensor analyse> of FcRn/Fc complexes. FeRn or Fe was coupled to a biosensor chip at -200. - 400. and - 1500 RU . 
Scnsorgrams (colored li nes) were anal yLed using a kim:ties-based method for the two lower coupl ing densities. A n equil ibrium-based 
method wa> used fo r ana lyses of data from all three coupling densi ties. y ielding results comparable to those of the kinetics-based analyses 
(data not shown) In each panel. the model used to fit the data (thin blad. li nes overlaid w ith the observed response) is listed along wi th 
derived aflinny eonstant(s) The simple 1. 1 model f i ts the data to the reac11on FeRn + Fe- Fc Rn:Fc The heterogeneous ligand model 
assumes thai there arc t" o populations of FeRn on the cl11p and fits the data according to the fo llowing reactions: FeRn + Fe- FcRn:Fc 
and Fe Rn + Fe- FcRn*·Fc K 0 's (K0 1 or K1).!) and the percentage of the tota l response due to each population of FeRn are deri ved for 
each react1on The b1 valen1 analyte model fits the data according to the fo llow1ng sequential reactions: FeRn + Fe= FeRn : Fe and FeRn: 
Fe+ FeRn - FcR n:Fc: FcRn . K 0 's (K 01;,,1 and Ko.~cumt l arc deri ved for each reaction (A) Sensorgrams from kinetics-based experiments 
in "hich the Indicated Fe is flowed over FeRn One representati ve set of 1n1ecllons from ex periments performed in duplicate or triplicate 
"sho" n fo1 each interaction on a ch1p coup led to - -100 Rll Similar rew lts were obtamcd for the -200 RU coupling density chips (wtFc: 
K t>l = 4 nM (58'X-). Ko.! = 185 nM (42'X-): K1)1i,,, = 10 1 nM. K0 ,".,,.1 = 136 nM hdFc· Kn = 86 nM ) ( 13) Sensorgrams from kinetics-
based expenmcnts 111 "hich FeRn 1s flo" eu over the tnd1cated Fe. One represen tative se t of injections from exper iments per formed in 
duplicate or tr iplica te IS shown for each interaction on a chip coupled to 200 R l l Similar results were obtai ned for the - 400 RlJ coupli ng 
density chips (wtFc K 0 = 500 nM hdFc: Kn = 460 nM ) 
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charactenzalion of the imcraclion between FeRn and its Fe 
ligand. 
Many biochemical ~lUdic~ of FeRn. a membrane-hound 
receptor that normally imcract~ with its ligand in the lumen 
or intracellular transport vesicle~. have hccn done in solution 
using a soluble version of the receptor. Under equi l ibrium 
conditions in solution. the FeRn/ligand complex i~ composed 
of three molecules. two FeRn 's and one Fe (10. II>. In the 
FcRn/Fc cocrystal s. there arc two di~tinct possihilnics that 
could account for the 2: I comp lex observed in solution. In 
one. a dimcr of FeRn molecules hind~ to only one FeRn 
binding ~nc on homodimeric Fe. In the other. single FeRn 
molecule; bmd to both FeRn b1mling 'ite~ on Fe (o). 
Here we describe the usc of recombinant Fe proteins 
comaining zero. one. or two binding sites for FeRn (nbFc. 
hdFc. and wtFc. rcspcclivcl yJ to determine the nature of the 
FcRn/Fc complex formed in 'olution. The experirncmal 
result~ con~istcntly demonstrate that the 2: I FcRn/Fc ~olution 
complex consists of two FeRn molecule' h1nding to both 
sides of wtFc . First. using an assay 1nvolving FeRn bound 
to a ~olid support. we show that more than one FeRn 
molecule can bind to wtFc but not to hdFc (Figure 3). In 
addition. gel tillration analyse~ under both equilibrium and 
noncqllllibnum condnion~ dcrnon~tratc that hdFc fonm a I : I 
complex with FeRn. whcrca~ wtFc forms a 2: I FcRn/Fc 
complex (Figure 4). The I : I nature of the FeRn complex 
with hdFc ~~ retlcctcd in biosensor analyse~ of thi' Interac-
tion. 111 that binding data involving hdFc could be li t to a 
~ 1mplc I : I binding model. By comrast. binding data for the 
interaction of coupled FeRn with wtFc or imact lgG must 
be fit to more complex binding models that incorporate 
binding to the ~ccond FeRn binding snc on Fe (Figure 5A). 
Combined with a previous demonstration that soluble FeRn 
is monomeric at rnicrornolar concentrations in solution (22). 
the presclll rc;ult; establish that FeRn docs not d11ncrizc 111 
solution. either alone or when bound to Fe. 
The result that the 2: I FcRn/Fc complex formed in solution 
doc; not include FeRn dimcrs cannot he used to 1ntcr that 
receptor d11nerization doc~ not occur under phy,iological 
condnion~. In biochemical experiments such a> those dc-
;crihcd here. soluble FeRn is studied at relatively low protem 
concemrations (micrornolar) that would not he expected to 
favor formation of receptor dimcrs or the olig.orncm: ribbon. 
In vivo. however. receptor> arc tethered to a membrane under 
conditions of high ctlcctivc molarity in which receptor 
dirncrization and oligomeric ribbon formation could he 
facilitated. Tethering of soluble FeRn to a hio~cn'or chip 
may to 'orne extent mimic the high local protem conccmra-
tions found in a membrane by facilitating dimcrization of 
FeRn. Previous studic' suggest that FeRn can dimcrizc on a 
biosensor chip. in that mutation~ at the FeRn dimer mtcrfacc 
that do not directly contact lgG resulted in reduced atTinitic~ 
for lgG (8). In addition. the prcviou~ observation that the 
affinity between FeRn and Fe or lgG is highest when the 
receptor rather than the ligand is coupled to a hw;cn~or chip 
(3 /) can now he interpreted by assuming that FeRn can 
dimcrize when coupled to a biosensor chip. This orientation 
effect i; not due to the ability of FeRn to hind lgG and wtFc 
at two sncs hecau; c it is also produced by hdFc. wh1ch can 
only be bound on one side by FeRn. A reasonable explana-
tion for this effect is that FeRn can form dimcr~ when 
coupled to the surface of the biosensor chip at high ctTcctivc 
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molanty and that these dimcr' bmd Fe and lg.G more stably 
than doc~ monomeric FeRn. wh1ch is the predominant ;pccic~ 
hindmg to immohili1ed Fe or lgG. 
The u~e of Fe molecule~ that contam LCro. one. or two 
FeRn binding site' ha~ allowed the JdcntificatJon of the 
trimolccular 2: I FcRn/Fc <.:omplcx that forms under micro-
molar condiuon~ in 'olut1on. Fwurc ~tudic~ of the interaction 
of the>c Fe molecule~ wnh membrane-hound FeRn will 
facilitate understanding of the more complex intcractJom 
between this receptor and it~ ligand under physiological 
condition,. 
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Crystal structure at 2.8 A of an FcRn/Heterodimeric Fe 
complex: Mechanism of pH-dependent binding 
This chapter describes the solution of FcRn!heterodimeric Fe complex crystals as 
well as the structure of the non-binding Fe. Dr. Anthony West assisted in the solution of 
FcRn/hdFc structure. Lu Gan purified the non-binding Fe, generated the non-binding Fe 
crystals, collected the diffraction data, and participated in the solution and refinement of 
the non-binding Fe. 
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Summary 
The neonatal Fe receptor (FeRn) transports immuno-
globulin G (lgG) across epithelia, binding lgG in acidic 
vesicles (pH :s 6.5) and releasing lgG in the blood at 
pH 7 .4. Well-ordered FcRn/Fc crystals are prevented 
by the formation of " oligomeric ribbons" of FeRn di-
mers bridged by Fe homodimers, thus we crystallized 
a 1:1 complex between rat FeRn and a heterodimeric 
Fe containing only one FeRn binding site. The 2.8 A 
complex structure demonstrates that FeRn uses its 
a2 and 132-microglobulin domains and carbohydrate 
to interact with the Fe C,2-C,3 interface. The structure 
reveals conformational changes in Fe and three titrat-
able salt bridges that confer pH-dependent binding, 
and can be used to guide rational design of therapeutic 
lgGs with longer serum half-lives. 
Introduction 
FeRn mediates transport of maternal lgG across the 
neonatal intestine in rodents and the placenta in hu-
mans, thereby conferring humoral immunity to the fetus 
or newborn against antigens encountered by the mother. 
In addition, FeRn protects lgG from degradation by serv-
ing as the receptor responsible for maintenance of the 
long half-life and high concentrations of lgG in serum 
(Simister and Mostov, 1989; Ghetie and Ward, 2000). In 
both its transport and protection receptor roles, FeRn 
binds lgG with nanomolar affinity at acidic pH (s 6.5) in 
intracellular transport vesicles and releases lgG upon 
encountering the basic pH of the bloodstream (7 .4) (Ghe-
tie and Ward, 2000). Understanding the details of the 
FeRn interaction with lgG is critical for efforts to increase 
the serum half-lives of antibody-based drugs and to 
deliver therapeutic lgGs across the placenta. 
FeRn shares 22%-29% sequence identity with class I 
major histocompatibility (MHC) molecules (Simister and 
Mostov, 1989), which present peptide antigens to cy1o-
toxic T cells. Both types of proteins are heterodimers 
composed of the soluble light chain [:12-microglobulin 
([:12m) and a membrane-bound heavy chain that includes 
three extracellular domains (o1, o2, and a3), a single-
pass transmembrane region , and a short cy1oplasmic 
domain. Crystal structures of rat (Burmeister et al., 
1994a) and human (West and Bjorkman, 2000) FeRn 
confirmed the structural similarity with class I MHC mol-
ecules, except that FeRn has a narrowed and nonfunc-
t To whom correspondence should be addressed (e-mail: bjorkman@ 
its.caltech.edu). 
tional version of the class I MHC peptide binding groove. 
The low resolution crystal structure (6.5 A) of a rat FeRn/ 
Fe complex revealed that the side of an FeRn a1-a2 
domain platform interacts with the C,2-C, 3 domain in-
terface on each chain of the Fe homodimer (Burmeister 
et al., 1994b). Many different surfaces on class I MHC 
and class I homologs are employed for interactions with 
protein ligands (Strong, 2000). By contrast, the Fe C, 2-
C,3 interface is the binding site for a number of proteins 
that bind lgG, including protein A (Deisenhofer, 1981), 
protein G (Sauer-Eriksson et al., 1995), rheumatoid fac -
tor (Corper et al., 1997), peptides selected for high-affin-
ity Fe binding (Del ano et al., 2000), and the herpes 
simplex virus lgG binding protein gE-gl (Chapman et al., 
1999). The limited resolution of the FcRn/Fc cocrystals 
prohibited detailed comparisons with the other Fe bind-
ing proteins and analyses of potential conformational 
changes induced by binding. Growth of well-ordered 
cocrystals is apparently prevented by the packing, in 
which Fe homodimers bridge between dimers of FeRn 
heterodimers to create an "oligomeric ribbon" (Fig-
ure 1 A). 
In order to obtain an FcRn/Fc cocrystal with a different 
packing arrangement, we engineered a heterodimeric 
version of Fe (hdFc) that cannot bridge between FeRn 
molecules because it contains only a single FeRn bind-
ing site (Martin and Bjorkman, 1999). The hdFc is com-
posed of a wild-type rat lgG2a Fe reg ion (wtFc) cova-
lently linked via hinge region disulfide bonds to a mutant 
rat lgG2a Fe (nonbinding Fe; nbFc) with substitutions 
that disrupt FeRn binding (Thr-252 to Gly, lle-253 to Gly, 
Thr-254 to Gly, His-31 0 to Glu, His-433 to Glu, and His-
435 to Glu). In solution, hdFc forms a 1:1 complex with 
FeRn, in contrast to wtFc homodimers, which form 2:1 
FcRn/Fc complexes (Martin and Bjorkman, 1999). Here 
we describe structures of a 1 :1 FcRn/hdFc complex and 
a nbFc homodimer solved to 2.8 A and 2.7 A, respec-
tively. The FcRn/hdFc structure reveals the molecular 
mechanism for the pH dependence of the FcRnllgG 
interaction and shows that ordered carbohydate from 
FeRn participates in binding Fe. Comparisons of the 
structures of free and FeRn-bound Fe molecules reveal 
domain rearrangements distant from the FeRn binding 
site and asymmetry in Fe that may result in negative 
cooperativity for binding the second FeRn to Fe. 
Results 
FcRn/hdFc and nbFc Structures 
Secreted forms of rat FeRn, hdFc, and nbFc were ex-
pressed in CHO cells and purified as described (Martin 
and Bjorkman, 1999). The FcRn/hdFc and nbFc struc-
tures were solved at pH 5.4 (complex crystals) or pH 
6.4 (nbFc crystals) by molecular replacement using the 
structures of rat FeRn (Burmeister et al., 1994a; Vaughn 
and Bjorkman, 1998) and/or human Fe (Deisenhofer, 
1981) (Table 1 ). The FcRn/hdFc structure consists of a 
1 :1 complex in which FeRn interacts specifically with 






Figure 1. FcRn/ Fc, FcRn/hdFc, and nbFc Structures 
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(A} FcAn/Fc complexes 1n the oligomeric ribbon observed in crystals of FeRn bound to wtFc. FcRn/Fc crystals grown using human, mouse, 
or rat FeRn and human, mouse, or rat Fe subclasses all appear to contain the oligomeric ribbon packing in which FeRn dimers are bridged 
by Fe homodimers. Such crystals diffract aniostropically to 3.5 A-8 A, with the highest resolution in the d irection of the long axis o f the FeRn 
dimer. 
(B) Ribbon diagrams of the structures of FcRn/hdFc and nbFc. Ordered N-linked carbohydrates are shown in ball-and-stick representation. 
Disulfide bonds are yellow. Regions of disorder in the distal C~2 domain are shown as dashed lines. The FcRnlhdFc complexes are packed 
in the crystals such that the nbFc chain of the hdFc contacts an FeRn in an adjacent FcRn/hdFc complex. This interaction involves a face of 
the FeRn a3 domain opposite from the Fe binding site, and the buried surface area (577 A2 total) is near the mean size buried in typical crystal 
con lacts (570 A') (Janin, 1997), thus it is a nonspeci fic interaction. 
(C) Close-up of the FcRn/hdFc interface. Interface residues are turquoise (positively charged), pink (negatively charged), and yellow (hydropho-
bic). The carbohydrate attached to residue Asn-87 was omitted for clarity. 
(D) The Fc Rn/hdFc model in the region of the N-linked carbohydrate attached to FeRn Asn-128 superimposed on a 2.8 A SIGMAA-weighted 
2Fo-Fe annealed omit electron density map contoured at 1.0 u. 
(E) Comparison of the Fe 251 to 256 loop in the wt (red) and nb (gold) sides of hdFc (Cn rms devialion of1.78 A). 
FcRn/Heterod imeric Fe Crystal Struc ture 
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Table 1. Data Collection and Refinem ent Statistics fo r the Fc RnlhdFc and nbfc Crystal Struc tures 
FcRn/hdFc nbf c 
Data Collection 
Space group P2,2,2, P2, 
Umt cell (A) 68.4, 74.4, 196.6 42.5, 73.4, 82.2, ll 103 
Resolution (A) 20-2.8 ( 2.~2.8) 30-2.6 (2.7-2.6) 
Waveleng th (A) 1.00 1.54 
Mosaicity \) 0.7 0.6 
Observations 96,527 (7836) 35,621 (3003) 
U mque reflections 25,112 (2234) 14,919 (1323) 
C ompleteness (% )• 98 .7 (89.8) 97 .5 (87.2) 
1/nl 18.9 (3.0) 13.4 (3.6) 
A,.....(% )' 8.0 (30.0) 6 .8 (26.1) 
Refinement 
Resolution (A) 20-2.8 20-2.7 
Work reflections 23.810 12,096 
Test reflections 11 95 1375 
R,..,.l! (o/o)C 22.2 24.1 
' R,_ 29.3 27.9 
No. of protein atom s 6241 3264 
No. of waters 6 0 
No. of carbohydrate atoms 323 198 
Average B factor (A') 79.1 41.2 
Anosotropic 6 correction B11 24.12 B11 7.9 B1 2 ~ 0.00 
B22 5.95 6 22 5.2 B1 3 = 0.66 
B33 18.16 6 33 2.7 6 23 0.00 
Rms deviations from ideal 
Bond lengths (A) 0.009 0.008 
Bond angles ( ) 1.6 1.4 
Ramachandran plot quality 
Most favored (% ) 77.8 89.1 
Additionally favored (% ) 20.8 9.8 
Generously allow ed (%) 1.4 1.1 
Disallowed (% ) 0.0 0.0 
Stat1St1cs in parentheses refer to the h1ghest resolution bm. 
• Completeness (number of independent reflections)/ total theoret1cal number. 
' R_,.. (I) f-'ll(i) <- l(h) ·l~l(i)), where l(i) is the i~ observation of the intensi ty o f the hkl reflec tion and < I / is the mean intensity from multiple 
measurem ents of the h,k,l reflection. 
' R,~., (F) ~h))Fobs(h)) I Fcalc(h)ll~hiFobs(h) l. where IFobs(h)) and IFcalc(h)l are the observed and calculated struc ture factor amplitudes 
for the h,k,l reflection. 
0 R,_ is calculated over reflections in a test set not included in atomic refinement. 
its a1-u2 domain platform recognizing the Fe C,2--C, 3 
dom ain interface (Figures 1 B and 1 C). The o ligomeric 
ribbon is completely disrupted, since FeRn does not 
dimerize and hdFc does not bridge between FeRn mole-
cules in the FcRn/hdFc crystals. There is o rdered elec-
tron density for FeRn, the Fc Rn/ Fc interface, N-linked 
carbohydrates on FeRn (Figure 1 D) and Fe, the proximal 
(FeRn-bound) side of the hdFc excluding the B-C 
loop of the C,2 domain, and the C, 3 d omain of the d is-
tal (nbFc) c hain. In the distal C, 2 d omain, only the 
C, 3-nearest half, the intradomain d isulfide, and the 
N-linked carbohydrates show ordered electron density, 
thus the remainder of the C, 2 domain was modeled 
using coordinates from the nbFc structure. Disorder of 
the same portion o f the d istal C,2 domain is also ob-
served in a 5 A structure derived from Fc Rn/ hdFc crys-
tals collected at room temperature 0/'1. L. M. and P. J . B., 
unpublished results). The same portions of the C, 2 do -
mains of human Fe (Deisenhofer, 1981 ), a human Fe/ 
protein A fragment c omplex (De isenhofer, 1981 ), and an 
intact antibody (Harris et al., 1997) also show disorder. 
The structure o f the nbFc homodimer (Figure 1 B) 
c losely resembles structures of human Fe (Deisenhofer, 
1981 ; Sauer-Eriksson et al., 1995; Corper et al. , 1997; 
Harris et al. , 1997; Delano et al., 2000). The most notable 
d ifference concerns the loop containing residues 252-
254, which are replaced by glycines. This loop is re-
a rranged relative to the corresponding loops in human 
Fe or the wtFc chain of hdFc (Figure 1 E), suggesting that 
movement of the 251-2561oop as well as the absence of 
FeRn-interacting side c hains contributes to the lack of 
binding between nbFc and FeRn. 
FcRn/Fc Interface 
The FcRn/Fc binding interface spans a large surface 
area and is highly complementary. The buried surface 
area at the interface (1870 A') (Table 2) is slightly larger 
than average protein-protein recognition interfaces 
(1560-1700 A') (Jones and Thornton, 1996) and larger 
than areas buried at the interface between Fe and other 
proteins that bind to C, 2--C, 3 interdomain region of Fe 
(protein A, protein G, and rheumatoid factor) (Table 2). 
In addition, the shape correlation statistic (Sc) (Lawrence 
and Colman, 1993) for the FcRn/hdFc complex is higher 
than indices fo r these and other protein/Fc complexes 




Table 2. CharacteristiCS of the FcAn/hdFc and Other Protein-Protein Interfaces 
Percentage Percentage Percentage 
Interface Area Shape Number of Nonpolar Polar Charged Proximal, Distal Fe 
Protein(s) (A') Complementarity Salt Bridges Interface Area Interface Area Interface Area C .,-C.,3 Angles 
FcRnlhdFc 1870 0.71 4 56 28 16 89 ' 81 
Protein AJFc 1320 0.66 0 61 36 3 99 ' 99 
Protein G/Fc 1370 0.56 56 33 11 100 ' 100 
RF/ Fc 1490 0.69 47 34 9 93 ' 93 
Fc-yRIII/ Fc 1730 0.67 0 67 24 9 93' 106 
Fc.RI!Fc• 1460 0.69 2 62 27 11 85 ' 98 
Free hFc 98 ', 95 
Free nbFc 92 ' 92 
Intac t mlgG 98 ' 94 
RF denotes rheumatoid factor. Interface area in column 2 IS the total buried surface area at a protein-protein interface and was calculated 
as described in Experimental Procedures. Shape correlation statistics (SJ were c alculated using SC (lawrence and Colman, 1993) (Sc 1 
for interfaces with perfect fits). Salt bridges are defined as atoms on each •nteract1ng protein with opposite c harges that are within 3.5 A of 
each other. Interface buried surface area in columns 5-7 is defmed and charactenzed as nonpolar, polar, or charged according to the criteria 
o f Lo Conte et al. (1999). The percentage in each category 1s calculated for all protein atoms at the Interface. The interdomain angle is the 
angle between the long axes of the C, 2-C, 3 domains of Fe calculated as described (Su et al. , 1998). 
the C-terminal portion of the a2 domain a helix and 
the first residues of [32m. On Fe, the FeRn binding site 
encompasses the residues identified by Delano et al. 
(2000) as common to all interactions involving the Fe 
C,2-C, 3 interface (residues 252-254 in the C, 2 A-Bloop 
and residues 434-436 in strand G of the C, 3 domain). 
In addition, the FeRn footprint on Fe includes residues 
in the C, 2 E-F loop (309-311) (Table 3). 
The center of the FcRn/Fc interface includes a core 
of hydrophobic residues in which FeRn Trp-133 con-
tacts Fe lle-253 and [32m lle-1 from FeRn contacts Fe 
Pro-307 (Figure 1C). Substitution of FeRn Trp-133, [32m 
lle-1 , or Fe lle-253 greatly reduces the interaction affinity 
(Table 3) (Popov et al. , 1996; Vaughn et al. , 1997; Shields 
et al. , 2001 ). Surrounding the hydrophobic core con-
taining Fe lle-253 is a network of salt bridges involving 
FeRn residues Glu-117, Glu-118, Glu-132, and Asp-137 
and Fe residues His-31 0, Arg-311 , His-435, and His-436 
(Figure 2A). Mutation of Glu-117, Glu-132, and Asp-137 
on FeRn and His-31 0, Arg-311 , His-435, and His-436 
on Fe, either individually or in conjunction with other 
residues, lowers the binding affinity substantially (Table 
3) (Kim et al., 1994a, 1999; Raghavan et al., 1995; Popov 
et al. , 1996; Ghetie and Ward, 1997; Medesan et al., 
1997, 1998; Vaughn et al., 1997; Shields et al., 2001). 
N-linked Carbohydrate Attached to FeRn 
Contributes to Fe Binding 
Unanticipated from the low-resolution FcRn/Fc struc-
ture (Burmeister et al. , 1994b), we find extensive interac-
tions involving N-linked carbohydrates from FeRn that 
contact Fe. Contacts between Fe and three sugar resi-
dues attached to FeRn Asn-128 account for 10% -1 5% 
of the buried surface area in the FcRn/Fc interface (Fig-
ures 1 C and 1 D; Table 3). The sugars contact four Fe 
residues, including His-433 (Figure 1 D), previously sug-
gested to contribute to binding of rat FeRn (Raghavan 
et al., 1995). The N-linked glycosylation site at Asn-128 
is found in rodent (Simister and Mostov, 1989; Ahouse 
et al. , 1993) but not human (Story et al., 1994) or bovine 
(Kacskovics et al., 2000), forms of FeRn (Table 3). In the 
case of mouse FeRn, differential glycosylation affects 
the receptor/ligand stoichiometry such that 1:1 FcRn/Fc 
complexes can be isolated using high-mannose forms of 
FeRn (Popov et al. , 1996; Sanchez et al., 1999), whereas 
2:1 complexes are observed under the same conditions 
using FeRn with complex carbohydrates (Sanchez et 
al., 1999). Contact between Fe and complex carbohy-
drate-specific sugar residues on FeRn (fucose and 
N-acetyl-glucosamine) (Table 3) suggests that maximal 
Fe binding affinity requires complex carbohydrate 
attached to FeRn Asn-128, thus the affinity for binding 
a second FeRn to Fe should be lower in high-mannose-
containing rather than complex carbohydrate-<:on-
taining forms of rodent FeRn (Schuck et al. , 1999). 
Conformational Changes at the 
FcRn/hdFc Interface 
FeRn does not undergo a major conformational change 
upon binding Fe, but there are slight but significant re-
arrangements in FeRn side chains at the binding inter-
face. In complexed FeRn, Glu-135 adopts a different 
rotamer to form hydrogen bonds with backbone amide 
nitrogens in Fe residues 253 and 254 (Figure 2B). [32m 
lle-1 swings out to make van der Waals contacts with 
Fe residues Val-309 and Pro-307 (Figure 2B). Another 
interface residue, FeRn Glu-132, adopts a different ro-
tamer to form a salt bridge with Fe His-435 (Figures 2A 
and 2B) . Overall, however, the structures of free and Fc-
bound FeRn superimpose well (0.89 A rms deviation for 
all C« atoms) . 
Fe side chains at the FeRn binding site are also reori-
ented in apparent response to receptor binding. His-
436, Arg-311 , and lle-253 assume different rotamers in 
the structure of FeRn-bound Fe compared with struc-
tures of free Fe or nbFc (Figure 2B). All three differences 
likely facilitate FeRn binding to Fe: His-436 forms a salt 
bridge with FeRn Asp-137, Arg-311 forms a salt bridge 
with FeRn Glu-118 and binds an ordered water also 
bound by Glu-117, and lle-253 makes van der Waals 
contacts with FeRn Trp-133. 
In addition to side chain changes at the FeRn binding 
site, we find quaternary structure rearrangements dis-
tant from the FeRn b inding site when the structures 
of free Fe (human Fe [Deisenhofer, 1981] or the nbFc 
homodimer), FeRn-bound Fe, and human Fe bound to 
other proteins (Deisenhofer, 1981 ; Sauer-Eriksson et al., 
FcRn/Heterodimeric Fe Crystal Structure 
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Mutation (Effect of Affinity 
for mFcRn or rFcRn} 
M252GI253GS254G 
(90 / U) 
M252GI253GS254G 
(90 >. ti) 
l309GH310GR311G 
(80 ' U) 
H310A 
(8·33 • U) 
L309GH31 OGR311 G 
(80 / ti ) 
M252GI253GS254G 
(90 >. ti) 
H435A 
(13-20 >. U) 
1253A 
(3000 ' U) 
H310A 
(8-33> U) 
L309GH31 OGR311 G 
H435A 
(13-20 ' U) 
M252GI253GS254G 




(90 / U) 
N434A 
(2 · U to no effect) 
N434A 
(2 '- U to no effect) 
H436A 
(3-6 / U) 
H433A 
(2 / U to no effect) 
N434A 
(2 · U to no effect) 
Mutation {Relat1ve 





































Pairwtse Interactions were 1dentif1ed by contact analys1s in CNS (BrUnger et al., 1998) using the FcRn/hdFc structure (rat FeRn bound to a 
rat lgG2a Fe). Contacting residues were defined as those contam1ng an atom withm 4.0 A of any nonhydrogen atom on the partner molecule. 
Counterpart residues in mouse (M) (Ahouse et al. , 1993), human (H) (Story et al., 1994), and bovine (B) (Kacskovics et al., 2000) FeRn and Fe 
regions are listed, with Fe sequences d1vided 1nto subclasses (Kabat et al., 1991 ). Percentage ASA (accessible surface area) is the percent 
of the totaltnterface ASA contributed by each res1due. Mutation nomenclature: E117S means Glu-117 was changed to serine. FeRn mutat1ons 
(column 3) were made 1n rat FeRn, and effects on bmd1ng to rat lgG1 or lgG2a were assayed (Vaughn et al., 1997). Fe mutants in column 9 
were introduced into human lgG1 or mouse lgG1 Fe regions, and effects on binding to mouse FeRn were assayed (Kim et al., 1994a, 1994b; 
Popov et al., 1996; Ghetie and Ward , 1997; Medesan et al., 1997; 1998) or introduced into a human lgG4 Fe region and evaluated using rat 
FeRn {Raghavan et at., 1995). Fe mutants in column 10 were introduced 1nto human lgG1 , and effects on binding to human FeRn were assayed 
(Shields et al., 2001}. Effects listed as .. relative bind1ng" are expressed as a ratio of the bmding of each mutant compared to wild-type lgG1 , 
thus values less than 1.0 indicate reduced bindmg of the mutant compared to wild~type Fe, and values greater than 1.0 indicate enhanced 
binding of the mutant compared to wild~type Fe. 
1995; Corper et al. , 1997; Delano et al. , 2000) are com-
pared. While the tertiary structures of individual Fe do-
mains are relatively unchanged in the FeRn-bound hdFc, 
quaternary structural changes result in altered interdo-
main relationships. In unliganded Fe and Fe complexes 
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F1gure 2. FcRn/hdFc Interface and Fe lnterdomain Angles 
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(A) Sal t bridge and hydrogen bond network at the interface between FeRn and Fe. Salt bridges are indicated by dotted yellow lines and were 
defined as interactions between oppositely charged atoms separated by less than 3.5 A. Water-mediated hydrogen bonds are indicated in 
gray. Positively charged residues from Fe are turquoise; negatively charged residues from Fe are pink. The oxygen atom of an ordered water 
molecule is shown as a blue sphere. 
(B) Comparison of residue conformations in the free and bound states of FeRn and Fe: FeRn from complex structure (turquoise), free FeRn 
(gray), Fe from complex s truc ture (pink), free Fe (gray) (from the structures o f human Fe [Oeisenhofer, 1981] and nbFc), FeRn backbone (dark 
blue tubes), and Fe backbone (red tubes). Only interface residues that differ between the free and bound states are shown. In addition to 
changes at the interface region, loop regions of FeRn that are distant from the Fe binding site differ in backbone conformation when comparing 
the free and hdFc-bound FeRn structures. These changes, which do not appear to be induced by Fe binding, involve the loops between o:2 
domain strands 1 and 2 (residues 101- 105, which includes an ordered N-linked carbohydrate not visible in previous structures [Burmeister 
et al. , 1994a; Vaughn and Bjorkman, 1998]), a3 strands 1 and 2 (residues 190-195), and [l2m strands 1 and 2 (residues 16-19) and 3 and 4 
(residues 41-45). The latter three loops are involved in formation of the FeRn dimer observed in three crystal forms of free FeRn (Burmeister 
et al., 1994a; Vaughn and Bjorkman, 1998) but not in the FcRn/hdFc crystals. 
(C) Compari son of Fe domain positions in hdFc, nbFc, and human Fe. The structures were aligned by superimposing a C13 domain on the 
proximal C, 3 domain of hdFc. 
approximate dyad axis of symmetry, thus the C, 2-C, 3 
interdomain angles (defined as described in Su et al., 
1998) are identical or nearly the same for both chains 
(Table 2). However, in the FcRn/hdFc complex and other 
Fe complexes with only one ligand, the interdomain 
angles of the two chains differ, creating asymmetric Fe 
homodimers (Table 2). The range of interdomain angles 
in the free and ligand-bound Fe structures (85° to 1 06°) 
and the degree of interdomain angle asymmetry in singly 
liganded Fe structures (8°-1 3 d ifferent) demonstrate the 
intrinsic flexibility and the potential for asymmetry of Fe 
regions, which could have functional implications. For 
example, Fe asymmetry contributes to the 1:1 receptor/ 
Fe stoichiometry observed in ligand binding by Fc-yRIII 
(Sondermann et al., 2000) and FcERI (Garman et al. , 
2000). FeRn can also form 1 :1 complexes with Fe under 
nonequilibrium conditions (Popov et al., 1996; Sanchez 
et al., 1999). The binding model for the FcRn/Fc interac-
lion assumes the following sequential reactions: FeRn + 
Fe = FcRn:Fc and FcRn:Fc -t FeRn = FcRn:Fc:FcRn, 
and analyses of biosensor (Martin and Bjorkman, 1999) 
and equilibrium analytical ultracentrifugation data 
(Schuck et al., 1999) suggest that FeRn binding to the 
first binding site on an Fe homodimer lowers the affinity 
for binding a second FeRn. This could be explained on 
a structural level by Fe asymmetry such as that observed 
in the FcRn/hdFc structure. We cannot exclude the pos-
sibility that the observed hdFc asymmetry arises from 
crystal packing interactions or mutations introduced in 
the nbFc chain. We note, however, that the chains in 
the nbFc homodimer structure have a different C, 2-C, 3 
interdomain angle (92°) than the angle in the nbFc chain 
of the hdFc structure (81 °) (Table 2). Thus, the introduced 
mutations cannot be solely responsible for alteration 
of the nbFc interdomain angle in FeRn-bound hdFc 
structure. 
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With the addition of the FcRn/hdFc structure to previous 
studies, we can now identify the residues involved in 
the sharp pH dependence of the FcRn/Fc interaction. In 
theory, pH-dependent binding and release could result 
from conformational c hanges in FeRn, Fe, or both. How-
ever, the structures of FeRn at pH 6.5 and 8 do not differ 
significantly (Vaughn and Bjorkman, 1998}, and the pH 
6.4 structure o f nbFc reveals no major changes (other 
than those induced by mutations) when compared with 
structures of human Fe solved at other pH values: pH 
6.5-7.0 (human Fe) (Deisenhofer, 1981), pH 4.1 (protein 
A/human Fe) (Deisenhofer, 1981 ), pH 7.8 (protein G/hu-
man Fe) (Sauer-Eriksson et al. , 1995), pH 6.0 (human 
Fc/peptide) (Delano et al., 2000), pH 5.6 (Fc-yRIII/human 
Fe) (Sondermann et al., 2000), pH 7.0 (rheumatoid factor/ 
human Fe) (Corper et al., 1997), and pH 8.0 (intact mouse 
lgG2a) (Harris et al., 1997). The pH dependence of the 
FcRn/Fc interaction must therefore be attributed to 
chemical, rather than conformational, changes at the 
interface. Titration of histidines, which have a pK, in 
the range of the FcRn/Fc affinity transition, has been 
proposed to account for the pH dependence (Simister 
and Mostov, 1989; Ghetie and Ward, 2000). There are 
three pairs of titrating salt bridges at the FcRn/hdFc 
interface, each involving an Fe histidine and an acidic 
FeRn residue: Fe His-31 0/FcRn Glu-117, Fe His-435/ 
FeRn Glu-132, and Fe His-436/FcRn Asp-137 (Figure 
2A). The mechanism of the pH-dependent FcRn/Fc affin-
ity transition appears straightforward : FeRn binds to Fe 
with high affinity at pH s 6.5 when Fe histidines 310, 
435, and 436 are positively charged and releases Fe 
upon deprotonation at pH values :2: 7.0. 
Although the FcRn/hdFc interface does not contain 
significantly more charged surface area than typical pro-
tein-protein interfaces (56% nonpolar, 29% polar, and 
15% charged) (lo Conte et al. , 1999}, the charged inter-
face residues are involved in more salt bridges than 
seen in other Fc/protein complexes (Table 3). Formation 
of salt bridges between surface-exposed residues is 
not generally energetically favorable due to the loss of 
conformational entropy (Goldman, 1995). However, His-
31 0 in unbound Fe and two of the three salt bridges at 
the FcRn/hdFc interface are buried (Fe His-31 0/ FcRn 
Glu-117 and Fe His-435/FcRn Glu-132), and with the 
exception of Glu-132, the residues in these salt bridges 
assume the same conformations m the bound and free 
forms of the proteins. In addition, the residues in these 
salt bridges form part of a network of ionic interactions 
similar to those found on the surface of thermostable 
proteins (Goldman, 1995), such that Fe Arg-311 interacts 
with FeRn Glu-118 and an ordered water, which in turn 
contacts FeRn Glu-117 (Figure 2A). Salt bridge networks 
are energetically favorable because the cost of re-
stricting the conformation of each additional residue is 
halved, while the coulombic benefit is essentially the 
same (Goldman, 1995). Since Fe Arg-311 is not con-
served, the network of salt bridges observed in the rat 
FcRn/hdFc structure is not found in all FcRn/Fc com-
plexes and must not be required for pH-dependent bind-
ing. In addition, the solvent-exposed salt bridge at the 
rat FcRn/Fc interface (Fe His-436/FcRn Asp-137) in-
volves residues that vary in FeRn and Fe sequences 
(Table 3). These observations suggest that formation of 
the two buried titratable salt bridges (Fe His-31 0/FcRn 
Glu-117 and Fe His-435/FcRn Glu-132) is sufficient to 
confer pH dependence to the FcRn/Fc interaction. Al-
though other proteins contact Fe histidines at the C,2-
C,3 interface, they do not show sharp pH-dependent 
Fe binding near neutral pH because they make fewer or 
no ionic interactions with Fe. For example, protein A 
and protein G do not form any salt bridges with Fe 
histidines (Deisenhofer, 1981 ; Sauer-Eriksson et al., 
1995), and rheumatoid factor forms one relatively sol-
vent-exposed salt bridge involving Fe His-433 (Corper 
et al. , 1997). 
Implications for Design of Fc-Containing Proteins 
with Increased Serum Half-Lives 
Mutations that decrease the affinity between FeRn and 
lgG result in reduced serum half-lives in vivo (Kim et al., 
1994a; Popov et al., 1996; Medesan et al., 1997), thus 
it has been suggested that mutant Fe regions with in-
creased affinity for FeRn should exhibit increased serum 
persistence (Ghetie et al. , 1997). Two studies have re-
ported Fe mutants with increased affinity for FeRn. In 
the first, positions 252, 254, and 256 in a mouse lgG1 Fe 
fragment were randomly mutagenized, and one mutant 
(T252L, T254S, and T256F) showed an approximately 
3.5-fold higher affinity for mouse FeRn and a longer [:1 
phase half-life when injected into mice (Ghetie et al., 
1997). Fe residues 252 and 254 contact FeRn in the rat 
FcRn/hdFc structure (Table 3) and are likely to make 
similar contacts in a mouse FeRn/mouse Fe complex, 
rationalizing their effects upon affinity for FeRn. In the 
second study, alanine scanning mutagenesis was used 
to alter all solvent-exposed residues in a human lgG1 
Fe, and binding to human FeRn was assessed (Shields et 
al. , 2001). Mutants that showed higher or lower relative 
binding to FeRn than wild-type Fe are listed in Table 4, 
and their locations are depicted on the human lgG1 
Fe structure (Deisenhofer, 1981) in Figure 3. To predict 
which residues on human Fe contact human FeRn, we 
constructed a model of a human FcRn/ Fc complex by 
overlaying the structures of human FeRn (West and 
Bjorkman, 2000) and human Fe (Deisenhofer, 1981) on 
the rat FcRn/hdFc structure. The model must be re-
garded as approximate since some interface residues 
are not conserved between human and rat versions of 
FeRn and Fe (Table 3). Using the human FcRn/Fc com-
plex model, we find that the majority of Fe mutations 
that result in diminished FeRn binding are in positions 
predicted to contact FeRn directly, whereas most of the 
mutations that enhance FeRn binding affect residues 
near but not actually inside of the region predicted to 
contac t FeRn directly (Figure 3). Enhanced binding to 
FeRn by mutation of residues outside of the FeRn bind-
ing site suggests that propagation of small conforma-
tional changes can result in changes to the binding site 
that increase affinity, which may translate into increased 
serum persistence. Combination of mutants that individ-
ually have only a slight effect on FeRn affinity can result 
in 8- to 12-fold increases in relative FeRn binding (Table 
4), suggesting that a synergistic effect on binding affinity 
can be achieved by this strategy. 
From these results and an analysis of the FcRn/hdFc 




Table 4 . Effect of Mutations in Human lgG1 Fe on Binding to Human FeRn 
Mutation Relative Predicted to Mutatton Relative Prediced to 
(Reduced Binding) Binding Contact FeRn? (Enhanced Binding) Binding Contact FeRn? 
1253A < 0.10 Yes P238A 1.49 No 
S254A < 0.10 Yes T256A 1.91 No 
R255A 0.59 No E272A 1.34 No 
K288A 0.38 Yes V305A 1.46 No 
l309A 0.63 Yes T307A 1.81 Yes 
S415A 0.44 No 0311A 1.62 Yes 
H433A 0.41 Yes D312A 1.50 No 
H435A < 0.10 Yes K317A 1.44 No 
Y436A < 0.10 Yes D376A 1.45 No 
A3780 1.32 No 
E380A 2.19 No 
E382A 1.51 No 
S424A 1.41 No 
N434A 3.46 Yes 
E380A I N434A 8.0 No/Yes 
T307A I E380A ' N434A 11 .8 Yes/No/Yes 
K288A • N434A 2.9 Yes/Yes 
Fe mutants were introduced into human lgG1 , and effects on binding to human FeRn were assayed (Shields et al., 2001). Effects listed as 
"relative blndtng'" are expressed as a ratio of the binding of each mutant compared to wild-type lgG1 , thus values less than 1.0 indtcate 
reduced binding of the mutant compared to wild-type Fe, and values greater than 1.0 indicate enhanced binding of the mutant compared to 
wild-type Fe. Only substitutions resulting in relative binding values less than 0 .70 or greater than 1.30 are listed. Wild-type residues at altered 
positions were evaluated lor likelihood of contacting FeRn using a human FeRn/human Fe complex model generated from the rat FcRn/hdFc 
structure. To account for possible inaccuracies in the human FcRn/Fc model, the cutoff for contact residues was extended from 4 A to 5 A. 
Thus, Fe residues are predicted to contact FeRn if they contain an atom within 5 A of FeRn. 
tion of Fe mutants with increased affinity for FeRn. First, 
critical "functional epitope" residues (defined as :.e.G > 
2 kcal/mol for substitution of a single amino acid to 
Figure 3. Pos itions that Affec t Affinity lor Human FeRn Highlighted 
on the Structure of Human Fe 
A single polypeptide chain from the structure of human Fe (coordi-
nates obtained from Marl< Ultsch, Genentech) is shown with side 
chains highlighting positions where substitutions result in reduced 
(red side chain) or enhanced (green side chain) affinity for human 
FeRn, based upon mutagenesis studies by Shields et at. (2001) 
(Table 4). Residues within the predicted interface with human FeRn 
(within 5 A o f an FeRn atom using a human FeRn/human Fe model 
generated from the rat FcRnlhdFc structure) are indicated by thick 
side chains and labels. Residues predicted to be outside of the 
interlace are indicated by thin side chains and smaller labels. 
alanine, which corresponds to affinity reductions of 
.> 30-fold) (Cunningham and Wells, 1993) should remain 
unchanged. By this criterion, lle-253, which contacts 
FeRn Trp 133, and His-31 0, which salt bridges with FeRn 
Glu-117 (Table 3), should not be altered. In addition, 
since FeRn-mediated rescue of lgG from catabolism 
requires pH-dependent binding (Ghetie and Ward, 
2000), the sharp pH dependence of the FcRnllgG inter-
action must be maintained in any mutants. This requires 
preserving His-435 as well as His-31 0. Although Fe His-
436 in rat Fe also participates in a titrating salt bridge, 
the Fe His-436/FcRn Asp-137 salt bridge seen in our 
structure would be absent in a human FcRn/Fc complex, 
being replaced instead by a hydrophobic interaction 
involving an Fe tyrosine or phenylalanine interacting with 
FeRn Leu-137 (Table 3). Fe position 436 is therefore a 
candidate for random mutagenesis to find human Fe 
regions with higher affinity for FeRn. Other interface 
positions that could be substituted to produce human 
lgGs with longer half-lives include Fe residues 252, 254, 
288, 307, 309, 311, 314, and 434, most of which have 
been modified by Ghetie et al. {1997) and/or Shields et 
al. (2001 ). Ideally, these residues would be targeted by a 
mutagenesis protocol allowing all possible non-glycine, 
non-proline substitutions at each position. A second 
category of candidates for mutagenesis includes resi-
dues that are near the FeRn binding site but do not 
make direct contact with FeRn. These residues include 
Fe positions 250, 251, 256, 257, 306, 308, 312, 431, 432, 
and 437. Alanine substitutions in many of these positions 
exhibited higher binding to human FeRn (Shields et al., 
2001 ), thus an approach involving random substitutions 
at these positions may y ield further increases in binding. 
A third category of potential mutants includes substitu-
t ions of residues buried between the C, 2 and C,3 do-
mains. Residues normally found at these positions allow 
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flexibility in the C,2-C, 3 interdomain angle. However, 
optimal binding to FeRn is likely to require a particular 
C, 2-C,3 interdomain angle from among a population of 
possible interdomain angles (e.g., see Table 2). Resi-
dues buried between the C, 2 and C,3 domains include 
247, 248, 251 , 376, 378, 428, and 430. A mutagenesis 
strategy involving insertion of larger and more hydro-
phobic side chains at these positions could result in 
stabilization of the optimal C,2-C, 3 interdomain angle 
for interaction with FeRn, thereby increasing the affinity 
for binding FeRn. 
Discussion 
The structure of the FcRn/Fc complex reported here 
allows a detailed analysis of FeRn binding to lgG, which 
increases our understanding of FeRn-mediated trans-
port and protection of lgG and will benefit efforts to 
design therapeutic antibodies with longer serum half-
lives. The hallmark of the FcRn/lgG interaction is the 
sharp pH dependence of the binding affinity that allows 
FeRn to associate with lgG in acidic intracellular vesicles 
and release lgG in the bloodstream. The FcRn/hdFc 
structure reveals a simple but elegant molecular mecha-
nism for pH-dependent binding , which relies completely 
on titrating residues on the ligand rather than the recep-
tor, such that Fe histidines interact favorably with nega-
tively charged residues on FeRn at acidic but not basic 
pH. The finding that the pH-dependent binding interac-
tion employed by FeRn is mediated entirely by titration 
of histidine side chains may be relevant to predicting 
the pH-dependent binding mechanisms of other recep-
tor-ligand pairs that traffic through endosomes, such 
as transferrin receptor/HFE (Lebron et al., 1998) and 
transferrin receptor/ape-transferrin (Richardson and 
Ponka, 1997) complexes. The pH-dependent affinity 
transition of the transferrin receptor/HFE interaction is 
in the opposite direction to that of FcRn/lgG (Lebron et 
al., 1998), by contrast to that of transferrin receptor/ 
ape-transferrin, which is the same direction as FeRn/ 
lgG (Richardson and Ponka, 1997). There are two histi-
dines at the interface between transferrin receptor and 
HFE (Bennett et al., 2000). Although neither histidine 
participates in a salt bridge, protonation at low pH could 
cause release of HFE from TfR. Alternatively, or perhaps 
concurrently, titration of histidines distant from the bind-
ing site, such as those at the transferrin receptor dimer 
interface, could result in a pH-dependent conforma-
tional change affecting binding of HFE and/or ape-trans-
ferrin (Bennett et al. , 2000). 
The FcRn/Fc structure also demonstrates the versatil-
ity of lgG recognition achieved by Fe receptors and 
other Fe binding proteins. Even among Fe binding pro-
teins that bind to the C, 2-C, 3 interdomain interface of 
Fe, there are a variety of different folds, yet the proteins 
make many chemically similar contacts to the same 
residues on Fe (De Lano et al., 2000). FeRn differs from 
other Fe binding proteins in exhibiting homology to MHC 
molecules. The significance of the structural similarity 
between FeRn and MHC molecules is not clear, given 
that FeRn does not bind peptides or use the counter-
parts of the binding sites on class I MHC molecules or 
class I homologs for binding Fe. Instead, FeRn employs 
a surface created by the juxtaposition of the 132m and 
a2 domains. Since the 132m/heavy chain interaction in 
FeRn is similar to that found in c lass I and c lass I homo-
log molecules (Burmeister et al. , 1994a; Zeng et al., 1997; 
Lebron et al., 1998; Strong, 2000), the common MHC 
heavy chain/132m interaction may predate the peptide 
and T cell-receptor binding functions of class I MHC 
proteins. 
Experimental Procedures 
Crystallization and Data Collection 
Soluble rat FeRn (residues 1-269 of the heavy chain eomplexed 
with rat (32m) was purified from the supernatants of transfected 
CHO cells as described (Gastinel el al., 1992). Expression vecton; 
encoding w1Fe (rat lgG2a residues 223-447) and nbFe (lgG2a resi -
dues 223-447 with introduced mutations and a C-terminal factor Xa 
cleavage site and 6x-His tag) were cotransfected into CHO cells 
(Martin and Bjorkman, 1999). hdFc and nbFe were purified from 
supernatants of CHO cells secreting a mixture of wiFe, hdFe, and 
nbFe as described (Martin and Bjorkman, 1999). Briefly, CHO super-
natants were passed over a Ni-NTA column, allowing separation of 
wtFc from 6x-His tagged species. hdFc and nbFc were eluted from 
the Ni-NTA column, then passed over an FeRn affinity column at 
pH 6.0. hdFc was eluted from the FeRn column at pH 8.0, and nbFe 
was recovered from the fiow1hrough. 
Crystals o f FeRn/hdFe (one 1:1 FeRnlhdFe complex per asymmet-
ric unit) were grown in hanging drops containing 15o/o PEG 4000, 
240 mM ammonium acetate , 120 mM sodium acetate (pH 4.5), and 
1 mM YtCI,. Crystal morphology was improved by serial rounds of 
streak-seeding. Improvements in crystal morphology accompanied 
improvements in crystal mosalcity (from 1.7' to 0.7') and diffraction 
quality (from 8 A to 2.8 A). Crystals were transferred stepwise in 
three 5% increments to artificial mother liquor containing 15o/o 
2-methyl-2.4-pentandiol, and 2.8 A native data were collected at 
170 C from flash-cooled crystals at SSRL beam line 9-2. 
Crystals of nbFc (one nbFc homodimer per asymmetric unit) were 
grown in 0.2 M ammonium acetate, 0.1 M trisodium acetate dihy-
drate (pH 5.6), and 30% PEG 4000 and eryoprolected as described 
for the complex crystals. A 2.6 A native data set was collected at 
170'C using an A-AXIS IV mounted on a Rigaku RU -200 rotating 
anode generator. 
Structure Determination and Refinement 
Data were processed with the HKL package (Otwinowski and Minor, 
1997). The structure of FcRn/hdFc was determined by molecular 
replacement using AmoRe (Navaza. 1994). The 2.2 A structure of 
rat FeRn (Protein Data Bank ID code 3FRU) (Burmeister el al., 1994a; 
Vaughn and Bjorkman, 1998) and the 2.8 A structure of human Fe 
(Protein Data Bank ID code 1FC1) (Deisenhofer, 1981 ) (noneon-
served side chams truncated to alanine) were used as search mod-
els. FeRn was first located (correlation coefficient: 34.9%; R factor 
of 58.6%), then Fe was found in rotation and translation searches 
in which FeRn was fixed (correlatton coeffictent: 38.8%; R factor of 
53.9%). Rigid body refinement (30--2.8 A) of the two molecules as 
a complex resulted tn an Rc..,.11 of 43.1% (R,,.. 42.2o/o). Solvent-
flattened maps calculated to 3.0 A were used for initial building 
using the program 0 (Jones and Kjeldgaard, 1997). Later stages of 
model buildmg meluded use of higher-resolution (1.65 A) human Fe 
structures provided by Mark Ullsch (Geneteeh) and the refined nbFe 
structure. For the nbFc structure solution, the truncated human 
Fe model was located using AmoRe (Navaza, 1994) (correlation 
coefficient: 23.7o/o; R factor of 51.5%), and rigid body refinement 
(30--2.7 A) resulted in an ~\~., of 46.6% (Row 46.2%). 
Refinement of the FeRnlhdFe and nbFe structures was done with 
CNS (Brtlnger et al., 1998) using overall anisotropic B factors, bulk 
solvent corrections, and light NCS restraints (300 keal/mol · A') for 
the Fe with separate NCS operators for the C, 3 and C, 2 domains. 
For the FcRnlhdFc complex, hdFe regions that differ between the 
two Fe chains (chemically different side chains and loops at the 
FeRn contact site or in crystal contacts) were not restrained. Refine-
mont of the FcRnlhdFc was conducted by alternating simulated 
Molecular Cell 
876 
annealing and grouped B factor refinement. The electron density 
for most of the domains in the structure is excellent. However, the 
half of lhe d1stal C, 2 domain furthest from the distal C, 3 appears 
to be totally disordered. This portion of the structure was modeled 
us1ng the nbFc coordmates that were placed into a Simulated an-
nealing omit electron density map (Hodel el al., 1992) in which the 
entire d1stal C.,2 domam was om1tted. Placement of the distal C"2 
was facilitated by density for the disulfide between Cys-261 and 
Cys-321 and ordered carbohydrate at Asn-297 . To determine 
whether disorder of the distal C.,2 domain resulted from cryopreser-
vatlon, data were collected at room temperature from FcAn/hdFc 
crystals using an A-AXIS IV image plate detector mounted on a 
R1gaku RU-200 rotating anode generator (R.._ 0.19; 30-5.0 A). 
The structure was solved by molecular replacement as described 
above (Rcrvu 0 .35). 2F0 ·Fc maps showed disorder of the same 
reg1on of the distal Cy2 domain that is disordered in maps derived 
from the 2.8 A data set collected from cryopreserved crystals. 
The Fc RnlhdFc model consists of residues ~269 of FeRn, 1-99 
of 1J2m, 239-443 of the proximal Fe (wiFe), 239-443 of lhe distal Fe 
(nbFc) . six water molecules, two cysteine molecules, 14 N-acetyl 
glucosam1ne, 4 fucose, and 8 mannose residues. Residues 1-4 of 
FeRn, the h1nge regions of both Fe cha~ns (res1dues 223-238), and 
the factor Xa cleavage site and 6x·His tag at the C terminus of the 
nbFc cham are disordered and not 1ncluded in the model. Ordered 
carbohydrate IS observed at all four potential N· hnked glycosylat1on 
sites on FeRn and at the N·linked glycosylation site in each C.,2 
domam. The unpaired cyste~nes at positions 48 and 226 of FeRn 
are blocked by groups that were modeled as cysteine molecules. 
Average B values for individual domains are: FeRn n 1-n 2, 57 A2; 
FeRn n3, 64 A': Jl2m, 60 A': proximal Fe C, 3. 82 A>: proximal Fe 
C. 2. 55 A' : d1stal Fe C,3, 72 A': distal Fe C, 2. 147 A': prox1mal Fe 
carbohydrate, 120 A': and distal Fe carbohydrate 198 A'. 
The nbFc model cons1sts of two chains of residues 239-443 of 
rat lgG2a Fe, each conta1ning 4 N·acetyl glucosamine, 1 fucose, 
and 3 mannose residues. Residues 223-238 (h1nge reg1on) and the 
C·term1nal factor Xa cleavage site and 6x·His tag are disordered in 
both chams. Average B values per domain are: C.,2 domains, 54 A2 , 
54 A>: C, 3 domains, 23 A>, 24 A': and carbohydrate, 91 A', 100 A'. 
Analyses of Structures 
Buned surlace areas were calculated from our structures and struc-
tures in the Protein Data Bank using a 1.4 A probe radius w1th the 
programs GRASP (Nicholls el al. , 1991) and Calc-surf (Gerstein, 
1992) and verified using CNS (Brunger el al. , 1998) and lhe Protein-
Protein Interaction Server (Jones and Thornton , 1996). lnterdomain 
angles were denved by determining the angle between the long 
axes of adJacent domains. approximated by elhpso•ds calculated 
from the coordinates using the program Dom_angle (Suet al ., 1998). 
Figures were made using Molscnpt (Krauhs. 1991) and rendered 
w11h Raster 3-D (Merrill and Murphy, 1994). 
Coordinate superpositions were done using LSQMAN (Jones and 
Kjeldgaard, 1997). Rms dev1at1ons for domain-by-domain compari-
sons of FeRn alone and FeRn bound lo hdFc: 0.6 A (~o1), 0.7 A (o2) , 
0.5 A (u3), and 0.5 A (IJ2m). Rms deviations comparing hdFc domains 
w1th domains 10 SIX other structures (nbFc homodimer, free human 
Fe (De1senhofer, 1981), human Fclproleln A (Deisenhofer, 1981), hu-
man Fclprolein G (Sauer-Eriksson el al., 1995], human Fclmeumaloid 
factor (Corper el al., 1997), and human Fc/Fc..,RIII (Sondermann el 
al., 2000)): prox1mal C, 2, 1.2 A. 1.8 A, 1.7 A, 1.8 A, 2.3 A, 2.0 A: prox-
imal C, 3, 0 .4 A, 0.7 A, 0.7 A, 0.7 A, 0.6 A, 0.8 A: distal c ,2. 1.6 A, 
2.3 A, 2.3 A, 2.3 A. 2.8 A, 2.6 A: and distal C, 3, 0 .5 A , 0 .7 A, 0 .7 A, 
0.7 A. 0 .6 A, 0.8A. 
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Chapter 4: 
Examination of the ability of the neonatal Fe receptor 
to form a receptor dimer 
This chapter covers the various studies that were conducted to ascertain whether 
FeRn forms a dimer of heterodimers. These studies include quantitative analyses of the 
FeRn dimer interface present in FeRn crystals and sedimentation equilibrium and 
dynamic light scattering studies of the soluble FeRn ectodomain performed by our 
collaborator, Dr. Ghirlando Rudolfo, at the NIH. We also performed experiments that 
attempted to address the behavior ofF eRn in the membrane. The first set of experiments 
involving membrane bound FeRn, ligand-induced cross-phosphorylation assays, was 
performed with Dr. T. S. Ramalingham, of our lab. These employed a chimera of the 
FeRn ectodomain and a dimerization reporter group consisting of cytoplasmic tyrosine 
kinase domain of TrkA constructed by Dr. Yang Liu. The second set of experiments, 
measurements of fluorescent resonance energy transfer, was performed with Dr. Mary 
Dickinson of the Biological Imaging Center. These employed a set of chimeras of the 
full-length FeRn protein with the cyan or yellow forms of green fluorescent protein fused 
to the carboxy-terminus of the FeRn cytoplasmic domain. 
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Introduction 
Previous studies of the neonatal Fe receptor (FeRn) have accumulated evidence 
that FeRn forms a dimer under some conditions. First, electron irradiation studies 
conducted on the FeRn isolated from the gut of neonatal rats suggested that the functional 
molecular weight is 110 k.Da, which corresponds to two FeRn molecules (Simister and 
Rees, 1985). Second, in three crystal forms FeRn forms the same dimer (Burmeister et 
al., 1994a). The same FeRn dimer is also observed in the low-resolution cocrystal 
structure (- 6.5 A) of a rat FeRn ectodomain/Fc complex, in which FeRn dimers were 
bridged by Fe molecules (Burmeister et al. , 1994b; See Appendix A for a description of 
the Fern dimer). Each of the two potential FeRn binding sites on Fe interacts with one of 
the FeRn molecules in the receptor dimer, resulting in a long oligomeric ribbon where 
there are two receptors for every Fe dimer (Burmeister et al. , 1994b). Surface plasmon 
resonance assays of FeRn molecules with site-directed mutations of positions at the 
crystallographic FeRn dimer interface (FeRn Gly191 and (32m Glu89) revealed that these 
mutant forms had lower affinities for Fe and IgG. These data suggested that receptor 
dimerization was necessary for high affinity binding of lgG, consistent with the receptor 
dimers being required for biological function (Vaughn et al., 1997; Appendix 1). 
Surface plasmon resonance, immune-precipitation, isothermal titration 
calorimetery, and equilibrium gel filtration studies with the soluble FeRn ectodomain and 
the Fe portion of IgG showed that the stoichiometry is two receptors per ligand (2 : 1) in 
solution (Vaughn et al. , 1997; Huber et al. , 1993; Sanchez and Bjorkman, 1999). This 
stoichiometry is also seen with the receptor anchored to solid support and in crystals 
(Vaughn et al. , 1997; Huber et al. , 1993; Sanchez and Bjorkman, 1999). The oligomeric 
ribbon presents two distinct complexes that have a 2:1 FeRn-Fe stoichiometry: Fe bound 
to the FeRn dimer observed in the FeRn crystals and the bridging of two separate FeRn 
molecules by Fe (See chapter 2 for a depiction of the oligomeric ribbon). To determine 
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which of the possible 2:1 FeRn Fe complexes forms in these conditions, a heterodimeric 
Fe (hdFc) molecule with one FeRn binding site was constructed. This molecule could 
bind a dimer of FeRn molecules but it could not bridge FeRn molecules (See Chapter 3). 
In surface plasmon resonance, immuno-precipitation, and equilibrium gel filtration 
studies this molecule bound to FeRn with 1:1 FcRn:hdFc stoichiometry (Martin and 
Bjorkman, 1999; Chapter 3). These data indicated that the 2:1 FcRn:Fc complex formed 
in solution and on a solid support was two separate FeRn molecules bridged by an Fe. 
In addition to the determination that an Fc-induced dimer of FeRn molecules was 
not observed in solution or with FeRn coupled to a solid support, other studies of FeRn 
indicated the FeRn dimer only forms at high concentrations of FeRn. In the C222t crystal 
form of rat FeRn at both acidic and alkaline pH, there are three FeRn molecules in the 
asymmetric unit and only two of the three FeRn molecules are in an FeRn dimer (Vaughn 
and Bjorkman, 1998). Both the crystal structure of human FeRn alone (West and 
Bjorkman, 2000) and the crystal structure of the rat FcRnlhdFc complex (Martin et al. , 
2001; Chapter 4) do not contain FeRn dimers. The FeRn concentration in the crystals is 
millimolar. The presence of an FeRn dimer in some crystals and the absence in other 
crystals suggests that the dissociation constant for dimer formation is on the order of 
millimolar. For the FeRn dimer to occur in living systems, it is reasonable to infer either 
or both of the following: the effective molarity of FeRn in a membrane is higher than 
millimolar, the affinity of full-length FeRn for itself is higher than that of the 
ectodomains alone. 
In order to address more definitively under what conditions FeRn forms an FeRn 
dimer, two different sets of investigations were pursued: the propensity of the FeRn 
ectodomain to form a dimer and the tendency of FeRn to form a dimer in a membrane. 
For the studies of the FeRn ectodomain, the FeRn-FeRn contacts in the FeRn crystals 
were analyzed to determine if they more resemble a nonspecific crystal contact or a 
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phy siologically relevant dimer interface. In addition we collaborated with Ghirlando 
Rudolfo of the NIH to perform sedimentation equilibrium and dynamic light scattering 
experiments to detect dimer formation with the soluble ectodomain at high 
concentrations. To examine the behavior of membrane-bound forms of FeRn two sets of 
FeRn-reporter group fusion proteins were made. The first set of fusion proteins consisted 
of the FeRn ectodomain fused to the transmembrane and cytoplasmic tyrosine kinase 
domains of TrkA. These chimeric proteins were assayed for ligand-induced cross-
phosphorylation as a read-out for dimerization. The second set of fusion proteins created 
was full-length FeRn fused to ECFP or EYFP. These chimeric proteins were constructed 
and assayed for fluoresence resonance energy transfer (FRET). The results from the 
FeRn ectodomain studies show only weak resemblance on the part of the crystallographic 
contacts to a physiologically relevant dimer interface and no detectable formation of 
dimer by the ectodomain alone in solution. The studies involving membrane bound 
forms of FeRn are more difficult to interpret. Some experiments have indicated that 
FeRn may form a ligand-induced dimer or may be a dimer constituitively. However, 
these results are not consistently reproduced and their biological significance is difficult 
to assess. Strategies are discussed for constructing a system in which FeRn dimer 
formation may be detected and its functional importance addressed. 
Results 
Analysis of the FeRn/FeRn crystal contact 
The crystal structures of rat FeRn at acidic pH (Burmeister et al. , 1994a) and at 
alkaline pH (Vaughn and Bjorkman, 1998) reveal a large area of contact between two of 
the three receptor heterodimers. As seen in Figure 1, each FeRn molecule buries 890 A2, 
in which the a3 domains of both receptors contact the a3 and f32m domains of the other 
receptor. The approximately two-fold symmetric interaction involves the loops between 
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the A and B. and E and F strands of the a3 domain as well as the G strand of (32m. In 
both the acidic and the alkaline pH FeRn structures this contact is enlarged considerably 
(from 1500 A 2 -1800 A 2 to 2600 A 2) by the ordered carbohydrate extending from Asn 
225 of the FeRn a3 domain across the other FeRn molecule (Vaughn and Bjorkman, 
1998). 
It is difficult to distinguish between a biologically meaningful and a nonspecific 
contact between proteins in the crystal, however there are several ways to analyze the 
structures to indicate the likelihood of whether a given contact is nonspecific or 
represents a biologically relevant interaction. The first method involves an analysis of 
the amount of surface area buried by the contact (Janin, 1997). The second method 
involves examining how well the proteins fit together (Lawrence and Colman, 1993). 
The third method involves determining if the surfaces in contact are associated with 
sequence that is more conserved than the sequence associated with other areas of the 
proteins surface (Elcock and McCammon, 2001 ). 
The method developed by Janin for judging whether crystal contacts represent a 
meaningful interaction is based on the observation that the larger the contact between 
proteins the more likely the contact is to be biologically significant. Janin compiled a 
database of 1320 pair-wise interfaces of 152 crystal forms of monomeric proteins with 
only one molecule per asymmetric unit (Janin and Rodier, 1995). A histogram of the 
frequency of interfaces of a given size is approximated by an exponential function. For 
contacts between proteins greater than 700 A2 in size, the probability of finding a 
nonspecific contact between monomeric proteins with the surface area in question or 
greater is equal to the area under the exponential decay from the surface area to infinity. 
The solution of this integral is the formula for the probability: 
P(B) - 4.2 exp ( -B/260), (1) 
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where B is the amount of surface area buried at the contact on both proteins. FeRn buries 
1780 A 2 total at the dimer interface (without considering the contribution of the ordered 
carbohydrate), by this method, the probability of a nonspecific contact between 
monomers being this size or larger is 0.4%. It must be noted that the FeRn crystal has 
three FeRn molecules per asymmetric unit and that the data set used in this method was 
constructed to include only crystal structures with one molecule per asymmetric unit. It 
should also be noted that monomeric molecules in crystals with point group symmetries, 
such as a crystallographic two-fold, often have contacts that are larger than those without 
(Janin and Rodier, 1995; Carugo and Argos, 1997). There are too few of these structures 
to generate a distribution that may be fit to a function with confidence. The FeRn contact 
in question is the interface about a non-crystallographic two-fold in the high resolution 
FeRn crystals, and this same contact occurs about a crystallographic two-fold in the 
FcRn!Fc complex crystals. For these reasons it is unclear how much predictive power 
this algorithm has for the contact in FeRn crystals. 
The second method for analyzing the FeRn-FeRn crystal contact is to measure the 
degree of fit between the FeRn molecules. Though it has not been examined 
systematically, it is intuitively satisfying to imagine that specific biological contacts have 
a higher degree of fit than nonspecific contacts. There are several ways to assess the 
degree of fit between two molecules. We chose to use the shape complementarity 
statistic (Lawrence and Colman, 1993). The shape complementarity statistic samples 
points on the surface between two proteins and assesses the distance between the points 
and the angle between the vectors normal to the surfaces at these points. The shape 
complementarity statistic that ranges from 0 to 1, where 1 is perfect complementarity, is 
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the median value of these samples. The shape complementarity of the FeRn-FeRn 
contact is 0.53, significantly lower than the average shape complementarity seen in 
nonobligate protein complexes (Appendix B). However, this is only suggestive of the 
interface being nonspecific. There are specific interfaces with shape complementarity 
this low, Protein G and Fe is 0.56 (Chapter 3), and there are nonspecific contacts with 
very high shape complementarity. The crystal structure of Fe-only hydrogenase (Peters et 
a!. , 1998), which is a monomer in solution, has a crystal contact of large surface area 
(1575 A2) (Elcock and McCammon, 2001). The shape complementarity ofthis contact is 
found here to be 0.75. The shape complementarity of the contact between FeRn 
molecules indicates a low degree of fit ; however, in the absence of a systematic review it 
is not clear how diagnostic this low degree of fit is to the biological significance. 
Recently, Elcock and McCammon demonstrated a third method for examining the 
biological significance of a crystal contact that employs protein sequence information as 
well as the crystal structure (Elcock and McCammon, 2001 ). The tendency of the 
sequence to vary at a given position is the disorder or entropy of the sequence at this 
position (defined mathematically in the methods). This method maps the tendency for 
the sequence to vary at a given position in sequence to the position on the surface of the 
structure by weighting the sequence entropy of a given residue by the amount of solvent 
accessible surface area associated with that residue. The average surface entropy for the 
surface buried in the contact is divided by the average surface entropy for the rest of the 
surface. If this ratio is less than one, the contact is considered to be biologically 
significant. To measure the sequence entropy of FeRn we used the 5 known FeRn 
sequences (rat, mouse, opossum, bovine and human) and 28 sequences of ~2 
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microglobulin. While the number of f32 microglobulin sequences is enough for this 
analysis (>20), the number of FeRn sequences is probably too low and may result in an 
overstatement of the sequence entropy (Elcock and McCammon, 2001). The surface 
sequence entropy for the FeRn-FeRn contact is slightly higher than the surface sequence 
entropy for the surface of FeRn generally. The 1.11 ratio is consistent with interpreting 
the FeRn dimer as a crystal contact and not as a biologically meaningful contact. 
However, the limiting number of FeRn sequences diminishes the significance of this 
estimate. 
Analyzing the FeRn-FeRn crystal contact computationally generates results that 
are not straightforward to interpret. The absence of a clear indication that the FeRn-FeRn 
crystal contact is biologically meaningful left any demonstration of its existence to direct 
experiments. Ghirlando Rudolfo (NIH) conducted the first set of experiments using the 
soluble FeRn ectodomain. The second set was performed on a chimeric protein 
expressed in CHO cells in which the soluble FeRn ectodomain was fused to the 
transmembrane and cytoplasmic domains of TrkA, a tyrosine kinase. The final set of 
experiments employs FcRn-ECFP and FcRn-EYFP chimeras constructed with the entire 
FeRn heavy chain with the enhanced yellow (or cyan) fluorescent protein fused carboxy-
terminus to the short (43 amino acid) cytoplasmic tail of FeRn. 
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Analytical Ultracentrifugation and dynamic light scattering of the soluble FeRn 
ectodomain 
Ghirlando Rudolfo (NIH) conducted the following experiments on our behalf with 
soluble FeRn we supplied him. These results are included for the purpose of presenting a 
more complete discussion of the relevant unpublished data. 
Sedimentation equilibrium experiments were carried out in order to determine the 
oligomeric state of FeRn in 0.15M NaCl and 0.063M sodium phosphate (pH= 6.0). At a 
loading concentration of 10.7 J..i.M sedimentation equilibrium gradients were best modeled 
in terms of a single ideal solute (see Materials and Methods: Equation [5]). Identical 
values of M(l - vp) were obtained at the different rotor speeds, averaged at 12,900 ± 140 
g mor1, showing that the sample is monodisperse (Figure 1 ). 
The experimental molecular mass, M, was calculated usmg equation [7] as 
described in (Ghirlando et a!. 1995). Based on the amino acid composition of the FeRn 
components, a protein molecular mass Mp of 41 ,930 g mor1 is calculated. Similarly, 
based on the consensus data published by Perkins (Perkins, 1986), a protein partial 
specific volume vp of0.7328 mL g·1 is determined. Assuming that the carbohydrate has a 
partial specific volume Vc of 0.650 mL g- 1 (Ghirlando et al., 1995; Durschlag, 1986), the 
experimentally determined molecular mass is calculated as 4 7,500 ± 510 g mor 1, 
showing that the FeRn is monomeric. These data are consistent with a 12% (w/w) 
glycosylation and are in reasonable agreement with the molecular mass of 49,260 g mor1 
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Figure 1: FeRn is a single, monodisperse monomer in 0.15M NaCl and 0 .063M sodium 
phosphate (pH = 6.0). Sedimentation equilibrium profile at 280 nrn for FeRn at a loading 
concentration of 10.7 ).!M, shown as a distribution of A280 at equilibrium. Data were 
collected at 4 .0° C and 12,000 rpm. The results are analyzed for the best single 
component M( 1 - vp) fit, shown as a line through the experimental points. The 
corresponding distribution of the residuals is shown above the plot. 
56 
Table 1 
Buoyant molecular mass as a function of the FeRn loading concentration. a 
[FeRn] I mM A. l nm Rotor speeds I 1 ,000 M(1 - vp) I g mor' 
rpm 
0 .0107 280 10, 12, 14 12,900 ± 140 
0.0214 298 10 12, 14 12,870 ± 350 
0.0429 302 10, 12, 14 12,880± 120 
0.0857 304 10, 12, 14 12,350 ± 110 
0.105 305 8, 10 12,330 ± 130 
0.172 306 10, 12, 14 11,870 ± 360 
0.210 305 8, 10 11,600 ± 40 
0.420 310 8 only"_ 10,760± 50 
1.00 365 6 onlyb 7,720 ± 80 
(a) Expenmental parameters for the determmatwn of the buoyant molecular mass. The 
values of M(l - vp) shown, obtained from the best fit of equation [5] to the 
experimental data, represent an average of the values determined at the different rotor 
speeds. 
(b) At these loading concentrations, spinning at high speeds leads to FeRn concentrations 
that scatter light. Data could not be collected at higher rotor speeds, values of M(1 -
vp) were determined at a single rotor speed. 
In order to determine whether the FeRn self-associates into higher order 
oligomers, sedimentation equilibrium experiments were carried out at a series of higher 
loading concentrations (Table 1). Even though the experimental data were always 
consistent with the presence of a monodisperse species, it was noted that the values of 
M(l - vp) decrease monotonically with increasing concentration (Table 1, Figure 2). In 
fact, it was found that the dependence ofM(l- vp) upon the FeRn concentration in g L- 1 
(wFcRn) was best described by the following linear relationship (Figure 2): 














FeRn buovant molecular mass as a 
function of the FeRn concentration 
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Figure 2: Buoyant molecular mass of FeRn in 0 .15M N aCl and 0.063M sodi urn phosphate (pH = 
6.0) as a function of the FeRn concentration. The line shows the best-fit linear analysis of the 
data. Based on the experimental molecular mass of 47,500 g mol·1, (in order to convert the 
concentration scale from [FeRn] in mM to w FcRn in g L-1) the best-fit line is described by equation 
[3] in the text. 
58 
A similar monotonic dependence of the buoyant molecular mass on the sample 
concentration has documented for monomeric BSA and monomeric fibrinogen (Rivas et 
a!. , 1999). In these cases, the decrease of the apparent molecular mass was interpreted in 
terms of volume exclusion (Rivas et a!., 1999; Minton, 1998). Data for the FeRn can be 
interpreted in a similar manner: the values of the activity coefficient y for the FeRn were 
calculated using equation [A] above and equation [6] described in Rivas eta!. (Rivas et 
a!. , 1999) (Figure 4). Treatment of the FeRn solution as a suspension of hard spherical 
particles (Equation [I 0] in Rivas et a!., 1999), shows that the variation of lny is best 
modeled in terms of a FeRn having a radius rFcRn = 2.8 nm (Figure 3). 
In order to verify the validity of this model, FeRn samples were studied by 
dynamic light scattering which allows for an independent measure of the effective 
particle radius in solution. As in the sedimentation equilibrium experiments, it was noted 
that the particle diffusion coefficient and radius depended on the sample concentration 
(Figure 4). This is due to a combination of volume exclusion and multiple scattering 
events. Extrapolation to a zero concentration using a simple quadratic equation leads to 
an extrapolated radius of 2. 7 ± 0.1 nm, a value which is identical to that determined in 
Figure 4. 
Therefore, the monotonic decrease of the molecular mass as a function of the 
FeRn concentration indicates that the FeRn does not form dimers or higher oligomers at 
the concentrations studied. The formation of such species would have been evidenced by 
a ' break ' in the linear dependence of the experimental molecular mass, as noted for 
fibrinogen in the presence of calcium ions (Figure 2 of Rivas et a!., 1999). This 
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Figure 3: Activity coefficients of FeRn calculated from the experimental data (equation 
[5]) and equation [6] in reference (4). Integrations were carried out numerically in 
Mathematica 4.0 (Wolfram Research) and the particle number density p0 in mL-
1 was 
calculated as J0-6[FcRn]Na, where Na is Avogadro's number and [FeRn] is the 
concentration in mM. The line shows the best-fit scaled particle theory based on hard 
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Figure 4: FeRn radius determined by dynamic light scattering as a function of the sample 
concentration. The line shows the quadratic best-fit. 
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molecular crowding. Analysis of the data in terms of a hard particle model is consistent 
with dynamic light scattering experiments, further supporting the conclusion that the 
FeRn does not self-associate under the conditions studied. 
In summary, sedimentation equilibrium and dynamic light scattering experiments 
on the soluble ectodomain of FeRn both indicate that soluble FeRn is a monomer in 
solution at concentrations up to 1.00 millimolar. 
Cross-phosphorylation assays of an FeRn-TrkA chimeras 
One way to determine whether FeRn formed a dimer while in a membrane was to 
attach a FeRn to a group that would report formation of a dimer. Dr. Yang Liu, a former 
graduate student in our lab, constructed the first such FeRn-reporter protein by attaching 
the tyrosine kinase domain of the high affinity nerve growth factor receptor, TrkA, to the 
ectodomain of FeRn. The FeRn-TrkA chimera includes the ectodomain of rat FeRn and 
the transmembrane domain and cytoplasmic domain of rat TrkA. Wild-type TrkA 
undergoes ligand induced cross-phosphorylation in the presence of nerve growth factor 
(Farooqui et a!. , 1997). Fusing the C-terminal domains of TrkA to FeRn thus couples a 
dimer-reporting function to the Fe binding domain of FeRn. An expression vector 
containing the gene for FcRn-TrkA was transfected into Chinese hamster ovary (CHO-
K 1) cells, stable transfectants were isolated by cell sorting using antibodies recognizing 
FeRn and rat [32 microglobulin (Liu and Bjorkman, unpublished results) . The 
transfected cells were shown to bind iodinated Fe (Figure 5). 
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Figure 5: Binding of wtFc and hdFc to FcRn-TrkA expressing cells. Biphasic analysis 
adopted from Vaughn & Bjorkman (1997). Dissociation constants are consistent with values 
generated in SPR studies of FeRn and the ligandswhen analyzed with the biphasic analysis 




In collaboration with Dr. T. S. Ramalingham, the cells were assayed for the 
induction of cross-phosphorylation in the presence and absence of added ligand (Figure 
6). The cells were serum-starved then serum and phosphate starved and then incubated 
with H3
32P04 . Afer a brief acivation in the presence or absence of the ligand, the cells 
were lysed and the FeRn was immunoprecipitated out of the lysates using the anti-FeRn 
heavy chain antibody, 103. The immunoprecipitates were subjected to SDS-PAOE, and 
the presence of radioactive phosphate was visualized with a phospho imager plate. Cross-
phosphorylation of the FeRn-TrkA chimera was observed at the binding pH (pH 6) in the 
presence of Fe and IgO but not in the absence of the Fe or IgO or at pH 8. Cross-
phosphorylation of the FeRn-TrkA chimera was observed at both pH values in the 
presence of the anti-FeRn heavy chain antibody 103, but not in the presence of 103 Fab, 
or a mutant Fe with no FeRn-binding sites (nbFc) at either pH. Cross-phosphorylation of 
the FeRn-TrkA chimera was also observed at the binding pH in the presence of the hdFc. 
Because the hdFc has only one FeRn binding site it cannot bridge FeRn molecules. The 
induction of cross-phosphorylation of the FeRn-TrkA chimera on the cell membrane is 
therefore consistent only with the hdFc inducing the formation of the FeRn dimer on the 
membrane (Figure 7). These results were reproduced six times. 
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Figure 6: Ligand-induced cross-phosphorylation of FeRn-TrkA (FcRn-NGFR) chimeras by 
IgG, wtFc, and hdFc. Cells expressing the chimera are briefly exposed to the ligand. Cells 
are lysed, and lysates are immunoprecipitated with 1 G3, an anti-FeRn antibody. Immuno-
precipitates are analyzed by SDS-PAGE and the presence of 32P is visualized with a 
phosphoimager plate. 








Figure 7: Cross-phosphorylation in the presence of the heterodimeric Fe (hdFc) is diagnostic for the 
presence of the FcRn-dimer. Cross phosphorylation in the presence of the wild-type Fe (wtFc) does 
not necessarily indicate the presence of the FeRn dimer. 
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To determine if the hdFc-induced cross-phosphorylation of FeRn-Trk.A could be 
disrupted by perturbing the FeRn dimer interface, a series of FeRn-Trk.A chimeras were 
constructed with mutations in the FeRn ectodomain. These mutants, one bearing the 
substitutions His250Glu and His251 Glu and the other Asn 192Glu, Ser193Glu, 
Asn225Asp, Cys226Ser, His250Glu, and His251Glu were transfected into CHO-Kl cells 
and stable clones were isolated as above. When these cells were assayed for induction of 
cross-phosphorylation with each of the ligands tested above, neither cell line showed any 
induced cross-phosphorylation. However, at this time the cell lines expressing the 
original FeRn-Trk.A chimera with the wild-type FeRn ectodomain showed no induction 
of cross-phosphorylation either. In these experiments all the bands in all the lanes were 
the same intensity, though the intensity of the bands varied between experiments (Figure 
8). This experiment was repeated 13 times. To further probe the failure to reproduce 
ligand-induced cross-phosphorylation, the assay was repeated but the samples were 
analyzed to detect phosphorylation of tyrosine specifically instead of the presence of 
radioactive phosphate. The samples were generated as before but split into two gels for 
two blots. One blot, probed with 1 G3 (Figure 9), shows the presence of the FeRn heavy 
chain in all the lanes. The other blot (Figure 9), probed with a cocktail of anti-
phosphotyrosine horseradish peroxidase antibody-conjugates (Zymed) showed no 









Figure 8: Constituitive cross-phosphorylation of FcRn-TrkA chimeras. Cells expressing the 
chimera are briefly exposed to the lidand. Cel ls are lysed, and lysates are immunoprecipitated 
with an anti-FeRn antibody. Immunoprecipitates are analyzed by SDS-PAGE and the 
presence of 32P is visualized with a phosphoimager plate. 
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Figure 9: Western Blots of FcRn-TrkA show no ligand-induced cross-phosphorylation. Cells 
expressing FcRn-TrkA or a GPI-linked form of FeRn were exposed to the ligand, lysed and 
immunoprecipitated with 103, an anti-FeRn antibody. Immunoprecipitates were subjected to 
SDS-PAGE and Western blot transfer. PVDF membranes were immuno-blotted with anti-
FeRn rabbit anti -sera or anti-phosphotyrosine cocktail. Antibody presence is detected with 
horse radish peroxidase. 
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We do not know the reason for the change in the results of the experiment. In the 
earlier series of assays, all the bands in all lanes corresponding ligand-induced cross-
phosphorylation were more intense than their respective bands in the non-ligand-induced 
lanes. The later series of assays shows no difference in the intensity between the induced 
and noninduced lanes. We speculate that signaling through the TrkA tyrosine kinase 
domain may have altered the cells at some point such that the phosphorylation activity 
became constituitive. Recent experiments in our lab have demonstrated that the bovine 
lgG in serum binds to FeRn in cultured cells (Ramalingham et al. , manuscript in 
preparation). It might be that extended growth in the presence of an activating ligand 
subjected the cells to an unanticipated selection pressure. Because of problems with 
reproducibility in this assay, we designed another assay that involves a non-enzymatic 
reporter group whose expression should not alter cells. 
Fluorescence Resonance Energy Transfer studies of FcRn-ECFP and FcRn-EYFP 
chimeras 
The second assay we used to detect FeRn dimer formation exploits a phenomenon 
called fluorescence resonance energy transfer (FRET). This is an interaction between the 
electronic excited states of two chromophore molecules. One chromophore, the donor 
(enhanced cyan fluorescent protein; ECFP), has an emission spectrum that overlaps with 
the excitation spectrum of the other chromophore, the acceptor (enhanced yellow 
fluorescent protein; EYFP) (Table II). Excitation is transferred from a donor molecule to 
an acceptor molecule without the emission of a photon. FRET is most useful when the 
emission spectrum of the acceptor molecule may be readily distinguished from the 
69 
emission spectra of the donor. In this case one may detect FRET by exciting at the donor 
excitation wavelength and detecting FRET in the form of emission at the acceptor 
emission wavelength. In the absence of FRET, excitation at the donor excitation 
wavelength will result in emission at the donor emission wavelength. FRET is useful for 
studying the association of biological macromolecules because it is dependent on the 
inverse sixth power of the intermolecular separation (Stryer and Haugland, 1967). 
Therefore, even with the correct donor and acceptor molecules FRET only occurs when 
they are close to each other (1 0-100 A). 
Table 2 
Excitation and emission wavelengths 
Chromophore Chromophore Single-photon Chromophore Two-photon Chromophore 
single-photon excitation A two-photon excitation A single-photon 
A of excitation from microscope A of excitation from microscope A of emission 
maxima laser maxima laser maxima 
ECFP 425, 450 458 850 800 475 
EYFP 515 488 1050 800 535 
To exploit FRET in studying FeRn, chromophores were attached to the receptor 
molecules. Taking advantage of the development of enhanced cyan and yellow versions 
of green fluorescent protein (GFP), FcRn-ECFP and FcRn-EYFP chimeras were 
constructed. These chimeras had the fluorescent proteins fused at the carboxy terminus 
of the complete FeRn heavy chain, such that the propensities of the ecto- , 
transmembrane, and cytoplasmic domains to form a dimer could be examined 
collectively. 
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The FcRn-ECFP and EYFP chimeras were co-transfected into Cos-7 cells and 
expression of the receptor was detected by the presence of the chromophore. Cell-surface 
expression ofthe receptor was detected by live-cell staining with the anti-FeRn antibody 
1G3 (Figure 10) but the majority of the fluorescence from ECFP and EYFP was found in 
intracellular compartments. Because the cells were transfected with both FcRn-
chromophore chimeras three possible dimer species occur on the cell surface, FcRn-
ECFP/FcRn-ECFP, FcRn-ECFP/FcRn-EYFP, and FcRn-EYFP/FcRn-EYFP. Assuming 
the association of the chimeras is random, the three possible dimer species occur 25%, 
50%, and 25% of the time respectively . Only the second species could give rise to a 
FRET signal we are detecting, the other two species contribute only to the noise. 
In order to calibrate the amount of FRET expected from dimer formation, we 
constructed positive and negative dimer control chimeras. To make a positive dimer 
control we needed an obligate heterodimer, we chose the MHC class II molecule HLA-
DR. This type I membrane protein has a and f3 chains to which we fused ECFP and 
EYFP at the carboxy-termini of the cytoplasmic tails. In transfected cells, only the HLA-
DRa-ECFP/HLA-DRf3-EYFP chimera would form and the chromophores would 
necessarily be close enough together to undergo FRET. As a negative control we needed 
a molecule that had no known tendency to associate with FeRn. We chose an MHC class 
I related protein, HFE. In transfected cells, any FRET observed would not be the result 
of any specific interaction between FcRn-ECFP and HFE-EYFP . 
In collaboration with Dr. Mary Dickinson of Scott Fraser's lab we accomplished 
detection of the FRET signal using a Zeiss LM-51 0 two-photon laser-scanning confocal 
fluorescence microscope in its two-photon excitation mode. A chromophore molecule 
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Figure 10: Images A-D are sections from the top-> down through the same cell. A) 1.0 mm 
into cell; B) 5.0 mm into cell; C) 7.0 mm into cell; D) 10.0 mm into cell. FcRn-EGFP is 
expressed on the cell surface of transiently transfected COS-7 cells. Live cells were stained 
with an anti-FeRn antibody, 103 and with a goat anti -mouse Alexa-Fluor 568 nm conjugate. 
Green fluoresence is intracellular FcRn-EGFP. Red fluorescence is the Alexa-F luor 568 nm 
conjugate. Yellow fluorescence is the colocalization of the green and red. We argue that the 
red and yellow fluorescence are indiciative of cell surface FeRn. 
72 
may be excited by a single photon if it has the correct energy. Two-photon 
excitation of a chromophore occurs when two photons, each with half the energy (twice 
the wavelength) required for a single photon, bombard the chromophore within one 
femtosecond (Hell et al. , 1995). Two-photon excitation is a rare event that requires a 
large flux of photons to generate excitation at detectable levels but it has several 
advantages generally over confocal microscopy and one particular advantage for this 
experiment. Compared to confocal microscopy, two-photon microscopy has a higher 
signal to noise ratio because it only excites chromophores in the focal point of the 
sample. Therefore, the whole sample is less photobleached by the excitation and there is 
almost no light leakage from areas in the sample that are not in the focal plane. In this 
experiment, two-photon excitation is particularly useful because the separation of the 
two-photon excitation maxima is twice the separation of the single photon maxima (see 
Table II). Thus there is a greater chance of exciting only the cyan chromophore with the 
laser. At the single photon excitation wavelengths it is very difficult to excite the cyan 
fluorescent protein without also exciting the yellow fluorescent proteins in a FRET-
independent manner. 
We excited the samples with a 50 kW, 76 MHz, 200 fs pulse of 800 nm light from 
a titanium-sapphire laser. The light emitted from the sample in this microscope is sent to 
directly to a spectrophotometer so that the spectra of the different samples, not solely the 
total intensity, may be compared. When we excite cells transfected with FcRn-ECFP we 
see emission spectra that peak at the cyan emission wavelength peak (Figure 11 b). When 
we excite cells transfected with FcRn-EYFP with this 800 nm pulse we see no light 
emitted from all but the very brightest samples. When we excite the cells transfected 
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Figure 11: Emission Spectra from the two-photon (800 nm) excitation of cells 
transfected with ECFP and EYFP chimeras. (A) and (C) Cells transfected with 
HLADRa-EYFP and HLADRj3-ECFP exhibit FRET. (B) Some cells transfected with 
FcRn-ECFP and FcRn-EYFP exhibit FRET. (C) Some cells transfected with FcRn-ECFP 
and FcRn-EYFP or with FcRn-ECFP and HFE-EYFP do not exhibit FRET. 
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with both FcRn-ECFP and FcRn-EYFP, we see emission at both the cyan and yellow 
wavelengths in some of the cells (Figure 11 b). If the cells are not extremely bright, 
emission at the yellow wavelength under these conditions is almost certainly the result of 
excitation by the cyan emission (FRET), and not by the two photon light. Some of the 
cells transfected with both FcRn-ECFP and FcRn-EYFP do not exhibit any emission peak 
at the yellow emission (535 nm, Figure 11c). As a positive control series, we also 
transfected cells with obligate heterodimer cyan and yellow fluorescent protein chimeras. 
Two-photon excitation of cells transfected with HLA-DRa ECFP and HLA-DRj3 ECFP 
generated an emission spectra peaked at the cyan emission maximum (Figure 11 a). Two-
photon excitation of cells transfected with HLA-DRa EYFP and HLA-DRI3 EYFP 
resulted in no emitted no light. When cells transfected with HLA-DRa ECFP and HLA-
DRj3 EYFP were excited by the 800 nm pulse, there was emission of light at both the 
cyan and yellow fluorescent protein maxima (Figure 11a and 11c). As a negative control, 
cells were transfected with FcRn-ECFP and a hereditary hemochromatosis linked MHC 
class I homolog molecule (HFE)-EYFP chimera. When excited with an 800 nm pulse of 
light, these cells generated fluorescence spectra with little emission at the yellow 
emission maxima (Figure11c). 
While the occurrence of FRET in some cells transfected with FcRn-ECFP and 
FcRn-EYFP is consistent with the chromophores being within 100 A of each other it is 
not necessarily the case that these molecules have formed the FeRn dimer seen in the 
crystals. An alternative explanation is that the FeRn expression level is so high in the 
transfected cells that there are molecules within 100 A of each other at expression 
bottlenecks inside the cell. Another difficulty in interpreting these results is explaining 
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why some cells transfected with FcRn-ECFP and FcRn-EYFP exhibit FRET while other 
such cells do not. The cells that exhibit FRET have a characteristic fluoresence pattern 
when viewed with epifluorescence, but whether that pattern is indicative of the 
biologically relevant expression is unknown. Also, as seen in Figure 10, though there is 
expression of the FeRn chimeras on the surface of the cell, the bulk of the expression is 
intracellular, in the perinuclear region. This expression pattern is consistent with cells 
that are over-expressing a protein. 
Most of these difficulties can be addressed by generating a stably transfected cell 
line, preferably with polarized cells, similar to cells that express FeRn in vivo. T.S. 
Ramalingham in our lab has generated and characterized the expression ofFcRn-EGFP in 
Mabin-Oarby canine kidney (MOCK) cells. These polarized cells, like the cells of the 
vascular endothelia where FeRn is expressed, grow in tight monolayers and present a 
cellular architecture that is convenient for addressing several aspects of FeRn mediated 
IgG transport. The MDCK cells transfected with FcRn-EGFP express the protein at 
physiological levels and these cells exhibit the biological function of FeRn, i.e., they 
trancystose lgG. The locus of the expression of FeRn in MOCK cells, in apical 
endosomes, at the apical cell-surface, or at the basolateral cell-surface may be modulated 
by the presence of IgG. Isolating stable MOCK cell transfectants expressing the FcRn-
ECFP and FcRn-EYFP chimeras would present a homogenous cellular population for 
FRET studies. Furthermore, as FeRn in MOCK cells exhibits the biological function of 
the receptor, we might be able to address whether the chimeras exhibit FRET while 
trancytosing lgG. As we can modify the locus of FeRn expression in these cells we can 
attempt to examine the incidence of FRET as a function of cellular localization. 
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Conclusions 
The experiments described here are attempts to determine if the FeRn dimer 
observed in some crystal forms is physiologically relevant. Analyses of the contacts in 
the crystal structures are equivocal in their characterization of the contact. The 
sedimentation equilibrium and dynamic light scattering experiments undertaken by our 
collaborator clearly indicate that the soluble ectodomain of FeRn is a monomer in 
solution at concentrations as high as one millimolar. There have been two analyses of 
FeRn chimaeras attempting to characterize the behavior of FeRn in a membrane. In the 
first study, FeRn-TrkA chimeras were used to show ligand-induced cross-
phosphorylation but these results can no longer be reproduced perhaps because of an 
alteration of the FeRn-TrkA cell-line. In the second study, cells transfected with FcRn-
ECFP and FcRn-EYFP chimeras exhibited FRET under some conditions but is difficult 
to assess if that sigal is do to the formation of the FeRn dimer. Some of the ambiguities 
in interpreting the FRET experiments may be alleviated by the generation and 
characterization of stable transfectants expressing the FcRn-ECFP and FcRn-EYFP 
chimeras. 
Materials and Methods 
Assessing the biological significance of a crystal contact by the amount of buried 
solvent accessible surface area: To calculate the probability of finding an crystal contact 
that buries greater than 700 A 2 in size in a monomeric crystal, we employed the formula 
of Janin: 
P(B) - 4.2 exp (-B/260) [I] 
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where B is the amount of surface area buried at the contact on both proteins. Using this 
formula we can say what the probability of finding an interface of the size found in the 
FeRn crystals ( 1780 A) would be if the FeRn crystals were crystals of monomeric 
proteins with one molecule in the asymmetric unit. 
Assessing the biological significance of a crystal contact by the surfaces' 
complementarity: To determine the shape complementarity of the FeRn-FeRn dimer 
interface, we used the "sc" component of the CCP4 suite. Developed by Lawrence and 
Colman, this metric finds the median of the population of complementarity values, a 
score of 1.0 is perfectly complementary, a score of 0.0 means the surfaces show not 
complementary. These values are computed between points on the molecular surface of 
the interface sampled at 15 dots per square angstrom. The complementarity value is 
calculated between the point on one surface and the point on the other surface closest to 
it. It is calculated using the distance between the two points and the unit vectors 
extending normal to the surface from the first point to the opposite surface and normal to 
the surface from the second point extending inward away from the first point. The value 
is computed multiplying the dot product of the unit vectors and an exponential term 
where the exponent is the product of a weighting term and the square of the difference 
between the two points. The overall statistic is the average of the medians from the 
populations of each surface with respect to the other. Derived in this way the shape 
complementarity statistic has two advantages which are germane to our review. At short 
inter-surface distances the complementarity of the shape dominates the term while the 
distance dominates a larger distances. Further, because the average of the median 
complementarity of each surface for the other is taken, the metric is insensitive to areas of 
the interface which are not complementary and only weights those areas that are truly in 
contact with one another. 
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Assessing the biological significance of a crystal contact by comparing the 
conservation of the sequence at the surface of the contact: Elcock and McCammon 
(200 1) begin their definition of sequence entropy by adopting the convention for 
describing sequence entropy employed by the Homology Derived Secondary Structure of 
Proteins database (HSSP) generated by the European Molecular Biology Laboratory at 
Heidelberg (ftp://ftpembl-heide1berg.de/put/databases/hssp; Sander and Schneider, 1993). 
This convention describes the sequence entropy at position i in an alignment s(i) as 
s(i) = (-1) L Pk *ln(pk), [2] 
where Pk is the observed probability of finding a given residue k at position i. As 
may be seen this definition weights all amino acid substitutions equally. To weight 
substitutions in a manner more indicative of the degree of chemical change caused by the 
substitution, the amino acids are classed according to Mimy and Shakhnovich (Mimy and 
Shakhnovich, 1999). Briefly the amino acids are classed as follows: (1) Arg, Lys; (2) 
Asp, Glu; (3) His, Phe, Trp, Tyr, Val; (4) Asn, Gln, Ser, Thr; (5) Als, lle, Leu, Met, Val; 
(6) Gly, Pro. In order to compare the sequence entropies of given surfaces Elcock and 
McCammon choose to weight the entropy of a given sequence according to its 
participation at the surface. This surface sequence entropy is defined as 
SSE(x) = L Pk *ln(pk) * ASA(sidechains/LASA(allatoms), [3] 
where Pi is the probability of finding residue type i at that position, and ASA is the 
associated surface area. Main chain atoms are not included in the numerator of the term, 
except in the rare cases where a mutation causes a change in the main-chain conformation 
the main chain atoms have essentially zero sequence entropy. To determine whether a 
contact surface is biologically meaningful or a nonspecific crystal contact the ratio: 
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SSE( contact-surface )/SSE(non-contact-surface) is calculated. If this ratio is greater than 
one the surface entropy of the contact is greater than the rest of the surface and the 
contact is deemed nonspecific. 
Sedimentation equilibrium : These experiments and their written summary was provided 
by Ghirlando Rudolfo of the NIH. Sedimentation equilibrium experiments were 
conducted at 4 .0° c on a Beckman Optima XL-A analytical ultracentrifuge. FeRn samples 
in 0.15M NaCl and 0.063M sodium phosphate (pH = 6.0) were analyzed at different 
loading concentrations and different rotor speeds as noted in Table 1. Data were acquired 
as an average of 8 absorbance measurements at a radial spacing of 0.001 em and nominal 
wavelengths ranging from 280 to 365 nm depending on the sample loading 
concentrations (Table 1). Equilibrium, as determined by scans taken six hours apart, was 
usually achieved within 48 hours. Data were analyzed in terms of a single ideal solute to 
obtain the buoyant molecular mass, M(l - vp ) , using the Optima XL-A data analysis 
software (Beckman) running under Microcal Origin 3.78, by fitting data from each scan 
to 
[5] 
where Ao is the absorbance at a reference point r0 , Ar is the absorbance at a given radial 
position r, H represents w2/2RT, w the angular speed in rad s-1, R is the gas constant, Tis 
the absolute temperature and E a small baseline correction. M represents the molecular 
mass of the glycoprotein, v its partial specific volume and p the solvent density. The 
residuals to the fit were calculated. In all cases, a random distribution of the residuals 
around zero(± 0.02) was obtained as a function of the radius. 
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Dynamic light scattering: These experiments and their written summary was provided 
by Ghirlando Rudolfo of the NIH. The translational diffusion coefficient D was measured 
from autocorrelation analysis of the quasielastically scattered light. The A = 514.5 nm 
emission of an argon ion laser (Lexel, Model 95) was used in the TEM00 mode. The 
output power was adjusted to 100 m W such that a constant light intensity was obtained. 
Autocorrelation functions were collected at 22° C using a Brookhaven Instruments BI-
9000 AT autocorrelator at an angle 8 of90° with sampling times of 1.0 J.!S to 100 ms. 
100 J.!L of the sample were transferred to a small volume fluorescence cuvette 
(Hellma) and autocorrelation functions were accumulated for 5 to 10 minutes . 
Normalized autocorrelation functions g 1(t) were obtained from the autocorrelated 
function G 1(t) and the measured baseline, b, as follows: 
[6] 
The second cumulant of g 1(t), r 2, determined using the Brookhaven Instruments analysis 
software was used to calculate the diffusion coefficient: 
[7] 
where n is the solution refractive index. The equivalent Stokes radius, r, for the FeRn is 
calculated as follows: 
r = kT/6nT)D, [8] 
where k is Boltzmann' s constant and rJ the solvent viscosity. 
FeRn concentrations were determined using an extinction coefficient Eat 280 nm 
of 84,900 M- 1 cm-1• 
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Construction of the FeRn-TrkA chimeric construct: Yang Liu generated the first 
FeRn-TrkA chimera vector used in these experiments. The DNA for the secretion signal 
sequence and the ectodomain of the mature rat FeRn heavy chain (residues 1-276) and 
the DNA for the transmembrane and cytoplasmic domains of rat TrkA (residues 417-
799) were amplified by PCR. The 5' end of the 3' primer for the FeRn amplification 
contained the sequence complementary to the 5' end of transmembrane domain of TrkA. 
The 5' end of the 5' primer for the TrkA amplification contained the sequence 
complementary to the 3' end of the FeRn ectodomain. The amplified pieces of FeRn and 
TrkA were purified and then fused by PCR with the 5' FeRn and 3 ' TrkA primer. The 
resulting construct fused the residues SPARSS (271-276) from FeRn to TPFGVS (417-
422) of TrkA. This construct was subcloned by Xhol - Notl double digestion from 
pBluescript IISK - (Stratagene) into pBJ-5GS. This vector allows for selection under 
glutamine free media and amplification in the presence of MSX. 
Generation and characterization of FcRn-TrkA stable transfectants: Yang Liu 
created the CHO-K1 cell line stably expressing the FeRn-TrkA chimera. The vector with 
the FcRn-TrkA chimera was cotransfected with the vector carrying rat f32 microglobulin 
into Chinese hamster ovary (CHO-Kl ) cells. Expression of the FeRn-TrkA chimera on 
the surface of the cells was confirmed by F ACS analysis. FeRn was detected with the 
anti-FeRn antibody 1 G3, the presence of 1 G3 was reported by a goat anti-mouse IgG R-
phycoerythrin conjugate. 
Detection of Fe binding to FcRn-TrkA cells: wtFc, hdFc, and nbFc were coupled to 1251 
using Iodobeads (Sigma). The specific activities were 4.0, 4.2 and 5.0 x 10-5 mCi/pmol 
Fe, respectively. Three-fold dilution series of eight samples of each of the proteins were 
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prepared with constant amounts of radiolabeled protein and increasing amounts of 
unlabeled protein. wtFc was varied from I J..i.M to O.I nM wtFc each with O. I nM 
iodinated wtFc; hdFc was varied from 6 J..i.M to 3.0 nM hdFc each with 3.0 nM iodinated 
hdFc; nbFc was varied from 6J..i.M to 3 nM wtFc each with 3.0 nM iodinated nbFc. Prior 
to the assay the number of FeRn-TrkA molecules/cell (I x 1 05) was quantified by 
incubating batches of 5 x I 05 cells with increasing amounts of wtFc until saturation 
occurred. 
Adherent cells were removed from solid support by incubation in PBS pH 7.4 
with 4mM EDT A, 0.5% w/v BSA. Cells were quantified using a hematocrit, 5 x I 05 
were used per reaction. Cells were washed with 50 mM sodium phosphate pH 6.0/ 150 
mM NaCl/0.5% w/v BSA and resuspended in the same buffer. Suspended cells were 
incubated with the proteins for 20 minutes, and then pelleted. Cells were washed three 
times in the incubation buffer before counting in a gamma-counter. Data were analyzed 
by Scatchard analysis and the dissociation constants were in good agreement with those 
found in surface plasmon resonance assays. 
Generation of soluble FeRn, wild-type, heterodimeric, and non-binding Fcs: Please 
see Chapter 2. 
FcRn-TrkA crossphosphorylation assay. Stably transfected cells expressing the FcRn-
TrkA chimeric protein were grown out in ten-centimeter dishes. Twelve hours prior to 
the assay, cells are incubated in media without serum. Three hours prior to the assay the 
cells are incubated in phosphate free media and 32P phosphoric acid at 250 uCi per plate. 
To assay the cells the radioactive media is removed and the cells are incubated for one 
minute with the protein of interest in 5mL of either 50mM Tris-Cl pH 8.0/150mM NaCl 
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or 50mM MES pH 6.0/150 mM NaCl. The activation buffer is removed and replaced by 
1.5 mL of lysis buffer (50mM HEPES pH 7.8, 250mM NaCl, 1% Triton X-100, 10% 
glycerol, 25mM NaF, 2mM NaVanadate, 1mM PMSF, 2ug/mL each pepstatin, leupeptin, 
and aprotinin). The cells are immediately placed on crushed dry ice and kept at - 80° C 
for 20 minutes. The cells are thawed at 4° C, transferred to microfuge tubes, and 
centrifuged at 14,000 rpm in an Eppendorf 5415C centrifuge at 4 o C. The supernatents 
are saved and assayed with the Pierce protein assay. Volumes of supernatent normalized 
for protein content were immunoprecipitated with an anti-FeRn monoclonal 1 G3 and 
protein G coupled to sepharose at 4° C. Immunoprecipitates were analyzed with SDS-
PAGE either phosphorylation was visualized either by exposing the gel to a phospho-
imager plate or by western blot analysis. Two Western blots were conducted in parallel 
following the method of (Sambrook et al. , 1989). The primary antibody for the first blot 
was 1 G3 . The secondary antibody was goat anti-mouse horse radish peroxidase 
conjugate. The other blot used cocktail of antiphosphotyrosine antibody-horse radish 
peroxidase conjugates available from Zymed. 
Construction of FcRn-ECFP and FcRn-EYFP expression vectors: The DNA for full-
length rat FeRn and rat 132 microglobulin were each amplified by PCR, incorporating a 5' 
Asp718 site and a 3' Hindlll site. The DNA for rat FeRn and EGFP (enhanced green 
fluorescent protein, codon optimized for mammalian cell expression, Clontech) were also 
amplified by PCR, incorporating a 5' Asp718 site and a 3' Xhol site and a 5' Xhol site and 
a 3' Hindlll site, respectively. The PCR products were directionally inserted into 
pBluescript II SK- (Stratagene). The Asp718-Xhol restricted form of rat FeRn was 
subcloned into the EGFP-containing pBluescript II SK-. This generated a fusion gene 
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with DNA encoding a secretion signal sequence, the entire FeRn heavy chain, ecto, 
transmembrane, and cytoplasmic domains, a leucine-glutamate linker, and then EGFP. 
The DNA for the full-length rat FeRn, rat j3 2 microglobulin, and the FcRn-EGFP fusion 
gene were directionally subcloned from pBluescript II SK- into a mammalian expression 
vector pCB6H, (kind gift of Ira Mellman, Yale) . The DNA for ECFP and EYFP 
(enhanced cyan and yellow fluorescent proteins, Clontech) were also amplified by PCR, 
incorporating a 5' Xhol site and a 3' Hindlll site, respectively. The DNA for EGFP was 
removed from the pCB6H vector containing the FcRn-EGFP fusion protein. The ECFP 
and EYFP genes were inserted into the remaining backbone. The pCB6H vector places 
the inserted genes under the hCMV promoter, and provides the gene for resistance to 
neomycm. 
Generation and characterization of transient transfectants: Cells are grown on 
coverslips in six well plates. The Superfect (Qiagen) transfection reagent and 2)lg of 
DNA per vector were used to transfect cells using the manufacturer's protocol. Each of 
the FcRn-EGFP, ECFP, EYFP vectors were cotransfected with the rat j32m vector into 
Cos-7 cells using the Superfect reagent (Qiagen) and the manufacturer ' s protocol. The 
expression of the transgenes could be detected by green fluorescence. Expression of 
FeRn at the cell surface was confirmed by the following protocol. To inhibit endocytosis 
all steps were conducted with buffers kept at 4° C and cells kept on ice. Live cells were 
incubated on ice in phosphate buffered saline pH 7.4 with 1% w/v BSA for ten minutes. 
They were incubated with an anti-FeRn monoclonal antibody 1 G3 for 10 minutes. Cells 
were washed with PBS pH 7.4 and then incubated with the goat-anti mouse Alexa-fluor 
568 nm antibody conjugate (Molecular Probes) for ten minutes. The secondary antibody 
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was removed by washing and the cells were then fixed with 4% paraformaldehyde and 
methanol. Images of fluorescence were obtained on a LeicaTCS SP confocal 
m1rcroscope. Samples were excited at 488 nm and 568 nm wavelengths. The 
fluorescence was collected in different channels gated such that none of the fluorescence 
from EGFP bled through to the fluorescence of the Alexa-fluor. 
Detection of fluorescence resonance energy transfer in transiently transfected cells: 
Cells are grown in ten-centimeter dishes and transfected with 8 J..lg per vector using the 
Superfect protocol (Qiagen). Cyan and yellow fluorescence in transfected cells was 
confirmed on the Zeiss LM-51 0 two-photon laser-scanning confocal fluorescence 
microscope in confocal mode by exciting the cells in the growth media at 458 run and 
488 run respectively. 
To evaluate FRET a Zeiss LM-51 0 two-photon laser-scanning confocal 
fluorescence microscope was used in two-photon mode using a 40x standard objective 
with a numerical aperature of 1.2. Before collecting the spectra the growth media is 
removed from the cells, the cells are washed in PBS pH 6.0 and incubated in PBS pH 6.0 
with 1% w/v BSA, this buffer is removed and coverslips are placed on the cells in the 
dish. Spectra were taken for areas in the field of view with fluoresence and in areas with 
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Chapter 5: 
A comparision of 171 nonobligate 
protein-protein interfaces 
This chapter is an analysis of a collection of 171 nonobligate protein-protein 
interfaces obtained from the protein data bank. Aspects of interfaces quantified in earlier 
studies are extended here over this larger database. A principal component analysis of 
the quantifiable aspects of protein interfaces reveals that the interfaces of antibodies and 
proteases are special cases somewhat distinct from the general population of nonobligate 
protein-protein interfaces. David Mathog suggested several years ago that I pursue 
conducting a principal component analysis on interface data. Ben Bornstein of the 
Machine Learning Group at JPL was a patient mentor both in explaining (repeatedly) the 
principal component analysis and (with Barbara Engelhardt of the Artificial Intelligence 
Group at JPL) in writing code that made the completing the patch-wise analyses of this 
study a trivial exercise. 
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Introduction 
This chapter is a review of a large number of structures of nonobligate protein-
protein complexes. The purpose of this chapter is to provide a context for understanding 
the crystal structure of the nonobligate complex between FeRn and hdFc. The 
understanding of protein structure has been enriched by analyses of collections of crystal 
structures. It is hoped that this analysis will enrich the understanding of nonobligate 
protein-protein complexes and of the FcRn/Fc complex in particular. 
Until recently the amount of data available limited the progress m studying 
nonobligate protein-protein complexes. While still a small number of samples from a 
statistical point of view, the 171 of samples in this review generated more complete 
Gaussian distributions for the metrics used than previous studies. This greater 
completeness made pursuing a principal component analysis of these data more 
reasonable. 
Selection criteria for inclusion in this study 
In reviewing nonobligate protein-protein complexes, we select only those 
complexes solved by X-ray diffraction, at resolutions between 4 A to 1.2 A resolution. All 
complexes between unique combinations of proteins are included. Included in this study 
are complexes between more than two proteins, each of which is stable on its own. 
Excluded from consideration are obligate complexes, homo-oligomers, structures solved 
by NMR, theoretical models, and multiple versions of a complex between identical 
proteins. This selection of complexes is drawn from the February 15, 2001 release of the 
Protein Data Bank. 
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The selection criteria generate a population of complexes shaped by several 
biases. A selection of crystal structures is biased first towards those proteins interesting 
to crystallographers and then towards those complexes that crystallize. As a result of the 
first bias, several types of complexes, antibody/antigen, protease/protein protease 
inhibitor, major histocompatability complex class I and class 11/T-cell receptor, IgG-
Fc/IgG-Fc binding proteins, and cell-surface receptors/protein ligands, are more 
thoroughly represented. The second bias skews the sample towards complexes between 
small, monomeric proteins, though this bias is diminishing as the Protein Data Bank 
grows. Finally, because the annotation of the files in the Protein Data Bank is not 
constructed to process these sorts of selection criteria, the population was assembled by 
hand. Therefore to be included in the population, the unique nonobligate complex of 
proteins had to be one that the author could recognize. This unintended selection 
criterion will bias the sample away from including protein complexes whose nonobligate 
Nature is unknown to the author. These biases, while unfortunate, are unavoidable given 
the scarcity of the available data and are common to all of the analyses of this type (Jones 
and Thornton 1996; LoConte et al., 1999). 
The categories of nonobligate complexes 
In this review we will compare structures 163 cocrystal complex structures 
containing 171 interfaces. These structures will be into divided into nine categories: 
1) 43 interfaces between proteases with protease inhibitors. 
2) 32 interfaces between antibodies with their antigens. 
3) 17 enzymes complexed with activators, inhibitors or other enzymes. 
4) II interfaces in which one of the two proteins is >90,000 Daltons. 
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5) 27 interfaces between G-proteins, cell-cycle proteins, or signal transduction proteins. 
6) 11 interfaces in which one of the two proteins is an MHC class I or II molecule or 
homolog. 
7) 5 interfaces between the Fe portion oflgG and another molecule. 
8) 19 interfaces between ectodomains of cell surface receptors with their ligands. 
9) 4 miscellaneous interfaces. 
The categories overlap m some cases, and the categories are determined by 
different criteria. Further, some interfaces could be included in more than one category. 
The protease/protease inhibitor and antibody/antigen categories have the least amount of 
variation. The enzyme complex and G-protein categories are the most heterogeneous 
populations of structures. The large complexes are separated out from other categories 
because it is believed that these proteins are more likely to undergo extensive 
conformational changes upon complex formation (Lo Conte et al. , 1999). The MHC 
class I and class II and homolog complexes are grouped separately because they are a 
more homogeneous subset of the cell-surface receptor ectodomain category. The Fe 
structures are separated for the same reason. This loose categorization on biological and 
structural criteria is adopted as a substitute for a more quantitative index based on the 
affinity of the interaction. At the moment, affinities of protein-protein interactions are not 
determined in any standard way nor are they stored in any convenient database. In the 
absence of such data we separate the interfaces upon the qualitative hierarchy. 
The analyses 
This review will analyze these interfaces with a combination of metrics readily 
available to a protein crystallographer. All the calculations except those involving 
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Voronoi volumes were completed only over the amino acid atoms of the polypeptide 
chains, sugars, cofactors and ordered waters were omitted. Voronoi volume calculations 
define atomic volumes by the surrounding atoms and therefore require using all atoms in 
the pdb file. The chains chosen to represent the given proteins in the given calculations 
are included in Appendix B. The following types of analyses, defined below, will be 
conducted on these complexes: interface surface area, circularity, planarity, atom 
accessibility, atom burial, atom packing, shape complementarity, number of hydrogen 
bonds, chemical Nature of constituent atoms, and residue composition of the interfaces. 
The numerical results of these analyses are included in Appendix B. 
The proteins' masses, volumes, and total solvent accessible surface areas are 
included as points of reference. The mass of the protein given is the mass of the protein 
atoms in the crystal. This value, while not necessarily the actual biological value, 
because regions of the protein that are disordered in the crystal are not included in the 
coordinates, is close to it. And importantly, it is the value directly related to the surface 
area values that are calculated with exactly these atoms. The whole protein volume 
values are calculated with the VOIDOO algorithm (Kleywegt and Jones, 1994) using the 
default settings and the standard 1.4 A radius probe sphere. The solvent accessible 
surface areas are calculated using the algorithm originally written by Lee and Richards, 
(1971 ). The chemical group radii are taken from Chothia, (1975) and the radius of the 
water probe is 1.4 A. 
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Protein level analyses 
Solvent accessible surface area 
The change in solvent associated surface area found upon complex formation is 
called the interface surface area. The interface surface area is used as a metric for 
studying protein-protein interactions because there is a correlation between it and the 
hydrophobic free energy of transfer from a polar environment to a hydrophobic 
environment (Chothia, 1974). The interface surface area is calculated as in LoConte et 
al., (1999) on a per atom contribution basis . The total surface for each protein is 
calculated, as is the total surface for the two proteins in complex. The difference is the 
interface surface area, and the atoms associated with the surface are known so the amount 
the amount of interface attributable to given amino acids, chains, and proteins is readily 
determined. 
The mean interface surface area per protein is 1106 A 2 (standard deviation, 785 
A 2) . This is higher than the 983 A 2 value reported by Jones and Thornton and the 1940 
A 2 per binary complex reported by LoConte et al., (1999). It reflects both the broader 
sampling of the database in this discussion and the trend as crystallography progresses 
towards solving larger complexes. The histogram of interface surface areas (Figure I) 
reveals a longer version of the tail observed in other studies (LoConte et al., 1999) of 
larger interface areas for which we have only a few observations. The new data indicate 
that this mean may continue to trend upward as more data are accumulated. 
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Figure 1: The histograms of interface surface area reveal a tail of larger complexes. This 
tail extends as more larger structures are solved. 
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Further support for a continuing upward trend in mean interface surface area may 
be drawn from the histograms for the different types of protein complexes. Small 
protease/protease-inhibitor interfaces and antibody/antigen interfaces continue to 
dominate the data set in terms of frequency and their similar narrow distributions are 
apparent, peaking at around 1000 A2 • There is another mode to the protease-protease 
inhibitor complex, first noted by LoConte et al. , which contains the more recently 
acquired thrombin complexes. Similarly, assuming a normal distribution of interface 
surface areas, the cell-surface receptor interfaces and the G-protein, cell-cycle, signal 
transduction interfaces show now that their current peaks may shift higher as more data 
are assembled. The large complexes are responsible for the largest interface surface 
areas, and the number of these to be solved is still insignificant. However, the total 
number of these large complexes employed in biological systems will probably a 
significantly reduced number. Their effect on the mean may not be overwhelming. It 
seems reasonable to predict that upon acquisition of most of the known protein-protein 
interactions that their mean interface area will reach somewhere in the 1200-1300 A 2 
range, rather than the 900-1000 A 2 range, where it current resides. 
Circularity 
The circularity of protein interfaces allows assessment of the intimacy of the 
association between the proteins on a protein-size scale (Jones and Thornton, 1996). The 
circularity is described by finding the least squares plane through the atoms involved in 
the interface and taking the ratio of the two principle axes (Jones and Thornton, 1996). In 
the discussion here, these calculations were conducted using least-squares plane 
99 
command of the MOLEMAN2 algorithm from the Uppsala Software Factory (Kleywegt 
and Jones, 1999). Mathematically, this is arrived at by a principal component analysis of 
the coordinates, where the eigenvalues of the covariance matrix correspond to the 
principle axes. By the convention adopted by Jones and Thornton (1996), the second 
principal component is divided by the first giving a ratio that is always less than 1 but 
approaching 1 as the interface approaches a perfect circle. 
The mean circularity of protein-protein interfaces in this study is 0.43 (standard 
deviation 0 .21 ). This is significantly less circular than the original work of Jones and 
Thornton. They found means for circularity ranging between 0.55 and 0.75 for 
nonobligate interface surfaces. Again the shift is the result of the broader sampling of the 
data that is now possible. The histograms of interface circularity (Figure 2) reveal that 
protein-protein interfaces sample the circularity spectrum comprehensively. Antibodies 
and antigens, the enzyme and inhibitors, activators or other enzyme category, and the 
graphically combined categories of MHC class I, II molecules, their homologs and 
ligands, and Fe molecules and ligands are more circular. 0-protein, cell-cycle, signal 
transduction interfaces and cell-surface receptor and ligand interfaces are less so. The 
extensive sampling of circularity space by nonobligate interface surfaces reveals how 
crude an approximation is a circular contact between globular proteins. 
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Figure 2: The low, broad distribution in the circularity histograms shows that nonobligate 
protein-protein complex interfaces assume all manner of oblong shapes. 
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The planarity 
It is intuitively satisfying to consider the third dimension, the thickness of the 
dispersion about the least-squares plane through the interface, by itself. To compare 
separate interface surfaces, we use the root mean squared deviation (RMSD) from the 
plane, to measure the degree of planarity. The RMSD is related to the third (smallest) 
eigenvalue from the principal component analysis of the dispersion of atoms at the 
interface. Because this is not a ratio of eigenvalues, we must normalize this third 
principal component by dividing it by the number of samples used to generate it, by 
convention we take the square root. Again we used the least squares plane command of 
MOLEMAN2 to find the principal axes of the least squares plane. 
The mean RMSD from the plane of the interface surface in this study is 3.1 7 A 
(standard deviation, 1.36 A). This is more convoluted than was reported previously 
(Jones and Thornton, 1996) due to the incorporation of new data. Specifically, we find 
the antibody/antigen category assuming a monomodal distribution at low RMSD, while 
the protease/protease inhibitor and G-protein, cell-cycle, signal transduction categories 
each have monomodal distributions with increasing mean RMSDs (Figure 3). The 
combined categories of MHC class I, II molecules, their homologs and ligands and Fe 
molecules and ligands assumes a bimodal distribution. This bimodal distribution is not 
explained by the combination of these categories as there is considerable overlap in the 
planarity values for these two groups. This bimodal pattern is adopted also by the enzyme 
and inhibitor, activator, or other enzyme category as well as the cell-surface receptor and 
ligand category. However, both of these distributions have higher mean RMSDs than 
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Figure 3: The planarity histograms assume slightly bimodal distributions for some of the 
protein categories. 
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To determine if the interface surface is more flat than the surface of a protein 
generally, it is necessary to extract samples ofthe rest ofthe surface. Jones and Thornton 
first attempted this on a smaller data set including 31 heterocomplexes with a patch-wise 
analysis of the surface (Jones and Thornton, 1997a). Their patch size depended per 
protein on the size of that protein ' s interface. They found that in contrast to small 
molecules the surfaces of proteins most likely to interact with other proteins are more flat 
than the surface is generally. We endeavored to repeat this analysis on this larger data 
set. To do this an algorithm had to be developed. We again sampled the surface by 
taking surface patches but we made their general dimensions constant. This can be done 
by choosing an atom and constructing a patch of all the atoms on the surface within a 
given distance. By generating these patches for every surface atom with a patch radius 
that generates a total patch surface area, equivalent to the average area of a protein-
protein interface, we can generate a data set to make an unbiased comparison. A rapid 
version of this algorithm was written by Ben Bornstein of the Machine Learning Group at 
JPL. 
We find an average RMSD to the plane of surface patches with the average area 
of 1000 A2 to be 4.1 A (standard deviation 1.5). This is an even greater difference 
between the average RMSD of interfaces and that of similarly sized surface patches than 
was previously determined (Jones and Thornton, 1997a). We noted previously how the 
larger amount of data in this discussion generated a broader range of interface surface 
areas and a thorough sampling of circularity space extending the descriptive power of 
these metrics but limiting their use as predictors of what surface is an interface. In the 
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case of the RMSD from the plane of the interface we find that the addition of data 
extends the predictive power of this metric. 
Summary: protein level analyses 
We have considered metrics, which describe protein-protein interfaces on a 
protein-size scale. The interface surface area describes how much desolvation of protein 
surface, the hydrophobic effect, is involved in complex formation. The circularity proved 
to be an evenly sampled characteristic suggesting that interfaces come in all manner of 
shapes. The RMSD from the plane of the interface is a predictor of what surface of a 
protein is likely to be involved in an interface. We turn now to different metrics, which 
assay protein interfaces on the atom-size scale. 
Atom level analyses 
Atom Accessibility 
The first atomic parameter we consider is atom accessibility. It was noted in the 
mapping of antibody epitopes onto viral coat proteins that the accessible surfaces were 
those that were usually bound by the antibody (Lou et al. , 1987). The atom accessibility 
metric is a derivative of the residue accessibility metric used in earlier patch-wise 
analysis of protein surfaces (Jones and Thornton, 1997a). Jones and Thornton found that 
the average accessibility of the residues of a protein interface had higher average surface 
area than residues in other patches of surface. Our parameter is defined as the average 
surface area per interface atom. The surface areas are those calculated by Gerstein's 
version of the Lee and Richards algorithm (Gerstein, 1992). 
The average surface area of an interface atom is 14.4 A2 (standard deviation 2.1 
A2). We find that the atom accessibility on the surface generally 11.1 A2 (standard 
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deviation 1.42 A 2) is less than atom accessibility at interfaces. This is consistent with the 
result of the Jones and Thornton (1997). Examining the histograms of the distributions 
by category (Figure 4) reveals the distributions of the proteases and protease inhibitors 
and antibodies and antigens categories being shifted below the mean. The other, newer, 
categories employ even more accessible surfaces of their proteins and their distributions 
peak above the current mean. Interfaces involve atoms with more surface area than 
surface atoms have on average and if anything this difference may increase with 
additional data. 
Atom Burial 
While compiling the data for the atom accessibility study, we noticed that the 
amount of surface buried per atom generated a striking series of distributions for our 
categories (Figure 5). This is distinct from the amount of surface area each atom exposes 
when the proteins are not in complex because not all atoms bury their entire surface upon 
complex formation . Proteases and protease inhibitors and antibody and antigen interfaces 
produce well-separated bimodal distributions with peaks on either side of the mean atom-
burial for all proteins. The protease interfaces have lower atom-burial while the inhibitors 
have higher atom-burial than average. Similarly, the atoms of the antibody interface 
surface have lower average burial while the antigens have higher than average burial. 
The enzymes and inhibitors, activators, or other enzymes category distributes broadly 
about the mean. The other three categories overlay rather tightly with distributions that 
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Figure 4: Interface atoms are more accessible than surface atoms generally. These 
histograms show that the average atom accessibility of proteins solved more recently is 
even higher suggesting that this difference may increase with additional data. 
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Figure 5: The atom burial histograms reveal the best alignment with the categories of 
complexes in this study. Note the bimodal distributions of antibodies and antigens, and 
proteases and protease inhibitors, while the other categories are monomodal and overlap 
tightly. This pattern is also seen in the principal component analysis. 
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Shape Complementarity 
To assess how intimately associated two proteins are at an atomic level we tum to 
the shape complementarity that the two protein interfaces have for each other. By 
examining directly the distances between and opposition of shapes of opposing surfaces 
this metric will give us an approximation of the extent and strength of the van der Waals 
contacts between the proteins. This is the most complex metric in our study, the index of 
surface complementarity, and it may be computed in a variety of ways. We adopt the 
"sc," algorithm (Lawrence and Colman, 1993), a part of the CCP4 program suite (CCP4, 
1994). We employ it using all the default settings. This metric finds the median of the 
population of complementarity values. These values may be between 0 and 1, where I is 
perfectly complementary. The complementarity value is calculated between the point on 
one surface and the point on the other surface closest to it. It is calculated using the 
distance between the two points and the unit vectors extending normal to the surface from 
the first point to the opposite surface and normal to the surface from the second point 
extending inward away from the first point. The value is computed multiplying the dot 
product of the unit vectors and an exponential term where the exponent is the product of a 
weighting term and the square of the difference between the two points. The overall 
statistic is the average of the medians from the populations of each surface with respect to 
the other. Derived in this way, the shape complementarity statistic has two advantages 
that are germane to our review. At short intersurface distances the complementarity of 
the shape dominates the term while the distance dominates a larger distances. Further, 
because the average of the median complementarity of each surface for the other is taken, 
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the metric is insensitive to areas of the interface that are not complementary and only 
weights those areas that are truly in contact with one another. 
The mean shape complementarity of the interfaces in this study is 0.69 (standard 
deviation 0.06). It was previously noted that proteases complexed with protease inhibitors 
have a higher shape complementarity than antibodies complexed with their antigens 
(Lawrence and Colman, 1993). Our histograms of shape complementarity (Figure 6) 
show now that the protease/protease inhibitor and G-protein, cell-cycle, signal 
transduction categories have higher shape complementarity. Cell-surface receptors and 
antibodies have similar shape complementarity distributions, both close to the mean for 
all complexes. The category, enzymes and inhibitors, activators, and other enzymes 
shows a slightly lower than normal index. This may be an artifact of the omission from 
these calculations of cofactors and water molecules that are an integral part of some of 
these complexes. The combined categories of MHC class I, II molecules, homo logs, and 
ligands and Fe molecules and ligands has the lowest average shape complementarity 
statistic. This is consistent with some crude correlation between shape complementarity 
and affinity. Six of the 16 complexes in this category contain interfaces between T -cell 
receptors and major histocompatability molecules, these complexes are selected to have 
comparatively low (J.!M) affinity. 
Atom Packing 
Another method for estimating the importance of van der Waals contacts across 
an interface is to measure the volume of the atoms at the interface with Voronoi 
polyhedra (Chothia, 1975; Harpaz et al. , 1994). A Voronoi polyhedron is generated 
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Figure 6: The shape complementarity histograms reveal a narrow distribution indicative 
of the uniform importance of van der Waals forces in protein-protein interactions. 
Ill 
of its neighbors are drawn and second planes normal to these lines are placed according 
to the van der Waals radii of the two atoms. Each plane extends until it intersects 
another. Atoms that are not surrounded by sufficient atoms are omitted from the 
calculations. This method is useful for judging atom packing because, except for a vertex 
error due to differences in atom radii, it includes all the space around the atoms in the 
calculation (Gerstein et al. , 1995). This calculation was conducted over all the atoms in 
the protein data bank file, including waters, sugars, metals, and cofactors. These atoms 
were included in this calculation because of the dependence of this measurement on the 
neighboring atoms. To assay the packing of atoms at the interface, we separate the 
interface atoms into two categories, those that are buried completely in the interface, and 
those that are not. To normalize these values from interface to interface, we divide the 
average atom volume for both the completely and partially buried interface atoms by the 
average volume of the atoms buried in the core of their respective proteins. This gives us 
two ratios that compare the packing of the interface atoms with the extraordinary packing 
ofthe protein core (Harpaz et al, 1994; LoConte eta!., 1999). 
The average volume of atoms completely buried m the interfaces was 1.1 
(standard deviation 0.12 ) times that of the atoms buried in the proteins' cores. This is 
higher than the 1.03 (standard deviation 0.03) reported earlier (LoConte et al. , 1999). 
The earlier study omitted 11 of 75 complexes from the calculation of this ratio where 
ours compares all 163 complexes. Despite the larger average volume found in our study 
for completely buried interface atoms, this volume is small and indicative of close 
packing. The packing of the atoms partially buried at the interface, is not as dense. The 
average atom volume of atoms partially buried in the interfaces was 1.9 (standard 
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deviation 0.26 A3) times that of the atoms buried in the proteins' cores. The less dense 
packing of these atoms may be the result of the omission, in lower resolution structures of 
what would be ordered water molecules in the interface periphery. The incorporation of 
such ordered waters in the periphery of interfaces has been proposed (LoConte et al. , 
1999) as an explanation of the observation that amino acid substitutions in the interface 
periphery generally have small effects on complex formation (Cunningham and Wells, 
1993; Clackson and Wells, 1995). An alternative explanation is that the periphery of an 
interface is not as well packed as the core of the interface and that the looser packing 
itself reduces the importance of the amino acids in the periphery to complex formation. 
Because the shape complementarity statistic and the atom packing are both attempts to 
measure the importance of the van der Waals forces in an interface one might expect the 
values to be correlated (LoConte et al. , 1999). Neither the average atom volume for 
completely buried atoms nor for partially buried atoms nor the ratios for these values over 
the average atom volumes of the protein cores show any correlation with the shape 
complementarity statistic. 
The packing of atoms at interfaces generates histograms with distributions that 
more closely resemble bimodal distributions than any other distributions in this study 
(Figure 7). This bimodality is echoed in the complexes between antibodies and antigens, 
between MHC class I, II molecules, homologs, Fe molecules and ligands, the complexes 
between proteases and protease inhibitors and the complexes in the G-proteins, cell-
cycle, and signal transduction categories. It is intriguing that the buried interface atoms 
of protease inhibitors and the antigens occupy larger volumes relative to their cores than 
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Figure 7: The atom packing histograms are consistently bimodal both as a whole and 
form the individual classes. This bimodality may indicate that one side of a non- obligate 
protein-protein interface is usually better packed than the other. This would mean that 
one side is more stabilized by van der Waals forces than the other. 
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are more tightly conserved than the other values. These data suggest that the catalytic 
sites of proteases and the antigen binding sites of antibodies are better packed than the 
antigens and the protease inhibitors. 
Hydrogen Bonds 
As the shape complementarity and atom volume addressed the extent of the van 
der Waals contacts across the interface, we now examine the extent of the electrostatic 
interactions by assaying the interfaces for the number of hydrogen bonds they contain. 
To find the hydrogen bonds across an interface, we use Skarzynski and Leslie's 
algorithm, available as "contact," in the CCP4 suite (CCP4, 1994). We set the program 
to find all the inter-surface hydrogen bonds between non-carbon atoms. We constrain the 
bonds found by limiting them in length to greater than 2.3 A and less than 3.3 A or 4.0 A, 
and by limiting the angle of 0 " H "·N hydrogen bonds to greater than 120° C, and the 
R ··o ···c bonds to greater than 90° C. These limits generate two sets of hydrogen bonds 
the strictly allowed (2 .3 A <length<3.3 A) and the generously allowed (2.3 A 
<length<4.0 A). 
The mean number of strictly and generously allowed hydrogen bonds per 
complex is 13 (standard deviation 9) and 24 (standard deviation 16), respectively. To 
compare this result with the values generated previously (Jones and Thornton, 1996), we 
also derived the number of hydrogen bonds per 100 A2 • Our values, 1.5 (standard 
deviation 1.2) strictly allowed and 2. 7 (standard deviation 2.1) generously allowed 
hydrogen bonds per 1 00 A 2 are higher than those posted by Jones and Thornton ( 1996) 
for nonobligate heterocomplexes, 1.1-1.4. Comparing the distributions of hydrogen 
bonds per complex and per 100 A 2 yields similar results. The distributions for the 
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different categories of interfaces overlap more tightly for this metric than they do for the 
all the others except the atom burial (Figure 8). The complexes between antibodies and 
antigens and between MHC class I, II molecules, homologs, and ligands and Fe 
molecules and ligands have slightly more hydrogen bonds. The complexes between 
proteases and protease inhibitors and the complexes in the G-proteins, cell-cycle, and 
signal transduction category have slightly fewer hydrogen bonds. This inversion of the 
results from the shape complementarity statistic indicates a trade-off between employing 
van der Waals forces and the more electrostatic hydrogen bond. 
Atom Type 
To consider the chemical Nature of the atoms at an interface surface independent 
of the interactions they form with the atoms on the opposing surface, we examine the 
percent of the interface surface area attributable to the different kinds of atoms of the 
protein at the interface. We adopt the convention of dividing the atoms of the 
polypeptide portions of proteins into nonpolar, polar, and charged categories and the 
definition of these atom types from previous work (Janin et al. , 1988). This atom-by-atom 
analysis classed the protein atoms observed in crystal structures into three groups: all 
carbon atoms were considered nonpolar, all oxygen, nitrogen, and sulfur atoms were 
considered polar, except the carboxylate oxygens, and the amino and guanadinium 
nitrogen atoms that were considered charged. To provide context for understanding the 
histograms for these data, we introduce a plot (Figure 9) demonstrating how dividing the 
atoms of a protein into these categories describes five parts of the proteins in this study. 
We measure the percent of the total atoms, percent of the core atoms, percent of the total 
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Figure 8: The hydrogen bond density histograms reveal distributions similar to those seen 
for atom burial. The various biological categories in our study use characteristic numbers 



















Figure 9: The atom type histograms reveal consistency in the relative amounts of 
different atom types or surface area attributed to atom types for the different parts of the 
protein. One significant difference is the lower proportion of charged atoms in the cores 
of proteins. 
118 
surface area, percent of the surface area not involved in known interfaces and the percent 
of the interface surface area attributable to nonpolar, polar, and charged atoms. It may be 
observed that the number of nonpolar atoms dominates proteins generally at around 60%. 
The exclusion of charged atoms from the core of proteins has been noted extensively in 
the literature (Janin et al. , 1988) and is shown in the second trio of columns. We note 
that for the surface where all atoms are being weighted by their degree of exposure, the 
interface surface has slightly less charged surface and slightly more nonpolar surface than 
the surface does generally . 
The interfaces of our study are 58.6% (standard deviation 7.6%) nonpolar, 26.6% 
(standard deviation 8.4%) polar, and 14.8% (standard deviation 8.8%) charged. These 
values agree well with the 56%, 29%, and 15%, observed in previous study that used 75 
complexes (Lo Conte et al. , 1999). Similarly, the changes in the proportions of the atom 
types from category to category of interface agree well with their results. What is 
apparent in the histograms here that is more difficult to glean from their presentation is 
that the categories segregate well by the percent of their surfaces that is nonpolar, less 
well by the polar atom type and not well by the charged atom (Figure 1 0). The antibodies 
and antigens interface surfaces have a lower percentage of nonpolar atoms than the mean. 
The proteases and protease inhibitor, and G-protein, cell-cycle, signal transduction 
interfaces have a higher nonpolar percentage than the mean. The cell-surface receptors 
and ligands and the combined categories of MHC class I, II molecules, their homologues, 
Fcs, and ligands are spread broadly about the mean. These data suggest that along with 
the circularity and the shape complementarity, the mean of the percent of the interface 
0 .25 
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Figure 1 Oa: These atom type histograms show that nonpolar atoms are present in levels 
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Figure 1 Ob: These atom type histograms show that polar atoms are present in levels less 
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Figure 1 Oc: These atom type histograms show that charged atoms are present in levels 
more consistent with the various categories of our study than the nonpolar atoms. 
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surface attributable to nonpolar atoms is probably stable and unlikely to be shifted by 
additional data. 
It is worth noting that decomposing the protein-level metric, the interface surface 
area, into the amount of interface surface area attributed to nonpolar, polar, and charged 
atoms we are, with the percent nonpolar surface, explicitly isolating the proportion of the 
protein-level metric that should be responsible for the hydrophobic effect. It is possible 
that the more consistent use of nonpolar surface area with the protein categories indicates 
that this percentage is more necessary to conserve than the polar and charged surface 
areas which may be more interchangeable. 
Amino Acid Composition 
The final metric we probed interface surfaces with is the percent of the surface 
area that may be attributable to different amino acids. Differences in the participation of 
residues at protein-protein interfaces may be used by protein biochemists to rapidly probe 
by mutagenesis the surface of a protein to find the protein interfaces. It is known that 
certain residues (tryptophan, tyrosine, arginine), when mutated to alanine, have on 
average, a larger effect on the affinity of an interaction than other residues (Bogan and 
Thorn, 1998). There could be several reasons for this, most obvious is that these are all 
large residues and the mutation to alanine is a sterically drastic change. The other 
reasons are subtler. It has been known for a long time that tryptophan and tyrosine, are 
uncommon ( 1.3% and 3.2% of all residues) in proteins generally (Creighton, 1984 p.4). 
It was shown more recently that tryptophan, tyrosine, methionine, cysteine contribute the 
total surface area of a protein in percentages that are very close to those of their 
frequency in proteins generally (LoConte et al. , 1999). LoConte further showed that 
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these same four residues contribute much larger percentages to the interfaces of protein-
protein interactions and that proline, lysine and glutamate contribute much less surface 
area to interfaces than they do the surface generally. Our review extends these same 
results over this larger database. 
We present two different charts. One presents the percent contribution a given 
amino acid makes to the total number of atoms, the number of core atoms, the total 
surface, the surface not involved in interfaces, and the surface involved in interfaces 
(Figure 11 ). From these charts, it may be seen that alanine is the only amino acid that 
contributes similar percentages to all the portions of the protein. It may also be noted that 
all those amino acids except arginine that are present at higher percentages on the surface 
generally are present at lower percentages at interfaces. It may also be observed that the 
residues that occupy a higher percent of core atoms than they do all atoms also consume a 
higher percentage of the interface surface area than they do the surface generally. In 
other words, core residues are also protein-protein interface surface residues, though not 
so dominantly. Finally, we present a plot that shows the ratio of the percentage of 
interface surface area occupied by an amino acid over the percentage of the surface area 
not involved in interface (Figure 12). This plot shows that for the finding the surface of 
a protein that interacts with another protein by mutagenesis, one has the greatest 
likelihood of success by scanning the tryptophans, tyrosines, methionines, 
phenylalanines, cysteines, isoleucines and histidines in that order. The odds are further 
enhanced if one knows whether the proteins are proteases or immunologically related. 
The former proteins employ cysteines and methionines at their interfaces on average 
while the latter do not. 
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Figure 12: This plot reveals how certain amino acids contribute more surface area to 
nonobligate protein-protein interfaces than they do to the rest of the surface of these 
proteins. 
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Summary: atom level analyses 
We have looked at the interfaces of proteins with metrics that assay proteins on 
the atom-size scale and found, as we did for the protein-size scale, metrics which will 
serve a variety of purposes. The atom accessibility, like the planarity allows us to 
distinguish which aspects of a surface are more likely to be involved in protein-protein 
interfaces. The amount of surface area buried delineates more than any other metric the 
biologically clustered categories used in this study. The atom-burial helps us describe 
structural distinctions between the categories of complexes. As the size of the interface 
surface area gives us a gross assessment of the extent of the hydrophobic effect, the 
percent of the interface surface area attributable to nonpolar surface may be a more 
precise measure of the hydrophobic effect. In contrast, the shape complementarity, the 
atom packing, and the hydrogen bond density allow us to address the extent of the van 
der Waals and electrostatic contacts between the surfaces. The decomposition of the 
interface atoms into the chemical categories generated broad distributions for most of the 
categories, the percent of interface surface area that can be attributed to nonpolar, polar 
and charged are good descriptors of interfaces. The final metric, the percent of the 
interface surface area attributable to given amino acids, provides both descriptive and 
predictive power. Areas of surface with high percentages of tryptophan are more likely 
to be interface surfaces than those surfaces with high percentages of lysine. Interface 
surfaces with cysteine and methionine are distinct from most other interfaces. 
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Correlation analysis 
Principal component analysis of the database 
We quantitatively described aspects of protein-protein interfaces in a variety of 
ways and we would like to know if any of these aspects are correlated with any other. To 
determine to what degree the analyses in this study generated highly correlated 
measurements of a protein interface, we conducted a principal component analysis of the 
various analyses over all the samples. In this way, we hope to be able to distinguish the 
different types of interfaces in a robust mathematical manner. Each metric (interface 
surface area, circularity, etc.) of each interface (Fab D1.3 , lysozyme, etc.) is a dimension. 
The dimensions of the interfaces are may be arranged horizontally and the dimensions of 
the metrics may be arranged vertically to construct a sample matrix. Each interface is a 
row vector and each metric is a column vector of this sample matrix. To conduct a 
principal component analysis the actual sample values in the sample matrix must be 
normalized by subtracting the mean observation for that variable from the sample and 
dividing the difference by the standard deviation. This creates a normalized sample 
matrix (N (r X c), where rand care the number ofrows and columns). These normalized 
values have a mean of 0 and a standard deviation of 1. A principal component analysis 
may be used to minimize the number of column vectors necessary to describe a sample 
by converting the normalized sample values into values that have no covariance, i.e. that 
are normal to each other. Mathematically this is accomplished by taking the covariance 
matrix of N. The column vectors of the covariance matrix will have different magnitude 
and describe different amounts of the variance. To normalize the magnitudes of the 
vectors and extract the differences in magnitude a singular value decomposition of the 
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covariance matrix is found . The results of the singular value decomposition of the 
covariance matrix of the normalized sample matrix used in a PCA are a c X c matrix 
whose orthonormal column vectors are the eigenvectors of the normalized sample matrix. 
The proportion of the total variance described by each eigenvector is found in the c X 1 
matrix of eigenvalues of the covariance matrix. In this study we used Matlab student 
release 5.3.0 to find the covariance matrix of the normalized sample matrix, and to do the 
singular value decomposition of the covariance matrix. We used a graphical program, 
authored by Ben Bornstein of the Machine Learning Group at JPL, to visualize the 
results. The three dimensional coordinates in these plots are the product of first three 
eigenvectors times the normalized sample matrix. 
We conducted two principal component analyses over all the interface samples 
considering the interface surface area, circularity , planarity, accessibility, shape 
complementarity, Voronoi volume of buried and partially buried atoms, hydrogen bond 
number, ( 4 A distance cutoff), and the percent surface area associated with the nonpolar, 
polar, and charged atom types. One analysis included the nitrogenase (ln2c, Schindelin 
et a!, 1997) and carbon monoxide ( 1 ffu, Haenzelmann et a!., 2000) complexes, these were 
found to cluster by themselves distant from the other interfaces largely because of their 
size. The other analysis reported here omitted the interfaces from these two structures. 
This analysis was subjected to a cross-validation analysis, where the principal component 
analysis was repeated with one of the variables deleted each time. The first three 
eigenvectors generated in the first principal component analysis describe collectively 
51.4% of the total variance contained in the eleven original measurements (Figure 13). 
Most of the variance described by the first eigenvector (this vector describes 23 .0% of the 
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total variance) comes from atom accessibility, the percent of charged interface surface, 
and anticorrelated contributions from the percent polar interface surface. The second 
eigenvector describes 15.8% of the total variance. The largest contributions of variance 
from the original parameters to the second eigenvector percent neutral surface area, the 
Voronoi volumes of atoms buried at the interface and anticorrelated contributions from 
the percent charged surface area. The third eigenvector accounts for 12.6% of the total 
variance. It has large contributions from the percent polar surface area and planarity that 
are anticorrelated to the shape complementarity and the circularity. The forth eigenvector 
accounts for 11.2% of the total variance and is dominated by the hydrogen bond 
measurement which is anticorrelated with the shape complementarity. 
This principal component analysis is consistent with the individual analyses of the 
metrics above and is informative about the correlations between the various analyses. 
The interfaces vary most in terms of the atom accessibility and the percent of the buried 
surface area attributed to neutral, polar, and charged groups. The anticorrelation between 
the number of hydrogen bonds and the shape complementarity seen here was noted 
above. Similar to the energetic trade-off implicated in that relationship, the correlation 
between the percent nonpolar interface surface and the Voronoi volumes of atoms buried 
at the interface suggests an exchange between the use of the hydrophobic effect and the 
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Figure 13: This principal component analysis reveals that for this diverse set ofmetrics 
the proteins in our study to not form separate clusters. 
2nd Component (8.54) 
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Principal Components Analysis (Total Variance: 28.19) 
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Figure 14: This principal component analysis reveals that for the percent of surface 
contributed by the different amino acids the proteins in our study do not form separate 
clusters, also. 
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A principal component analysis that measured the covariance between the 
contributions to the interface surface area attributable to different amino acids was also 
conducted over the complete database and the database without the interfaces from the 
nitrogenase and carbon monoxidase (Figure 14). For the amino acid percentages, these 
databases generated identical results. The first three eigenvectors describe 28.2% of the 
total variance captured in these twenty percentages. The first eigenvector ( 12.1% of the 
total variance) has sizable, correlated contributions from tyrosine, tryptophan, asparagine, 
and serine. The second eigenvector (8.5% of the total variance) contains large correlated 
contributions from methionine, histidine, and phenylalanine. The third eigenvector (7.5% 
of the total variance) has correlated contributions from cysteine and arginine and 
anticorrelated contributions from leucine and valine. 
Visualizing the principal component analyses revealed that the categories used in 
the analyses above might be improved. To view the clustering, there are three-
dimensional scatter plots with axes of the three eigenvectors with the largest eigenvalues, 
that is the three new dimensions that describe the greatest amount of variance. 
Visualizing the principal component analyses revealed that a change in the category 
scheme would be informative. The color-coding of the independent analyses is based on 
the categories outlined at the beginning of the paper. These categories were chosen in 
part because they were consistent with previous analyses (Jones and Thornton, 1996; 
LoConte et al , 1999). The new category scheme, shown in the color-coding of the 
principal component analyses is based on categories that may consist of only one side of 
an interface. In this new scheme, the proteases are yellow, the protease inhibitors are 
magenta, antibodies are yellow, antigens are red. The other categories are compressed 
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into enzymes (green), cell-surface receptors (dark blue), ligands (empty yellow squares), 
and signal-transduction molecules (black). 
Even with the modified category scheme, examining the plots of the principal 
component analyses reveals that the categories do not form completely separate clusters. 
These plots show that the categories of interfaces overlap even when the descriptors are 
orthonormal to each other, even when the axes of the plot maximize the variance between 
the interfaces they to not form separate clusters. This means that in most cases the 
different categories of proteins complexes form interfaces in largely the same way. There 
are however two interesting exceptions. It may be seen from these plots is that the 
interfaces of proteases (yellow) and antibodies (light blue) generate a scatter that has a 
center removed from that of the general scatter. In other words, based on the 
measurements in this study the interfaces surfaces of proteases and antibodies are special 
cases of interfaces and distinctly not representative of the average protein interfaces. 
That they are distinct is intriguing because they were the first structures to be determined 
(Janin and Chothia, 1990) and they have shaped our understanding of what protein-
protein interfaces are. 
Conclusions 
Examining a large data set with this broad set of commonly used metrics largely 
confirms and extends previous attempts to examine protein-protein interfaces. The 
protein-level analyses describe the shape and size of the interface and in the interface 
surface area provide a crude method of estimating the role of the hydrophobic effect in 
the association of the proteins. As has been noted earlier (Jones and Thornton, 1997b ), 
the protein-level metric, planarity, and the atom-level metric, atom accessibility, are 
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aspects of interface surfaces that are different on average from the protein surface 
generally. The atom-level analyses are more descriptive of the chemical forces involved 
in forming interfaces. The shape complementarity and atom packing are ways of 
estimating the van der Waals forces. The hydrogen bond density as well as the percent of 
the interface surface attributable to charged atoms might be descriptive of the 
electrostatic component of the interaction. The percent of the interface surface 
attributable to nonpolar atoms is probably a more precise method of describing the role of 
the hydrophobic effect than the size of the interface surface area. The amino-acid 
composition of protein-protein interfaces reveals that the amino acids more likely to be 
present in protein cores than in a protein in general are also more likely to be present at 
interfaces than at the surface in general. The surface of interfaces attributed to certain 
amino acids, tryptophan, tyrosine, and methionine, is a greater percentage of interface 
surface area than these two amino acids contribute to surface area generally. The 
opposite is true for lysine, proline, and glutamate. By using the trends examined here in 
amino acid composition, planarity, and atom accessibility, a protein biochemist may more 
rapidly identify the surface of a protein involved in interacting with another protein. 
The principal component analyses of the interface metrics are original to this 
work, they corroborate the previous analyses and illuminate several questions that may be 
worth further consideration. The principal component analysis conducted on the 
interface surface area, circularity, planarity, accessibility, shape complementarity, 
packing of buried and partially buried atoms, hydrogen bond number, ( 4 A distance 
cutoff), and the percent surface area associated with the nonpolar, polar, and charged 
atom types, explained 51.4% of the total variance with three variables. This analysis 
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confirmed the ability of the atom accessibility and the percent of interface surface area 
attributable to the different atom types to describe the variance seen in protein interfaces. 
This analysis also confirmed an anticorrelation noted between the surface 
complementarity and the number of hydrogen bonds and discovered a correlation 
between the amount of nonpolar interface surface and the Voronoi volume of atoms 
buried at the interface surface that is indicative of a similar energetic exchange. The 
principal component analysis of the percent interface surface attributable to different 
amino acids showed that tryptophan, tyrosine, serine, and asparagine are responsible for a 
large amount of the variance in protein interfaces. 
Visualizing the principal component analyses showed three things. The principal 
component analyses showed how the categories of interfaces could be informative if the 
categories can contain only the related halves of nonobligate complexes. Both principal 
component analyses revealed that the interfaces do not cluster into completely separate 
groups. However, these analyses also reveal the proteases and the antibodies are more 
removed from the general cluster of interfaces. As such they represent somewhat 
exceptional instead of typical nonobligate protein-protein complexes. 
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This chapter discusses the conclusions of the work described above, the related 
work of my collaborators in the lab, the relationship between the various efforts, and the 
planned future experiments. The studies of FeRn function were conducted in 
collaboration with Dr. T. S. Ramalingham, and lately, Scott Detmer, a rotation student in 
the lab. My contribution to these studies was to generate and purify the DNA necessary 
to construct the various cell lines and design, generate and purify many of the various 
proteins involved in the assays. This chapter discusses the implications of the FcRn:hdFc 
structure, implications that lead us to design an antibody with a longer serum half life. 
Pavel Strop of the Rees lab was instrumental in the development of this project. After 
describing how understanding protein-protein interactions played a role in the progress of 
this work, chapter concludes by discussing the new experiments to be pursued in 
extending these results. 
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Introduction 
This thesis involves two distinct efforts. The first effort was an attempt to 
understand the functional significance of an oligomeric ribbon structure observed in 
FcRn/Fc complex crystals (See chapters 2, 3 and Figure 1 here for a description of the 
oligomeric ribbon). The basic strategy was to disrupt the various protein-protein 
interactions that are required to form the ribbon and observe their effect on the function 
of FeRn. This strategy resulted in the creation and characterization of the heterodimeric 
Fe (hdFc). This basic strategy also guided attempts to generate a form of FeRn that does 
not form an FeRn dimer. Studies of FeRn dimer formation have lead to experiments 
proposed at the end of this chapter that may address the significance of the oligomeric 
ribbon with a new technique. 
The decision to study the role of the oligomeric ribbon in FeRn function by 
disrupting the protein-protein interactions in the ribbon lead to the second effort of this 
thesis. In order to disrupt the various protein-protein interactions it became important to 
understand the phenomenon of protein-protein interactions thoroughly . A deeper 
understanding of protein-protein interactions resulted in proposing experiments to 
improve the FcRn:Fc interaction discussed at the end of this chapter. The deeper 
understanding of protein-protein interactions has also indicated possible difficulties in the 
strategy of disrupting the oligomeric ribbon. Circumventing these difficulties is possible 
in the experiments utilizing the new strategy mentioned above. 











2:1 FcRn-Fc complex 






Figure 1: The oligomeric ribbon observed in cocrystals as a model for the 
formation of higher order oligomers upon binding of IgG to membrane bound FeRn. A) Top 
view of the ribbon. FeRn dimers are bridged by Fe molecules. Under physiological 
conditions, each FeRn dimer would be associated with a membrane parallel to the plane of 
the paper: the left-most dimer is associated with a membrane below the paper; the central 
dimer with a membrane above the paper, and the right-most dimer is again associated with a 
membrane below the paper. Lego representations of the shaded portions are shown below the o 
corresponding region of the ribbon. B) Side view, rotated by 90 about the horizontal axis 
from the view in part A . The FeRn dimers are seen looking down their long axes (vertical in 
A). Formation of the ribbon in acidic vesicles would result in close juxtaposition (-200 A) 
of two parallel membranes and a clustering of FeRn cytoplasmic tails into an ordered array. 
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Discussion: 
Attempts to determine the importance of the "oligomeric ribbon" to FeRn function 
The possibility that the oligomeric ribbon that forms in FcRn/Fc complex crystals 
is important to FeRn function stimulated the first effort of my thesis. We proposed that 
the oligomeric ribbon might be important to FeRn function if it formed inside cells 
between narrowly opposed (- 200 A) membranes (Chapter 2). In MDCK cells expressing 
FeRn or FcRn-EGFP, FeRn is localized in apical endosomes, where the acidic pH 
permits FcRn-IgG binding (Ramalingham et al. , manuscript in preparation). From the 
apical endosomes of these cells FcRn/IgG complexes are either trancytosed to basolateral 
surface of the cells or recycled to the cell surface (Ramalingham et al. , manuscript in 
preparation). We had several conjectures as to when the oligomeric ribbon might occur 
during these processes. Small FcRn-IgG complexes with all the interactions seen in the 
oligomeric ribbon might form as a signal for transport inside endosomes. More extensive 
ribbon-like structures might also exist as narrow tubules transiently extending from 
endosomes to the cell surface. The narrow size of the oligomeric ribbon and the its 
possibly ephemeral Nature made it unclear whether visualizing the ribbon directly was 
possible. Even if the oligomeric ribbon could be visualized directly it would still not be 
clear whether forming the ribbon was necessary for FeRn to recycle or transcytose lgG. 
Ribbon testing strategy 
In order to determine whether ribbion formation was necessary to FeRn function, 
we proposed to disrupt the ribbon and determine if FeRn would still trancytose IgG. The 
most direct way to disrupt the ribbon was to alter its components. The formation of the 
oligomeric ribbon requires two distinct 2 :1 FcRn:Fc complexes: a 2:1 complex with an 
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FeRn dimer and a2: 1 complex with a bridging Fe. We thought that if we could disrupt 
each of these complexes selectively and if each of these disruptions to the ribbon were 
deleterious to FeRn function we could argue persuasively that the ribbon was necessary 
for FeRn function. 
The earliest experiments in which we participated, indicated that one of the 2:1 
FcRn:Fc complexes, the complex of one Fe bound to a dimer of FeRn molecules, was 
important to FeRn function. In the experiments described in Appendix A, we found that 
mutations made at positions in the FeRn dimer interface affected the affinity of the 
interaction between FeRn and IgG. The apparent importance of the FeRn dimer to the 
high affinity binding of lgG lead us to determine whether disrupting the other 2:1 
FcRn:Fc complex would affect FeRn function. 
Generating and characterizing the hdFc 
We were successful in disrupting the other 2:1 FcRn:Fc complex, the complex of 
wild-type Fe (wtFc) bound on either side by FeRn. This complex was disrupted by the 
generation of the hdFc (Chapter 2). The hdFc is a wild-type Fe molecule with one FeRn 
binding site removed by site-directed mutagenesis. In solution studies and in 
experiments with FeRn anchored to a solid support, the hdFc does not bind a second 
FeRn (Chapter 2). We also showed that hdFc binds FeRn as well as wtFc binds FeRn ats 
high affinity binding site but that the wtFc shows higher avidity for the ligand. Because 
the hdFc bound one FeRn with high affinity we felt that examining its behavior in a 
trancytosis assay would indicate whether the complex of Fe bound on either side by FeRn 
was necessary for FeRn function . 
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hdFc in functional assays 
The disruption of the complex of Fe bound on either side by FeRn by the hdFc 
was shown to be deleterious to FeRn function (Ramalingham et al., manuscript in 
preparation, Figure 2). The hdFc was trancytosed at levels not much above background. 
Ramalingham also developed a method for assaying the formation of ribbon like structure 
in a test tube. In an assay using liposomes containing a GPI-linked form of FeRn, the 
wtFc induced the aggregation of liposomes at pH 6 but not at pH 8 (Ramalingham et al. , 
manuscript in preparation, Figure 3). The hdFc largely fails to induce liposome 
aggregation in this assay. It is not clear what causes the small level of trancystosis of 
hdFc or the slight tendency of the hdFc to induce liposome aggregation. As the wtFc is 
expressed in the same cells as the hdFc these small effects might be the result of residual 
amounts of wtFc in the purified hdFc. Because this small level of activity occurs in both 
assays we believe that the small level of hdFc that undergoes trancytosis is a part of 
experimental noise and that is not inconsistent with the oligomeric ribbon being 
necessary for FeRn function. 
hdFc in FcRn:hdFc cocrystals 
The hdFc forms FcRn:hdFc crystals that do not contain the oligomeric ribbon. 
These crystals diffracted to 2.8 Aresolutions and allowed the first detailed analysis of the 
FcRn/Fc interface (Chapter 3). The structure contains ordered carbohydrate at the 
FcRn/Fc interface that was helpful in explaining why high mannose forms of FeRn bound 
Fe less well than FeRn forms with complex carbohydrates (Popov et al., 1996; Sanchez et 
al. , 1999). The FcRn:hdFc structure illustrated the mechanism of pH-dependent binding. 
Three histidines form salt-bridges with 2 glutamates and one aspartate. The one salt-
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Figure 3: Aggregation of liposomes containing GPI-Iinked FeRn by wtFc and not by hdFc. 
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bridge that is conserved in the rat, mouse, bovine, and human sequences of FeRn and lgG 
is the salt-bridge that is most buried in the structure. In conjunction with the extensive 
mutagenesis work done by our lab and others we were able to use this structure to suggest 
strategies for making lgG antibodies with longer serum half-lives. One of these 
strategies, an attempt to bias the observed flexibility between the Cy2 and Cy3 domains 
(proposed in Chapter 3) towards the relative orientation between the domains observed 
when binding FeRn is a future experiment we intend to pursue. 
FeRn dimer studies 
The hdFc gave us the ability to disrupt the complex of Fe bound on either side by 
FeRn and the ability to distinguish between this complex and 2: I FeRn: Fe complex 
involving the formation of the FeRn dimer (Chapter 4). We used this ability to show that 
the FeRn-TrkA chimera in the presence of hdFc was capable of forming the FeRn dimer. 
It was our hope that by introducing mutations at positions in the FeRn dimer interface to 
the FeRn-TrkA chimera we would be able to isolate a form of FeRn that does not 
undergo ligand-induced dimerization. Unfortunately, by the time these mutant forms 
were prepared we were no longer able to observe the hdFc inducing the FeRn dimer. We 
are unsure why the results of this experiment changed but one possibility is an alteration 
of the cell line, perhaps in response to non-native signalling by the chimeric protein. 
Because of the failure to reproduce this result and because the hdFc did not induce a 
dimer of FeRn molecules in the FcRn:hdFc crystals (Chapter 3) we designed an assay 
that would allow us to determine if FeRn forms a dimer without inducing any signalling 
cascades and independent of the presence of the ligand. 
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FeRn dimer FRET assays 
We designed FcRn-ECFP and FcRn-EYFP chimeras, transiently transfected Cos-
7 cells with the constructs and assayed for fluorescence resonance energy transfer 
(FRET) using a two-photon microscope (Chapter 4). We were able to observe FRET in 
some cells. These results were consistent with the formation of the FeRn dimer in these 
cells but they are not conclusive proof. There was difficulty in assessing whether the 
observed FRET was the result of the formation of the FeRn dimer or the result of general 
crowding in cells expressing the chimeras at high levels. This difficulty combined with 
the inconsistency and variability in these results suggest that more interpretable results 
might be obtained with cell lines stably transfected with these chimeras. 
The current view of the importance of the oligomeric ribbon to FeRn function 
The results of this thesis are not conclusive on the importance of the oligomeric 
ribbon to FeRn function. The importance of residues at the FeRn dimer interface for Fe 
binding is consistent with an FeRn dimer being used in cells to bind Fe. The low amount 
of hdFc trancytosed by FeRn is consistent with both FeRn binding sites being required 
for efficient transcytosis. The absence of the FeRn dimer in the FcRn:hdFc crystals and 
the difficulty in observing the formation of the FeRn dimer in conditions outside the 
crystals does not demonstrate the FeRn dimer is unimportant but does not support its 
importance either. The wtFc-dependent aggregation of liposomes is consistent with 
oligomeric ribbon structures forming between the liposomes but it is unclear whether 
these studies replicate what occurs inside the cell. 
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Lessons gleaned from reviewing protein-protein interactions 
Our study of protein-protein interactions began early in this work and was the 
result of wishing to know how best to disrupt the FcRn:Fc interaction. We learned that 
not all residues are equally represented in nonobligate protein-protein interfaces and that 
not all residues in nonobligate protein-protein interfaces are equally important to the 
formation of the complex (Chapters 1 and 5). In particular, we learned that only the 
residues at the core of these interfaces are likely to be critical to the formation of the 
complex. We also learned that these residues are usually buried away from solvent and 
extremely well packed. This latter understanding was helpful in deciding how to try to 
enhance the FcRn:Fc interaction (see below). Finally, reviewing protein-protein 
interactions revealed that while disrupting a high affinity interaction is easy to detect, 
disrupting interactions of low affinity is much more difficult. Because the affinity of the 
FeRn-FeRn dimer interaction is on the order of millimolar (Chapter 4) even in the 
presence of the ligand (Chapter 3), disrupting the formation of this complex will be 
difficult to detect. This illuminates how one aspect of our general strategy for 
demonstrating the ribbon was impractical. Because disrupting the FeRn dimer is difficult 
to detect, we feel that demonstrating its importance to FeRn function might be better 
accomplished by determining when and where it occurs as FeRn transcytoses IgG. 
Proposed experiments 
It is the conclusion of this thesis that two experiments in this system should be 
pursued. To monitor the formation of the FeRn dimer throughout the FeRn-mediated 
trancystosis of lgG we propose to generate stable FcRn-ECFP/FcRn-EYFP transfectant 
of MDCK cells as proposed in chapter 4. This cell line will allow us to monitor the 
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formation of FeRn dimers directly by two-photon microscopy and it will allow us to 
circumvent obtaining mutant forms of FeRn that do not form an FeRn dimer. 
The second experiment we propose is to generate a mutant form of the Fe protein 
that may have a higher affinity for FeRn. For reasons outlined in Chapter 3 we propose 
to make a high affinity Fe by constraining the considerable flexibility between the Cy2 
and Cy3 domains. To constrain this flexibility we decided to try pack this interface as 
densely as possible. To do this we collaborated with Pavel Strop of the Rees group who 
utilized the ORBIT program (Dahiyat and Mayo, 1997) to predict amino acid 
substitutions that would generate a stable core between these two domains. To do this the 
amino acids at positions in between the Cy2 and Cy3 domains were selected by visual 
inspection. The type of amino acids and the conformation of the side chain at these 
positions were allowed to vary. At all other positions the amino acid type was held 
constant but the conformation of the side chain could vary. The positions of the main 








248 250 251 314 338 376 428 430 
Lys Val Leu Leu Lys Asp Leu Glu 
Arg Ile Leu Leu Lys Leu Phe Glu 
Independent calculations by the author confirm that the density of atoms in the 
Cy2 and Cy3 interface should be significantly improved in the mutant protein. 
Generating this mutant protein and assaying its ability to bind FeRn will allow us to 
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determine if packing the Cy2 and Cy3 interface results in an Fe that binds FeRn better. 
Obtaining crystals of the mutant protein will allow us to determine if packing the Cy2 and 
Cy3 interface biased the orientation of the two domains towards the conformation they 
assume when binding FeRn. 
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Identification of Critical lgG Binding Epitopes on the 
Neonatal Fe Receptor 
This appendix describes the characterization of the Fe binding site on FeRn and 
the FeRn dimer interface by assaying the ability of mutant forms of FeRn to bind lgG in 
surface plasmon resonance experiments. My contribution to this work occurred during 
my rotation in the Bjorkman lab and involved making six of the 11 site-directed 
mutations by the Kunkel method. I also subcloned the DNA for the mutant proteins into 
the mammalian cell expression vectors. 
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The neonatal Fe receptor (FeRn) binds maternal immunoglobulin G (lgG) 
during the acquisition of passive immunity by the fetus or newborn. 
FeRn also binds lgG and returns it to the bloodstream, thus protecting 
lgG from a default degradative pathway. Biosensor assays have been 
used to characterize the interaction of a soluble form of rat FeRn with 
lgG, and demonstrate that FeRn dimerization and immobilization are 
necessary to reproduce in vivo binding characteristics. Here, we report 
the identification of several FeRn amino acid substitutions that disrupt its 
affinity for lgG and examine the effect of alteration of residues at the 
FeRn dimer interface. The role of these amino acids is discussed in the 
context of the previously reported structures of rat FeRn and a complex 
of FeRn with the Fe portion of lgG. 
(f 1997 Academic Press Limited 
"Corresponding author 
Keywords: surface plasmon resonance; biosensor; structural binding site; 
functional epitope; binding free energy 
Introduction 
The neonatal Fe receptor (FeRn) binds immuno-
globul.in G (lgG) in two important physiological 
processes (Junghans, 1997). In the transmission of 
passive immunity from mother to offspring, FeRn 
mediates the transcytosis of maternal lgG across 
fetal and / or neonatal tissues, depending on the 
species involved. FeRn also binds lgG inside cells 
that degrade serum proteins and returns it to the 
bloodstream, thus rescuing it from a default degra-
dative pathway. Each of these processes is facili-
tated by the pH dependence of FeRn interaction 
with lgG (Rodewald, 1976; Rodewald & 
Kraehenbuhl, 1984). Under slightly acidic con-
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fluorescence-activated cell sorting; FITC, fluorescein 
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ditions (pH 6.0), FeRn binds lgG with a K0 of 
approximately 20 nM, while under slightly alkaline 
conditions (pH 7.5) there is no detectable binding 
for lgG concentrations of severalj!M (Raghavan 
eta/., 1995a). 
Unlike other known Fe receptors which are com-
posed of tandemly repeated immunoglobulin-like 
domains, FeRn is homologous to class I major 
histocompatibility complex (MHC) molecules 
(reviewed by Raghavan & Bjorkman, 1996). The 
FeRn light chain is 132-microglobulin (132m; Simister 
& Rees, 1985), the same light chain that associates 
with class I MHC heavy chains. The heavy chains 
of both FeRn and class I MHC molecules consist of 
three extracellular domains, cx1, cx2 and cx3, fol-
lowed by a transmembrane region and a short 
cytoplasmic sequence (Bjorkman & Parham, 1990; 
Simister & Mostov, 1989). The extracellular region 
of FeRn and class I MHC heavy chains exhibit low 
but significant sequence identity (22 to 30% for the 
cx1 and cx2 domains, 35 to 37% for the cx3 domain; 
Simister & Mostov, 1989). A 2.2 A crystal structure 
of the extracellular region of rat FeRn revealed the 
expected structural similarity to MHC molecules 
and suggested the participation of a dimer of FeRn 
heterodimers in ligand binding (Burmeister et al., 
1994a). In each of the three crystal forms in the 
FeRn structure determination, a dimer of FeRn 
molecules mediated by contacts between the cx3 
and 132m domains was observed. The FeRn dimer 
(j) 1997 Academic Press Limited 
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was also observed in the crystal structure of a 2:1 
complex of FeRn and the Fe fragment of rat IgG 
which was solved to a resolution of "='6.5 A 
(Burmeister eta/., 1994b). Although the limited res-
o lution of this structure determination prohibited a 
detai led analysis of the molecular interaction, the 
approximate binding region on each molecule 
could be localized (Figure 1). 
Results from studies to map the binding sites on 
FeRn and IgG are consistent w ith the binding inter-
action observed in the FcRn/Fc crystal structure. 
Three sites on the IgG ligand have been identified 
as important for the binding of mouse and rat 
FeRn: Ile253, His310, and the region including 
His433, His435 and His436 (Kim et a/., 1994a,b,c; 
Medesan et a/., 1997; Raghavan et a/., 1994, 1995a; 
Figure 2a and b). Mutation of residues within each 
of these epitopes disrupts both binding to FeRn 
in vitro and FeRn mediated transport in vivo (Kim 
et a/., 1994a,b,c; Medesan et a/., 1997; Raghavan 
et a/., 1995a). There is less information available 
concerning the functional epitope on FeRn for 
binding IgG. Site-di rected mutagenesis was used 
to identify two regions on rat FeRn that exert a 
slight effect on its affinity for rat IgG: His 250 and 
His251, and the cx3 domain loop comprising resi-
J>rimm·y FeRn Sccondar·y FeRn 
Figure 1. Ribbon diagram of the co-crystal structure of 
the FeRn dimer binding to its Fe ligand. The high affi-
nity binding site for IgG is formed by a homodimer 
of two FeRn molecules identified as the "primary FeRn" 
(cyan and light green) and the "secondary FeRn" (blue 
and dark green). Each FeRn molecule is composed of a 
multidomain heavy chain (cyan or blue) and a single 
domain light chain (!}2m; green). The Fe ligand (red) 
interacts with the heavy chain a.2 domain and !}2m 
domain of the primary FeRn, and the heavy chain a.3 
domain of the secondary receptor. Previously character-
ized FeRn heavy chain mutations that affect ligand bind-
ing (see text for details) are shown in magenta. The 
FeRn dimer interface shown as a close-up in Figure 2c is 
indicated by a black box. 
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dues 219 to 224 (Raghavan eta/., 1994). Neither of 
these regions is at the direct interface between the 
" primary" FeRn molecule that shows the majority 
of contacts with Fe in the 2:1 complex involving 
the FeRn dimer (Figure 1). His250 and His251 are 
at the FeRn dimer interface where they may exert 
their effect in IgG binding a ffinity either by modu-
la ting formation of the FeRn dimer, which is 
required for high affinity binding of IgG 
(Raghavan eta/., 1994, 1995b), or by direct contact 
between Fe and the "secondary" FeRn molecule of 
the FeRn dimer (Figure 1; Z. Weng, K. Gulukota, 
D.E.V., P.J.B. & C. DeLisi, unpublished results). 
Similarly, residues 219 to 224 of the secondary, but 
not the primary, FeRn molecule are in a position to 
contact Fe (Z. Weng, K. Gulukota, D.E.V., P.J.B. & 
C. DeLisi, unpublished results). 
Because of the low resolution of the available 
FcRn/Fc co-crystal structure, we cannot identify 
specific FeRn residues at the IgG interface w ith cer-
tainty. To characterize further the epitope on FeRn, 
we designed, constructed, and expressed mutants 
of rat FeRn a t the predicted interfaces with IgG 
and w ith the second FeRn in the receptor dimer. 
We have quantitatively characterized the IgG bind-
ing interaction for each of these FeRn mutants 
using a biosensor based assay (Raghavan et a/., 
1994, 1995a,b; Vaughn & Bjorkman, 1997). In this 
assay, soluble FeRn immobilized on a biosensor 
surface reproduces the affinity for lgG and the pH 
dependent interaction observed for membrane 
bound FeRn in vivo and on transfected cells 
(Mackenzie, 1984; Raghavan eta/., 1994). We have 
used the assay to demonstrate that high affinity 
binding of IgG requires both FeRn dimerization 
and receptor immobilization (Raghavan et a/., 
1995b; Vaughn & Bjorkman, 1997). Here, we ident-
ify several residues on rat FeRn that exert a major 
effect on binding affinity for murine or rat IgG, dis-
cuss the implications for pH dependent FcRn / IgG 
binding and FeRn dimerization, and compare the 
res ults to other known receptor- ligand and pro-
tein - protein interaction systems. 
Results 
~2m mutants at the FcRn-Fc interface 
Using the FcRn/Fc co-crysta l structure 
(Burmeister et a/., 1994b), we identified FeRn resi-
dues predicted to contact Fe. Most are located on 
the cx2 domain of the primary recepto r, wi th fewer 
contributions from the cxl and 132m domains of the 
primary receptor and the cx3 domain of the second-
ary (dimer-related) receptor. To verify the contacts 
between Fe and the primary FeRn predicted by the 
low resolution co-crystal structure, we constructed 
eight FeRn mutants. 
The co-crysta l structure pred icts that the N-
terminal portion of 132m contacts the Fe CH2 
domain (Figures 1 and 2a). To test this hypoth-
esis we examined the binding of three mutants: 
I3I1A, 13Q2A, and 13-1Y (Table 1). In order to 
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Figure 2. Close-up views of the mutated amino acids on FeRn. Orientations are the same as shown in Figure 1 (a and 
b) or rotated by 45• about a horizontal axis (c). Substituted amino acids are highlighted in yellow (mutations 
described and characterized in this text) or magenta (previously characterized mutations). Other colors are as 
described for Figure 1. Highlighted positions are: (a) Ilel (11) and Gln2 (Q2) of 132m, amino acids 84 to 86 and Trp133 
(W133) of the FeRn heavy chain, and Fe Ile253 (1253}; (b) His310 (H310), His433 (H433), His435 (H435), and His436 
(H436) of the Fe and Glul17 (El17}, Glu132 (E132}, Glul35 (E135}, and Aspl37 (0137) of the FeRn heavy chain; and 
(c) Gly191 (G191}, His250 (H250), His251 (H251) of the FeRn heavy chain, and Glu89 (E89) of 132m. 
avoid potential exchange of mutant ra t P2m for 
endogenous hamster P2m or bovine P2m in the 
medium, these mutations were introduced into a 
lipid-linked version of rat P2m that associates 
with the truncated FeRn heavy chain a t the cell 
surface. This form o f lipid-linked w ild-type FeRn 
was previously shown to bind IgG with the 
known physiological pH dependence (Gastinel 
et a/., 1992). The affinity of these mutants for 
radiolabeled lgG was evalua ted using a cell bind-
ing assay (Table 2). The binding response a t equi-
librium was plotted as a function of the log of 
the concentra tion of IgG and fit to a model 
assuming one class of b inding s ites (Figure 3a). 
The binding behavior of FeRn at the cell surface 
may be more complicated (sec Vaughn & 
Bjorkman, 1997 for discussion), but the data from 
the cell binding assays are too noisy to reliably 
Table 1. FeRn mutants 
Mutant Domain 














fit more complica ted binding models. However, 
the affinity derived us ing the cell binding assay 
agrees with high affinity binding constants 
obtained using a biosensor assay (K0 = 24 nM, 
cell binding assay; K0 = 24 nM, biosensor assay 
(Vaug hn & Bjorkman, 1997); in both cases a rat 
IgG2a monoclona l antibody against C D4 was 
used). When the mutants were examined using 
the cell binding assay, we find that substitution 
o f the N-terminal lie of P2m with alanine (PilA), 
o r extension of the N te rminus by one additional 
residue (P-lY), elimina tes significant IgG binding 
at concentrations up to 0.9 1-1M, corresponding to 
a 66G of >2 kcal/mol (Table 2). However, sub-
stitution of Gln2 of the P2m domain with alanine 
{PQ2A) results in binding similar to w ild-type 
FeRn (Table 2; Figure 3a and b), a lthough the 
total binding response is increased presumably 
Position(s) Mutation 
1 1-> A 
2 Q->A 
N terminus add Y 
133 W->A 
84- 86 NQI-> GYY 
117 E->5 
132 and 135 BothE-> Q 
137 o .... N 
191 c .... E 
191 c .... H 
89 E .... H 
89 E .... K 
185 
600 
Table 2. Characterization of lgG binding to FeRn mutants 
Mutant Ku.1 (nM) 
Fe-FeRn interface: 




Wild-Type 12 ± 2 
Wl33A >8000 
84-86 6 .0 ± 0.6 





Wild-Type 6.3 ± 0.4 
Gl91E 25 ±5 
Gl91H 21 ±4 
Wild-type 10± 1 
Gl91E 57±5 
Gl91H 90±30 






N .B. =no binding detected. 






39 ± 2 
54±3 








1.1 ± 0.3 
0.9 ± 0.2 
0.7 ± 0.2 
0.9±0.1 
2.2 ± 0.7 
1.9 ± 0.5 
0.9 ± 0.2 
4.4 ± 0.9 
5±4 
0.8±0.1 
1.2 ± 0.2 
1.4 ±0.2 
0.6 ± 0.2 
1.7 ± 0.5 
1.5± 0.4 
• Arbitrary units on the same relative scale. 
• Affinity measurements done using lipid-linked FeRn at the cell surface. 
'Observed binding response at highest 1gG concentration (8 I'M). 
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Rm ... t"' (RU) t.t.G (kcal / mol) Receptor (RU) 
0.129 ± 0.008' (ceU)" 
N .B. »2 (ceU) 
0.60± 0.04' -0.5 (ceU) 
N.B. »2 (ceU) 
910 ± 30 2370 
130' >4 3370 
1430 ± 30 -0.4 1850 
1890 ± 30 2660 
250' >4 2160 
N.B. »4 3820 
N.B. '*>4 3770 
1410±20 2660 
650 ± 40 0.8 2820 
740 ± 30 0.7 3600 
580 ± 20 1460 
370 ± 20 1.1 2450 
350 ± 60 1.4 1650 
1250 ± 20 2700 
1180±30 0.6 2670 
1310 ± 20 0.7 2000 
880 ± 20 1170 
no±30 0.8 1390 
660 ± 20 0.7 1450 
because the J32QA mutant is expressed at a high-
er level than the wild-type construct as demon-
strated by fluorescence-activated cell sorting 
(FACS) analysis (data not shown). 
FeRn heavy chain mutants at the 
FcRn- Fc interface 
In order to characterize more completely the 
binding, we used a surface plasmon resonance 
assay to measure the binding affinities between 
IgG and soluble forms of wild-type and mutant 
receptors. Biosensor analyses of the interaction of 
IgG with soluble FeRn immobilized on a biosensor 
chip show non-linear behavior in Scatchard plots 
(Raghavan et a/., 1995a,b). We recently demon-
strated that the interaction of IgG with immobi-
lized FeRn is best described as two classes of non-
interacting FcRn/lgG complexes: a slow-dissociat-
ing population with an affinity in the range of 
values calculated in studies using membrane-
bound FeRn (Mackenzie, 1984; Raghavan et a/., 
1994), and a fast-dissociating population with 
lower affinity (Vaughn & Bjorkman, 1997). As pre-
viously described (Vaughn & Bjorkman, 1997), 
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Figure 3. IgG binding to 132m 
mutants at the FcRn-Fc interface. 
Equilibrium IgG binding to mem-
brane associated wild-type and 
mutant IJQ2A FeRn (expressed in 
arbitrary units proportional to the 
amount of IgG bound) is plotted as 
a function of the log of the IgG 
concentration. The best fit binding 
curves (continuous lines), modelled 
as a single class of non-interacting 
binding sites, correspond to the 
values reported in Table 2. Two 
additional mutants ll112A and ~ 
I Y) showed no significant binding 
at lgG concentrations of ~0.9 11M 
(data not shown). 
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Figure 4. lgG binding to FeRn 
heavy chain mutants at the FcRn-
Fc interface. Equilibrium lgG bind-
ing to wild type and mutant FeRn 
proteins immobilized on a biosen-
sor chip is plotted as a function of 
the log of the lgG concentration. 
The best fit binding curves (con-
tinuous lines), modelled as two 
classes of non-interacting binding 
sites, correspond to the values 
reported in Table 2. 
of the concentration of injected ligand were 
analyzed using non-linear regression to derive the 
percent of FcRn/lgG complexes comprising each 
population (/1 and / 2), the high and low affinity 
binding constants (K0 .1 and K0 .2, respectively), and 
the maximum combined binding response (Rmax,tot; 
Table 2). 
Two mutations to the FeRn heavy chain were 
made in order to test the importance of potential 
aromatic and/or aliphatic contacts predicted from 
the co-crystal structure: W133A and 84-86 
{Table 1). FeRn Trp133 is exposed to solvent in 
the structure of FeRn alone (Burmeister et a/., 
1994a), and is in a position where it could inter-
act with the Ile253 of Fe, which was identified as 
a critical residue on Fe for interaction with FeRn 
(Kim et a/., 1994a,b,c; Medesan et a/., 1997; 
Raghavan et a/., 1995a) (Figure 2a). We find that 
IgG binding to the W133A mutant is extremely 
weak even at 11M concentrations (Figure 4a). Thus 
the affinity of this mutant for IgG is >8 11M corre-
sponding to a t.t.G of >4 kcal / mol {Table 2). 
The 84-86 mutation {Table 1) encompasses three 
of the four amino acids in the cx1 domain that 
are predicted to be within 5 A of the Fe ligand in 
the co-crystal structure (Figure 2a). We find that 
replacement of these residues with the corre-
sponding residues from class I MHC molecules 
(Kabat et a/., 1991) results in a binding affinity 
similar to wild-type (Figure 4a; Table 2). 
Much of the pH dependence of the FcRn- Fc 
interaction has been assigned to the titration of his-
tidine residues on the Fe ligand (Raghavan et a/., 
1995a). There are several acidic residues on the cx2 
domain of the receptor that could interact electro-
statically with the protonated form of these histi-
dine residues. Glu117 is positioned near Fe His310, 
Glu132 and Glu135 are near Fe His435, and 
Asp137 is in the vicinity of Fe His 435 (Figure 2b). 
Three mutations (E117S, E132Q&E135Q, and 
D137N) were constructed to test the functional 
importance of these acidic residues {Table 1). 
Neither E117S nor E132Q&E135Q bind IgG signifi-
cantly at concentrations up to 8 11M (Figure 4b; 
Table 2). The D137N mutant binds IgG slightly 
at 11M concentrations, but the binding affinity is 
also >8 11M (Figure 4b; Table 2). For each mutant, 
the calculated high affinity binding is reduced by 
greater than 1000-fold, corresponding to a t.t.G of 
more than 4 kcal/mol. 
FeRn mutants at the dimer interface 
In order to examine the effects on IgG binding of 
mutations at the FcRn-dimer interface, we made 
mutations at two additional positions within FeRn. 
Based on the crystal structures of FeRn alone and 
the FcRn/Fc complex (Burmeister et a/., 1994a,b), 
Gly191 is positioned such that side-chains intro-
duced at this position should interact with position 
191 of the dimer related FeRn molecule (Figure 2c). 
We constructed two mutants (G191E and G191H) 
to examine the effect of substitution at position 191 
{Table 1). Both mutations have a slight (::::fourfold) 
effect on the high affinity binding constant (Ko,,) 
when FeRn is coupled at densities greater than 
2500 RU (Figure Sa; Table 2). Both mutants also 
show a reduction in the total number of binding 
sites (Rmax,tot) and the fraction of high affinity bind-
ing sites (/1) compared to wild-type FeRn. IgG 
binding is further reduced when the FeRn concen-
tration on the chip is lowered by coupling at lower 
densities. Under these conditions, high a ffinity 
binding is reduced (six- to tenfold) and the fraction 
of high affinity and total number of binding sites 
are again reduced relative to wild-type FeRn 
(Figure Sb; Table 2). 
We next examined the effects of mutating P2m 
residue Glu89. This residue is in position to form a 
salt bridge with either His250 or His251 of the 
dimer-related FeRn heavy chain (Figure 2c). We 
previously showed that mutation of His250 and 
His251 results in a sixfold reduction in affinity for 
IgG (Raghavan et a/., 1994). Two mutations were 
constructed (pE89H and PE89K) to test the role of 
Glu89 in dimer formation and IgG binding 
(Table 1). Similar to the mutations at Gly191, sub-
stitution of Glu89 with either a histidine or a lysine 
residue results in a slight reduction in high affinity 
IgG binding, and a reduction in the fraction of 
high affinity IgG binding sites (Figure Sc; Table 2). 
Unlike the Gly191 mutations, however, the total 
number of binding sites is not reduced, and the 
effect on affinity is largely independent of coupling 
density (Figure Sd; Table 2). 
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Figure 5. IgG binding to FeRn 
mutants at the dimer interface. 
Equilibrium IgG binding to wild-
type and mutant FeRn proteins 
immobilized on a biosensor chip is 
plotted as a function of the log of 
the IgG concentration. The best fit 
binding curves (continuous lines), 
modelled as two classes of non-
interacting binding sites, corre-
spond to the values reported in 
Table 2. Experiments were per-
formed at high (a and c) and low 
(b and d) coupling densities. 
Values for coupling densities are 
indicated in parentheses. 
(lgO) lnM) 
Discussion 
Functionally critical residues for protein-protein 
interactions can be mapped by site-directed muta-
genesis followed by determination of mutant bind-
ing affinities. This is an especially powerful 
method when high resolution structures are avail-
able to identify the residues at the receptor-ligand 
interface. One of the best characterized protein-
protein interfaces is the interaction between human 
growth hormone (hGH) and its receptor (hGHR). 
Wells and co-workers have systematically changed 
all the residues that compose the crystallographi-
cally observed interface between the hormone and 
its receptor (DeVos eta/., 1992) to alanine residues, 
and find that only a small subset of the amino 
acids at the interface (approximately 5 of the 24 to 
31 residues) are responsible for most of the binding 
affinity (Wells & DeVos, 1996). Thus there is a dis-
tinction between the " functional epitope" (those 
residues that exert a major effect upon the binding 
affinity; 66G > 2 kcal / mol for substitution of a 
single amino acid to alanine) and the "structural 
binding site" (all residues at the interface). 
In the case of the interaction between FeRn and 
IgG, the structural binding site cannot be identified 
with certainty using the available low resolution 
FcRn/Fc co-crystal structure (Burmeister et a/., 
1994b). The IgG binding site was tentatively ident-
ified as primarily formed from a surface of the cx2 
domain with additional potential contributions 
from residues in the cx1 domain, the top surface of 
the P2m domain, and/or the cx3 domain of a dimer 
related molecule (Burmeister et a/, 1994b). Because 
the complex structure was determined using 
crystals that diffracted to only about 6.5 A and a 
portion of the Fe CH2 domains was disordered in 
the final electron density maps, we sought exper-
imental confirmation of the IgG binding site on 
FeRn. The identification of several amino acid 
substitutions that substantially disrupt IgG binding 
within the structural epitope predicted from the 
low resolution co-crystal structure provides this 
confirmation. We have identified several amino 
acid mutations (W133A, E117S, D137N, 
E132Q&E135Q, PllA and P-lY) that result in a 
decrease in the free energy of binding of more than 
2 kcal/mol (Table 2). These mutants, and all 
mutants in this study, are correctly folded as 
assayed by monoclonal antibody reactivity and 
heterodimer assembly (see Methods). Thus FeRn 
heavy chain residues Trp133, Glu117, Asp137, 
either Glu132, Glu135 or both, as well as lle1 and 
the N terminus of P2m comprise much of the func-
tional IgG binding epitope. 
Well-characterized functional binding epitopes 
for protein- protein interfaces often include surface 
exposed hydrophobic residues that make import-
ant contributions to the free energy of binding. For 
example, hydrophobic interactions contribute to 
the binding energy in several antibody- antigen 
interactions (Dall' Acqua et a/., 1996; Kelley & 
O'Connell, 1993; Tsumoto et a/., 1995). In addition, 
the binding affinity for the hGH/hGHR interaction 
arises primarily from hydrophobic interactions, 
with electrostatic interactions being less important 
(Wells & DeVos, 1996). For hGHR, the largest con-
tributions to the free energy of binding come from 
Trp104 and Trp169. Replacement of either residue 
with an alanine results in a loss of binding free 
energy of more than 4.5 kcal/mol. The next three 
largest contributions also are made by hydro-
phobic residues (lle103, lle105, and Pro106), each 
with a loss of binding free energy of 1.5 to 
3.5 kcal/mol. For the hormone, both polar and 
hydrophobic residues show significant decreases in 
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binding free energy when substituted with alanine 
residues. interestingly, several of the polar residues 
(e.g. Lysl72, Thr175, and Arg43) use the aliphatic 
portions of their side-chains to contact the receptor. 
There is also a strong hydrophobic component to 
the interaction between FeRn and its IgG ligand. 
Previous reports have implicated Jle253 as part of 
the ligand's functional epitope (Kim el a/., 
1994a,b,c; Medesan et a/., 1997; Raghavan et a/., 
1995a). Here we have shown that Trp133 is part of 
the receptor's functional epitope. From the crystal 
structure of the complex, these two hydrophobic 
side-chains are known to be positioned near each 
other (Figure 2a). Thus Jle253 of the ligand and 
Trp133 of the receptor are likely to form the hydro-
phobic core of a binding interface similar to those 
seen for hGH-hGHR and in several antibody-
antigen interactions (Dall' Acqua et a/., 1996; Kelley 
& O'Connell, 1993; Tsumoto et a/ ., 1995; Wells & 
DeVos, 1996). 
ln addition to hydrophobic effects, the FcRn-Fc 
interface relies on strong electrostatic interactions 
to provide binding free energy. It was previously 
shown that His310 and one or more of histidine 
residues 433, 435, and 436 of the Fe ligand are 
necessary for full binding affinity and in vivo func-
tion (Kim et a/., 1994a,b,c; Medesan et a/., 1997; 
Raghavan eta/., 1994, 1995a). Here, we have ident-
ified three FeRn mutations, E117S, D137N, and 
E132Q&E135Q, that dramatically reduce binding 
affinity. Since these substitutions are conservative, 
most replacing only the negatively charged carbox-
ylate group with a neutral amide group, it is likely 
that the disrupted interactions are salt bridges. ln 
the FcRn/Fc cocrystal structure, each of the 
mutated acidic residues from FeRn are near one or 
more of the implicated Fe histidine residues 
(Figure 2b), suggesting that the protonated histi-
dine residues form a pH-dependent salt bridge to 
the corresponding acidic residues on FeRn. 
The approximately wild-type binding of the 
84-86 mutant, suggests that these residues within 
the FeRn al domain do not contribute to the func-
tional IgG binding site, while the substantially 
reduced binding of PllA and P-lY demonstrates 
that the P2m light chain does. The hydrophobic lie 
side-chain at the N terminus of P2m is positioned 
near the side-chains of Fe residue 309 (Leu, Val, 
Gin, or Met in rat, murine, and human IgGs; 
(Kabat eta/., 1991)) and Fe residue 311 (Gin or Arg 
in rat, murine, and human IgGs; (Kabat et a/., 
1991)), and could form a hydrophobic interaction 
with the aliphatic portions of one or the other of 
these side-chains. Extension of the N terminus by 
one residue by the addition of a bulky tyrosine 
residue (P-1 Y) could reduce binding through a ster-
ic hindrance. Alternatively, the N-terminal exten-
sion could affect binding by blocking a specific 
interaction with the N-terminal amino group. ln 
proteins, a-NH2 groups have a pK. that is gener-
ally ~8 (Fersht, 1985). ln FeRn, the presumably 
protonated a-NH2 group of P2m is positioned 
where it can form a hydrogen bond with the back-
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bone carbonyl of residue 115 on the heavy chain 
and also a pH dependent salt-bridge with Glul17. 
Thus the protonated a-NH2 group of P2m could 
help position Glu117 of the heavy chain to form an 
anionic binding site for His310 of the Fe ligand. 
Inhibition studies using anti-P2m specific mono-
clonal antibodies previously suggested the involve-
ment of the FeRn P2m domain in binding to IgG 
(Raghavan el a/., 1994). This suggestion is con-
firmed by the present demonstration that the 
N-terminal region of P2m constitutes a functional 
epitope for ligand binding. Crystal structures show 
that P2m interacts similarly with the heavy chains 
of class I MHC molecules and FeRn (Bjorkman & 
Parham, 1990; Burmeister et a/., 1994a). ln both 
cases, the P2m and a3 immunoglobulin-like 
domains of FeRn and class I MHC molecules are 
related by a 152{± 7}0 rotation followed by a 
::::::13 A translation that positions the P2m domain 
underneath the a1-a2 domain platform (Burmeister 
et a/., 1994a and references therein). The conserva-
tion of this asymmetric a3-P2m interaction serves 
different functional purposes since the P2m pos-
ition in FeRn is critical for interaction with its IgG 
ligand, yet the same P2m position is found in 
MHC molecules, which do not function as recep-
tors for IgG. 
The present study extends the results from pre-
vious work indicating that two FeRn molecules 
dimerize, as observed in FeRn and FcRn/Fc crys-
tals (Burmeister et a/., 1994a,b), to form the high 
affinity binding site for a single IgG. We previously 
reported that FeRn mutants with alterations that 
specifically affect the interaction of IgG with FeRn 
dimers but not with monomers (residues 250 and 
251 or the loop comprising residues 219 to 224; 
Figure 1) showed reduced affinities in biosensor 
assays and in measurements of labeled IgG bind-
ing to cell surface FeRn (Raghavan et a/., 1994). 
Here, we report two additional regions that affect 
FeRn dimerization and/or the interaction of Fe 
with the FeRn dimer. Mutations at FeRn residue 
191, which interacts with its counterpart on the 
dimer related receptor, result in a lower affinity 
and fewer high affinity binding sites. These effects 
are enhanced at lower receptor density, suggesting 
that mutation of this residue exerts its effect 
through interference with FeRn dimer formation . 
By contrast, mutation of P2m residue Glu89 results 
in a slight reduction in binding affinity which is 
not dependent upon FeRn coupling density and is 
not accompanied by a significant reduction in the 
number of binding sites. These results suggest that 
P2m Glu89 interacts primarily with the IgG ligand 
directly rather than the dimer-related FeRn heavy 
chain. Disorder of the Fe CH2 domain makes it dif-
ficult to identify potential contacts for Glu89 from 
the co-crystal structure (Burmeister et a/., 1994b). 
However, a direct interaction between the Fe CH2 
domain and residues at the dimer interface near 
P2m Glu89 (FeRn His250 and His251) was 
suggested by modeling studies using a compu-
tational docking algorithm to predict the orien-
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tation of the Fe CH2 domain when bound to FeRn 
(Weng et a/., 1997). If Fe becomes distorted upon 
binding to the FeRn dimer as predicted by the 
modeling studies, 132m Glu89 could contact the 
CH2 domain. 
Conclusions 
We have designed and constructed several 
amino acid substitutions on FeRn to map its bind-
ing site for IgG. The identification of several 
mutations that reduce the IgG affinity confirm and 
further define the IgG binding site on FeRn that 
was identified at low resolution in the FeRn-Fe co-
crystal structure (Burmeister et a/., 1994b). These 
functionally important IgG binding epitopes on 
FeRn complement previously reported binding epi-
topes on Fe (Kim et a/., 1994a,b,c; Medesan et a/., 
1997; Raghavan eta/., 1994, 1995a). Ile253 of Fe and 
Trp133 of FeRn are likely to form the core of a 
strong hydrophobic interaction, while Glu117, 
Glu132, Glu135 and Asp137 on the receptor pro-
vide anionic binding partners for the protonated 
forms of His310, His433, His435 and His436 of the 
ligand. Finally, amino acid substitutions for Gly191 
at the dimer interface display an FeRn concen-
tration dependent effect on lgG affinity, providing 
additional evidence that FeRn dimerization is 
necessary for normal high affinity IgG binding. 
Methods 
Reagents 
1 B5, a mouse IgG1 monoclonal antibody against 
human Zn-cx2-glycoprotein (Sanchez et a/., 1997) 
whose interaction with wild-type FeRn has been 
previously characterized (Vaughn & Bjorkman, 
1997), was used for biosensor binding assays. Anti-
CD4 (rat IgG2a) used in the cell binding assays 
was purchased from Boehringer Mannheim. Its 
interaction with wild-type FeRn has also been 
characterized in a biosensor assay (Vaughn & 
Bjorkman, 1997). Two mouse lgG1 anti-FeRn 
monoclonal antibodies, 1G3 and 4C11 (Raghavan 
eta/., 1994), were used for immunoaffinity chroma-
tography, enzyme-linked immunosorbent assays 
(ELISAs), immunoprecipitations, and fluorescence-
activated cell sorting (FACS). Rabbit anti-human 
132m and peroxidase-conjugated anti-mouse, as 
well as goat fluorescein isothiocyanate (FITC)-con-
jugated anti-rabbit antibodies were purchased 
from Boehringer Mannheim. Iodobeads were 
obtained from Pierce. 1251 (specific activity ""100 
mCi / ml) was obtained from Amersham in the 
form of sodium iodide. N-ethyl-N'-(3-diethylamino-
propyl)-carbodiimide (EDC), N-hydroxysuccini-
mide (NHS), BIAcore surfactant P20, and CM5 
sensor chips were obtained from BIAcore AB. 
CNBr-activated Sepharose and PD-10 columns 
were purchased from Pharmacia. 
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Construction and expression of mutant 
FeRn molecules 
Locations for FeRn mutants were chosen using 
the crystal structures of FeRn alone (Protein Data 
Bank entry 1 FRU) and a complex between FeRn 
and Fe (Protein Data Bank entry 1FRT). For 
expression of soluble mutant FeRn heterodimers, 
the cDNAs encoding the truncated FeRn heavy 
chain (residues 1 to 269) (Gastinel et a/., 1992) or 
rat 132m were altered by site-directed mutagenesis 
(Kunkel et a/., 1987). After verifying the sequence 
of the altered cDNAs, the mutant cDNAs were 
subcloned into the expression vector pBJ5-GS 
which carries the glutamine synthetase gene as a 
means of selection and amplification in the pre-
sence of the drug methionine sulfoximine 
(Bebbington & Hentschel, 1987). Co-transfection of 
FeRn and 132m expression vectors into Chinese 
hamster ovary (CHO) cells, selection, and amplifi-
cation were carried out as described (Gastinel et a/., 
1992; Raghavan et a/., 1994). Cell supernatants 
were screened for FeRn heterodimer expression by 
a sandwich ELISA, using either the FeRn heavy 
chain-specific monoclonal antibody 1G3 or 4C11 as 
the capture antibody and a polyclonal antiserum 
against human 132m to detect positive samples as 
described (Raghavan et a/., 1995b), and confirmed 
by immunoprecipitation with the other antibody. 
Mutant proteins that retained functional binding to 
IgG were purified from the supernatants of the 
highest expressing clones by pH dependent bind-
ing to a rat IgG column (Gastinel et a/., 1992). 
Mutants that did not bind IgG sufficiently for IgG-
affinity chromatography were purified using an 
immunoaffinity column constructed with an anti-
FeRn monoclonal antibody. Purified 1G3 antibody 
was covalently attached to CNBr-activated Sepha-
rose following the manufacturer's protocol. Bind-
ing and elution conditions for FeRn binding to the 
1G3 column were identified using a biosensor 
assay of wild type FeRn interacting with amine 
coupled 1G3 at pH 8 (see below). Supernatants 
from cells expressing wild-type or mutant FeRn 
proteins were passed over the 1G3 column at pH 
7.5, which was subsequently washed with :=:::ten 
column volumes of 50 mM sodium phosphate (pH 
7.5 to 8.5) and eluted with 50 mM sodium phos-
phate (pH 3.0). Eluates were immediately neutral-
ized with 1 M disodium phosphate. These elution 
conditions did not affect the ability of wild-type 
FeRn to bond again to the 1G3 column or the beha-
vior of wild-type FeRn in subsequent biosensor 
assays (data not shown). 
For expression of membrane-bound FeRn 
mutants, mutations were introduced into a pre-
viously described lipid-linked version of rat 132m 
that pairs with the truncated FeRn heavy chain at 
the surface of transfected cells (Gastinel et a/., 
1992). The lipid-linked 132m protein consists of the 
phosphatidylinositol anchoring signal of decay 
accelerating factor (DAF; residues 311 to 347; 
(Caras el a/., 1987)) fused to the final amino acid of 
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~2m (p2m-DAF). Altered ~2m-DAF cDNAs were 
sequenced and subcloned into the PBJS-GS 
expression vector, which was co-transfected into 
CHO cells along with the expression vector encod-
ing wild type soluble FeRn. After two to four 
weeks, populations were screened for heterodimer 
expression by immunostaining at pH 8.0 with the 
anti-FeRn antibody 1G3 and FITC-conjugated goat 
anti-mouse secondary antibody. High expressing 
lines were isolated by single cell FACS. Cell sorting 
and analysis was performed on a Coulter Epics 
Elite flow cytometer using Coulter Elite software 
version 3.0. 
The correct folding of each of the FeRn mutants 
used in this study was demonstrated by several 
experiments. First, each of the mutants is either 
expressed on the cell surface or secreted, therefore 
none of the mutations result in intracellular reten-
tion as would be expected for misfolded proteins. 
Secondly, all mutants assemble into heterodimers, 
as verified either by SDS-PAGE analysis of purified 
protein and in a sandwich ELISA for secreted 
mutants, or by cell surface reactivity with an anti-
FeRn heavy chain monoclonal antibody for the 
mutations introduced into lipid-linked ~2m and 
expressed as heterodimers with soluble FeRn 
heavy chains (data not shown). Finally, each 
mutant retains the immunoreactivity of wild-type 
FeRn for monoclonal antibodies generated against 
correctly folded wild-type FeRn (4C11 and 1G3; 
Raghavan et a/., 1994). All secreted mutants were 
selected using a sandwich ELISA and immuno-
precipitation employing 4C11 and 1G3, non-IgG 
binding mutants were purified on a 1G3 immuno-
affinity column, and cells expressing lipid-linked 
mutants were isolated by flow cytometry using 
1G3. The correct folding of each mutant was 
expected since each of the mutations was intro-
duced into residues that are solvent exposed in the 
crystal structure of FeRn (Burmeister eta/., 1994a). 
Purification and iodination of lgG 
Purified anti CD4 was iodinated using iodo-
beads according to the manufacturer's protocol. 
Briefly, one or two beads were rinsed in 1 ml of 
100 mM sodium phosphate buffer (pH 6.0), dried 
on filter paper and added to a mixture of 20 Ill of 
1251 in 180 Ill of the same buffer. After five minutes, 
0.5 ml (0.4 mg) of purified IgG was added and the 
mixture was allowed to incubate for approximatell, 
15 minutes at room temperature. Unreacted 12 I 
was removed by gel fi ltration using a PD-10 col-
umn. 
Cell binding assays 
Cells expressing wild-type FcRn/~2m-DAF or 
mutant FcRn/~2m-DAF were grown to confluence 
in tissue culture plates and assayed for IgG bind-
ing as described (Raghavan eta/., 1994). Cells were 
detached, pelleted, washed and resuspended in 
binding buffer (Hank's balanced salt solution, 
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10 mM Hepes, 0.25% bovine serum albumin, pH 
6.0) to a concentration of approximately 3 x l<r' 
cells/mi. In triplicate assays 3 x 105 to 5 x 105 cells 
were mixed with various amounts of 1251 labeled 
IgG and binding buffer to a total volume of 0.5 mi. 
The samples were incubated for at least two hours 
at room temperature, then pelleted and the super-
natants removed and set aside. Cell pellets were 
washed with 1.0 ml of cold binding buffer. The 
levels of radioactivity in the supernatants and cell 
pellets were measured using a Beckman gamma 
5500 counter. Non-specific binding was determined 
by similar treatment of untransfected CHO cells. 
The concentration of free IgG was determined 
from the radioactivity in the supernatant and the 
specific activity of the labeled IgG. The binding 
response was similarly calculated from the radioac-
tivity in the washed cell pellet. 
Biosensor experiments 
A BJAcore biosensor system (Biacore AB) was 
used to evaluate the interaction of secreted mutant 
and wild type FeRn proteins with IgG as pre-
viously reported (Vaughn & Bjorkman, 1997; and 
references therein). Briefly, wild-type or mutant 
FeRn proteins were immobilized to a biosensor 
chip surface using standard amine coupling chem-
istry as described in the BIAcore manual, and 
different concentrations of purified IgG were 
injected over the immobilized FeRn. IgG concen-
trations were determined spectrophotometrically 
using an extinction coefficient at 280 nm of 
216,000 M- 1 cm- 1 (lgG; Fasman, 1989). Sensor chip 
surfaces were regenerated by injecting a p ulse of 
50 mM phosphate, 150 mM NaCl (pH 8). Variation 
in coupling densities was achieved by varying the 
chip activation step from four to seven minutes. 
Because systematic errors can contribute to the 
uncertainty of K0 determinants (including slight 
variations in the pH of the binding buffer, the spe-
cifics of the coupling reaction, the concentration of 
the ligand, and the specific batch and purification 
state of the ligand), K0 values can be more accu-
rately compared for experiments conducted in par-
allel on the same chip. For each experiment, wild-
type FeRn, one or two mutants, and buffer without 
protein were coupled in one of the four available 
flowcells. The same dilution series of ligand and a 
buffer blank were passed over each flow cell, and 
the response at ten minutes (taken as the equili-
brium response) was recorded after subtraction of 
the buffer response. A modest response was 
observed for higher ligand concentrations 
(> ::::::: 62 nM) in mock-coupled flow cells, reaching a 
maximum of :::::::200 RU at the highest ligand con-
centration of 8 j!M. This blank response, most 
likely due to either the bulk refractive index contri-
bution of the ligand and/or a nonspecific low affi-
nity interaction with the dextran matrix of the 
chip, was subtracted from the equilibrium 
responses recorded for FeRn coupled flow cells to 
yield a net equilibrium response. 
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Calculation of binding affinities and changes 
in the free energy of binding 
For both the cell binding and biosensor assays, 
the equilibrium binding response was plotted as a 
function of the log of free IgG concentration. These 
data were fit to either a model of one or two non-
interacting binding sites by non-linear regression 
as previously described (Vaughn & Bjorkman, 
1997). In each case in which a model of two non-
interacting sites is used, the two site model pro-
duces a lower cross-validated residual (Vaughn & 
Bjorkman, 1997) than the one site model. K0 and 
Rmax (response corresponding to complete binding) 
values are presented when a single class of non-
interacting sites was modeled, and K0 ,1 (high affi-
nity binding constant), K0 .2 (low-affinity binding 
constant), f 1 (fraction of total binding sites corre-
sponding to the high affinity class of binding sites) 
and Rmax,tot (response corresponding to complete 
occupancy of both classes of binding sites) values 
are presented when two classes of non-interacting 
sites were modeled (Table 2). For each of these par-
ameters, standard errors are also reported as deter-
mined in the KaleidaGraphS implementation of 
the Levenberg-Marquardt algorithm, which reflect 
the precision of individual curve fittings (Table 2). 
The reproducibility of the derived affinities is 
± "" 20% as evaluated by comparing the six inde-
pendent K0 values reported for wild-type FeRn 
from experiments conducted on different biosensor 
chips (Table 2). t.t.G values were calculated as 
2.303RT log(Kmu.l Kw.tl for the high affinity binding 
constant (K0 ,1) where R is the gas constant 
(1.99 x 10- 3 kcal moi-1 K-1) and T is the absolute 
temperature (295 K). Results from biosensor exper-
iments in Table 2 correspond to the interaction of 
wild type and mutant FeRn proteins with the 1 B5 
monoclonal IgG. Similar results were obtained for 
experiments on FeRn mutants that interact directly 
with IgG using the anti-CD4 IgG (data not shown). 
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Appendix B: 
Protein Interface Properties 
This appendix contains the data table of the quantifiable aspects of the 171 
nonobligate protein-protein interfaces used for the analysis made in Chapter 5. 
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pdbid Reso- Protein Average Total interface 
lution mass volume surface area 
Protease-protease inhibitor A Daltons A"3 area A"2 A"2 
Chymotrypsin 1acb A E 3 25198 43430 10380 7.3E+02 
elgin C 1acb B I 3 7315 13630 4189 8.1E+02 
Thrombin 1avg A H L 1.2 34453 59510 13600 7.2E+02 
tria bin 1avg B I 1.2 15984 28400 7474 6.5E+02 
Trypsin 1avw A A 3.2 23280 39400 9084 8.1 E+02 
soybean trypsin inhibitor 1avw B B 3.2 17958 32210 8361 9.2E+02 
Collagenase 1azz A AB 2.8 46926 79930 18520 1.4E+03 
ecotin 1azz B c 2.8 14868 29020 9283 1.5E+03 
Trypsin var. D189G, G2260 1brc A E 3 23418 40400 9375 5.9E+02 
amyloid beta-protein precursor 1 brc B I 3 5909 10950 3476 7.2E+02 
Thrombin 1 bth A LH 3.5 32674 56350 13330 1.1E+03 
bovine pancreatic trypsin inhibitor 1 bth B p 3.5 6510 11990 3753 1.2E+03 
Trypsin 1 c9t A A 3.5 23269 39350 9076 5.3E+02 
Bdellstasin 1 c9t B G 3.5 5627 11000 3896 7.0E+02 
Chymotrypsin 1ca0 A FGH 2.9 10052 19900 6921 4 .3E+02 
amyloid beta-protein precursor 1ca0 B I 2.9 5988 10980 3586 4.6E+02 
Chymotrypsin 1cbw A FGH 2 .3 25028 42980 1 0050 6.4E+02 
Bovine pancreatic trypsin inhibitor 1cbw B I 2 .3 6510 12240 3926 7.5E+02 
Chymotrypsin 1cgi A E 1.9 25625 44180 10470 9.4E+02 
trypsin inhibitor var 3 1cgi B I 1.9 6327 12040 3995 1.1 E+03 
Chymotrypsin 1cgj A E 1. 7 25625 44130 10470 9.3E+02 
trypsin inhibitor var 4 1 cgj B I 1. 7 6277 11860 3920 1.0E+03 
Chymotrypsin 1cho A E 3 24925 42820 9920 6 .6E+02 
turkey ovomucoid 1cho B I 3 5753 10880 3629 7 .9E+02 
Subtilisin Carlsberg 1cse A E 2.4 27246 45260 9696 6.4E+02 
elgin C 1cse B I 2.4 7315 13740 4125 8.3E+02 
Factor VIla 1dan A LH 2.4 42615 76800 20470 1.9E+03 
soluble tissue factor 1dan B TU 2.4 21986 40010 10790 1.8E+03 
Elastase 1eai A B 2 .9 25877 46470 11010 9.5E+02 
Chymotrypsin/elastase inhibitor 1eai B 0 2.9 6583 12890 4526 1.1 E+03 
ecotin 1ezs A AB 1.65 27136 51820 14960 1.2E+03 
Trypsin II anionic 1ezs B c 1.65 23753 40760 9408 1.1 E+03 
anti-trypsin 1ezx A A 2 .7 41148 70790 15090 4 .5E+02 
Trypsin 1ezx B B 2.7 14246 25930 7011 3.9E+02 
Natural Killer Cell protease 1fi8 A A 1.9 23738 41600 10130 7.3E+02 
ecotin 1fi8 B CD 1.9 27325 27110 8617 7.7E+02 
Elastase 1fle A E 3.7 25877 44440 10490 8.1 E+02 
elafin 1fle B I 3.7 5005 9882 3548 9.5E+02 
Caspase activator 1g73 A AB 2.5 34806 64290 19120 9.8E+02 
inhibitor 1g73 B c 2 .5 10277 18340 5219 8.3E+02 
Kallikrein 1 hia A AB 3 .25 25365 43280 10060 7.7E+02 
hirustasin 1 hi a B I 3 .25 5180 10060 3608 9.6E+02 
Factor Xa 1kig A HL 2 .9 32377 55090 13320 8.5E+02 
anti-coagulant 1kig B I 2 .9 6953 12830 4214 9.2E+02 
Trypsin 1mct A A 2 .3 23440 39690 9025 6. 7E+02 
bitter gourd inhibitor 1mct B I 2 .3 3153 6256 2323 8.3E+02 
Mesenterocopeptidase 1mee A A 2 .6 27613 45960 9819 8.1E+02 
elgin C 1mee B I 2.6 7428 13850 4091 9.4E+02 
Thrombin 1mkw A LH 2 .5 32728 55920 12730 6 .1 E+02 
prethrombin-2 1mkw B K 2.5 32983 57630 14190 6 .6E+02 
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pdbid Circularity RMSD Atom Atom 
to plane burial access-
Protease-protease inhibitor ibility 
Chymotrypsin 1acb A E 6 .3E-01 2 .9E+OO 7.3E+OO 1.2E+01 
elgin C 1acb 8 I 5.1E-01 2 .1 E+OO 1.0E+01 1.6E+01 
Thrombin 1avg A HL 3.5E-01 2 .2E+OO 9.5E+OO 1.7E+01 
tria bin 1avg 8 I 3.3E-01 2.2E+OO 7.7E+OO 1.4E+01 
Trypsin 1avw A A 6.4E-01 2 .8E+OO 7.0E+OO 9.6E+OO 
soybean trypsin inhibitor 1avw 8 8 5.2E-01 2 .7E+OO 1.1E+01 1.4E+01 
Collagenase 1azz A AB 8.4E-02 3.8E+OO 7.7E+OO 1.2E+01 
ecotin 1 azz 8 c 6 .0E-02 3.2E+OO 1.1E+01 1.5E+01 
Trypsin var. D189G, G226D 1 brc A E 6.3E-01 2.8E+OO 6 .6E+OO 9.8E+OO 
amyloid beta-protein precursor 1 brc 8 I 3.7E-01 2 .1 E+OO 1.2E+01 1.7E+01 
Thrombin 1 bth A LH 7.7E-01 4 .2E+OO 7.5E+OO 1.1E+01 
bovine pancreatic trypsin inhibitor 1 bth 8 p ?.OE-01 3.5E+OO 1.1E+01 1.4E+01 
Trypsin 1 c9t A A 3.7E-01 2 . 7E+OO 6 .1 E+OO 9.4E+OO 
Bdellstasin 1 c9t 8 G 1.9E-01 2.2E+OO 1.3E+01 1.8E+01 
Chymotrypsin 1ca0 A FGH 5.0E-01 2 .3E+OO 7.9E+OO 1.3E+01 
amyloid beta-protein precursor 1ca0 8 I 5.0E-01 2 .1 E+OO 9.8E+OO 1.5E+01 
Chymotrypsin 1cbw A FGH 5.3E-01 2 .9E+OO 7.3E+OO 1.2E+01 
Bovine pancreatic trypsin inhibitor 1cbw 8 I 2.6E-01 2 .5E+OO 1.1 E+01 1.5E+01 
Chymotrypsin 1cgi A E 6.3E-01 3.1 E+OO 7.6E+OO 1.1E+01 
trypsin inhibitor var 3 1cgi 8 I 3.2E-01 2 .9E+OO 1.1E+01 1.5E+01 
Chymotrypsin 1 cgj A E 6.0E-01 3.0E+OO 7.5E+OO 1.2E+01 
trypsin inhibitor var 4 1cgj 8 I 3.0E-01 2 .7E+OO 1.1E+01 1.5E+01 
Chymotrypsin 1cho A E 4.8E-01 2 .7E+OO 7.1E+OO 1.1E+01 
turkey ovomucoid 1cho 8 I 2.9E-01 2 .2E+OO 1.1E+01 1.6E+01 
Subtilisin Carlsberg 1cse A E 5.9E-01 2 .6E+OO 7.0E+OO 1.2E+01 
elgin C 1cse 8 I 4 .6E-01 3.0E+OO 1.2E+01 1.7E+01 
Factor VIla 1dan A LH 1.7E-01 4.3E+OO 1.1E+01 1.7E+01 
soluble tissue factor 1dan 8 TU 1.5E-01 5.1 E+OO 8.7E+OO 1.6E+01 
Elastase 1eai A 8 5.3E-01 3.6E+OO 8.0E+OO 1.3E+01 
Chymotrypsin/elastase inhibitor 1eai 8 D 5.2E-01 2.9E+OO 1.1E+01 1.7E+01 
ecotin 1ezs A AB 6.6E-01 3.5E+OO 1.1E+01 1.7E+01 
Trypsin II anionic 1ezs 8 c 8.2E-01 3.5E+OO 7.2E+OO 1.2E+01 
anti-trypsin 1ezx A A 4.5E-01 1.4E+OO 1.1E+01 1.7E+01 
Trypsin 1ezx 8 8 7.5E-01 1.6E+OO 8.6E+OO 1.6E+01 
Natural Killer Cell protease 1fi8 A A 5.3E-01 3.0E+OO 7.8E+OO 1.2E+01 
ecotin 1fi8 8 CD 4.1 E-01 2. 9E+OO 1.0E+01 1.7E+01 
Elastase 1fle A E 8.4E-01 3.4E+OO 7.8E+OO 1.3E+01 
elafin 1fle 8 I 6.9E-01 2. 7E+OO 1.1E+01 1.8E+01 
Caspase activator 1g73 A AB 3.9E-01 3.7E+OO 1.1E+01 1.8E+01 
inhibitor 1g73 8 c 5.2E-01 3.9E+OO 7.2E+OO 1.5E+01 
Kallikrein 1 hia A AB 4.1 E-01 3.1 E+OO 7.8E+OO 1.1 E+01 
hirustasin 1 hia 8 I 2.3E-01 3.1 E+OO 1.2E+01 1.8E+01 
Factor Xa 1kig A H L 4 .5E-01 3.8E+OO 7.4E+OO 1.1E+01 
anti-coagulant 1 kig 8 I 5.3E-01 3.6E+OO 1.1E+01 1.4E+01 
Trypsin 1mct A A 5.4E-01 2.8E+OO 6.2E+OO 9.4E+OO 
bitter gourd inhibitor 1mct 8 I 2.3E-01 2.9E+OO 1.2E+01 1.6E+01 
Mesenterocopeptidase 1mee A A 6.2E-01 2. 7E+OO 7.6E+OO 1.1E+01 
elgin C 1mee 8 I 4.1 E-01 2 .9E+OO 1.0E+01 1.4E+01 
Thrombin 1mkw A L H 6 .9E-01 2 .3E+OO 6.8E+OO 1.3E+01 
prethrombin-2 1mkw 8 K 6.9E-01 2 .2E+OO 9.1 E+OO 1.9E+01 
196 
pdbid Shape Vol. Ratio Vol. Ratio 
comple- infc core/ infc perim/ 
Protease-protease inhibitor mentarity prot. core prot. core 
Chymotrypsin 1acb A E 7.0E-01 1.0E+OO 1.9E+OO 
elgin C 1acb B I 7.0E-01 1.0E+OO 1.8E+OO 
Thrombin 1avg A HL 5.6E-01 1.0E+OO 2 .2E+OO 
triabin 1avg B I 5.6E-01 1.1E+OO 2 .1 E+OO 
Trypsin 1avw A A 7.6E-01 1.0E+OO 1.6E+OO 
soybean trypsin inhibitor 1avw B B 7.6E-01 1.2E+OO 1.7E+OO 
Collagenase 1azz A AB 7.6E-01 9.9E-01 1.8E+OO 
ecotin 1azz B c 7.6E-01 9.7E-01 2 .1 E+OO 
Trypsin var. 0189G, G2260 1brc A E 7.1 E-01 1.0E+OO 1.6E+OO 
amyloid beta-protein precursor 1 brc B I 7.1 E-01 1.1 E+OO 2 .0E+OO 
Thrombin 1 bth A LH 6.8E-01 1.0E+OO 1.9E+OO 
bovine pancreatic trypsin inhibitor 1 bth B p 6.8E-01 1.2E+OO 2.1 E+OO 
Trypsin 1 c9t A A 7.2E-01 9.2E-01 2 .0E+OO 
Bdellstasin 1c9t B G 7.2E-01 1.2E+OO 2 .3E+OO 
Chymotrypsin 1ca0 A FGH 7.4E-01 8. 7E-01 1.6E+OO 
amyloid beta-protein precursor 1ca0 B I 7.4E-01 9.2E-01 1.9E+OO 
Chymotrypsin 1cbw A FGH 6.9E-01 1.1 E+OO 1.9E+OO 
Bovine pancreatic trypsin inhibitor 1cbw B I 6.9E-01 1.1E+OO 1.9E+OO 
Chymotrypsin 1cgi A E 7.2E-01 1.2E+OO 1.8E+OO 
trypsin inhibitor var 3 1cgi B I 7.2E-01 1.1E+OO 1.9E+OO 
Chymotrypsin 1 cgj A E 7.0E-01 1.2E+OO 1.8E+OO 
trypsin inhibitor var 4 1 cgj B I 7.0E-01 1.1E+OO 2 .1 E+OO 
Chymotrypsin 1cho A E 7.1 E-01 1.0E+OO 1.7E+OO 
turkey ovomucoid 1cho B I 7.1E-01 1.1E+OO 1. 7E+OO 
Subtilisin Carlsberg 1cse A E 7.3E-01 1.1E+OO 1.6E+OO 
elgin C 1cse B I 7.3E-01 1.2E+OO 1.7E+OO 
Factor VIla 1dan A LH 6.6E-01 1.0E+OO 1.9E+OO 
soluble tissue factor 1dan B TU 6.6E-01 1.1E+OO 1.7E+OO 
Elastase 1eai A B 6 .8E-01 1.1E+OO 2.2E+OO 
Chymotrypsin/elastase inhibitor 1eai B 0 6 .8E-01 1.1E+OO 2.5E+OO 
ecotin 1ezs A AB 7.3E-01 8.8E-01 2.2E+OO 
Trypsin II anionic 1ezs B c 7.3E-01 9.6E-01 1.8E+OO 
anti-trypsin 1ezx A A 5.7E-01 1.1E+OO 1.8E+OO 
Trypsin 1ezx B B 5.7E-01 1.1 E+OO 2.1 E+OO 
Natural Killer Cell protease 1fi8 A A 6 .8E-01 1.0E+OO 2.1 E+OO 
ecotin 1fi8 B CD 6.8E-01 1.2E+OO 2.1 E+OO 
Elastase 1fle A E 7.1 E-01 1.0E+OO 2.0E+OO 
elafin 1fle B I 7.1E-01 1.2E+OO 1.9E+OO 
Caspase activator 1g73 A AB 7.6E-01 1.0E+OO 1.8E+OO 
inhibitor 1g73 B c 7.6E-01 1.1E+OO 2.2E+OO 
Kallikrein 1 hia A AB 7.3E-01 1.1 E+OO 1.8E+OO 
hirustasin 1 hia B I 7.3E-01 1.1E+OO 2.2E+OO 
Factor Xa 1 kig A HL 7.9E-01 1.0E+OO 1.8E+OO 
anti-coagulant 1 kig B I 7.9E-01 1.3E+OO 2.1 E+OO 
Trypsin 1mct A A 7.8E-01 9.9E-01 1.6E+OO 
bitter gourd inhibitor 1mct B I 7.8E-01 1.1E+OO 2.0E+OO 
Mesenterocopeptidase 1mee A A 7.7E-01 1.2E+OO 1.5E+OO 
elgin C 1mee B I 7.7E-01 1.1E+OO 1.6E+OO 
Thrombin 1mkw A LH 6 .9E-01 1.1E+OO 1.8E+OO 
prethrombin-2 1mkw B K 6 .9E-01 7.1 E-01 1.7E+OO 
197 
pdbid Hbonds per 100 Hbonds per 100 
<3.3 A sq angstro1 <4.0 A sq angstro 
Protease-protease inhibitor 
Chymotrypsin 1acb A E 1.1E+01 1.5E+OO 2 .1 E+01 2 .9E+OO 
elgin C 1acb 8 I 1.1E+01 1.4E+OO 2 .1E+01 2 .6E+OO 
Thrombin 1avg A HL 1.1E+01 1.5E+OO 2.4E+01 3.3E+OO 
tria bin 1avg 8 I 1.1E+01 1.7E+OO 2 .4E+01 3.7E+OO 
Trypsin 1avw A A 1.0E+01 1.2E+OO 2 .2E+01 2 .7E+OO 
soybean trypsin inhibitor 1avw 8 8 1.0E+01 1.1 E+OO 2 .2E+01 2.4E+OO 
Collagenase 1azz A AS 8 .0E+OO 5.9E-01 1.8E+01 1.3E+OO 
ecotin 1azz 8 c 8 .0E+OO 5.3E-01 1.8E+01 1.2E+OO 
Trypsin var. D189G, G226D 1brc A E 1.1E+01 1.9E+OO 1.6E+01 2.7E+OO 
amyloid beta-protein precursor 1 brc 8 I 1.1E+01 1.5E+OO 1.6E+01 2.2E+OO 
Thrombin 1 bth A LH 1.0E+OO 8.9E-02 1.0E+OO 8.9E-02 
bovine pancreatic trypsin inhibitor 1 bth 8 p 1.0E+OO 8.1 E-02 1.0E+OO 8.1 E-02 
Trypsin 1 c9t A A 1.2E+01 2.2E+OO 1.9E+01 3.6E+OO 
Bdellstasin 1 c9t 8 G 1.2E+01 1.7E+OO 1.9E+01 2 .7E+OO 
Chymotrypsin 1ca0 A FGH 2.2E+01 5.1 E+OO 3.1E+01 7 .2E+OO 
amyloid beta-protein precursor 1ca0 8 I 2 .2E+01 4 .8E+OO 3.1E+01 6.7E+OO 
Chymotrypsin 1cbw A FGH 2.2E+01 3.5E+OO 4 .0E+01 6 .3E+OO 
Bovine pancreatic trypsin inhibitor 1cbw 8 I 2 .2E+01 2 .9E+OO 4.0E+01 5.4E+OO 
Chymotrypsin 1cgi A E 9.0E+OO 9.6E-01 1.9E+01 2 .0E+OO 
trypsin inhibitor var 3 1cgi 8 I 9.0E+OO 8.3E-01 1.9E+01 1.7E+OO 
Chymotrypsin 1 cgj A E 6 .0E+OO 6.5E-01 1.4E+01 1.5E+OO 
trypsin inhibitor var 4 1 cgj 8 I 6 .0E+OO 5.7E-01 1.4E+01 1.3E+OO 
Chymotrypsin 1cho A E 1.1E+01 1. 7E+OO 1.9E+01 2 .9E+OO 
turkey ovomucoid 1cho 8 I 1.1E+01 1.4E+OO 1.9E+01 2.4E+OO 
Subtilisin Carlsberg 1cse A E 2 .0E+01 3.1 E+OO 3 .5E+01 5.5E+OO 
elgin C 1cse 8 I 2.0E+01 2 .4E+OO 3 .5E+01 4 .2E+OO 
Factor VIla 1dan A LH 1.0E+01 5.3E-01 1.9E+01 1.0E+OO 
soluble tissue factor 1dan 8 TU 1.0E+01 5.6E-01 1.9E+01 1.1E+OO 
Elastase 1eai A 8 7 .0E+OO 7.4E-01 1.5E+01 1.6E+OO 
Chymotrypsin/elastase inhibitor 1eai 8 D 7.0E+OO 6.4E-01 1.5E+01 1.4E+OO 
ecotin 1ezs A AS 1.3E+01 1.0E+OO 2 .6E+01 2.1 E+OO 
Trypsin II anionic 1ezs 8 c 1.3E+01 1.2E+OO 2.6E+01 2 .3E+OO 
anti-trypsin 1ezx A A 1.3E+01 2 .9E+OO 1.8E+01 4 .0E+OO 
Trypsin 1ezx 8 8 1.3E+01 3.3E+OO 1.8E+01 4 .6E+OO 
Natural Killer Cell protease 1fi8 A A 1.3E+01 1.8E+OO 2.5E+01 3.4E+OO 
ecotin 1fi8 8 CD 1.3E+01 1.7E+OO 2.5E+01 3.3E+OO 
Elastase 1fle A E 1.2E+01 1.5E+OO 1.5E+01 1.9E+OO 
elafin 1fle 8 I 1.2E+01 1.3E+.OO 1.5E+01 1.6E+OO 
Caspase activator 1g73 A AS 9.0E+OO 9.2E-01 1.3E+01 1.3E+OO 
inhibitor 1g73 8 c 9.0E+OO 1.1 E+OO 1.3E+01 1.6E+OO 
Kallikrein 1 hia A AS 9.0E+OO 1.2E+OO 1.6E+01 2.1 E+OO 
hirustasin 1 hia 8 I 9.0E+OO 9.4E-01 1.6E+01 1.7E+OO 
Factor Xa 1 kig A H L 1.1E+01 1.3E+OO 2.8E+01 3.3E+OO 
anti-coagulant 1 kig 8 I 1.1E+01 1.2E+OO 2.8E+01 3.1 E+OO 
Trypsin 1mct A A 9.0E+OO 1.4E+OO 2.1 E+01 3.2E+OO 
bitter gourd inhibitor 1mct 8 I 9.0E+OO 1.1 E+OO 2 .1E+01 2 .5E+OO 
Mesenterocopeptidase 1mee A A 1.1E+01 1.4E+OO 2 .0E+01 2 .5E+OO 
elgin C 1mee 8 I 1.1E+01 1.2E+OO 2 .0E+01 2.1 E+OO 
Thrombin 1mkw A LH 1.3E+01 2 .1 E+OO 1.7E+01 2 .8E+OO 
prethrombin-2 1mkw 8 K 1.3E+01 2 .0E+OO 1.7E+01 2 .6E+OO 
198 
pdbid %non-pola %polar %charged 
Protease-protease inhibitor 
Chymotrypsin 1acb A E ?.OE-01 2.9E-01 4 .5E-03 
elgin C 1acb 8 I 6 .9E-01 2.1 E-01 9.4E-02 
Thrombin 1avg A HL 4 .9E-01 3.0E-01 2.1E-01 
tria bin 1avg 8 I 6 .7E-01 2 .0E-01 1.3E-01 
Trypsin 1avw A A 5.6E-01 4 .3E-01 1.2E-02 
soybean trypsin inhibitor 1avw 8 8 6.0E-01 1. ?E-01 2.3E-01 
Collagenase 1azz A AB 6.1 E-01 3. ?E-01 2 .1 E-02 
ecotin 1azz 8 c 6.6E-01 2.6E-01 8.6E-02 
Trypsin var. D189G, G226D 1 brc A E 6.1 E-01 3.7E-01 2.3E-02 
amyloid beta-protein precursor 1 brc 8 I 5.8E-01 2.6E-01 1.6E-01 
Thrombin 1 bth A LH 5.9E-01 3.4E-01 6.9E-02 
bovine pancreatic trypsin inhibitor 1 bth 8 p S.SE-01 2 .2E-01 2.3E-01 
Trypsin 1 c9t A A 6.0E-01 3.9E-01 3.9E-03 
Bdellstasin 1 c9t 8 G ?.OE-01 2.1 E-01 9.7E-02 
Chymotrypsin 1ca0 A FGH 6.3E-01 3.7E-01 O.OE+OO 
amyloid beta-protein precursor 1ca0 8 I 4 .9E-01 3.0E-01 2 .2E-01 
Chymotrypsin 1cbw A FGH 6.7E-01 3.3E-01 2 .5E-04 
Bovine pancreatic trypsin inhibitor 1cbw 8 I 6.0E-01 2 .0E-01 1.9E-01 
Chymotrypsin 1cgi A E 6.8E-01 3.0E-01 2 .0E-02 
trypsin inhibitor var 3 1cgi 8 I 6.7E-01 2 .0E-01 1.2E-01 
Chymotrypsin 1cgj A E ?.OE-01 2.8E-01 2 .4E-02 
trypsin inhibitor var 4 1cgj 8 I 6.9E-01 1.8E-01 1.3E-01 
Chymotrypsin 1cho A E 6.8E-01 2 .8E-01 3.5E-02 
turkey ovomucoid 1cho 8 I 6.3E-01 2.4E-01 1.3E-01 
Subtilisin Carlsberg 1cse A E S.SE-01 4 .5E-01 O.OE+OO 
elgin C 1cse 8 I 6.9E-01 1.6E-01 1.5E-01 
Factor VIla 1dan A LH 5.9E-01 1.9E-01 2.3E-01 
soluble tissue factor 1dan 8 TU S.OE-01 2 .3E-01 2.7E-01 
Elastase 1eai A 8 5.8E-01 3.2E-01 9.1 E-02 
Chymotrypsin/elastase inhibitor 1eai 8 D 6.0E-01 3.1 E-01 9.5E-02 
ecotin 1ezs A AB 5.8E-01 2 .0E-01 2 .2E-01 
Trypsin II anionic 1ezs 8 c 6.0E-01 2 .7E-01 1.3E-01 
anti-trypsin 1ezx A A 5.6E-01 2.9E-01 1.5E-01 
Trypsin 1ezx 8 8 4.9E-01 4.7E-01 3.4E-02 
Natural Killer Cell protease 1fi8 A A 5.9E-01 3. ?E-01 4.4E-02 
ecotin 1fi8 8 CD 5.8E-01 2 .5E-01 1.6E-01 
Elastase 1fle A E 5.4E-01 2 .2E-01 2.3E-01 
elafin 1fle 8 I ?.OE-01 2 .5E-01 5.9E-02 
Caspase activator 1g73 A AB 6.4E-01 2 .3E-01 1.3E-01 
inhibitor 1g73 8 c 6.0E-01 2 .9E-01 1.1E-01 
Kallikrein 1 hia A AB 6.0E-01 3.8E-01 2.3E-02 
hirustasin 1 hia 8 I 6.0E-01 1.6E-01 2.4E-01 
Factor Xa 1 kig A H L 4 .6E-01 2.9E-01 2.6E-01 
anti-coagulant 1 kig 8 I S.SE-01 2.5E-01 2.0E-01 
Trypsin 1mct A A S.?E-01 4 .2E-01 7.2E-03 
bitter gourd inhibitor 1mct 8 I 6.3E-01 2 .0E-01 1.7E-01 
Mesenterocopeptidase 1mee A A 5.9E-01 3.8E-01 3.7E-02 
elgin C 1mee 8 I ?.OE-01 1.9E-01 1.0E-01 
Thrombin 1mkw A LH ?.OE-01 2 .3E-01 6 .1 E-02 
prethrombin-2 1mkw 8 K 6.4E-01 2.4E-01 1.3E-01 
199 
pdbid Reso- Protein Average Total interface 
lution mass volume surface area 
Protease-protease inhibitor A Daltons A"3 area A"2 A"2 
Trypsin 1ppe A E 2 .8 23269 39500 9008 7.6E+02 
cucurbita maxima 1ppe B I 2 .8 3266 6585 2478 9.0E+02 
Human leukocyte elastase 1 ppf A E 2.4 23277 41190 10100 5.8E+02 
turkey ovomucoid 1 ppf B I 2.4 6008 11550 3909 7.3E+02 
Papain 1 stf A E 2.5 23396 39610 9289 8.0E+02 
Stefin B 1stf B I 2 .5 11135 20670 5974 9.6E+02 
Trypsin 1 tab A E 2.6 23269 39330 9074 5.7E+02 
Bowman Bark inhibitor Hab B I 2.6 4055 8295 3354 7.8E+02 
Thrombin Hbq A LH 3.2 35392 61310 14100 1.7E+03 
rhodniin 1 tbq B R 3.2 11046 21020 7301 1.8E+03 
Thermitase Hec A E 2.3 28323 45970 9483 6 .5E+02 
elgin C 1 tee B I 2.3 7315 13630 4056 8. 7E+02 
Trypsin 1 tfx A B 2.7 23440 39930 9256 5.8E+02 
tissue factore pathway inhibitor Hfx B D 2.7 6830 12700 4005 7.6E+02 
Trypsinogen 1 tgs A z 2 .2 23511 40260 9285 7.9E+02 
PPTI 1tgs B I 2.2 6011 11760 4069 9.1 E+02 
Thrombin Hoc A AB 2.9 33014 56960 13220 1.7E+03 
Ornithodorin Hoc B R 2.9 12686 23790 7987 1.8E+03 
Anhydro trypsin Hpa A E 2 .1 23252 39540 9069 6 .7E+02 
PTI Hpa B I 2 .1 6510 12250 3886 7.7E+02 
Kallikrein 2kai A AB 3 25534 43560 10430 6.4E+02 
BPTI 2kai B I 3 6281 11810 3803 7.8E+02 
beta-Trypsin 2ptc A E 2 .9 23269 39560 9069 6 .6E+02 
PTI 2ptc B I 2 .9 6510 12180 3865 7.6E+02 
Subtilisin Carlsberg 2sic A E 2 .65 27488 45500 9797 7.1E+02 
streptomyces inhibitor 2sic B I 2 .65 10912 20090 5857 8.8E+02 
Subtilisin Carlsberg 2sni A E 2 27488 45580 9845 7.3E+02 
chymotrypsin inhibitor 2sni B I 2 7269 13940 4314 8.8E+02 
Proteinase B streptomyces B 3sgb A E 3 18631 31220 7366 5.9E+02 
turkey ovomucoid 3sgb B I 3 5468 10360 3468 6.7E+02 
Trypsinogen 3tpi A z 3 .2 23269 39930 9439 6.5E+02 
PTI 3tpi B I 3 .2 6510 12160 3874 7.6E+02 
Thrombin 4htc A LH 2 .7 32932 57110 13610 1.5E+03 
Hirudin 4htc B I 2 .7 6434 12820 4835 1.7E+03 
Antibody-antigen 
HIV-1 capsid 1afv A AB 2 .65 47320 80330 19060 7.0E+02 
Fab 25.3 1 afv B LH 2 .65 33342 60040 8110 6.9E+02 
Ab Fv 1 ar1 A CD 2 .3 25006 42640 9964 6.5E+02 
Cytochrome C 1 ar1 B AB 2 .3 86930 141900 26990 6.6E+02 
Fab 1 bj1 A HL 2 .8 23290 39400 20090 9.1 E+02 
Vascular endothelial GF 1 bj1 B vw 2 .8 21892 73830 13720 1.1 E+03 
Fab Hyhel-5 1 bql A LH 2 .5 46043 79750 19320 7.9E+02 
Bobtail quail lysozyme 1 bql B y 2 .5 14254 24730 6287 8.2E+02 
Fab Hulys11 1 bvk A DE 2 .8 24720 42510 10310 6.4E+02 
Lysozyme 1bvk B F 2 .8 14297 24950 6543 6.5E+02 
Fab Hyhel-63 1 dqj A AB 2 .5 46023 78860 18710 8 .5E+02 
Lysozyme 1dqj B B 2 .5 14297 24640 6478 9.0E+02 
Fv D1 .3 1 dvf A AB 2 .3 24498 41550 9689 7.9E+02 
Fv DE5.2 1dvf B CD 2 .3 25028 43070 10230 8 .3E+02 
200 
pdbid Circularity RMSD Atom Atom 
to plane burial access-
Protease-protease inhibitor ibility 
Trypsin 1ppe A E 5.3E-01 3.0E+OO 6 .3E+OO 9.5E+OO 
cucurbita maxima 1ppe B I 3.3E-01 2 .9E+OO 1.1E+01 1.5E+01 
Human leukocyte elastase 1 ppf A E 7.2E-01 2 .8E+OO 7.0E+OO 1.1E+01 
turkey ovomucoid 1 ppf B I 6.8E-01 2 .3E+OO 1.0E+01 1.6E+01 
Papain 1 stf A E 3.9E-01 3.6E+OO 6 .8E+OO 1.1E+01 
Stefin B 1stf B I 3.0E-01 2 .0E+OO 1.1 E+01 1.7E+01 
Trypsin 1tab A E 5.4E-01 2. 7E+OO 5. 7E+OO 8.4E+OO 
Bowman Bark inhibitor 1tab B I 2 .1 E-01 2.4E+OO 1.4E+01 1.9E+01 
Thrombin 1tbq A LH 2 .2E-01 4.4E+OO 7.9E+OO 1.3E+01 
rhodniin 1tbq B R 1.2E-01 4 .2E+OO 1.0E+01 1.5E+01 
Thermitase 1tec A E 5.0E-01 2 .6E+OO 7.4E+OO 1.0E+01 
elgin C 1tec B I 3.5E-01 2 .8E+OO 1.2E+01 1.5E+01 
Trypsin 1tfx A B 6 .5E-01 2 .8E+OO 6.0E+OO 9.8E+OO 
tissue factore pathway inhibitor 1tfx B D 3.7E-01 2.0E+OO 1.2E+01 1.7E+01 
Trypsinogen 1tgs A z 5.1E-01 3.2E+OO 7.0E+OO 1.1E+01 
PPTI 1tgs B I 2.5E-01 3.4E+OO 1.1E+01 1.7E+01 
Thrombin 1toc A AB 2 .9E-01 4 .4E+OO 8.2E+OO 1.3E+01 
Ornithodorin 1toc B R 1.4E-01 4 .1 E+OO 9.8E+OO 1.5E+01 
Anhydro trypsin 1tpa A E 4 .6E-01 2 .7E+OO 6.2E+OO 9.7E+OO 
PTI 1tpa B I 2.9E-01 1.9E+OO 1.3E+01 1.6E+01 
Kallikrein 2kai A AB 5.2E-01 3.4E+OO 6.3E+OO 9.7E+OO 
BPTI 2kai B I 2 .9E-01 2 .5E+OO 1.3E+01 1.6E+01 
beta-Trypsin 2ptc A E 4 .8E-01 2 .6E+OO 6.5E+OO 9.9E+OO 
PTI 2ptc B I 3.2E-01 1.9E+OO 1.2E+01 1.7E+01 
Subtilisin Carlsberg 2sic A E 4 .7E-01 3.1 E+OO 6.6E+OO 1.1E+01 
streptomyces inhibitor 2sic B I 1.9E-01 2.4E+OO 1.1E+01 1.5E+01 
Subtilisin Carlsberg 2sni A E 5.3E-01 3.1 E+OO 7.0E+OO 1.1E+01 
chymotrypsin inhibitor 2sni B I 4 .1 E-01 3.3E+OO 1.1E+01 1.6E+01 
Proteinase B streptomyces B 3sgb A E 6 .2E-01 2 .6E+OO 7.0E+OO 1.1E+01 
turkey ovomucoid 3sgb B I 3.2E-01 2 .5E+OO 9.7E+OO 1.5E+01 
Trypsinogen 3tpi A z 4 .5E-01 2.7E+OO 6.4E+OO 9.6E+OO 
PTI 3tpi B I 3.1 E-01 1.9E+OO 1.2E+01 1.6E+01 
Thrombin 4htc A LH 2.4E-01 3.6E+OO 7.7E+OO 1.3E+01 
Hirudin 4htc B I 1.2E-01 3.1 E+OO 1.1E+01 1.7E+01 
Antibody-antigen 
HIV-1 capsid 1afv A AB 9.2E-01 2.6E+OO 8.2E+OO 1.3E+01 
Fab 25.3 1afv B LH 3.9E-01 2 .2E+OO 9.2E+OO 1.4E+01 
Ab Fv 1 ar1 A CD 2 .1 E-01 1.6E+OO 8.2E+OO 1.4E+01 
Cytochrome C 1 ar1 B AB 1.9E-01 1.1 E+OO 8.5E+OO 1.4E+01 
Fab 1 bj1 A H L 1.2E-01 4 .7E+OO 7.2E+OO 1.0E+01 
Vascular endothelial GF 1 bj1 B vw 3.0E-01 5.9E+OO 1.0E+01 1.4E+01 
Fab Hyhel-5 1 bql A LH 6 .0E-01 2.6E+OO 8.4E+OO 1.4E+01 
Bobtail quail lysozyme 1 bql B y 5.4E-01 2.5E+OO 9.9E+OO 1.6E+01 
Fab Hulys11 1 bvk A DE 5.6E-01 1.7E+OO 8.1 E+OO 1.3E+01 
Lysozyme 1 bvk B F 7 .5E-01 1.6E+OO 9.0E+OO 1.5E+01 
Fab Hyhel-63 1dqj A AB 3.6E-01 2.4E+OO 8.1 E+OO 1.3E+01 
Lysozyme 1 dqj B B 3.8E-01 2.4E+OO 9.3E+OO 1.3E+01 
Fv D1 .3 1dvf A AB 7.5E-01 2.2E+OO 7.9E+OO 1.4E+01 
Fv DE5.2 1dvf B CD 6 .5E-01 2.1 E+OO 1.0E+01 1.6E+01 
201 
pdbid Shape Vol. Ratio Vol. Ratio 
comple- infc core/ infc perim/ 
Protease-protease inhibitor mentarity prot. core prot. core 
Trypsin 1 ppe A E 7.5E-01 1.0E+OO 1.5E+OO 
cucurbita maxima 1ppe B I 7.5E-01 1.2E+OO 2.0E+OO 
Human leukocyte elastase 1 ppf A E 7.7E-01 1.0E+OO 1.9E+OO 
turkey ovomucoid 1 ppf B I 7.7E-01 1.1E+OO 1.7E+OO 
Papain 1 stf A E 6 .6E-01 1.1E+OO 1. 7E+OO 
Stefin B 1 stf B I 6 .6E-01 1.1E+OO 1.9E+OO 
Trypsin 1tab A E 6 .8E-01 9.9E-01 1.6E+OO 
Bowman Bark inhibitor 1tab B I 6 .8E-01 1.3E+OO 2.6E+OO 
Thrombin 1tbq A LH 6.9E-01 1.0E+OO 2 .0E+OO 
rhodniin 1tbq B R 6.9E-01 1.3E+OO 2.0E+OO 
Thermitase 1tec A E 7.5E-01 1.2E+OO 1.7E+OO 
elgin C 1 tee B I 7.5E-01 1.2E+OO 1.8E+OO 
Trypsin 1 tfx A B 7.4E-01 1.0E+OO 1.6E+OO 
tissue factore pathway inhibitor 1 tfx B D 7.4E-01 1.1E+OO 2 .1 E+OO 
Trypsinogen 1tgs A z 7.5E-01 1.0E+OO 1.7E+OO 
PPTI 1 tgs B I 7.5E-01 1.0E+OO 2 .0E+OO 
Thrombin 1toc A AB 6 .5E-01 1.0E+OO 2.0E+OO 
Ornithodorin 1toc B R 6.5E-01 1.1 E+OO 2 .2E+OO 
Anhydro trypsin 1 tpa A E 7.6E-01 1.0E+OO 1.6E+OO 
PTI 1 tpa B I 7.6E-01 1.2E+OO 1.9E+OO 
Kallikrein 2kai A AB 7.4E-01 1.1E+OO 1.9E+OO 
BPTI 2kai B I 7.4E-01 1.3E+OO 2 .0E+OO 
beta-Trypsin 2ptc A E 7.7E-01 9.8E-01 1.5E+OO 
PTI 2ptc B I 7.7E-01 1.2E+OO 1.9E+OO 
Subtilisin Carlsberg 2sic A E 7.4E-01 1.2E+OO 1.6E+OO 
streptomyces inhibitor 2sic B I 7.4E-01 1.0E+OO 1.7E+OO 
Subtilisin Carlsberg 2sni A E 7.2E-01 1.3E+OO 1.8E+OO 
chymotrypsin inhibitor 2sni B I 7.2E-01 1.1E+OO 2 .1E+OO 
Proteinase B streptomyces B 3sgb A E 7.9E-01 1.1E+OO 1.5E+OO 
turkey ovomucoid 3sgb B I 7.9E-01 9.6E-01 1.7E+OO 
Trypsinogen 3tpi A z 7.7E-01 1.1E+OO 1.5E+OO 
PTI 3tpi B I 7. 7E-01 1.1E+OO 1.8E+OO 
Thrombin 4htc A LH 6 .5E-01 1.1E+OO 1.7E+OO 
Hirudin 4htc B I 6.5E-01 1.4E+OO 1.8E+OO 
Antibody-antigen 
HIV-1 capsid 1afv A AB 6 .3E-01 1.0E+OO 2.1 E+OO 
Fab 25.3 1afv B LH 6 .3E-01 1.0E+OO 2.2E+OO 
Ab Fv 1 ar1 A CD 6 .9E-01 1.0E+OO 2.0E+OO 
Cytochrome C 1 ar1 B AB 6 .9E-01 1.1E+OO 2.2E+OO 
Fab 1 bj1 A H L 7.9E-01 1.1E+OO 1.9E+OO 
Vascular endothelial GF 1 bj1 B vw 7.9E-01 1.0E+OO 1.8E+OO 
Fab Hyhel-5 1 bql A LH 7.0E-01 9.8E-01 1.8E+OO 
Bobtail quail lysozyme 1 bql B y 7.0E-01 1.1 E+OO 1.7E+OO 
Fab Hulys11 1 bvk A DE 6.9E-01 9.9E-01 1.8E+OO 
Lysozyme 1 bvk B F 6 .9E-01 9.1 E-01 1.8E+OO 
Fab Hyhel-63 1dqj A AB 7 .0E-01 1.1E+OO 1.6E+OO 
Lysozyme 1dqj B B 7.0E-01 1.1E+OO 1.5E+OO 
Fv D1 .3 1dvf A AB 7 .5E-01 9.5E-01 1.7E+OO 
Fv DE5.2 1dvf B CD 7.5E-01 9.5E-01 1.7E+OO 
202 
pdbid Hbonds per 100 Hbonds per 100 
<3.3 A sq angstrot <4.0 A sq angstro 
Protease-protease inhibitor 
Trypsin 1ppe A E 2.0E+OO 2 .6E-01 9.0E+OO 1.2E+OO 
cucurbita maxima 1ppe B I 2 .0E+OO 2 .2E-01 9 .0E+OO 1.0E+OO 
Human leukocyte elastase 1 ppf A E 1.9E+01 3.3E+OO 4 .2E+01 7 .3E+OO 
turkey ovomucoid 1 ppf B I 1.9E+01 2 .6E+OO 4 .2E+01 5.7E+OO 
Papain 1stf A E 1.2E+01 1.5E+OO 2.0E+01 2 .5E+OO 
Stefin B 1 stf B I 1.2E+01 1.3E+OO 2 .0E+01 2.1 E+OO 
Trypsin 1 tab A E 1.2E+01 2 .1 E+OO 1.4E+01 2.4E+OO 
Bowman Bark inhibitor 1 tab B I 1.2E+01 1.5E+OO 1.4E+01 1.8E+OO 
Thrombin 1tbq A LH 1.5E+01 9.1E-01 2 .0E+01 1.2E+OO 
rhodniin 1 tbq B R 1.5E+01 8.3E-01 2 .0E+01 1.1 E+OO 
Thermitase 1tec A E 5.0E+OO 7 .7E-01 9.0E+OO 1.4E+OO 
elgin C 1tec B I 5.0E+OO 5.8E-01 9.0E+OO 1.0E+OO 
Trypsin 1 tfx A B 7.0E+OO 1.2E+OO 2 .0E+01 3.4E+OO 
tissue factore pathway inhibitor 1 tfx B D 7.0E+OO 9.2E-01 2 .0E+01 2.6E+OO 
Trypsinogen 1tgs A z 1.6E+01 2.0E+OO 2 .7E+01 3.4E+OO 
PPTI 1 tgs B I 1.6E+01 1.8E+OO 2 .7E+01 3.0E+OO 
Thrombin 1toc A AB 7.0E+OO 4 .1 E-01 1.7E+01 1.0E+OO 
Ornithodorin 1toc B R 7.0E+OO 4 .0E-01 1.7E+01 9.6E-01 
Anhydro trypsin 1tpa A E 3.4E+01 5.1 E+OO 5.2E+01 7 .8E+OO 
PTI 1tpa B I 3 .4E+01 4 .4E+OO 5.2E+01 6 .8E+OO 
Kallikrein 2kai A AB 1.8E+01 2 .8E+OO 3.1 E+01 4 .8E+OO 
BPTI 2kai B I 1.8E+01 2.3E+OO 3.1 E+01 4 .0E+OO 
beta-Trypsin 2ptc A E 2.5E+01 3.8E+OO 5.5E+01 8.3E+OO 
PTI 2ptc B I 2 .5E+01 3.3E+OO 5.5E+01 7 .2E+OO 
Subtilisin Carlsberg 2sic A E 1.3E+01 1.8E+OO 2 .8E+01 3.9E+OO 
streptomyces inhibitor 2sic B I 1.3E+01 1.5E+OO 2 .8E+01 3.2E+OO 
Subtilisin Carlsberg 2sni A E 1.1E+01 1.5E+OO 2 .1 E+01 2.9E+OO 
chymotrypsin inhibitor 2sni B I 1.1E+01 1.3E+OO 2 .1 E+01 2.4E+OO 
Proteinase B streptomyces B 3sgb A E 1.8E+01 3.1 E+OO 3.0E+01 5.1 E+OO 
turkey ovomucoid 3sgb B I 1.8E+01 2 .7E+OO 3.0E+01 4 .5E+OO 
Trypsinogen 3tpi A z 6 .0E+OO 9.2E-01 1.6E+01 2.5E+OO 
PTI 3tpi B I 6 .0E+OO 7 .8E-01 1.6E+01 2.1 E+OO 
Thrombin 4htc A LH 9.0E+OO 5.8E-01 1.3E+01 8.4E-01 
Hirudin 4htc B I 9 .0E+OO 5.2E-01 1.3E+01 7 .5E-01 
Antibody-antigen 
HIV-1 capsid 1afv A AB 2. 1E+01 3.0E+OO 3.7E+01 5.3E+OO 
Fab 25.3 1afv B LH 2.1E+01 3.1 E+OO 3.7E+01 5.4E+OO 
Ab Fv 1 ar1 A CD 1.8E+01 2 .8E+OO 3.1 E+01 4 .7E+OO 
Cytochrome C 1 ar1 B AB 1.8E+01 2 .7E+OO 3.1 E+01 4 .7E+OO 
Fab 1 bj1 A H L 1.4E+01 1.5E+OO 2.7E+01 3.0E+OO 
Vascular endothel ial GF 1 bj1 B vw 1.4E+01 1.3E+OO 2 .7E+01 2 .5E+OO 
Fab Hyhel-5 1 bql A LH 2.0E+01 2 .5E+OO 3.7E+01 4 .7E+OO 
Bobtail quail lysozyme 1 bql B y 2.0E+01 2 .5E+OO 3.7E+01 4 .5E+OO 
Fab Hulys11 1 bvk A DE 6.0E+OO 9.4E-01 1.3E+01 2.0E+OO 
Lysozyme 1 bvk B F 6.0E+OO 9.2E-01 1.3E+01 2 .0E+OO 
Fab Hyhel-63 1 dqj A AB 1.1E+01 1.3E+OO 1.8E+01 2.1 E+OO 
Lysozyme 1 dqj B B 1.1E+01 1.2E+OO 1.8E+01 2.0E+OO 
Fv D1 .3 1dvf A AB 2.0E+OO 2.5E-01 7 .0E+OO 8.9E-01 
Fv DE5.2 1dvf B CD 2 .0E+OO 2.4E-01 7 .0E+OO 8.4E-01 
203 
pdbid %non-pola %polar %charged 
Protease-protease inhibitor 
Trypsin 1ppe A E 5.5E-01 4 .2E-01 3.0E-02 
cucurbita maxima 1ppe B I 6.2E-01 1.8E-01 2.0E-01 
Human leukocyte elastase 1 ppf A E 7.4E-01 2 . 7E-01 O.OE+OO 
turkey ovomucoid 1 ppf B I 7.3E-01 2 .2E-01 5.5E-02 
Papain 1 stf A E 5.9E-01 4 .0E-01 7.6E-03 
Stefin B 1stf B I 7.0E-01 2 .9E-01 1.8E-02 
Trypsin 1tab A E 5.3E-01 4 .4E-01 3.8E-02 
Bowman Bark inhibitor 1 tab B I 5.2E-01 2 .9E-01 1. 9E-01 
Thrombin 1tbq A LH 5.8E-01 2 .0E-01 2.2E-01 
rhodniin 1tbq B R 6.0E-01 2 .6E-01 1.4E-01 
Thermitase 1tec A E 5.6E-01 4.4E-01 O.OE+OO 
elgin C 1tec B I 7.0E-01 1.8E-01 1.2E-01 
Trypsin 1tfx A B 5.7E-01 4 .1 E-01 2.3E-02 
tissue factore pathway inhibitor 1 tfx B D 5.9E-01 2.4E-01 1.7E-01 
Trypsinogen 1tgs A z 5.7E-01 4.2E-01 6.6E-03 
PPTI 1tgs B I 7.0E-01 2 .4E-01 6.7E-02 
Thrombin 1toc A AB 4.9E-01 2.9E-01 2.3E-01 
Ornithodorin 1toc B R 6.4E-01 2 .7E-01 9.5E-02 
Anhydro trypsin 1tpa A E 5.8E-01 4 .2E-01 4 .5E-03 
PTI 1tpa B I 5.6E-01 2 .0E-01 2.4E-01 
Kallikrein 2kai A AB 6.5E-01 3.3E-01 2.3E-02 
BPTI 2kai B I 5.7E-01 2 .3E-01 2.0E-01 
beta-Trypsin 2ptc A E 5.7E-01 4 .2E-01 6.5E-03 
PTI 2ptc B I 5.5E-01 2 .0E-01 2.5E-01 
Subtilisin Carlsberg 2sic A E 6.3E-01 3.3E-01 4 .4E-02 
streptomyces inhibitor 2sic B I 6.1 E-01 3.1 E-01 8.3E-02 
Subtilisin Carlsberg 2sni A E 5.6E-01 3.9E-01 5.7E-02 
chymotrypsin inhibitor 2sni B I 7 .4E-01 1. 7E-01 9.1 E-02 
Proteinase B streptomyces B 3sgb A E 6.2E-01 3.2E-01 5.4E-02 
turkey ovomucoid 3sgb B I 6.9E-01 2 .0E-01 1.0E-01 
Trypsinogen 3tpi A z 5.9E-01 4.0E-01 7.1 E-03 
PTI 3tpi B I 5.4E-01 2.0E-01 2.6E-01 
Thrombin 4htc A LH 5.3E-01 2.2E-01 2 .5E-01 
Hirudin 4htc B I 6.1 E-01 2.7E-01 1.2E-01 
Antibody-antigen 
HIV-1 capsid 1afv A AB 5.9E-01 3.5E-01 6 .0E-02 
Fab 25.3 1afv B LH 5.5E-01 1.0E-01 3.5E-01 
Ab Fv 1 ar1 A CD 4.5E-01 4.1 E-01 1.4E-01 
Cytochrome C 1 ar1 B AB 5.7E-01 2.2E-01 2.2E-01 
Fab 1 bj1 A H L 6.0E-01 4 .0E-01 O.OE+OO 
Vascular endothelial GF 1 bj1 B vw 5.1 E-01 4.2E-01 6.4E-02 
Fab Hyhel-5 1 bql A LH 5.4E-01 3.2E-01 1.4E-01 
Bobtail quail lysozyme 1 bql B y 5.5E-01 3.2E-01 1.4E-01 
Fab Hulys11 1bvk A DE 5.0E-01 3.2E-01 1.8E-01 
Lysozyme 1bvk B F 5.1 E-01 3.6E-01 1.3E-01 
Fab Hyhel-63 1 dqj A AB 4.6E-01 4 .9E-01 4.4E-02 
Lysozyme 1 dqj B B 5.0E-01 2 .8E-01 2.3E-01 
Fv D1 .3 1dvf A AB 4.7E-01 3.4E-01 1. 9E-01 
Fv DE5.2 1dvf B CD 4.5E-01 4 .1E-01 1.4E-01 
204 
pdbid Reso- Protein Average Total interface 
lution mass volume surface area 
Antibody-antigen A Oaltons A"3 area A"2 A"2 
Scfv 1f9 1dzb A A8 2 .1 24456 42550 10350 7.7E+02 
turkey lysozyme 1dzb 8 X 2 .1 14193 24590 6358 8.9E+02 
Fab 1 e6j A HL 2.5 46457 81490 19730 5.7E+02 
Capsid protein p24 1e6j 8 p 2 .5 23339 44140 13290 6 .7E+02 
Fab 1eo8 A H L 2 .5 46385 78850 18920 7.6E+02 
Hemaglutinin 1eo8 8 A8 2 .5 55146 94560 23160 7 .6E+02 
Fab F9.13.7 1fbi A LH 2 .5 46289 80930 19680 8.5E+02 
Lysozyme 1fbi 8 X 2 .5 14292 25070 6667 8.3E+02 
Fab nmc-4 1fns A LH 2 .6 47188 80950 19400 6.1 E+02 
von Willebrand factor 1fns 8 A 2 .6 22361 39150 9311 6 .7E+02 
Kappa Fab 1fsk A K L 2 47445 81120 19300 7.3E+02 
major pollen antigen bet v 1-a 1fsk 8 J 2 17364 31270 8323 8 .7E+02 
Fab 17b 1gc1 A H L 2.5 47694 81220 18780 5.6E+02 
gp120 1gc1 8 GC 2.5 52858 92170 9413 6 .0E+02 
Fab 730.1.4 1 iai A LH 2 .8 47386 83050 19590 9.3E+02 
Fab 409.5.3 1 iai 8 Ml 2 .8 47252 81990 19190 9.4E+02 
Fab 1jhl A LH 2.3 24780 42470 10120 5.9E+02 
protein G domain Ill 1jhl 8 A 2 .3 14238 24730 6364 6.4E+02 
Fab A6 1jrh A LH 2 .6 37906 67800 17710 7 .5E+02 
interferon gamma receptor alpha ch< 1jrh 8 I 2 .6 10770 20360 6045 7.9E+02 
Fab desire-1 1 kb5 A LH 2.2 47186 80360 18840 1.1 E+03 
Kb5-c20 T-cell receptor 1 kb5 8 A8 2 .2 26110 45150 11090 1.2E+03 
Lysozyme 1mel A L 2 14027 23920 6137 7 .9E+02 
VH single domain antibody 1mel 8 A 2 13854 24340 6413 8.9E+02 
Lysozyme 1mlc A E 2 .3 14297 24460 6358 7.2E+02 
Fab 044.1 1mlc 8 A8 2 .3 46704 80120 19090 6 .5E+02 
Fab 1nca A LH 2 .3 47222 81220 19170 9.2E+02 
N9 neuraminidase-nc41 1nca 8 N 2 .3 43720 71700 14820 9.8E+02 
N 15 a-[3 T -cell receptor 1 nfd A A8 1.9 47226 82100 20900 7.5E+02 
Fab h57 1 nfd 8 EF 1.9 49772 86580 21240 8.6E+02 
Fab NC-10 1nmb A LH 2 25491 43730 10740 6 .4E+02 
N9-neuraminidase 1nmb 8 N 2 43528 71060 14570 6 .9E+02 
Kappa Fab 1nsn A LH 2 .2 46550 80060 19110 8.8E+02 
staphylococcal nuclease 1nsn 8 s 2 .2 15703 28740 7966 8.8E+02 
Fab 184.1 1osp A LH 2 .6 47024 80940 19510 7.6E+02 
protein A outer surface 1osp 8 0 2 .6 26940 50150 14150 6 .9E+02 
Fab 1qfw A HLIM 2 .3 48647 86710 22180 1.5E+03 
Gonadotropin 1qfw 8 A8 2 .3 21310 39700 11420 1.7E+03 
rhinovirus coat protein 1 rvf A VWXY 3.5 88839 151400 31330 9.1 E+02 
Fab 17-1a 1 rvf 8 H L 3.5 24831 40570 9697 8.8E+02 
Fv 01 .3 1vfb A A8 2 .8 24498 42110 9966 6 .5E+02 
Lysozyme 1vfb 8 c 2 .8 14297 24880 6438 7.1 E+02 
Fab e8 1wej A H L 2 .7 47380 81080 19260 5.3E+02 
cytochrome C 1wej 8 F 2 .7 11676 21560 6139 6 .1 E+02 
lambda Fab 2vir A A8 3.95 46259 79760 19280 6 .5E+02 
hemagglutinin 2vir 8 c 3.95 29449 49800 11610 6 .0E+02 
hyhel-5 3hfl A LH 2 46043 79430 19030 8.4E+02 
Lysozyme 3hfl 8 y 2 14297 24660 6286 8.5E+02 
hyhel-10 3hfm A LH 3.2 46758 81600 19440 7.4E+02 
Lysozyme 3hfm 8 y 3.2 14297 24910 6560 8.3E+02 
205 
pdbid Circularity RMSO Atom Atom 
to plane burial access-
Antibody-antigen ibility 
Scfv 1f9 1dzb A AB 5.2E-01 2 .5E+OO 7.0E+OO 1.1E+01 
turkey lysozyme 1dzb B X 5.1 E-01 2 .6E+OO 1.0E+01 1.5E+01 
Fab 1e6j A HL 6 .9E-01 2 .1 E+OO 6.1 E+OO 1.0E+01 
Capsid protein p24 1e6j B p 7.8E-01 2 .1 E+OO 1.1E+01 1.7E+01 
Fab 1eo8 A HL 4 .9E-01 2 .1 E+OO 8.9E+OO 1.4E+01 
Hemaglutinin 1eo8 B AB 4.4E-01 2 .2E+OO 8.4E+OO 1.3E+01 
Fab F9.13.7 1fbi A LH 5.2E-01 2.1 E+OO 9.1 E+OO 1.3E+01 
Lysozyme 1fbi B X 4 .9E-01 1.9E+OO 8.1 E+OO 1.3E+01 
Fab nmc-4 1fns A LH 5.1 E-01 2 .3E+OO 7.5E+OO 1.1E+01 
von Willebrand factor 1fns B A 7.1E-01 2 .3E+OO 1.1E+01 1.7E+01 
Kappa Fab 1fsk A KL 8.4E-01 2 .6E+OO 6 .2E+OO 1.1E+01 
major pollen antigen bet v 1-a 1fsk B J 8.2E-01 2 .6E+OO 1.0E+01 1.4E+01 
Fab 17b 1gc1 A HL 3.3E-01 1.7E+OO 8.2E+OO 1.3E+01 
gp120 1gc1 B GC 3.8E-01 1.7E+OO 1.0E+01 1.3E+01 
Fab 730.1.4 1iai A LH 3.5E-01 2 .7E+OO 8.8E+OO 1.3E+01 
Fab 409.5.3 1iai B Ml 3.3E-01 2 .9E+OO 8.5E+OO 1.4E+01 
Fab 1jhl A LH 6.2E-01 1.7E+OO 7.2E+OO 1.3E+01 
protein G domain Ill 1jhl B A 5.3E-01 1.8E+OO 8.8E+OO 1.5E+01 
Fab A6 1jrh A LH 4 .4E-01 2 .5E+OO 8.1 E+OO 1.3E+01 
interferon gamma receptor alpha ch< 1jrh B I 6.3E-01 2 .3E+OO 1.0E+01 1.5E+01 
Fab desire-1 1 kb5 A LH 4 .8E-01 3.0E+OO 9.3E+OO 1.5E+01 
Kb5-c20 T-cell receptor 1kb5 B AB 7.7E-01 2.9E+OO 9.2E+OO 1.4E+01 
Lysozyme 1mel A L 6.1 E-01 3.3E+OO 8.3E+OO 1.3E+01 
VH single domain antibody 1mel B A 9.0E-01 3.4E+OO 1.0E+01 1.4E+01 
Lysozyme 1mlc A E 5.2E-01 2.0E+OO 1.0E+01 1.5E+01 
Fab 044.1 1mlc 8 AB 6.2E-01 1.7E+OO 7.6E+OO 1.1E+01 
Fab 1nca A LH 6.5E-01 2.4E+OO 7.5E+OO 1.3E+01 
N9 neuraminidase-nc41 1nca B N 4.7E-01 2.2E+OO 9.7E+OO 1.6E+01 
N 15 a-J3 T -cell receptor 1 nfd A AB 4.6E-01 3.0E+OO 7.2E+OO 1.4E+01 
Fab h57 1 nfd B EF 7.6E-01 3.3E+OO 1.1E+01 1.5E+01 
Fab NC-1 0 1nmb A LH 2.3E-01 1.6E+OO 8.0E+OO 1.3E+01 
N9-neuraminidase 1nmb 8 N 2.3E-01 1.5E+OO 1.0E+01 1.6E+01 
Kappa Fab 1nsn A LH 4.8E-01 3.4E+OO 9.0E+OO 1.7E+01 
staphylococcal nuclease 1nsn B s 7.5E-01 3.5E+OO 8.5E+OO 1.5E+01 
Fab 184.1 1osp A LH 2.6E-01 1. 7E+OO 9.2E+OO 1.4E+01 
protein A outer surface 1osp B 0 2.7E-01 1.6E+OO 8.5E+OO 1.5E+01 
Fab 1qfw A HLIM 2.3E-02 4 .0E+OO 7 .6E+OO 1.3E+01 
Gonadotropin 1qfw B AB 2.9E-02 3.3E+OO 1.0E+01 1.6E+01 
rhinovirus coat protein 1 rvf A VWXY 1.8E-01 3.4E+OO 9.4E+OO 1.6E+01 
Fab 17-1a 1 rvf B H L 2.4E-01 3.5E+OO 8.1 E+OO 1.3E+01 
Fv 01 .3 1vfb A AB 6.1 E-01 1.6E+OO 8.0E+OO 1.3E+01 
Lysozyme 1vfb B c 6.8E-01 1.7E+OO 9.0E+OO 1.4E+01 
Fab e8 1wej A H L 2.6E-01 1.5E+OO 7.2E+OO 1.3E+01 
cytochrome C 1wej B F 3.8E-01 1.6E+OO 1.0E+01 1.6E+01 
lambda Fab 2vir A A8 5.6E-01 1.8E+OO 8.9E+OO 1.4E+01 
hemagglutinin 2vir B c 4.8E-01 2.4E+OO 7.5E+OO 1.3E+01 
hyhel-5 3hfl A LH 6.3E-01 2 .8E+OO 7.5E+OO 1.2E+01 
Lysozyme 3hfl B y 4.7E-01 3.0E+OO 8.3E+OO 1.3E+01 
hyhel-10 3hfm A LH 3.8E-01 2.5E+OO 8.0E+OO 1.2E+01 
Lysozyme 3hfm B y 3.8E-01 2.4E+OO 8.7E+OO 1.3E+01 
206 
pdbid Shape Vol. Ratio Vol. Ratio 
comple- infc core/ infc perim/ 
Antibody-antigen mentarity prot. core prot. core 
Scfv 1f9 1dzb A AB 6 .8E-01 1.1E+OO 1.7E+OO 
turkey lysozyme 1dzb B X 6 .8E-01 1.0E+OO 1.7E+OO 
Fab 1 e6j A HL 7.4E-01 1.1E+OO 1.9E+OO 
Capsid protein p24 1 e6j B p 7.4E-01 1.3E+OO 2.3E+OO 
Fab 1eo8 A HL 7.3E-01 1.1 E+OO 2.0E+OO 
Hemaglutinin 1eo8 B AB 7.3E-01 1.1E+OO 1.8E+OO 
Fab F9.13.7 1fbi A LH 6.5E-01 1.2E+OO 1.6E+OO 
Lysozyme 1fbi B X 6 .5E-01 1.1E+OO 1.9E+OO 
Fab nmc-4 1fns A LH 8.3E-01 1.2E+OO 2.2E+OO 
von Willebrand factor 1 fns B A 8.3E-01 1.5E+OO 2.4E+OO 
Kappa Fab 1fsk A KL 7.0E-01 9.2E-01 2.0E+OO 
major pollen antigen bet v 1-a 1fsk B J 7.0E-01 1.0E+OO 1.9E+OO 
Fab 17b 1gc1 A HL 7.0E-01 1.1E+OO 2.2E+OO 
gp120 1gc1 B GC 7.0E-01 1.2E+OO 2.6E+OO 
Fab 730.1.4 1 iai A LH 6 .2E-01 9.2E-01 2.0E+OO 
Fab 409.5.3 1 iai B Ml 6 .2E-01 9.3E-01 2.0E+OO 
Fab 1jhl A LH 6 .5E-01 1.0E+OO 1.8E+OO 
protein G domain Ill 1jhl B A 6 .5E-01 9.5E-01 1.9E+OO 
Fab A6 1jrh A LH 7.8E-01 1.1E+OO 1.9E+OO 
interferon gamma receptor alpha ch< 1jrh B I 7.8E-01 1.0E+OO 2.1 E+OO 
Fab desire-1 1 kb5 A LH 5.4E-01 1.0E+OO 1.8E+OO 
Kb5-c20 T-cell receptor 1 kb5 B AB 5.4E-01 1.1 E+OO 1.7E+OO 
Lysozyme 1mel A L 7.8E-01 1.2E+OO 1.9E+OO 
VH single domain antibody 1mel B A 7.8E-01 1.1E+OO 1.8E+OO 
Lysozyme 1mlc A E 6 .6E-01 1.2E+OO 1.7E+OO 
Fab 044.1 1mlc B AB 6 .6E-01 9.7E-01 1.8E+OO 
Fab 1 nca A LH 6 .5E-01 1.1E+OO 2.1 E+OO 
N9 neuraminidase-nc41 1nca B N 6.5E-01 1.1E+OO 2.4E+OO 
N 15 a-13 T -cell receptor 1 nfd A AB 6 .7E-01 1.1E+OO 2.0E+OO 
Fab h57 1 nfd B EF 6.7E-01 8. ?E-01 2.0E+OO 
Fab NC-10 1nmb A LH 6 .6E-01 9. 7E-01 1.6E+OO 
N9-neuraminidase 1nmb B N 6 .6E-01 1.0E+OO 1.8E+OO 
Kappa Fab 1nsn A LH 5.9E-01 1.1E+OO 2.1 E+OO 
staphylococcal nuclease 1nsn B s 5.9E-01 1.0E+OO 2.2E+OO 
Fab 184.1 1osp A LH 7.7E-01 9.7E-01 1.5E+OO 
protein A outer surface 1osp B 0 7.7E-01 1.1E+OO 1.8E+OO 
Fab 1qfw A HLIM 5.9E-01 1.0E+OO 1.9E+OO 
Gonadotropin 1qfw B AB 5.9E-01 1.1E+OO 2.1 E+OO 
rhinovirus coat protein 1 rvf A VWXY 6.3E-01 1.2E+OO 2.6E+OO 
Fab 17-1a 1 rvf B HL 6 .3E-01 1.2E+OO 2.2E+OO 
Fv 01 .3 1vfb A AB 7.3E-01 8.8E-01 1.4E+OO 
Lysozyme 1vfb B c 7.3E-01 9.2E-01 1.4E+OO 
Fab e8 1wej A HL 7.8E-01 9.8E-01 1.5E+OO 
cytochrome C 1wej B F 7.8E-01 1.3E+OO 1. 7E+OO 
lambda Fab 2vir A AB 6 .6E-01 -9.0E-02 2.0E+OO 
hemagglutinin 2vir B c 6 .6E-01 -3.0E-01 2.0E+OO 
hyhel-5 3hfl A LH 7.2E-01 1.0E+OO 1.7E+OO 
Lysozyme 3hfl B y 7.2E-01 1.0E+OO 1.6E+OO 
hyhel-10 3hfm A LH 6.8E-01 1.0E+OO 1.9E+OO 
Lysozyme 3hfm B y 6.8E-01 1.1E+OO 1.9E+OO 
207 
pdbid Hbonds per 100 Hbonds per 100 
<3.3 A sq angstro1 <4.0 A sq angstro 
Antibody-antigen 
Scfv 1f9 1dzb A AB 9.0E+OO 1.2E+OO 1.6E+01 2 .1 E+OO 
turkey lysozyme 1dzb B X 9.0E+OO 1.0E+OO 1.6E+01 1.8E+OO 
Fab 1e6j A HL 9.0E+OO 1.6E+OO 1.6E+01 2 .8E+OO 
Capsid protein p24 1e6j B p 9.0E+OO 1.3E+OO 1.6E+01 2.4E+OO 
Fab 1eo8 A HL 7.0E+OO 9.2E-01 1.9E+01 2 .5E+OO 
Hemaglutinin 1eo8 B AB 7.0E+OO 9.3E-01 1.9E+01 2 .5E+OO 
Fab F9.13.7 1fbi A LH 1.3E+01 1.5E+OO 2.1 E+01 2 .5E+OO 
Lysozyme 1fbi B X 1.3E+01 1.6E+OO 2.1 E+01 2 .5E+OO 
Fab nmc-4 1fns A LH 1.1 E+01 1.8E+OO 2 .0E+01 3.3E+OO 
von Willebrand factor 1fns B A 1.1E+01 1.6E+OO 2 .0E+01 3.0E+OO 
Kappa Fab 1fsk A KL 9.0E+OO 1.2E+OO 2 .0E+01 2 .7E+OO 
major pollen antigen bet v 1-a 1fsk B J 9.0E+OO 1.0E+OO 2 .0E+01 2 .3E+OO 
Fab 17b 1 gc1 A HL 8.0E+OO 1.4E+OO 2 .4E+01 4 .3E+OO 
gp120 1 gc1 B GC 8.0E+OO 1.3E+OO 2.4E+01 4 .0E+OO 
Fab 730.1.4 1 iai A LH 1.5E+01 1.6E+OO 2 .6E+01 2 .8E+OO 
Fab 409.5.3 1iai B Ml 1.5E+01 1.6E+OO 2 .6E+01 2 .8E+OO 
Fab 1jhl A LH 1.9E+01 3.2E+OO 3.1E+01 5.3E+OO 
protein G domain Ill 1jhl B A 1.9E+01 3.0E+OO 3.1E+01 4 .8E+OO 
Fab A6 1jrh A LH 5.0E+OO 6 .7E-01 1.0E+01 1.3E+OO 
interferon gamma receptor alpha ch< 1jrh B I 5.0E+OO 6 .3E-01 1.0E+01 1.3E+OO 
Fab desire-1 1 kb5 A LH 9.0E+OO B.OE-01 2 .5E+01 2 .2E+OO 
Kb5-c20 T -cell receptor 1 kb5 B AB 9.0E+OO 7 .8E-01 2.5E+01 2.2E+OO 
Lysozyme 1mel A L 1.2E+01 1.5E+OO 2 .6E+01 3.3E+OO 
VH single domain antibody 1mel B A 1.2E+01 1.4E+OO 2 .6E+01 2 .9E+OO 
Lysozyme 1mlc A E 1.0E+01 1.4E+OO 2 .3E+01 3.2E+OO 
Fab 044.1 1mlc B AB 1.0E+01 1.5E+OO 2 .3E+01 3.5E+OO 
Fab 1 nca A LH 1.0E+01 1.1 E+OO 1.9E+01 2 .1 E+OO 
N9 neuraminidase-nc41 1nca B N 1.0E+01 1.0E+OO 1.9E+01 1.9E+OO 
N 15 a-13 T -cell receptor 1 nfd A AB 1.4E+01 1.9E+OO 2 .7E+01 3.6E+OO 
Fab h57 1 nfd B EF 1.4E+01 1.6E+OO 2 .7E+01 3.1 E+OO 
Fab NC-10 1nmb A LH 1.0E+01 1.6E+OO 2 .5E+01 3.9E+OO 
N9-neuraminidase 1nmb B N 1.0E+01 1.5E+OO 2 .5E+01 3.6E+OO 
Kappa Fab 1nsn A LH 9.0E+OO 1.0E+OO 1.7E+01 1.9E+OO 
staphylococcal nuclease 1nsn B s 9.0E+OO 1.0E+OO 1.7E+01 1.9E+OO 
Fab 184.1 1osp A LH 3.0E+OO 3.9E-01 5.0E+OO 6 .6E-01 
protein A outer surface 1osp B 0 3.0E+OO 4 .3E-01 5.0E+OO 7.2E-01 
Fab 1qfw A HLIM 2.0E+01 1.3E+OO 4 .0E+01 2 .7E+OO 
Gonadotropin 1qfw B AB 2.0E+01 1.2E+OO 4 .0E+01 2 .4E+OO 
rhinovirus coat protein 1 rvf A VWXY 8.0E+OO 8.8E-01 1.6E+01 1.8E+OO 
Fab 17-1a 1 rvf B H L 8.0E+OO 9.0E-01 1.6E+01 1.8E+OO 
Fv 01 .3 1vfb A AB 1.2E+01 1.9E+OO 1.6E+01 2 .5E+OO 
Lysozyme 1vfb B c 1.2E+01 1.7E+OO 1.6E+01 2 .3E+OO 
Fab e8 1wej A H L 1.5E+01 2 .8E+OO 2 .9E+01 5.5E+OO 
cytochrome C 1wej B F 1.5E+01 2 .4E+OO 2.9E+01 4 .7E+OO 
lambda Fab 2vir A AB 1.0E+OO 1.5E-01 2 .0E+OO 3.1 E-01 
hemagglutinin 2vir B c 1.0E+OO 1. 7E-01 2 .0E+OO 3.3E-01 
hyhel-5 3hfl A LH 1.5E+01 1.8E+OO 2.2E+01 2.6E+OO 
Lysozyme 3hfl B y 1.5E+01 1.8E+OO 2.2E+01 2.6E+OO 
hyhel-10 3hfm A LH 1.2E+01 1.6E+OO 2.5E+01 3.4E+OO 
Lysozyme 3hfm B y 1.2E+01 1.4E+OO 2 .5E+01 3.0E+OO 
208 
pdbid o/onon-pola %polar %charged 
Antibody-antigen 
Scfv 1f9 1dzb A AB 5.4E-01 3.3E-01 1.3E-01 
turkey lysozyme 1dzb B X 5.2E-01 2 .6E-01 2.2E-01 
Fab 1e6j A HL 6.4E-01 3.6E-01 O.OE+OO 
Capsid protein p24 1e6j B p 7.1 E-01 1.7E-01 1.3E-01 
Fab 1eo8 A HL 5.4E-01 3.6E-01 1.1E-01 
Hemaglutinin 1eo8 B AB 7 .OE-01 9.9E-02 2.0E-01 
Fab F9.13.7 1fbi A LH 5.5E-01 3.5E-01 1.0E-01 
Lysozyme 1fbi B X 4.8E-01 2 .6E-01 2.6E-01 
Fab nmc-4 1fns A LH 5.8E-01 2 .9E-01 1.2E-01 
von Willebrand factor 1fns B A 5.0E-01 1.6E-01 3.4E-01 
Kappa Fab 1fsk A KL 6.1 E-01 3.1 E-01 8.2E-02 
major pollen antigen bet v 1-a 1fsk B J 5.2E-01 2 .6E-01 2.2E-01 
Fab 17b 1gc1 A HL 6.0E-01 3.1 E-01 8.3E-02 
gp120 1gc1 B GC 5.9E-01 2 .1 E-01 2.0E-01 
Fab 730.1.4 1iai A LH 5.2E-01 4 .5E-01 3.9E-02 
Fab 409.5.3 1iai B Ml 5.7E-01 4 .0E-01 3.6E-02 
Fab 1jhl A LH 5.2E-01 4 .1 E-01 6.9E-02 
protein G domain Ill 1jhl B A 5.2E-01 2 .9E-01 1.9E-01 
Fab A6 1jrh A LH 5.3E-01 3.4E-01 1.2E-01 
interferon gamma receptor alpha ch< 1jrh B I 5.8E-01 3.0E-01 1.2E-01 
Fab desire-1 1 kb5 A LH 5.0E-01 3.9E-01 1.1 E-01 
Kb5-c20 T-cell receptor 1 kb5 B AB 5.2E-01 2 .7E-01 2.1E-01 
Lysozyme 1mel A L 5.2E-01 2 .5E-01 2.3E-01 
VH single domain antibody 1mel B A 7.5E-01 2.4E-01 9.0E-03 
Lysozyme 1mlc A E 5.8E-01 2.4E-01 1.8E-01 
Fab 044.1 1mlc B AB 5.8E-01 3.8E-01 4 .6E-02 
Fab 1nca A LH 5.0E-01 4 .0E-01 1.0E-01 
N9 neuraminidase-nc41 1nca B N 5.7E-01 3.5E-01 8.1 E-02 
N 15 a-13 T -cell receptor 1 nfd A AB 5.1 E-01 3.3E-01 1.6E-01 
Fab h57 1 nfd B EF 5.3E-01 1.6E-01 3.1E-01 
Fab NC-10 1nmb A LH 5.1 E-01 4 .1 E-01 8.0E-02 
N9-neuraminidase 1nmb B N 5.8E-01 3.9E-01 2.9E-02 
Kappa Fab 1 nsn A LH 5.3E-01 4 .2E-01 5.0E-02 
staphylococcal nuclease 1nsn B s 5.7E-01 2 .0E-01 2.3E-01 
Fab 184.1 1osp A LH 5.4E-01 2 .0E-01 2 .6E-01 
protein A outer surface 1osp B 0 5.4E-01 2 .6E-01 2 .0E-01 
Fab 1qfw A HLIM 5.2E-01 3.6E-01 1.2E-01 
Gonadotropin 1qfw B AB 5.8E-01 2 .7E-01 1.5E-01 
rhinovirus coat protein 1 rvf A VWXY 4 .8E-01 2.2E-01 3.1 E-01 
Fab 17-1a 1 rvf B HL 5.4E-01 3.1 E-01 1.5E-01 
Fv 01 .3 1vfb A AB 5.0E-01 3.0E-01 1.9E-01 
Lysozyme 1vfb B c 4.8E-01 3.8E-01 1.4E-01 
Fab e8 1wej A HL 5.0E-01 4 .2E-01 8.2E-02 
cytochrome C 1wej B F 5.3E-01 2.0E-01 2 .7E-01 
lambda Fab 2vir A AB 5.5E-01 3.3E-01 1.2E-01 
hemagglutinin 2vir B c 5.2E-01 4.3E-01 4 .8E-02 
hyhel-5 3hfl A LH 5.2E-01 3.3E-01 1.5E-01 
Lysozyme 3hfl B y 5.1 E-01 3.4E-01 1.5E-01 
hyhel-10 3hfm A LH 4.4E-01 5.4E-01 2.0E-02 
Lysozyme 3hfm B y 5.3E-01 2 .0E-01 2.7E-01 
209 
pdbid Reso- Protein Average Total interface 
I uti on mass volume surface area 
Enzyme complexes A Daltons N'3 area A"2 A"2 
Actin 1 atn A A 2 .6 41357 71260 16600 9.4E+02 
DNAase I 1 atn B D 2 .6 28814 47770 10270 8.1 E+02 
Barley alpha-amylase/subtilisin inhibi 1 ava A D 1.8 19846 34880 8645 1.2E+03 
Barley alpha-amylase 2 1ava B B 1.8 44842 74310 14920 1.1E+03 
VC1 1azs A A 2 42073 73540 17180 1.0E+03 
IIC2 1azs B B 2 39502 69740 17140 8.9E+02 
Cyclin-dependent kinase 6 1bi8 A A 3.2 29889 52790 13460 1.0E+03 
cyclin-dependent kinase inhibitor 1 biB B B 3.2 16392 28080 7085 9.4E+02 
plasmin 1bml A AB 1.9 54486 93000 10590 2.1 E+03 
streptokinase 1bml B c 1.9 36079 66080 18040 2 .0E+03 
Barnase 1 brs A E 2 .2 12162 21690 5837 7.8E+02 
Barstar C40A, C82A 1 brs B I 2 .2 9758 17880 4800 7.6E+02 
plasmin 1 bui A AB 3 52892 90060 20600 1. 7E+03 
staphylokinase sak-c-phi-c 1 bui B c 3 13473 24940 7111 1.5E+03 
m-calpain 1 dfO A A 2 .3 70253 124500 30630 2.8E+03 
cal pain 1 dfO B B 2 .3 20279 37210 10620 2.7E+03 
ribonuclease A 1 dfj A E 2 .6 13667 24670 6921 1.3E+03 
ribonuclease inhibitor 1 dfj B I 2 .6 48929 84370 18590 1.2E+03 
porcine pancreatic a-amylase 1dhk A A 2.4 55145 89950 17760 1.4E+03 
bean lectin-like inhibitor 1dhk B B 2 .4 21517 37340 8871 1.6E+03 
DNA polymerase processivity factor 1dml A A 1.6 29194 52340 13240 1.4E+03 
DNA polymerase 1dml B B 1.6 3739 8036 3262 1.4E+03 
triacylglycerol acyl-hydrolase 1 eth A A 3.1 49768 81490 17860 7.4E+02 
co lipase 1 eth B B 3 .1 9477 17300 5413 8.0E+02 
thioredoxin reductase 1f6m A EF 2 .2 68822 117400 13450 9.2E+02 
thioredoxin 1 1f6m B G 2 .2 11629 20650 5454 8.7E+02 
botulinum neurotoxin type B 1 f83 A A 2 .55 48924 83940 19440 1.8E+03 
synaptobrevin II 1 f83 B BC 2.55 4058 9858 4617 2.3E+03 
acetylcholinesterase 1fss A A 3 59753 98120 19830 9.4E+02 
fasciculin II 1fss B B 3 6748 12560 4034 1.0E+03 
glycerol kinase 1gla A F 3 17008 31030 8242 6.1 E+02 
glucose specific factor Ill 1gla B G 3 53559 88730 17960 6 .7E+02 
serine/threonine phosphatase 82 1tco A AB 2.95 59700 100900 22800 9.5E+02 
Fk506-binding protein 1tco B c 2.95 11711 20900 5678 9.2E+02 
uracil-dna glycosylase 1 udi A E 2.96 25716 44660 10400 1.0E+03 
uracil-dna glycosylase inhibitor prate 1 udi B I 2 .96 9314 17280 5044 9.8E+02 
beta-actin 2btf A A 2 .35 41525 71670 16570 1.0E+03 
profilin 2btf B B 2 .35 14900 26520 6797 1.0E+03 
cytochrome C peroxidase 2pcc A A 2 .3 33413 56590 12940 5.6E+02 
iso-1-cytochrome C 2pcc B B 2 .3 12027 21820 6109 5.7E+02 
Large complexes 
ribonuclease inhibitor 1a4y A AD 2 .8 48904 163200 16180 1.3E+03 
angiogenin 1a4y B B 2 .8 14128 25040 6864 1.4E+03 
allophycocyanin a - 13 1b33 A ACEBDF 2.5 102954 176100 41090 2 .0E+03 
phycobilisome 1b33 B N 2 .5 7732 15600 5245 2 .1 E+03 
tp7 mab 1 bgx A LH 1.9 46003 83030 19410 2 .9E+03 
Taq DNA polymerase 1 bgx B T 1.9 92869 171600 39390 2 .9E+03 
Hemachromatosis protein hfe 1de4 A A 2 .5 43302 75140 18580 1.0E+03 
transferrin receptor 1de4 B B 2 .5 141842 234500 22820 1.0E+03 
210 
pdbid Circularity RMSD Atom Atom 
to plane burial access-
Enzyme complexes ibility 
Actin 1 atn A A 3.5E-01 2 .8E+OO 1.1E+01 1.5E+01 
DNAase I 1 atn B D 6.0E-01 3 .1 E+OO 7.5E+OO 1.1E+01 
Barley alpha-amylase/subtilisin inhibi 1 ava A D 4.5E-01 3 .6E+OO 8.4E+OO 1.3E+01 
Barley alpha-amylase 2 1ava B B 3.6E-01 3.9E+OO 8.4E+OO 1.4E+01 
VC1 1azs A A 8 .5E-01 3 .5E+OO 1.0E+01 1.5E+01 
IIC2 1azs B B 7 .5E-01 3.3E+OO 8.2E+OO 1.3E+01 
Cyclin-dependent kinase 6 1 biB A A 6 .7E-01 2.6E+OO 9.3E+OO 1.4E+01 
cyclin-dependent kinase inhibitor 1bi8 B B 8.4E-01 2.3E+OO 8.2E+OO 1.3E+01 
plasmin 1bml A AB 5.9E-01 4.4E+OO 1.0E+01 1.6E+01 
streptokinase 1bml B c 5.0E-01 5 .2E+OO 8.2E+OO 1.4E+01 
Barnase 1 brs A E 4.0E-01 2 .6E+OO 8.2E+OO 1.2E+01 
Barstar C40A, C82A 1 brs B I 6 .2E-01 2 .6E+OO 8.5E+OO 1.2E+01 
plasmin 1 bui A AB 7.6E-01 5.5E+OO 8.7E+OO 1.4E+01 
staphylokinase sak-c-phi-c 1 bui B c 3.8E-01 5.2E+OO 8.7E+OO 1.4E+01 
m-calpain 1 dfO A A 6.9E-01 5.7E+OO 1.0E+01 1.5E+01 
calpain 1 dfO B B 9.2E-01 5 .3E+OO 9.5E+OO 1.4E+01 
ribonuclease A 1 dfj A E 2.7E-01 5 .1 E+OO 9.2E+OO 1.6E+01 
ribonuclease inhibitor 1 dfj B I 3.6E-01 5 .3E+OO 7.7E+OO 1.5E+01 
porcine pancreatic a-amylase 1dhk A A 6.8E-01 5.5E+OO 8.1 E+OO 1.2E+01 
bean lectin-like inhibitor 1dhk B B 8.6E-01 5.2E+OO 9.0E+OO 1.3E+01 
DNA polymerase processivity factor 1dml A A 4.5E-01 4 .0E+OO 9.6E+OO 1.3E+01 
DNA polymerase 1dml B B 5.2E-01 2 .9E+OO 1.0E+01 1.7E+01 
triacyfglycerol acyl-hydrolase 1eth A A 1.8E-01 2 .5E+OO 8.9E+OO 1.5E+01 
colipase 1 eth B B 1.5E-01 2 . 7E+OO 1.0E+01 1.6E+01 
thioredoxin reductase 1f6m A EF 2.2E-01 3.2E+OO 8. 7E+OO 1.5E+01 
thioredoxin 1 1f6m B G 2 .7E-01 3 .4E+OO 9.2E+OO 1.5E+01 
botulinum neurotoxin type B 1f83 A A 1.6E-01 4.9E+OO 6 .9E+OO 1.1E+01 
synaptobrevin II 1f83 B BC 7.1 E-02 4 .1 E+OO 1.2E+01 1.8E+01 
acetylcholinesterase 1fss A A 6 .6E-01 3 .1 E+OO 7.6E+OO 1.2E+01 
fasciculin II 1fss B B 4.1 E-01 2 .8E+OO 1.0E+01 1.6E+01 
glycerol kinase 1gla A F 5.9E-01 1.9E+OO 8.2E+OO 1.4E+01 
glucose specific factor Ill 1gla B G 5.1 E-01 1.9E+OO 1.0E+01 1.9E+01 
serine/threonine phosphatase B2 1tco A AB 6.4E-01 3 .9E+OO 9.5E+OO 1.7E+01 
Fk506-binding protein 1tco B c 8.4E-01 3.7E+OO 8.9E+OO 1.7E+01 
uracil-dna glycosylase 1 ud i A E 8 .5E-01 3 .0E+OO 9.8E+OO 1.6E+01 
uracil-dna glycosylase inhibitor prate 1 udi B I 7 .9E-01 3.0E+OO 8.9E+OO 1.4E+01 
beta-actin 2btf A A 2.5E-01 2 .8E+OO 8.1 E+OO 1.2E+01 
profilin 2btf B B 4 .6E-01 3 .4E+OO 7.3E+OO 1.1E+01 
cytochrome C peroxidase 2pcc A A 8 .1E-0 1 1.4E+OO 1.0E+01 1.8E+01 
iso-1-cytochrome C 2pcc B B 7.5E-01 1.4E+OO 1.0E+01 2. 1 E+01 
Large complexes 
ribonuclease inhibitor 1a4y A AD 5.0E-01 5 .9E+OO 7 .6E+OO 1.3E+01 
angiogenin 1a4y B B 3.4E-01 4 .9E+OO 9.8E+OO 1.6E+01 
allophycocyanin a-13 1b33 A ACEBDF 2 .9E-01 5 .5E+OO 8.2E+OO 1.4E+01 
phycobilisome 1b33 B N 1.6E-01 4 .7E+OO 1.0E+01 1.7E+01 
tp7 mab 1bgx A LH 5.4E-01 6 .2E+OO 8.6E+OO 1.3E+01 
Taq DNA polymerase 1bgx B T 5.0E-01 6 .5E+OO 9.4E+OO 1.5E+01 
Hemachromatosis protein hfe 1de4 A A 7 .6E-01 1.9E+OO 8.8E+OO 1.5E+01 
transferrin receptor 1de4 B B 5.0E-01 6 .1 E+OO 9.1 E+OO 1.5E+01 
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pdbid Shape Vol. Ratio Vol. Ratio 
comple- infc core/ infc perim/ 
Enzyme complexes mentarity prot. core prot. core 
Actin 1 atn A A 7 .4E-01 1.0E+OO 1.8E+OO 
DNAase I 1 atn B D 7 .4E-01 1.0E+OO 1.9E+OO 
Barley alpha-amylase/subtilisin inhibi 1 ava A D 6.4E-01 1.1E+OO 1.6E+OO 
Barley alpha-amylase 2 1ava B B 6.4E-01 9.9E-01 1.6E+OO 
VC1 1azs A A 6.6E-01 1.2E+OO 1.8E+OO 
IIC2 1azs B B 6.6E-01 1.2E+OO 2.2E+OO 
Cyclin-dependent kinase 6 1 bi8 A A 6.3E-01 1.1E+OO 2.3E+OO 
cyclin-dependent kinase inhibitor 1 bi8 B B 6 .3E-01 1.1E+OO 2.0E+OO 
plasmin 1bml A AB 6.5E-01 9.9E-01 2.2E+OO 
streptokinase 1bml B c 6 .5E-01 1.2E+OO 2.0E+OO 
Barnase 1 brs A E 7.2E-01 1.0E+OO 1.3E+OO 
Barstar C40A, C82A 1brs B I 7.2E-01 9.2E-01 1.2E+OO 
plasmin 1 bui A AB 6 .0E-01 1.0E+OO 1.9E+OO 
staphylokinase sak-c-phi-c 1 bui B c 6 .0E-01 1.1E+OO 1.9E+OO 
m-calpain 1 dfO A A 6 .5E-01 1.2E+OO 2.1 E+OO 
calpain 1 dfO B B 6 .5E-01 1.1E+OO 2.0E+OO 
ribonuclease A 1 dfj A E 5.8E-01 1.2E+OO 2.0E+OO 
ribonuclease inhibitor 1 dfj B I 5.8E-01 1.1E+OO 2.4E+OO 
porcine pancreatic a-amylase 1dhk A A 6 .2E-01 1.0E+OO 1.6E+OO 
bean lectin-like inhibitor 1dhk B B 6.2E-01 9.8E-01 1.6E+OO 
DNA polymerase processivity factor 1dml A A 7.1 E-01 1.1E+OO 2.0E+OO 
DNA polymerase 1dml B B 7.1 E-01 1.4E+OO 2.7E+OO 
triacylglycerol acyl-hydrolase 1 eth A A 6 .4E-01 1.1E+OO 2 .0E+OO 
colipase 1 eth B B 6.4E-01 1.2E+OO 2.2E+OO 
thioredoxin reductase 1f6m A EF 6 .7E-01 1.1 E+OO 1.6E+OO 
thioredoxin 1 1f6m B G 6 .7E-01 1.1 E+OO 1.5E+OO 
botulinum neurotoxin type B 1f83 A A 6 .1 E-01 1.0E+OO 1.5E+OO 
synaptobrevin II 1f83 B BC 6 .1 E-01 9.6E-01 2.2E+OO 
acetylcholinesterase 1fss A A 6 .9E-01 1.1E+OO 2.0E+OO 
fasciculin II 1fss B B 6 .9E-01 1.0E+OO 2.0E+OO 
glycerol kinase 1 gla A F 6 .3E-01 1.1E+OO 1.9E+OO 
glucose specific factor Ill 1 gla B G 6 .3E-01 1.1 E+OO 2.3E+OO 
serine/threonine phosphatase B2 1tco A AB 7.1 E-01 9.5E-01 1.5E+OO 
Fk506-binding protein 1tco B c 7.1 E-01 1.1E+OO 1.6E+OO 
uracil-dna glycosylase 1 udi A E 6 .4E-01 1.2E+OO 1.9E+OO 
uracil-dna glycosylase inhibitor prate 1 udi B I 6.4E-01 1.5E+OO 2.1 E+OO 
beta-actin 2btf A A 6 .9E-01 1.1E+OO 2.1 E+OO 
profilin 2btf B B 6.9E-01 1.1E+OO 2 .1 E+OO 
cytochrome C peroxidase 2pcc A A 5.6E-01 8.3E-01 1.8E+OO 
iso-1-cytochrome C 2pcc B B 5.6E-01 1.0E+OO 2 .0E+OO 
Large complexes 
ribonuclease inhibitor 1a4y A AD 6 .8E-01 1.0E+OO 1.8E+OO 
angiogenin 1a4y B B 6 .8E-01 1.3E+OO 2.0E+OO 
allophycocyanin a - 13 1b33 A ACEBDF 7.0E-01 1.1E+OO 1.7E+OO 
phycobilisome 1b33 B N 7.0E-01 1.2E+OO 1.9E+OO 
tp7 mab 1 bgx A LH 5.1E-01 1.0E+OO 1.8E+OO 
Taq DNA polymerase 1bgx B T 5.1 E-01 1.0E+OO 2 .2E+OO 
Hemachromatosis protein hfe 1de4 A A 7.3E-01 1.1E+OO 2 .0E+OO 
transferrin receptor 1de4 B B 7.3E-01 1.0E+OO 2 .0E+OO 
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pdbid Hbonds per 100 Hbonds per 100 
<3.3 A sq angstro1 <4.0 A sq angstro 
Enzyme complexes 
Actin 1 atn A A 8 .0E+OO 8.5E-01 1.8E+01 1.9E+OO 
DNAase I 1 atn B D 8.0E+OO 9.8E-01 1.8E+01 2 .2E+OO 
Barley alpha-amylase/subtilisin inhibi 1 ava A D 8.0E+OO 6 .9E-01 1.9E+01 1.6E+OO 
Barley alpha-amylase 2 1ava B B 8.0E+OO ?.OE-01 1.9E+01 1.7E+OO 
VC1 1azs A A 2 .7E+01 2.7E+OO 4 .2E+01 4 .2E+OO 
IIC2 1azs B B 2 .7E+01 3.0E+OO 4 .2E+01 4 .7E+OO 
Cyclin-dependent kinase 6 1 bi8 A A 4 .0E+OO 3.9E-01 1.5E+01 1.5E+OO 
cyclin-dependent kinase inhibitor 1 bi8 B B 4 .0E+OO 4 .2E-01 1.5E+01 1.6E+OO 
plasmin 1bml A AB 2 .8E+01 1.3E+OO 4.4E+01 2 .1 E+OO 
streptokinase 1bml B c 2.8E+01 1.4E+OO 4 .4E+01 2 .2E+OO 
Barnase 1 brs A E 1.1E+01 1.4E+OO 2 .2E+01 2 .8E+OO 
Barstar C40A, C82A 1 brs B I 1.1E+01 1.4E+OO 2 .2E+01 2 .9E+OO 
plasmin 1 bui A AB 1.2E+01 7.2E-01 2 .7E+01 1.6E+OO 
staphylokinase sak-c-phi-c 1 bui B c 1.2E+01 7.8E-01 2 .7E+01 1.8E+OO 
m-calpain 1df0 A A 1.6E+01 5.8E-01 2 .2E+01 8.0E-01 
cal pain 1 dfO B B 1.6E+01 5.9E-01 2 .2E+01 8.2E-01 
ribonuclease A 1 dfj A E 1.5E+01 1.1 E+OO 2 .0E+01 1.5E+OO 
ribonuclease inhibitor 1 dfj B I 1.5E+01 1.2E+OO 2 .0E+01 1.6E+OO 
porcine pancreatic a-amylase 1dhk A A 8.0E+OO 5.5E-01 1.5E+01 1.0E+OO 
bean lectin-like inhibitor 1dhk B B 8.0E+OO 5.1 E-01 1.5E+01 9.6E-01 
DNA polymerase processivity factor 1dml A A 1.3E+01 9.5E-01 2.1E+01 1.5E+OO 
DNA polymerase 1dml B B 1.3E+01 9.4E-01 2 .1E+01 1.5E+OO 
triacylglycerol acyl-hydrolase 1 eth A A 2 .6E+01 3.5E+OO 5 .0E+01 6.7E+OO 
colipase 1 eth B B 2.6E+01 3.2E+OO 5.0E+01 6.2E+OO 
thioredoxin reductase 1f6m A EF 1.4E+01 1.5E+OO 2 .7E+01 2 .9E+OO 
thioredoxin 1 1f6m B G 1.4E+01 1.6E+OO 2 .7E+01 3.1 E+OO 
botulinum neurotoxin type B 1 f83 A A 1.5E+01 8.4E-01 2 .7E+01 1.5E+OO 
synaptobrevin II 1f83 B BC 1.5E+01 6.5E-01 2.7E+01 1.2E+OO 
acetylcholinesterase 1fss A A 8.0E+OO 8.5E-01 1.1E+01 1.2E+OO 
fasciculin II 1fss B B 8.0E+OO 7.9E-01 1.1E+01 1.1 E+OO 
glycerol kinase 1gla A F 1.4E+01 2 .3E+OO 2.8E+01 4 .6E+OO 
glucose specific factor Ill 1gla B G 1.4E+01 2.1 E+OO 2.8E+01 4 .2E+OO 
serine/threonine phosphatase B2 1tco A AB 8.0E+OO 8.4E-01 1.0E+01 1.1E+OO 
Fk506-binding protein 1tco B c 8.0E+OO 8.7E-01 1.0E+01 1.1 E+OO 
uracil-dna glycosylase 1 udi A E 2 .0E+01 2 .0E+OO 4 .1 E+01 4.0E+OO 
uracil-dna glycosylase inhibitor prote 1 udi B I 2.0E+01 2.0E+OO 4 .1 E+01 4 .2E+OO 
beta-actin 2btf A A 7.0E+01 6 .8E+OO 1.2E+02 1.1E+01 
profilin 2btf B B 7 .0E+01 6 .9E+OO 1.2E+02 1.2E+01 
cytochrome C peroxidase 2pcc A A 3.0E+01 5.4E+OO 4 .8E+01 8.6E+OO 
iso-1-cytochrome C 2pcc B B 3.0E+01 5.3E+OO 4 .8E+01 8.4E+OO 
Large complexes 
ribonuclease inhibitor 1a4y A AD 1.5E+01 1.2E+OO 2.3E+01 1.8E+OO 
angiogenin 1a4y B B 1.5E+01 1.1 E+OO 2.3E+01 1.7E+OO 
allophycocyanin a - 13 1b33 A ACEBDF 1.2E+01 5.9E-01 2.5E+01 1.2E+OO 
phycobilisome 1b33 B N 1.2E+01 5.7E-01 2 .5E+01 1.2E+OO 
tp7 mab 1bgx A LH 1.3E+01 4 .5E-01 2 .3E+01 8.0E-01 
Taq DNA polymerase 1 bgx B T 1.3E+01 4 .5E-01 2 .3E+01 8.0E-01 
Hemachromatosis protein hfe 1de4 A A 1.3E+01 1.3E+OO 3.2E+01 3.2E+OO 
transferrin receptor 1de4 B B 1.3E+01 1.2E+OO 3.2E+01 3.1 E+OO 
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pdbid %non-pola %polar %charged 
Enzyme complexes 
Actin 1 atn A A 7.1 E-01 2 .8E-01 1.3E-02 
DNAase I 1 atn B D 7.4E-01 2 .4E-01 1.8E-02 
Barley alpha-amylase/subtilisin inhibi 1 ava A D 5.5E-01 2.8E-01 1. 7E-01 
Barley alpha-amylase 2 1ava B 8 6.1E-01 2 .9E-01 9.9E-02 
VC1 1azs A A 7.1E-01 2 .0E-01 9.4E-02 
IIC2 1azs B B 5.5E-01 2 .9E-01 1.6E-01 
Cyclin-dependent kinase 6 1 bi8 A A 5.6E-01 1.6E-01 2.8E-01 
cyclin-dependent kinase inhibitor 1 bi8 B B 6.2E-01 1.7E-01 2.1E-01 
plasmin 1bml A AB 5.6E-01 2 .5E-01 2.0E-01 
streptokinase 1bml B c 5.8E-01 2.4E-01 1. 7E-01 
Barnase 1brs A E 5.5E-01 1.8E-01 2.7E-01 
Barstar C40A, C82A 1brs B I 5.6E-01 2.4E-01 2.0E-01 
plasmin 1 bui A AB 5.8E-01 2.4E-01 1.8E-01 
staphylokinase sak-c-phi-c 1 bui B c 6.5E-01 2 .8E-01 7.7E-02 
m-calpain 1 dfO A A 7.1E-01 1.2E-01 1.8E-01 
cal pain 1 dfO B B 5.9E-01 2 .5E-01 1.6E-01 
ribonuclease A 1 dfj A E 5.2E-01 3.0E-01 1.8E-01 
ribonuclease inhibitor 1 dfj B I 4.7E-01 2 .8E-01 2.5E-01 
porcine pancreatic a-amylase 1dhk A A 6.1 E-01 2.4E-01 1.5E-01 
bean lectin-like inhibitor 1dhk B B 5.8E-01 3.2E-01 9.9E-02 
DNA polymerase processivity factor 1dml A A 6.9E-01 1.8E-01 1.3E-01 
DNA polymerase 1dml B B 6.9E-01 1. 9E-01 1.2E-01 
triacylglycerol acyl-hydrolase 1 eth A A 5.4E-01 2.7E-01 1.8E-01 
colipase 1 eth B 8 4.9E-01 1.4E-01 3.8E-01 
thioredoxin reductase 1f6m A EF 5.6E-01 3.4E-01 1.0E-01 
thioredoxin 1 1f6m B G 6.0E-01 2 .5E-01 1.5E-01 
botulinum neurotoxin type B 1 f83 A A 5.6E-01 2 .1 E-01 2.3E-01 
synaptobrevin II 1 f83 B BC 5.7E-01 2 .5E-01 1.9E-01 
acety lchol i neste rase 1fss A A 5.9E-01 2 .9E-01 1.2E-01 
fasciculin II 1fss B B 5.7E-01 2 .5E-01 1.9E-01 
glycerol kinase 1gla A F 7 .4E-01 7.5E-02 1.8E-01 
glucose specific factor Ill 1gla B G 5.5E-01 2.1E-01 2.4E-01 
serine/threonine phosphatase 82 1tco A AB 5.4E-01 3.6E-01 1.0E-01 
Fk506-binding protein 1tco B c 6.0E-01 2 .2E-01 1.8E-01 
uracil-dna glycosylase 1 udi A E 6.7E-01 2.4E-01 9.4E-02 
uracil-dna glycosylase inhibitor prote 1 udi B I 5.9E-01 2 .9E-01 1.2E-01 
beta-actin 2btf A A 5.6E-01 1.9E-01 2.5E-01 
profilin 2btf B B 6.1 E-01 2 .1 E-01 1.9E-01 
cytochrome C peroxidase 2pcc A A 4.7E-01 3.3E-01 2.0E-01 
iso-1-cytochrome C 2pcc B B 6.0E-01 1. 9E-01 2.2E-01 
Large complexes 
ribonuclease inhibitor 1a4y A AD 5.0E-01 3.1 E-01 2.0E-01 
angiogenin 1a4y B B 5.1 E-01 2 .1 E-01 2.8E-01 
allophycocyanin a - 13 1b33 A ACEBDF 4.6E-01 3.1 E-01 2.2E-01 
phycobilisome 1b33 B N 5.7E-01 3.4E-01 9.0E-02 
tp7 mab 1bgx A LH 5.8E-01 3.4E-01 7.8E-02 
Taq DNA polymerase 1bgx B T 6 .3E-01 2 .0E-01 1.7E-01 
Hemachromatosis protein hfe 1de4 A A 6 .7E-01 2 .5E-01 8.3E-02 
transferrin receptor 1de4 B B 5.9E-01 2 .0E-01 2 .1 E-01 
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pdbid Reso- Protein Average Total interface 
lution mass volume surface area 
Large complexes A Daltons A''3 area A"2 A"2 
dihydrolipoamide dehydrogenase 1ebd A AB 1.95 95042 162100 34620 6 .1 E+02 
dihydrolipoamide acetyltransferase 1ebd B c 1.95 4320 8691 2992 6.4E+02 
Fe-S and Mo subunits carbon mono: 1 ffu A ADBE 2.1 206155 334800 61200 4 .0E+03 
Flavoprotein carbon monoxide 1ffu B CF 2 .1 60666 106300 53180 4 .6E+03 
Fe-S and flavo subunits carbon mon 1 ffu A ADCF 2.4 94693 384000 25290 6 .5E+03 
Mo subunit carbon monoxide 1ffu B BE 2.4 172128 61740 74320 6 .7E+03 
Mo and flavo subunits carbon mono: 1 ffu A BECF 2 .65 232794 163500 36900 6.1 E+03 
Fe-S subunit carbon monoxide 1ffu B AD 2 .65 34027 281300 16730 6 .1 E+03 
nitrogenase Mo-Fe 1n2c A ABCD 1.9 225968 353200 57690 3.7E+03 
nitrogenase Fe 1n2c B EF 1.9 59180 97380 18270 1.8E+03 
Cytochrome C oxidase 1qle A ABCD 3 123414 206700 41400 6.4E+02 
Fab 1qle B HL 3 25077 42800 10220 6 .8E+02 
HIV reverse transcriptase 2hmi A AB 1.6 107412 189900 45060 6 .2E+02 
Fab 28 2hmi B CD 1.6 46330 79700 19160 6 .0E+02 
G-protein , cell cycle, signal transduction 
C-fos, C-jun 1a02 A FJ 2 .5 12430 25650 9342 6 .9E+02 
NFAT 1a02 B N 2 .5 31239 56910 15260 7.0E+02 
CheY 1a0o A A 2 13933 24940 6472 5.7E+02 
CheA 1a0o B B 2 7438 14200 4213 5.5E+02 
nuclear transport factor 2 1a2k A AB 3.15 28202 49020 11620 7 .3E+02 
ran 1a2k B c 3.15 22162 39310 9764 8.6E+02 
guanine nucleotide-binding protein C 1 agr A A 2 .6 39794 68870 17420 8.2E+02 
RGS4 1agr B E 2 .6 15060 26590 7428 8.0E+02 
elongation factor TU T. thermophilus 1 aip A E 2 .8 40695 71400 17380 1.4E+03 
elongation factor TS T. thermophilus 1 aip B GH 2 .8 43671 78510 21090 2 .9E+03 
Fk506-binding protein 1b6c A A 1.85 11781 21320 5924 8.5E+02 
TGF-B superfamily receptor type 1 1b6c B B 1.85 36974 64130 15270 8.8E+02 
death domain of pelle 1d2z A A 2 11772 21600 5975 7 .8E+02 
death domain of tube 1d2z B B 2 16661 30360 8407 8.9E+02 
mothers agains decapentaplegic 1dev A A 2.9 21998 37420 9223 1.2E+03 
smad anchor for receptor activation 1dev B B 2.9 4125 9339 4203 1.4E+03 
fyn tyrosine kinase 1 efn A A 2 .7 5990 11130 3486 6 .2E+02 
HIV-1 NEF protein 1 efn B B 2 .7 12304 22030 6169 6 .2E+02 
elongation factor TU E. coli 1efu A A 2 .37 39726 69060 16620 1. 7E+03 
elongation factor TS E. coli 1 efu B B 2 .37 30218 54980 15480 1.9E+03 
dimerization cofactor of hepatocyte r 1 f93 A AB 3.2 22476 40600 10850 9.4E+02 
hepatocyte nuclear factor 1-a 1f93 B EF 3.2 6017 12200 4099 9.6E+02 
cbl 1fbv A A 2 .3 45444 78510 19040 8.7E+02 
zap-70 1fbv B B 2 .3 16280 30740 8627 9.0E+02 
cyclin-dependent kinase-2 1fin A A 2 .3 33871 58500 13930 1.6E+03 
cyclin-A 1fin B B 2 .3 29773 51150 12200 1.8E+03 
ralgds 11fd A AC 2 .9 19868 36390 10120 1.8E+03 
ras 11fd B BD 2.9 37852 65640 15750 1.8E+03 
cyclin-dependent kinase-6 and inhib 1 g3n A AE 2 99786 115700 25530 2 .4E+03 
v-cyclin 1g3n B G 2 51102 44900 24950 1.2E+03 
cyclin-dependent kinase-6 and V-cyc 1 g3n A AE 2.9 117376 115700 10750 1.8E+03 
cyclin-dependent kinase-6 inhibitor 1g3n B B 2 .9 33512 29200 7360 8.2E+02 
Gia 1 1gg2 A A 3.5 39221 69110 17760 1.2E+03 
Gi~1 1gg2 B BG 3 .5 43094 71800 16360 1.1 E+03 
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pdbid Circularity RMSD Atom Atom 
to plane burial access-
Large complexes ibility 
dihydrolipoamide dehydrogenase 1ebd A AB 3.5E-01 2.6E+OO 8.0E+ OO 1.5E+01 
dihydrolipoamide acetyltransferase 1ebd B c 2.1 E-01 2.3E+OO 1.2E+01 1.8E+01 
Fe-S and Mo subunits carbon mono: 1 ffu A ADBE 5.8E-02 8.2E+OO 8.0E+OO 1.3E+01 
Flavoprotein carbon monoxide 1ffu B CF 4 .5E-02 7 .8E+OO 1.1E+01 1.4E+01 
Fe-S and flavo subunits carbon man 1 ffu A ADCF 2 .0E-01 8.2E+OO 9.1 E+OO 1.5E+01 
Mo subunit carbon monoxide 1ffu B BE 1.5E-01 7.4E+OO 9.3E+ OO 1.2E+01 
Mo and flavo subunits carbon mono: 1 ffu A BECF 8.5E-02 7.9E+OO 8.9E+OO 1.3E+01 
Fe-S subunit carbon monoxide 1 ffu B AD 8.1 E-02 8.1 E+OO 1.0E+01 1.3E+01 
nitrogenase Mo-Fe 1n2c A ABCD 5.3E-02 9.5E+OO 9.5E+OO 1.5E+01 
nitrogenase Fe 1n2c B EF 8.2E-01 3.9E+OO 8.4E+OO 1.3E+01 
Cytochrome C oxidase 1qle A ABCD 1. 7E-01 1.5E+OO 8.2E+OO 1.3E+01 
Fab 1qle B HL 2.5E-01 1.4E+OO 9.1 E+OO 1.5E+01 
HIV reverse transcriptase 2hmi A AB 4.5E-01 2.7E+OO 8.1 E+OO 1.4E+01 
Fab 28 2hmi B CD 7.1 E-01 2.4E+OO 7.7E+OO 1.3E+01 
G-protein, cell cycle, signal transduction 
C-fos, C-jun 1a02 A FJ 2 .5E-01 3.3E+OO 8.6E+OO 1.9E+01 
NFAT 1a02 B N 4 .5E-01 3.8E+OO 9.4E+OO 2.2E+01 
CheY 1a0o A A 3.2E-01 2.7E+OO 1.0E+01 1.7E+01 
CheA 1a0o B B 3.8E-01 2.6E+OO 8.2E+OO 1.5E+01 
nuclear transport factor 2 1a2k A AB 4.1 E-01 2 .7E+OO 8.9E+OO 1.4E+01 
ran 1a2k B c 4.8E-01 2.7E+OO 1.1E+01 1.5E+01 
guanine nucleotide-binding protein C 1 agr A A 8.2E-01 2.3E+OO 9.0E+OO 1.4E+01 
RGS4 1agr B E 6.1 E-01 2.2E+OO 7.8E+OO 1.3E+01 
elongation factor TU T. thermophil us 1 aip A E 7.6E-02 3.1 E+OO 9.0E+OO 1.4E+01 
elongation factor TS T. thermophilus 1 aip B GH 1.5E-01 5.4E+OO 9.9E+OO 1.6E+01 
Fk506-binding protein 1b6c A A 8.2E-01 2 .9E+OO 8.0E+OO 1.2E+01 
TGF-B superfamily receptor type 1 1b6c B B 7.6E-01 2 .5E+OO 9.4E+OO 1.4E+01 
death domain of pelle 1d2z A A 3.9E-01 2.8E+OO 7.4E+OO 1.3E+01 
death domain of tube 1d2z B B 2.1 E-01 3.1E+OO 1.1E+01 1.7E+01 
mothers agains decapentaplegic 1dev A A 2.3E-01 3.4E+OO 7.0E+OO 1.3E+01 
smad anchor for receptor activation 1dev B B 2 .7E-01 2 .8E+OO 1.0E+01 1.8E+01 
fyn tyrosine kinase 1efn A A 5.1 E-01 1.8E+OO 9.0E+OO 1.4E+01 
HIV-1 NEF protein 1efn B B 3.6E-01 1.8E+OO 9.4E+OO 1.4E+01 
elongation factor TU E. coli 1efu A A 3.5E-01 3.3E+OO 8.5E+OO 1.4E+01 
elongation factor TS E. coli 1efu B B 4 .1 E-01 3.3E+OO 1.0E+01 1.6E+01 
dimerization cofactor of hepatocyte r 1 f93 A AB 5.6E-01 2 .1 E+OO 9.6E+OO 1.4E+01 
hepatocyte nuclear factor 1-a 1f93 B EF 6 .3E-01 2 .0E+OO 1.1 E+01 1.6E+01 
cbl 1fbv A A 1.7E-01 3.6E+OO 8.5E+OO 1.4E+01 
zap-70 1fbv B B 2.2E-01 3.4E+OO 9.9E+OO 1.6E+01 
cyclin-dependent kinase-2 1fin A A 2.8E-01 3.4E+OO 8.2E+OO 1.3E+01 
cyclin-A 1fin B B 2 .7E-01 3.4E+OO 1.0E+01 1.4E+01 
ralgds 11fd A AC 2.9E-01 5.3E+OO 9.8E+OO 1.5E+01 
ras 11fd B BD 2.4E-01 5.1 E+OO 9.4E+OO 1.5E+01 
cyclin-dependent kinase-6 and inhibi 1 g3n A AE 3.9E-01 3.0E+OO 9.6E+OO 1.5E+01 
v-cyclin 1g3n B G 2.4E-01 2.3E+OO 9.2E+OO 1.4E+01 
cyclin-dependent kinase-6 and V-cyc 1 g3n A AE 5.2E-02 4 .4E+OO 9.8E+OO 1.5E+01 
cyclin-dependent kinase-6 inhibitor 1g3n B B 7.0E-01 2.2E+OO 8.4E+OO 1.2E+01 
Gia1 1gg2 A A 1.6E-01 5.2E+OO 9.6E+OO 1.7E+01 
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pdbid Shape Vol. Ratio Vol. Ratio 
comple- infc core/ infc perimf 
Large complexes mentarity prot. core prot. core 
dihydrolipoamide dehydrogenase 1ebd A AB 6.9E-01 8.8E-01 2 .3E+OO 
dihydrolipoamide acetyltransferase 1ebd B c 6.9E-01 8.2E-01 2 .4E+OO 
Fe-S and Mo subunits carbon mono: 1 ffu A ADBE 7.0E-01 1.0E+OO 2 .1 E+OO 
Flavoprotein carbon monoxide 1 ffu B CF 7.0E-01 1.2E+OO 2 .1 E+OO 
Fe-S and flavo subunits carbon mon 1 ffu A ADCF 7.1 E-01 1.2E+OO 2.3E+OO 
Mo subunit carbon monoxide 1ffu B BE 7 .1 E-01 1.1E+OO 2 .3E+OO 
Mo and flavo subunits carbon mono: 1 ffu A BECF 7.3E-01 1.2E+OO 2 .4E+OO 
Fe-S subunit carbon monoxide 1 ffu B AD 7.3E-01 1.2E+OO 2.3E+OO 
nitrogenase Mo-Fe 1n2c A ABCD 7.0E-01 1.1 E+OO 2 .2E+OO 
nitrogenase Fe 1n2c B EF 7.0E-01 1.0E+OO 2 .0E+OO 
Cytochrome C oxidase 1qle A ABCD 7.0E-01 1.0E+OO 2 .0E+OO 
Fab 1qle B HL 7.0E-01 1.1 E+OO 1.9E+OO 
HIV reverse transcriptase 2hmi A AB 7.1 E-01 1.0E+OO 1.9E+OO 
Fab 28 2hmi B CD 7.1 E-01 9.9E-01 2 .0E+OO 
G-protein, cell cycle, signal transduction 
C-fos, C-jun 1a02 A FJ 7.1 E-01 1.1 E+OO 2.7E+OO 
NFAT 1a02 B N 7.1 E-01 8.9E-01 2 .1 E+OO 
CheY 1a0o A A 6 .7E-01 1.1 E+OO 2 .2E+OO 
CheA 1a0o B B 6 .7E-01 1.0E+OO 1.8E+OO 
nuclear transport factor 2 1a2k A AB 6 .3E-01 1.3E+OO 2 .2E+OO 
ran 1a2k B c 6 .3E-01 1.0E+OO 1.6E+OO 
guanine nucleotide-binding protein C 1 agr A A 7.3E-01 1.1E+OO 2 .0E+OO 
RGS4 1agr B E 7.3E-01 1.0E+OO 2 .1 E+OO 
elongation factor TU T. thermophil us 1 aip A E 6 .5E-01 1.1E+OO 2 .3E+OO 
elongation factor TS T. thermophilus 1 aip B GH 6 .5E-01 1.2E+OO 2.5E+OO 
Fk506-binding protein 1b6c A A 7.1E-01 1.1E+OO 1.9E+OO 
TGF-B superfamily receptor type 1 1b6c B B 7.1E-01 1.0E+OO 2 .0E+OO 
death domain of pelle 1d2z A A 7.3E-01 1.1E+OO 1.6E+OO 
death domain of tube 1d2z B B 7.3E-01 1.0E+OO 1.6E+OO 
mothers agains decapentaplegic 1dev A A 8.0E-01 1.2E+OO 1.9E+OO 
smad anchor for receptor activation 1dev B B 8.0E-01 1.4E+OO 2 .6E+OO 
fyn tyrosine kinase 1 efn A A 7.7E-01 1.1 E+OO 1.8E+OO 
HIV-1 NEF protein 1 efn B B 7.7E-01 1.1E+OO 1.8E+OO 
elongation factor TU E. coli 1 efu A A 7.7E-01 1.1E+OO 1.6E+OO 
elongation factor TS E. coli 1 efu B B 7.7E-01 1.2E+OO 1.8E+OO 
dimerization cofactor of hepatocyte r 1 f93 A AB 7. 1 E-01 1.2E+OO 1.5E+OO 
hepatocyte nuclear factor 1-a 1f93 B EF 7.1 E-01 9.5E-01 1.5E+OO 
cbl 1fbv A A 7.6E-01 1.1E+OO 1. 7E+OO 
zap-70 1 fbv B B 7.6E-01 1.1E+OO 1.9E+OO 
cyclin -dependent kinase-2 1fin A A 6.7E-01 1.0E+OO 1.9E+OO 
cyclin-A 1fin B B 6.7E-01 1.2E+OO 2 .1E+OO 
ralgds 11fd A AC 7.0E-01 1.1E+OO 1.9E+OO 
ras 11fd B BD 7.0E-01 1.0E+OO 1.8E+OO 
cyclin-dependent kinase-6 and inhibi 1 g3n A AE 6 .6E-01 1.2E+OO 1.6E+OO 
v-cyclin 1g3n B G 6.6E-01 1.3E+OO 1.9E+OO 
cyclin -dependent kinase-6 and V-cyc 1 g3n A AE 6 .8E-01 1.1E+OO 2.3E+OO 
cyclin-dependent kinase-6 inhibitor 1g3n B B 6 .8E-01 1.0E+OO 1.7E+OO 
Gia 1 1gg2 A A 8.0E-01 1.1 E+OO 1.9E+OO 
Gij31 1gg2 B BG 8.0E-01 1.3E+OO 1.8E+OO 
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pdbid Hbonds per 100 Hbonds per 100 
<3.3 A sq angstro1 <4.0 A sq angstro 
Large complexes 
dihydrolipoamide dehydrogenase 1ebd A AB 8.0E+OO 1.3E+OO 2.1 E+01 3.4E+OO 
dihydrolipoamide acetyltransferase 1 ebd 8 c 8.0E+OO 1.2E+OO 2.1 E+01 3.3E+OO 
Fe-S and Mo subunits carbon mono: 1 ffu A ADBE 9.0E+OO 2.2E-01 1.9E+01 4 .7E-01 
Flavoprotein carbon monoxide 1 ffu 8 CF 9.0E+OO 2.0E-01 1.9E+01 4 .2E-01 
Fe-S and flavo subunits carbon man 1 ffu A ADCF 3.5E+01 5.4E-01 5.7E+01 8.8E-01 
Mo subunit carbon monoxide 1 ffu 8 BE 3.5E+01 5.2E-01 5.7E+01 8.5E-01 
Mo and flavo subunits carbon mono: 1 ffu A BECF 1.7E+01 2.8E-01 2.4E+01 3.9E-01 
Fe-S subunit carbon monoxide 1ffu 8 AD 1.7E+01 2.8E-01 2.4E+01 4 .0E-01 
nitrogenase Mo-Fe 1n2c A ABCD 1.4E+01 3.8E-01 2.5E+01 6.8E-01 
nitrogenase Fe 1n2c 8 EF 1.4E+01 7.8E-01 2.5E+01 1.4E+OO 
Cytochrome C oxidase 1qle A ABCD 1.0E+01 1.6E+OO 2.4E+01 3.7E+OO 
Fab 1qle 8 HL 1.0E+01 1.5E+OO 2.4E+01 3.5E+OO 
HIV reverse transcriptase 2hmi A AB 5.0E+01 8.0E+OO 8.4E+01 1.3E+01 
Fab 28 2hmi 8 CD 5.0E+01 8.4E+OO 8.4E+01 1.4E+01 
G-protein, cell cycle, signal transduction 
C-fos, C-jun 1a02 A FJ 1.0E+01 1.4E+OO 1.5E+01 2.2E+OO 
NFAT 1a02 8 N 1.0E+01 1.4E+OO 1.5E+01 2.1 E+OO 
CheY 1a0o A A 1.0E+01 1.7E+OO 1.6E+01 2.8E+OO 
CheA 1a0o 8 8 1.0E+01 1.8E+OO 1.6E+01 2 .9E+OO 
nuclear transport factor 2 1a2k A AB 9 .0E+OO 1.2E+OO 1.4E+01 1.9E+OO 
ran 1a2k 8 c 9.0E+OO 1.0E+OO 1.4E+01 1.6E+OO 
guanine nucleotide-binding protein C 1 agr A A 1.6E+01 1.9E+OO 2 .5E+01 3.0E+OO 
RGS4 1agr 8 E 1.6E+01 2 .0E+OO 2.5E+01 3.1 E+OO 
elongation factor TU T. thermophil us 1 aip A E 1.2E+01 8.7E-01 2 .1 E+01 1.5E+OO 
elongation factor TS T. thermophil us 1 a ip 8 GH 1.2E+01 4.1 E-01 2 .1E+01 7.2E-01 
Fk506-binding protein 1b6c A A 1.6E+01 1.9E+OO 2 .8E+01 3.3E+OO 
TGF-8 superfamily receptor type 1 1b6c 8 8 1.6E+01 1.8E+OO 2 .8E+01 3.2E+OO 
death domain of pelle 1d2z A A 1.4E+01 1.8E+OO 2.7E+01 3.5E+OO 
death domain of tube 1d2z 8 8 1.4E+01 1.6E+OO 2 .7E+01 3.0E+OO 
mothers agains decapentaplegic 1dev A A 8.0E+OO 6.8E-01 1.8E+01 1.5E+OO 
smad anchor for receptor activation 1dev 8 8 8.0E+OO 5.7E-01 1.8E+01 1.3E+OO 
fyn tyrosine kinase 1efn A A 9.0E+OO 1.5E+OO 1.4E+01 2.3E+OO 
HIV-1 NEF protein 1 efn 8 8 9.0E+OO 1.4E+OO 1.4E+01 2.3E+OO 
elongation factor TU E. coli 1efu A A 7.0E+OO 4 .1 E-01 1.3E+01 7.7E-01 
elongation factor TS E. coli 1 efu 8 8 7.0E+OO 3.7E-01 1.3E+01 6.9E-01 
dimerization cofactor of hepatocyte r 1 f93 A AB 7.0E+OO 7.5E-01 2.2E+01 2.3E+OO 
hepatocyte nuclear factor 1-a 1f93 8 EF 7.0E+OO 7.3E-01 2.2 E+01 2.3E+OO 
cbl 1fbv A A 3.0E+OO 3.5E-01 7.0E+OO 8.1 E-01 
zap-70 1fbv 8 8 3.0E+OO 3.3E-01 7.0E+OO 7.8E-01 
cyclin-dependent kinase-2 1fin A A 1.9E+01 1.2E+OO 3.6E+01 2.2E+OO 
cyclin-A 1fin 8 8 1.9E+01 1.1E+OO 3.6E+01 2.0E+OO 
ralgds 11fd A AC 1.3E+01 7.4E-01 2 .2E+01 1.3E+OO 
ras 11fd 8 BD 1.3E+01 7.1 E-01 2 .2E+01 1.2E+OO 
cyclin-dependent kinase-6 and inhib 1 g3n A AE 1.2E+01 S.OE-01 2.0E+01 8.4E-01 
v-cyclin 1g3n 8 G 1.2E+01 1.0E+OO 2.0E+01 1.7E+OO 
cyclin-dependent kinase-6 and V-cyc 1 g3n A AE 1.5E+01 8.3E-01 2.7E+01 1.5E+OO 
cyclin-dependent kinase-6 inhibitor 1g3n 8 8 1.5E+01 1.8E+OO 2 .7E+01 3.3E+OO 
Gia1 1gg2 A A 1.2E+01 1.0E+OO 3.1 E+01 2 .6E+OO 
GiP1 1gg2 8 BG 1.2E+01 1.1E+OO 3.1 E+01 2 .8E+OO 
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pdbid o/onon-pola %polar %charged 
Large complexes 
dihydrolipoamide dehydrogenase 1ebd A AB 4 .8E-01 2.1 E-01 3.1 E-01 
dihydrolipoamide acetyltransferase 1ebd 8 c 5.6E-01 1.8E-01 2 .7E-01 
Fe-S and Mo subunits carbon mono: 1 ffu A ADBE 6 .3E-01 2.0E-01 1.7E-01 
Flavoprotein carbon monoxide 1 ffu 8 CF 6 .2E-01 1.6E-01 2.2E-01 
Fe-S and flavo subunits carbon mon 1 ffu A ADCF 5.7E-01 2 .3E-01 2.1E-01 
Mo subunit carbon monoxide 1ffu 8 BE 6 .7E-01 1.9E-01 1.4E-01 
Mo and flavo subunits carbon mono: 1 ffu A BECF 6 .6E-01 2 .1 E-01 1.3E-01 
Fe-S subunit carbon monoxide 1ffu B AD 5.8E-01 2 .6E-01 1.7E-01 
nitrogenase Mo-Fe 1n2c A ABCD 5.8E-01 2.3E-01 1.9E-01 
nitrogenase Fe 1n2c B EF 6 .1 E-01 1.6E-01 2 .3E-01 
Cytochrome C oxidase 1qle A ABCD 5.6E-01 2.2E-01 2 .2E-01 
Fab 1qle 8 HL 3.9E-01 4.5E-01 1.6E-01 
HIV reverse transcriptase 2hmi A AB 7.0E-01 1.1E-01 1.9E-01 
Fab 28 2hmi 8 CD 6.4E-01 2.5E-01 1.1E-01 
G-protein, cell cycle, signal transduction 
C-fos, C-jun 1a02 A FJ 3.5E-01 1.9E-01 4 .6E-01 
NFAT 1a02 8 N 5.1 E-01 3.0E-01 1.9E-01 
CheY 1a0o A A 6 .1 E-01 1.9E-01 2 .0E-01 
CheA 1a0o 8 8 6 .3E-01 2.0E-01 1.6E-01 
nuclear transport factor 2 1a2k A AB 6 .5E-01 2.6E-01 9.8E-02 
ran 1a2k 8 c 6 .2E-01 2.2E-01 1.6E-01 
guanine nucleotide-binding protein < 1 ag r A A 6 .1 E-01 2.2E-01 1.6E-01 
RGS4 1agr 8 E 4 .8E-01 2.6E-01 2 .5E-01 
elongation factor TU T. thermophilus 1 aip A E 6 .1 E-01 2.4E-01 1.5E-01 
elongation factor TS T. thermophilus 1 aip 8 GH 5.9E-01 2.5E-01 1.6E-01 
Fk506-binding protein 1b6c A A 6 .7E-01 2.4E-01 8.8E-02 
TGF-8 superfamily receptor type 1 1b6c 8 8 7.1E-01 1.8E-01 1.1E-01 
death domain of pelle 1d2z A A 5.8E-01 3.4E-01 B.OE-02 
death domain of tube 1d2z 8 8 6.0E-01 2.6E-01 1.4E-01 
mothers agains decapentapleg ic 1dev A A 6.4E-01 3.1 E-01 4 . 7E-02 
smad anchor for receptor activation 1dev 8 B 7.5E-01 2.5E-01 3.2E-04 
fyn tyrosine kinase 1efn A A 6.4E-01 2.8E-01 7.6E-02 
HIV-1 NEF protein 1efn 8 8 6 .3E-01 1.3E-01 2.5E-01 
elongation factor TU E. coli 1efu A A 6.6E-01 2.2E-01 1.2E-01 
elongation factor TS E. coli 1 efu 8 8 6.5E-01 1.9E-01 1.6E-01 
dimerization cofactor of hepatocyte r 1 f93 A AB 5.6E-01 7.1 E-02 3.7E-01 
hepatocyte nuclear factor 1-a 1f93 8 EF 7.1 E-01 1.3E-01 1.6E-01 
cbl 1fbv A A 6 .3E-01 2.0E-01 1.7E-01 
zap-70 1fbv 8 8 6 .0E-01 8.3E-02 3.2E-01 
cyclin-dependent kinase-2 1fin A A 6 .3E-01 2.3E-01 1.4E-01 
cyclin-A 1fin 8 B 6.4E-01 2.6E-01 1.1E-01 
ralgds 11fd A AC 5.5E-01 3.0E-01 1.5E-01 
ras 11fd 8 BD 5.2E-01 2.4E-01 2.4E-01 
cyclin-dependent kinase-6 and inhib1 1 g3n A AE 6 .6E-01 1.9E-01 1.5E-01 
v-cyclin 1g3n B G 6 .6E-01 1.5E-01 1.9E-01 
cyclin-dependent kinase-6 and V-cyc 1 g3n A AE 5.6E-01 2.2E-01 2 .2E-01 
cyclin-dependent kinase-6 inhibitor 1g3n 8 8 6 .6E-01 1.7E-01 1.8E-01 
Gia 1 1gg2 A A 6.2E-01 1.8E-01 2.0E-01 
Gil31 1gg2 8 BG 5.5E-01 2 .8E-01 1.7E-01 
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pdbid Reso- Protein Average Total interface 
lution mass volume surface area 
G-protein, cell cycle, signal transduction A Daltons A 11 3 area A 112 A 112 
Giy2 1 got A A 4 37189 67710 18020 1.2E+03 
Gta-Gia 1 got B BG 4 43975 72840 16100 1.2E+03 
Gt(3 1gua A A 1.8 18983 33890 8654 6 .4E+02 
Gty 1gua B B 1.8 8673 16670 4921 6 .3E+02 
mcm1 transcriptiona regulator 1mnm A AB 2 .3 18474 34890 9476 6 .2E+02 
mat-a-2 repressor 1mnm B c 2.3 8619 17200 5938 1.2E+03 
ran 1 rrp A A 2 .7 23109 42250 11930 2 .4E+03 
nuclear core complex protein nup35: 1 rrp B B 2 .7 15641 29430 8980 2.3E+03 
p50-rhogap 1tx4 A A 2.25 22257 39150 9593 1.1 E+03 
rho a 1tx4 B B 2 .25 19621 35110 9331 1.1 E+03 
elongin B 1vcb A D 2 .3 20571 37080 9574 9.5E+02 
elongin C 1vcb B E 2 .3 16285 29960 8495 1.0E+03 
p53 1ycs A A 2 .95 21487 37680 9599 7.7E+02 
p53bp2 1ycs B B 2.95 21570 37090 9560 7.1E+02 
CAMP dependent protein kinase 1ydr A E 2.35 38870 67210 15310 9.0E+02 
protein kinase inhibitor peptide 1ydr B I 2.35 2219 5164 2362 1.1 E+03 
peroxisome proliferator receptor y 2prg A AB 2.75 58933 103500 24380 1.3E+03 
nuclear receptor coactivator src-1 2prg B c 2 .75 3658 8739 3978 1.3E+03 
transducin 2trc A BG 2 45331 77010 17850 2.1 E+03 
posducin 2trc B p 2 22803 44310 13940 2.2E+03 
MHC and homologs complexed with others 
CD8 1 akj A DE 2 .4 25638 45510 11320 9.2E+02 
MHC class I HLA-A2 1 akj B ABC 2 .4 44431 76950 18830 1.0E+03 
T-cell receptor 1ao7 A DE 2 35761 63660 16170 9.8E+02 
MHC class I HLA-A2 1ao7 B ABC 2 44445 77730 18980 9.9E+02 
MHC class I H-2 1bqh A DEF 2 .5 44168 76240 18660 1.4E+03 
CD8 1bqh B Kl 2 .5 27709 50150 13300 1.4E+03 
T-cell receptor D10 1d9k A EF 2 .8 24468 42670 10810 1.0E+03 
MHC class II 1-Ak 1d9k B GHQ 2 .8 44875 76430 18680 9.7E+02 
KIR2dl2 1efx A DE 3 .1 43262 76650 20260 7.3E+02 
MHC class I HLA-CW3 1efx B ABC 3 .1 44788 77580 19270 7.9E+02 
MHC class I H-2Kb 1fo0 A HLP 2.7 44437 76960 19170 6.5E+02 
T-cell receptor BM3.3 1fo0 B AB 2.7 25685 45000 11120 6.9E+02 
MHC class II HLA-DR-1 1fyt A ABC 2 .8 43149 74360 17580 1.0E+03 
T-cell receptor 1fyt B DE 2 .8 48985 85020 20450 1.0E+03 
MHC class II HLA-DR-1 1 hqr A ABC 1.9 40726 71100 17230 7.5E+02 
Streptococcal pyrogenic exotoxin C 1 hqr B D 1.9 23176 40650 10110 8.1 E+02 
FeRn 1 i1 a A AB 2 .3 41398 72090 17510 7.1E+02 
Fe 1 i1 a B CD 2 .3 46193 81610 20720 7.1E+02 
ly49a 1qo3 A CD 3.5 29011 52230 14150 4 .6E+02 
MHC class I H-2Dd 1qo3 B ABP 3.5 44604 77630 19210 5.2E+02 
T -cell receptor 2ckb A AB 2 .35 48453 84870 21330 9.5E+02 
MHC class I H-2Kb 2ckb B HLP 2 .35 44274 77160 19090 1.0E+03 
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pdbid Circularity RMSD Atom Atom 
to plane burial access-
G-protein , cell cycle, signal transduction ibility 
Giy2 1 got A A 1.5E-01 5.1 E+OO 9.2E+OO 1.5E+01 
Gta-Gia 1 got B BG 2.7E-01 4.4E+OO 9.2E+OO 1.4E+01 
Gtl3 1gua A A 5.9E-01 1.4E+OO 8.7E+OO 1.4E+01 
Gty 1gua B B 6.6E-01 1.2E+OO 9.5E+OO 1.7E+01 
mcm1 transcriptiona regulator 1mnm A AB 3.5E-01 2 .5E+OO 6 .7E+OO 1.1E+01 
mat-a-2 repressor 1mnm B c 3.5E-01 3.2E+OO 1.0E+01 1.7E+01 
ran 1 rrp A A 3.3E-01 4 .5E+OO 9.1 E+OO 1.6E+01 
nuclear core complex protein nup35: 1 rrp B B 3.0E-01 4 .9E+OO 9.4E+OO 1.6E+01 
p50-rhogap 1tx4 A A 6.0E-01 2.8E+OO 9.8E+OO 1.6E+01 
rho a 1tx4 B B 6.0E-01 2.7E+OO 9.2E+OO 1.5E+01 
elongin B 1vcb A D 2.8E-01 2.3E+OO 8.1 E+OO 1.3E+01 
elongin C 1vcb B E 1.8E-01 2.2E+OO 1.0E+01 1.6E+01 
p53 1ycs A A 4 .3E-01 2.9E+OO 9 .6E+OO 1.7E+01 
p53bp2 1ycs B B 3.1 E-01 2.6E+OO 7 .6E+OO 1.4E+01 
CAMP dependent protein kinase 1ydr A E 5.1 E-01 3.6E+OO 7.5E+OO 1.3E+01 
protein kinase inhibitor peptide 1ydr B I 1.9E-01 2.4E+OO 1.2E+01 1.8E+01 
peroxisome proliferator receptor y 2prg A AB 1.0E-01 4.6E+OO 9.0E+OO 1.4E+01 
nuclear receptor coactivator src-1 2prg B c 8.4E-02 3.7E+OO 1.1E+01 2 .0E+01 
transducin 2trc A BG 4.6E-01 4 .1 E+OO 8.6E+OO 1.3E+01 
posducin 2trc B p 3.0E-01 4 .1 E+OO 9.3E+OO 1.5E+01 
MHC and homologs complexed with others 
CD8 1akj A DE 2.9E-01 4 .3E+OO 8.7E+OO 1.7E+01 
MHC class I HLA-A2 1akj B ABC 2.5E-01 4 .5E+OO 9.2E+OO 1.8E+01 
T -cell receptor 1ao7 A DE 3.9E-01 2.4E+OO 8.5E+OO 1.4E+01 
MHC class I HLA-A2 1ao7 B ABC 6.1 E-01 2 .7E+OO 8.2E+OO 1.3E+01 
MHC class I H-2 1bqh A DEF 4.8E-01 4.1 E+OO 9.2E+OO 1.5E+01 
CD8 1 bqh B Kl 5.1 E-01 4.0E+OO 9.2E+OO 1.5E+01 
T-cell receptor D1 0 1d9k A EF 5.0E-01 2.0E+OO 9.2E+OO 1.5E+01 
MHC class II 1-Ak 1d9k B GHQ 9.4E-01 2.1 E+OO 8.5E+OO 1.3E+01 
KIR2dl2 1efx A DE 3.7E-01 1.5E+OO 8.6E+OO 1.3E+01 
MHC class I HLA-CW3 1efx B ABC 4 .8E-01 1.5E+OO 1.1E+01 1.6E+01 
MHC class I H-2Kb 1fo0 A HLP 9.6E-01 2.1 E+OO 7.6E+OO 1.4E+01 
T-cell receptor BM3.3 1fo0 B AB 5.0E-01 1.7E+OO 9.6E+OO 1.7E+01 
MHC class II HLA-DR-1 1 fyt A ABC 7.7E-01 2.4E+OO 9.2E+OO 1.4E+01 
T-cell receptor 1 fyt B DE 7.1E-01 2.2E+OO 1.0E+01 1.5E+01 
MHC class II HLA-DR-1 1 hqr A ABC 6.9E-01 2.1 E+OO 8.0E+OO 1.2E+01 
Streptococcal pyrogenic exotoxin C 1hqr B D 3.9E-01 2.0E+OO 9.0E+OO 1.4E+01 
FeRn 1 i1 a A AB 4 .5E-01 2.6E+OO 9.0E+OO 1.4E+01 
Fe 1 i1 a B CD 3.0E-01 2.5E+OO 9.5E+OO 1.4E+01 
ly49a 1qo3 A CD 3.0E-01 1.8E+OO 9.5E+OO 1.8E+01 
MHC class I H-2Dd 1qo3 B ABP 4 .1 E-01 1.8E+OO 1.0E+01 1.9E+01 
T-cell receptor 2ckb A AB 4 .1 E-01 1.7E+OO 8.2E+OO 1.4E+01 
MHC class I H-2Kb 2ckb B HLP 6 .0E-01 2 .2E+OO 8.7E+OO 1.4E+01 
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pdbid Shape Vol. Ratio Vol. Ratio 
comple- infc core/ infc perim/ 
G-protein , cell cycle, signal transduction mentarity prot. core prot. core 
Giy2 1 got A A 7.7E-01 1.2E+OO 1.6E+OO 
Gta -Gia 1 got B BG 7.7E-01 1.1E+OO 1.6E+OO 
Gtj3 1gua A A 7.7E-01 1.0E+OO 2 .0E+OO 
Gty 1gua B B 7.7E-01 9.2E-01 2 .0E+OO 
mcm1 transcriptiona regulator 1mnm A AB 6 .6E-01 1.4E+OO 2 .0E+OO 
mat-a-2 repressor 1mnm B c 6 .6E-01 1.1 E+OO 2.3E+OO 
ran 1 rrp A A 7.0E-01 9.5E-01 2 .0E+OO 
nuclear core complex protein nup35: 1 rrp B B 7.0E-01 1.1E+OO 2.1 E+OO 
p50-rhogap 1tx4 A A 7.3E-01 1.2E+OO 1. 7E+OO 
rho a 1tx4 B B 7.3E-01 1.0E+OO 1.4E+OO 
elongin B 1vcb A D 6 .6E-01 1.3E+OO 1.9E+OO 
elongin C 1vcb B E 6.6E-01 1.3E+OO 2 .0E+OO 
p53 1ycs A A 7.6E-01 1.0E+OO 2 .1 E+OO 
p53bp2 1ycs B B 7.6E-01 1.1E+OO 1.BE+OO 
CAMP dependent protein kinase 1ydr A E 7.2E-01 1.2E+OO 1.BE+OO 
protein kinase inhibitor peptide 1ydr B I 7.2E-01 1.4E+OO 2.6E+OO 
peroxisome proliferator receptor y 2prg A AB 7.3E-01 1.3E+OO 1.9E+OO 
nuclear receptor coactivator src-1 2prg B c 7.3E-01 1.5E+OO 2.7E+OO 
transducin 2trc A BG 7.1 E-01 1.1E+OO 1.7E+OO 
posducin 2trc B p 7.1 E-01 1.1E+OO 1.9E+OO 
MHC and homologs complexed with others 
COB 1akj A DE 6.6E-01 1.2E+OO 2 .2E+OO 
MHC class I HLA-A2 1 akj B ABC 6.6E-01 9.1 E-01 2 .2E+OO 
T-cell receptor 1ao7 A DE 6.3E-01 1.0E+OO 2 .0E+OO 
MHC class I HLA-A2 1ao7 B ABC 6.3E-01 1.1E+OO 1.9E+OO 
MHC class I H-2 1bqh A DEF 6.0E-01 1.0E+OO 2 .2E+OO 
COB 1bqh B Kl 6.0E-01 1.0E+OO 1.9E+OO 
T-cell receptor 010 1d9k A EF 6.1 E-01 9.9E-01 2 .0E+OO 
MHC class II 1-Ak 1d9k B GHQ 6.1 E-01 1.1E+OO 2 .0E+OO 
KIR2dl2 1 efx A DE 6.BE-01 1.3E+OO 1.BE+OO 
MHC class I HLA-CW3 1efx B ABC 6.BE-01 1.0E+OO 1.9E+OO 
MHC class I H-2Kb 1fo0 A HLP 6.0E-01 1.3E+OO 1. 7E+OO 
T-cell receptor BM3.3 1fo0 B AB 6.0E-01 1.4E+OO 1.7E+OO 
MHC class II HLA-DR-1 1fyt A ABC 5.6E-01 9.9E-01 2 .0E+OO 
T-cell receptor 1fyt B DE 5.6E-01 9.0E-01 1.6E+OO 
MHC class II HLA-DR-1 1 hqr A ABC 6.9E-01 1.1E+OO 2 .1 E+OO 
Streptococcal pyrogenic exotoxin C 1 hqr B D 6.9E-01 1.1E+OO 1.9E+OO 
FeRn 1 i1 a A AB 7.2E-01 1.1E+OO 2 .1 E+OO 
Fe 1 i1 a B CD 7.2E-01 1.0E+OO 2 .3E+OO 
ly49a 1qo3 A CD 7.7E-01 1.0E+OO 1.7E+OO 
MHC class I H-2Dd 1qo3 B ASP 7.7E-01 9.1 E-01 1.6E+OO 
T-cell receptor 2ckb A AB 4 .1 E-01 9.3E-01 1.9E+OO 
MHC class I H-2Kb 2ckb B HLP 4 .1 E-01 1.2E+OO 1.9E+OO 
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pdbid Hbonds per 100 Hbonds per 100 
<3.3 A sq angstrot <4.0 A sq angstro 
G-protein, cell cycle, signal transduction 
Giy2 1 got A A S.OE+OO 6.4E-01 2.6E+01 2.1 E+OO 
Gta-Gia 1 got B BG S.OE+OO 6.6E-01 2.6E+01 2 .1 E+OO 
Gtl3 1gua A A 1.3E+01 2 .0E+OO 2.1E+01 3.3E+OO 
Gty 1gua B B 1.3E+01 2 .1 E+OO 2.1E+01 3.4E+OO 
mcm1 transcriptiona regulator 1mnm A AB 1.3E+01 2.1 E+OO 2 .1E+01 3.4E+OO 
mat-a-2 repressor 1mnm B c 1.3E+01 1.1E+OO 2.1 E+01 1.SE+OO 
ran 1 rrp A A 1.0E+OO 4 .2E-02 4 .0E+OO 1.7E-01 
nuclear core complex protein nup35: 1 rrp B B 1.0E+OO 4 .3E-02 4 .0E+OO 1.7E-01 
p50-rhogap 1tx4 A A S.OE+OO 7.2E-01 1.3E+01 1.2E+OO 
rho a 1tx4 B B S.OE+OO 7.0E-01 1.3E+01 1.1 E+OO 
elongin B 1vcb A D 1.1E+01 1.2E+OO 1.7E+01 1.SE+OO 
elongin C 1vcb B E 1.1E+01 1.1E+OO 1.7E+01 1.6E+OO 
p53 1ycs A A 1.2E+01 1.6E+OO 2.0E+01 2 .6E+OO 
p53bp2 1ycs B B 1.2E+01 1.7E+OO 2 .0E+01 2 .SE+OO 
CAMP dependent protein kinase 1ydr A E 3 .7E+01 4 .1 E+OO 6.3E+01 7.0E+OO 
protein kinase inhibitor peptide 1ydr B I 3.7E+01 3.5E+OO 6 .3E+01 5.9E+OO 
peroxisome proliferator receptor y 2prg A AB 1.0E+01 7.9E-01 2 .2E+01 1.7E+OO 
nuclear receptor coactivator src-1 2prg B c 1.0E+01 7.5E-01 2 .2E+01 1. 7E+OO 
transducin 2trc A BG 2 .0E+01 9.4E-01 4.5E+01 2 .1 E+OO 
posducin 2trc B p 2 .0E+01 S.9E-01 4 .5E+01 2 .0E+OO 
MHC and homologs complexed with others 
CDS 1 akj A DE 1.3E+01 1.4E+OO 2 .3E+01 2 .5E+OO 
MHC class I HLA-A2 1akj B ABC 1.3E+01 1.2E+OO 2 .3E+01 2 .2E+OO 
T -cell receptor 1ao7 A DE 1.4E+01 1.4E+OO 2 .1E+01 2 .1 E+OO 
MHC class I HLA-A2 1ao7 B ABC 1.4E+01 1.4E+OO 2 .1 E+01 2 .1 E+OO 
MHC class I H-2 1bqh A DEF S.OE+OO 5.5E-01 1.3E+01 9.0E-01 
CDS 1bqh B Kl S.OE+OO 5.6E-01 1.3E+01 9.0E-01 
T-cell receptor D1 0 1d9k A EF 6 .0E+OO 5.9E-01 1.SE+01 1.SE+OO 
MHC class II 1-Ak 1d9k B GHQ 6 .0E+OO 6 .2E-01 1.SE+01 1.SE+OO 
KIR2dl2 1efx A DE 1.9E+01 2 .6E+OO 3.5E+01 4 .SE+OO 
MHC class I HLA-CW3 1efx B ABC 1.9E+01 2.4E+OO 3.5E+01 4.4E+OO 
MHC class I H-2Kb 1fo0 A HLP 1.4E+01 2.1 E+OO 2 .0E+01 3.1 E+OO 
T-cell receptor BM3.3 1 foO B AB 1.4E+01 2.0E+OO 2 .0E+01 2 .9E+OO 
MHC class II HLA-DR-1 1 fyt A ABC S.OE+OO 7.9E-01 1.5E+01 1.5E+OO 
T -cell receptor 1 fyt B DE S.OE+OO 7.7E-01 1.5E+01 1.4E+OO 
MHC class II HLA-DR-1 1 hqr A ABC 1.3E+01 1.7E+OO 2 .3E+01 3.1 E+OO 
Streptococcal pyrogenic exotoxin C 1 hqr B D 1.3E+01 1.6E+OO 2.3E+01 2 .SE+OO 
FeRn 1 i1a A AB 2 .1 E+01 3.0E+OO 3.5E+01 4 .9E+OO 
Fe 1 i1 a B CD 2 .1 E+01 3.0E+OO 3.5E+01 4 .9E+OO 
ly49a 1qo3 A CD 1.9E+01 4 .1 E+OO 5.1 E+01 1.1E+01 
MHC class I H-2Dd 1qo3 B ABP 1.9E+01 3.7E+OO 5 .1E+01 9 .SE+OO 
T -cell receptor 2ckb A AB 7.5E+01 7.9E+OO 1.3E+02 1.3E+01 
MHC class I H-2Kb 2ckb B HLP 7.5E+01 7.5E+OO 1.3E+02 1.2E+01 
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pdbid %non-pola %polar %charged 
G-protein, cell cycle, signal transduction 
Giy2 1 got A A 6 .2E-01 2 .0E-01 1.BE-01 
Gta-Gia 1 got B BG 5.6E-01 2.9E-01 1.5E-01 
Gtl3 1gua A A 4 .BE-01 2.1 E-01 3.1 E-01 
Gty 1gua B B 4 . 7E-01 3.4E-01 1.9E-01 
mcm1 transcriptiona regulator 1mnm A AB 6.9E-01 2.0E-01 1.2E-01 
mat-a-2 repressor 1mnm B c 6 .1 E-01 2.BE-01 1.1 E-01 
ran 1 rrp A A 6 .5E-01 2.4E-01 1.2E-01 
nuclear core complex protein nup35: 1 rrp B B 6.4E-01 1. 7E-01 1.9E-01 
p50-rhogap 1tx4 A A 5.BE-01 2.5E-01 1.7E-01 
rho a 1tx4 B B 6.2E-01 2.5E-01 1.3E-01 
elongin B 1vcb A D 6 .7E-01 2 .2E-01 1.1 E-01 
elongin C 1vcb B E 7.BE-01 1. 7E-01 5.6E-02 
p53 1ycs A A 4 .2E-01 3.0E-01 2.BE-01 
p53bp2 1ycs B B 5.0E-01 3.4E-01 1.6E-01 
CAMP dependent protein kinase 1ydr A E 5.7E-01 1.7E-01 2 .6E-01 
protein kinase inhibitor peptide 1ydr B I 6.1 E-01 1.5E-01 2.4E-01 
peroxisome proliferator receptor y 2prg A AB 7.0E-01 5.9E-02 2.4E-01 
nuclear receptor coactivator src-1 2prg B c 7.9E-01 1.7E-01 4.2E-02 
transducin 2trc A BG 4.7E-01 2 .9E-01 2.5E-01 
posducin 2trc B p 6.2E-01 2.0E-01 1.9E-01 
MHC and homologs complexed with others 
COB 1akj A DE 3.BE-01 4.4E-01 1. 7E-01 
MHC class I HLA-A2 1akj B ABC 4.4E-01 2 .9E-01 2 .7E-01 
T -cell receptor 1ao7 A DE 5.BE-01 2 .7E-01 1.4E-01 
MHC class I HLA-A2 1ao7 B ABC 5.BE-01 2 .4E-01 1.BE-01 
MHC class I H-2 1bqh A DEF 5.1 E-01 2 .5E-01 2.4E-01 
COB 1bqh B Kl 4.4E-01 4 .3E-01 1.3E-01 
T -cell receptor 010 1d9k A EF 5.5E-01 2 .7E-01 1.7E-01 
MHC class II 1-Ak 1d9k B GHQ 5.3E-01 2 .5E-01 2.3E-01 
KIR2dl2 1efx A DE 5.7E-01 2 .5E-01 1.BE-01 
MHC class I HLA-CW3 1efx B ABC 5.1 E-01 1.3E-01 3.6E-01 
MHC class I H-2Kb 1fo0 A HLP 5.4E-01 2.4E-01 2.2E-01 
T-cell receptor BM3.3 1fo0 B AB 4 .5E-01 2 .9E-01 2.6E-01 
MHC class II HLA-DR-1 1 fyt A ABC 6 .2E-01 2 .0E-01 1.BE-01 
T -cell receptor 1 fyt B DE 6 .3E-01 1.BE-01 1.9E-01 
MHC class II HLA-DR-1 1 hqr A ABC 6.BE-01 1.BE-01 1.4E-01 
Streptococcal pyrogenic exotoxin C 1 hqr B D 4 .6E-01 4 .6E-01 7.4E-02 
FeRn 1 i1 a A AB 6 .1 E-01 1.6E-01 2.3E-01 
Fe 1 i1 a B CD 5.BE-01 3.3E-01 9.6E-02 
ly49a 1qo3 A CD 3.4E-01 2 .5E-01 4.1 E-01 
MHC class I H-2Dd 1qo3 B ABP 3.7E-01 1.5E-01 4.BE-01 
T -cell receptor 2ckb A AB 6.0E-01 3.7E-01 3.1 E-02 
MHC class I H-2Kb 2ckb B HLP 5.6E-01 1.9E-01 2.5E-01 
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pdbid Reso- Protein Average Total interface 
lution mass volume surface area 
Fe complexes A Daltons N'3 area A"2 A " 2 
Fe lgG4 1adq A A 2 .36 23413 43330 12220 6.7E+02 
rheumatoid factor 1adq B H L 2 .36 47109 82750 20360 7 .5E+02 
Fey Rill 1e4k A c 2 .8 48738 87270 22830 8.0E+02 
Fe lgG1 1e4k B AB 2 .8 19541 35090 9582 8.1 E+02 
Fec:RI 1f6a A A 1.8 19826 36750 10330 8.7E+02 
FeigE 1f6a B BD 1.8 48441 89290 24110 8.2E+02 
fragment B of protein A 1fc2 A c 1.9 4990 9848 3294 6 .3E+02 
Fe lgG 1fc2 B D 1.9 23445 43090 12120 6.6E+02 
Fe lgG 1fcc A A 1.8 23446 42950 12010 6 .6E+02 
protein G 1fcc B c 1.8 6133 11770 3738 6 .8E+02 
Cell surface receptor ligand 
fibroblast GF2 1evs A AB 2 .6 14715 25880 6530 1. 7E+03 
fibroblast-GFR 1 1evs B c 2 .6 43512 79200 22590 1. 7E+03 
death receptor-5 1d0g A ABO 2 52731 90200 20280 1.5E+03 
apoptosis-2 ligand 1d0g B R 2 12058 22660 7559 1.5E+03 
fibroblast GF1 1e0o A A 2 .5 13847 24590 6302 8.6E+02 
fibroblast GFR2 1e0o B B 2 .5 21302 61790 11440 8.9E+02 
erythropoietin receptor 1ebp A AB 1.8 46500 86040 24220 9.4E+02 
epo mimetic peptide 1ebp B CD 1.8 3694 7399 2654 9.7E+02 
erythropoietin 1eer A A 2 .3 18330 33850 9564 1.6E+03 
erythropoietin receptor 1eer B BC 2 .3 47092 84110 22630 1.7E+03 
bone-morphogenetic protein-2 1es7 A AC 1.8 23180 41620 11170 1.1 E+03 
bone-morphogenetic protein recepto 1 es7 B B 1.8 9246 17780 5922 1.1 E+03 
fibroblast-GF2 1ev2 A A 2 .85 13730 24980 6443 1.3E+03 
fibroblast-GFR2 1ev2 B E 2 .85 20403 38660 11390 1.3E+03 
prolactin receptor 1f6f A BC 2 .2 42805 78240 20810 1.8E+03 
placental lactogen 1f6f B A 2.2 20925 38940 10700 1.7E+03 
interferon y 1 fg9 A AB 1.8 29592 52370 13510 9.4E+02 
interferon y receptor a chain 1 fg9 B D 1.8 22991 41630 11640 8.9E+02 
tnf receptor associated factor 3 1fll A A 2 .7 23107 43280 12990 5.6E+02 
CD40 1fll B X 2 .7 2170 5313 2576 6.2E+02 
fibroblast-GF2 1 fq9 A A 2 29430 25840 6567 1.7E+03 
fibroblast-GFR 1 1 fq9 B CD 2 23207 81580 23250 1.7E+03 
gp120 1gc1 A HLG 2 .8 80503 138400 22040 9 .7E+02 
CD4 1gc1 B c 2 .8 20049 35730 32150 9.4E+02 
growth hormone 1hwg A A 2 .6 20626 37090 9670 2.1 E+03 
growth hormone binding protein 1hwg B BC 2 .6 43682 76960 19320 2.1 E+03 
interleukin-4 1 iar A A 3.3 14939 27300 7408 7.4E+02 
interleukin-4 receptor a 1 iar B B 3.3 21457 38810 10780 8.0E+02 
T-cell receptor 14.3.0 1jck A AC 2 .4 51584 89870 22920 2.1 E+03 
Staphylococcal enterotoxin C3 1jck B BD 2. 4 55124 94700 22780 2.1 E+03 
C02 1qa9 A A 2 .8 11962 23000 6670 7.0E+02 
CD 58 1qa9 B B 2 .8 10965 20560 5990 6.3E+02 
vascular endothelial growth factor 1 qty A vw 2 .2 22148 39390 10880 7.8E+02 
FMS-Iike tyrosine kinase-1 1 qty B X 2 .2 10756 19990 5747 8.4E+02 
tumor necrosis factor receptor p55 1tnr A A 2 .6 15834 28940 7768 5.7E+02 
tumor necrosis factor beta 1tnr B R 2 .6 15661 29570 9568 6 .3E+02 
nerve growth factor 1www A vw 2.6 24485 45090 12920 2.1 E+03 
TRKa receptor 1www B XY 2 .6 22130 40650 11940 2.2E+03 
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pdbid Circularity RMSD Atom Atom 
to plane burial access-
Fe complexes ibility 
Fe lgG4 1adq A A 3.6E-01 2 .0E+OO 8.4E+OO 1.5E+01 
rheumatoid factor 1adq B HL 5.5E-01 1.9E+OO 9.3E+OO 1.6E+01 
FcyRIII 1e4k A c 2.4E-01 3.3E+OO 8.8E+OO 1.7E+01 
Fe lgG1 1e4k B AB 3.0E-01 3.4E+OO 8.4E+OO 1.5E+01 
FcERI 1f6a A A 3.2E-01 3.6E+OO 8.9E+OO 1.4E+01 
Fe lgE 1 f6a B BD 2.3E-01 4 .0E+OO 7.3E+OO 1.4E+01 
fragment B of protein A 1fc2 A c 5.6E-01 2 .1 E+OO 8.8E+OO 1.4E+01 
Fe lgG 1fc2 B D 5.3E-01 2 .5E+OO 8.9E+OO 1.3E+01 
Fe lgG 1fcc A A 6.7E-01 2.0E+OO 9.4E+OO 1.5E+01 
protein G 1fcc B c 8.5E-01 1.9E+OO 9.5E+OO 1.4E+01 
Cell surface receptor ligand 
fibroblast GF2 1cvs A AB 4.7E-01 4 .9E+OO 9.5E+OO 1.4E+01 
fibroblast-GFR 1 1cvs B c 3.4E-01 5.1 E+OO 8.8E+OO 1.4E+01 
death receptor-S 1d0g A ABO 2.8E-01 3.3E+OO 8.7E+OO 1.6E+01 
apoptosis-2 ligand 1d0g B R 1.7E-01 3.4E+OO 1.1E+01 1.7E+01 
fibroblast GF1 1e0o A A 2.8E-01 4 .0E+OO 8.9E+OO 1.5E+01 
fibroblast GFR2 1e0o B B 1.5E-01 3.9E+OO 9.7E+OO 1.7E+01 
erythropoietin receptor 1ebp A AB 3.8E-01 5.1 E+OO 9.5E+OO 1.5E+01 
epo mimetic peptide 1ebp B CD 5.3E-01 4 .5E+OO 9.6E+OO 1.5E+01 
erythropoietin 1eer A A 4 .3E-01 5.0E+OO 9.5E+OO 1.5E+01 
erythropoietin receptor 1eer B BC 2.8E-01 4 .8E+OO 9.3E+OO 1.4E+01 
bone-morphogenetic protein-2 1es7 A AC 5.2E-01 3.5E+OO 9.3E+OO 1.4E+01 
bone-morphogenetic protein recepto 1 es7 B B 4 .7E-01 2.7E+OO 9.4E+OO 1.5E+01 
fibroblast-GF2 1ev2 A A 3.1 E-01 4.4E+OO 9. 7E+OO 1.5E+01 
fibroblast-GFR2 1ev2 B E 2.8E-01 4 .0E+OO 9.3E+OO 1.5E+01 
prolactin receptor 1 f6f A BC 1.2E-01 4 .8E+OO 9.1 E+OO 1.4E+01 
placental lactogen 1 f6f B A 1.8E-01 4 .3E+OO 9.2E+OO 1.4E+01 
interferon y 1fg9 A AB 3.4E-01 2.1 E+OO 9.6E+OO 1.6E+01 
interferon y receptor a chain 1fg9 B D 2.0E-01 2.0E+OO 7.5E+OO 1.3E+01 
tnf receptor associated factor 3 1 fll A A 2.2E-01 2.7E+OO 7.2E+OO 1.4E+01 
CD40 1 fll B X 1.0E-01 1.9E+OO 1.0E+01 1.9E+01 
fibroblast-GF2 1fq9 A A 4.6E-01 4 .9E+OO 9.6E+OO 1.4E+01 
fibroblast-GFR 1 1fq9 B CD 2.9E-01 5.0E+OO 8.9E+OO 1.4E+01 
gp120 1 gc1 A HLG 2.3E-01 4.7E+OO 8.3E+OO 1.8E+01 
CD4 1 gc1 B c 2.8E-01 3.9E+OO 9.8E+OO 1.5E+01 
growth hormone 1hwg A A 2.4E-01 5.5E+OO 8.9E+OO 1.4E+01 
growth hormone binding protein 1hwg B BC 1.6E-01 5.9E+OO 8.7E+OO 1.4E+01 
interleukin-4 1 iar A A 5.6E-01 2.3E+OO 9.2E+OO 1.3E+01 
interleukin-4 receptor a 1 iar B B 3.8E-01 2.4E+OO 9.9E+OO 1.5E+01 
T-cell receptor 14.3.0 1jck A AC 1.1E-01 7.4E+OO 9.7E+OO 1.7E+01 
Staphylococcal enterotoxin C3 1jck B BD 1.0E-01 7.1 E+OO 8.1 E+OO 1.6E+01 
C02 1qa9 A A 5.1 E-01 1.9E+OO 1.0E+01 1.8E+01 
CD 58 1qa9 B B 6.6E-01 2.0E+OO 9.1 E+OO 1.7E+01 
vascular endothelial growth factor 1 qty A vw 6.0E-01 2.0E+OO 8.7E+OO 1.6E+01 
FMS-Iike tyrosine kinase-1 1 qty B X 6.1 E-01 1.8E+OO 1.1E+01 1.7E+01 
tumor necrosis factor receptor p55 1tnr A A 1.2E-01 2.4E+OO 8.2E+OO 1.6E+01 
tumor necrosis factor beta 1 tnr B R 1.0E-01 2.3E+OO 9.4E+OO 1.7E+01 
nerve growth factor 1www A vw 5.7E-01 5.6E+OO 8.2E+OO 1.4E+01 
TRKa receptor 1www B XY 2.6E-01 5.5E+OO 1.0E+01 1.6E+01 
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pdbid Shape Vol. Ratio Vol. Ratio 
comple- infc core/ infc perim/ 
Fe complexes mentarity prot. core prot. core 
Fe lgG4 1adq A A 6 .9E-01 1.1E+OO 2.2E+OO 
rheumatoid factor 1adq B HL 6.9E-01 B.BE-01 2.1 E+OO 
FcyRIII 1e4k A c 6.7E-01 9.7E-01 2 .2E+OO 
Fe lgG1 1e4k B AB 6.7E-01 9 .6E-01 2 .2E+OO 
FcERI 1f6a A A 6.9E-01 1.0E+OO 2 .0E+OO 
FeigE 1f6a B BD 6.9E-01 1.0E+OO 1.9E+OO 
fragment B of protein A 1fc2 A c 6.6E-01 1.2E+OO 1.9E+OO 
Fe lgG 1fc2 B D 6.6E-01 1.4E+OO 1.8E+OO 
Fe lgG 1fcc A A 5.7E-01 9.8E-01 1.7E+OO 
protein G 1fcc B c 5.7E-01 1.1E+OO 1.7E+OO 
Cell surface receptor ligand 
fibroblast GF2 1cvs A AB 6.5E-01 1.1E+OO 2 .1 E+OO 
fibroblast-GFR 1 1cvs B c 6.5E-01 1.0E+OO 2 .1 E+OO 
death receptor-5 1d0g A ABO 6.9E-01 1.1E+OO 1.7E+OO 
apoptosis-2 ligand 1d0g B R 6.9E-01 1.4E+OO 2 .2E+OO 
fibroblast GF1 1e0o A A 6.6E-01 1.1E+OO 2 .0E+OO 
fibroblast GFR2 1e0o B B 6.6E-01 1.1E+OO 2.3E+OO 
erythropoietin receptor 1ebp A AB 7.5E-01 1.3E+OO 2 .5E+OO 
epa mimetic peptide 1ebp B CD 7.5E-01 1.0E+OO 2 .0E+OO 
erythropoietin 1eer A A 6.5E-01 1.1E+OO 1.8E+OO 
erythropoietin receptor 1eer B BC 6.5E-01 1.2E+OO 1.6E+OO 
bone-morphogenetic protein-2 1es7 A AC 6.9E-01 1.3E+OO 2 .0E+OO 
bone-morphogenetic protein recepto 1 es7 B B 6.9E-01 1.1 E+OO 2 .0E+OO 
fibroblast-GF2 1ev2 A A 7.0E-01 1.1E+OO 1.9E+OO 
fibroblast-GFR2 1ev2 B E 7.0E-01 1.1E+OO 2 .0E+OO 
prolactin receptor 1f6f A BC 6.9E-01 1.0E+OO 1.9E+OO 
placental lactogen 1f6f B A 6.9E-01 1.2E+OO 2 .0E+OO 
interferon y 1fg9 A AB 7.2E-01 1.1E+OO 2 .1 E+OO 
interferon y receptor a chain 1fg9 B D 7.2E-01 1.0E+OO 2 .1 E+OO 
tnf receptor associated factor 3 1fll A A 6.0E-01 1.2E+OO 1.7E+OO 
CD40 1fll B X 6.0E-01 1.2E+OO 1.8E+OO 
fibroblast-GF2 1 fq9 A A 6.8E-01 1.0E+OO 1.3E+OO 
fibroblast-GFR 1 1fq9 B CD 6.8E-01 1.0E+OO 1.4E+OO 
gp120 1gc1 A HLG 7.2E-01 1.1E+OO 2 .1 E+OO 
CD4 1gc1 B c 7.2E-01 1.1E+OO 2 .1 E+OO 
growth hormone 1hwg A A 6.9E-01 1.2E+OO 1.9E+OO 
growth hormone binding protein 1hwg B BC 6.9E-01 1.1E+OO 1.9E+OO 
interleukin-4 1 iar A A 7.4E-01 1.0E+OO 1.8E+OO 
interleukin-4 receptor a 1 iar B B 7.4E-01 1.1E+OO 1.5E+OO 
T-cell receptor 14.3.0 1jck A AC 5.2E-01 1.0E+OO 2.4E+OO 
Staphylococcal enterotoxin C3 1jck B BD 5.2E-01 9.0E-01 2 .3E+OO 
C02 1qa9 A A 5.6E-01 1.1E+OO 2 .3E+OO 
CD 58 1qa9 B B 5.6E-01 1.1E+OO 2 .1 E+OO 
vascular endothelial growth factor 1 qty A vw 6.1 E-01 1.3E+OO 2.2E+OO 
FMS-Iike tyrosine kinase-1 1 qty B X 6.1 E-01 1.5E+OO 2 .1 E+OO 
tumor necrosis factor receptor p55 1tnr A A 6.3E-01 1.0E+OO 2 .1 E+OO 
tumor necrosis factor beta 1tnr B R 6.3E-01 9 .6E-01 2 .5E+OO 
nerve growth factor 1www A vw 7.1 E-01 1.2E+OO 1.8E+OO 
TRKa receptor 1www B XY 7.1 E-01 1.1E+OO 1.8E+OO 
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pdbid Hbonds per 100 Hbonds per 100 
<3.3 A sq angstrot <4.0 A sq angstro 
Fe complexes 
Fe lgG4 1adq A A 7.0E+OO 1.0E+OO 1.0E+01 1.5E+OO 
rheumatoid factor 1adq B H L 7.0E+OO 9 .3E-01 1.0E+01 1.3E+OO 
FcyRIII 1e4k A c B.OE+OO 9.9E-01 2 .3E+01 2 .9E+OO 
Fe lgG1 1e4k B AB B.OE+OO 9.9E-01 2 .3E+01 2 .8E+OO 
Fcc:RI 1f6a A A 1.0E+OO 1.2E-01 1.0E+OO 1.2E-01 
FeigE 1 f6a B BD 1.0E+OO 1.2E-01 1.0E+OO 1.2E-01 
fragment B of protein A 1fc2 A c 1.4E+01 2 .2E+OO 2 .7E+01 4 .3E+OO 
Fe lgG 1fc2 B D 1.4E+01 2 .1 E+OO 2 .7E+01 4 .1 E+OO 
Fe lgG 1fcc A A 1.0E+01 1.5E+OO 2 .0E+01 3.0E+OO 
protein G 1fcc B c 1.0E+01 1.5E+OO 2.0E+01 2 .9E+OO 
Cell surface receptor ligand 
fibroblast GF2 1cvs A AB 5.0E+OO 3.0E-01 7 .0E+OO 4.2E-01 
fibroblast-GFR 1 1cvs B c 5.0E+OO 3.0E-01 7 .0E+OO 4.2E-01 
death receptor-S 1d0g A ABD 1.7E+01 1.1 E+OO 2.7E+01 1.8E+OO 
apoptosis-2 ligand 1d0g B R 1.7E+01 1.1 E+OO 2 .7E+01 1.8E+OO 
fibroblast GF1 1e0o A A 1.2E+01 1.4E+OO 2 .3E+01 2.7E+OO 
fibroblast GFR2 1e0o B B 1.2E+01 1.3E+OO 2 .3E+01 2.6E+OO 
erythropoietin receptor 1ebp A AB 7.0E+OO 7.5E-01 1.4E+01 1.5E+OO 
epa mimetic peptide 1ebp B CD 7.0E+OO 7 .2E-01 1.4E+01 1.4E+OO 
erythropoietin 1eer A A 1.1E+01 6 .7E-01 1.9E+01 1.2E+OO 
erythropoietin receptor 1eer B BC 1.1E+01 6 .6E-01 1.9E+01 1.1E+OO 
bone-morphogenetic protein-2 1es7 A AC 1.4E+01 1.3E+OO 2 .4E+01 2.2E+OO 
bone-morphogenetic protein recepto 1 es7 B B 1.4E+01 1.2E+OO 2.4E+01 2.1 E+OO 
fibroblast-GF2 1ev2 A A 6.0E+OO 4 .5E-01 1.0E+01 7.5E-01 
fibroblast-GFR2 1ev2 B E 6.0E+OO 4 .5E-01 1.0E+01 7.4E-01 
prolactin receptor 1 f6f A BC 1.0E+01 5.7E-01 2 .1E+01 1.2E+OO 
placental lactogen 1f6f B A 1.0E+01 5.8E-01 2.1E+01 1.2E+OO 
interferon y 1fg9 A AB B.OE+OO 8.5E-01 1.3E+01 1.4E+OO 
interferon y receptor a chain 1fg9 B D B.OE+OO 8.9E-01 1.3E+01 1.5E+OO 
tnf receptor associated factor 3 1fll A A 7.0E+OO 1.2E+OO 1.4E+01 2 .5E+OO 
CD40 1fll B X 7.0E+OO 1.1 E+OO 1.4E+01 2 .3E+OO 
fibroblast-GF2 1fq9 A A 1.8E+01 1.1 E+OO 3.5E+01 2 .1 E+OO 
fibroblast-GFR 1 1 fq9 B CD 1.8E+01 1.1E+OO 3.5E+01 2 .1 E+OO 
gp120 1gc1 A HLG 1.5E+01 1.5E+OO 2 .6E+01 2 .7E+OO 
CD4 1 gc1 B c 1.5E+01 1.6E+OO 2 .6E+01 2 .BE+OO 
growth hormone 1hwg A A B.OE+OO 3.9E-01 1.0E+01 4 .8E-01 
growth hormone binding protein 1hwg B BC B.OE+OO 3.BE-01 1.0E+01 4 .8E-01 
interleukin-4 1 iar A A 9.0E+OO 1.2E+OO 1.6E+01 2 .2E+OO 
interleukin-4 receptor a 1 iar B B 9.0E+OO 1.1E+OO 1.6E+01 2 .0E+OO 
T-cell receptor 14.3.D 1jck A AC 9.0E+OO 4 .2E-01 1.6E+01 7.5E-01 
Staphylococcal enterotoxin C3 1jck B BD 9.0E+OO 4.4E-01 1.6E+01 7.8E-01 
CD2 1qa9 A A 7 .0E+OO 1.0E+OO 1.4E+01 2 .0E+OO 
CD 58 1qa9 B B 7.0E+OO 1.1 E+OO 1.4E+01 2.2E+OO 
vascular endothelial growth factor 1 qty A vw 1.6E+01 2 .1 E+OO 3.7E+01 4 .8E+OO 
FMS-Iike tyrosine kinase-1 1qty B X 1.6E+01 1.9E+OO 3.7E+01 4.4E+OO 
tumor necrosis factor receptor p55 1 tnr A A 1.6E+01 2 .8E+OO 2.3E+01 4.0E+OO 
tumor necrosis factor beta 1tnr B R 1.6E+01 2 .5E+OO 2.3E+01 3.7E+OO 
nerve growth factor 1www A vw 6.0E+OO 2.9E-01 1.3E+01 6 .3E-01 
TRKa receptor 1www B XY 6 .0E+OO 2.8E-01 1.3E+01 6 .0E-01 
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pdbid o/onon-pola %polar %charged 
Fe complexes 
Fe lgG4 1adq A A 5.2E-01 4.4E-01 4 .0E-02 
rheumatoid factor 1adq 8 HL 6.0E-01 2.4E-01 1.6E-01 
FcyRIII 1e4k A c 6.6E-01 2.9E-01 5.4E-02 
Fe lgG1 1e4k 8 AB 6.8E-01 1.9E-01 1.2E-01 
FceRI 1 f6a A A 6.3E-01 2.7E-01 9.6E-02 
Fe lgE 1 f6a 8 BD 6.1 E-01 2 .5E-01 1.4E-01 
fragment 8 of protein A 1fc2 A c 6.2E-01 3.5E-01 3.4E-02 
Fe lgG 1fc2 8 D 6.0E-01 3.7E-01 2.8E-02 
Fe lgG 1fcc A A 5.6E-01 3.7E-01 7.3E-02 
protein G 1fcc 8 c 5.2E-01 2 .3E-01 2.5E-01 
Cell surface receptor ligand 
fibroblast GF2 1cvs A AB 6.0E-01 2.7E-01 1.4E-01 
fibroblast-GFR 1 1cvs 8 c 6.8E-01 1.9E-01 1.3E-01 
death receptor-5 1d0g A ABO 4.6E-01 3.4E-01 2.0E-01 
apoptosis-2 ligand 1d0g 8 R 5.6E-01 1.4E-01 2.9E-01 
fibroblast GF1 1e0o A A 5.6E-01 2.4E-01 2.0E-01 
fibroblast GFR2 1e0o 8 8 6.3E-01 1.3E-01 2.4E-01 
erythropoietin receptor 1ebp A AB 7.0E-01 3.0E-01 9.1 E-04 
epo mimetic peptide 1ebp 8 CD 7.1 E-01 2 .9E-01 O.OE+OO 
erythropoietin 1eer A A 5.4E-01 1.6E-01 3.0E-01 
erythropoietin receptor 1eer 8 BC 5.7E-01 2 .7E-01 1.6E-01 
bone-morphogenetic protein-2 1es7 A AC 6.6E-01 2.8E-01 6.6E-02 
bone-morphogenetic protein recepto 1 es7 8 8 6.0E-01 1.9E-01 2.1E-01 
fibroblast-GF2 1ev2 A A 6.1 E-01 2.4E-01 1.4E-01 
fibroblast-GFR2 1ev2 8 E 6.3E-01 2.3E-01 1.4E-01 
prolactin receptor 1f6f A BC 6.4E-01 1.9E-01 1. 7E-01 
placental lactogen 1f6f 8 A 5.7E-01 2.4E-01 1.8E-01 
interferon y 1 fg9 A AB 5.6E-01 2.9E-01 1.5E-01 
interferon y receptor a chain 1 fg9 8 D 5.3E-01 3.4E-01 1.3E-01 
tnf receptor associated factor 3 1fll A A 5.7E-01 2.3E-01 2.0E-01 
CD40 1fll 8 X 6.3E-01 2.6E-01 1.1 E-01 
fibroblast-GF2 1fq9 A A 5.9E-01 2.6E-01 1.5E-01 
fibroblast-GFR 1 1fq9 8 CD 6.9E-01 1. 9E-01 1.2E-01 
gp120 1gc1 A HLG 6.1 E-01 2.7E-01 1.2E-01 
CD4 1gc1 8 c 6.2E-01 2.8E-01 9.9E-02 
growth hormone 1hwg A A 6.1 E-01 1.9E-01 2.0E-01 
growth hormone binding protein 1hwg 8 BC 5.8E-01 2.5E-01 1.7E-01 
interleukin-4 1 iar A A 4 .9E-01 1.6E-01 3.6E-01 
interleukin-4 receptor a 1 iar 8 8 6.6E-01 1.9E-01 1.4E-01 
T-cell receptor 14.3.0 1jck A AC 5.1 E-01 4 .0E-01 9.2E-02 
Staphylococcal enterotoxin C3 1jck 8 BD 6.0E-01 3.2E-01 7.9E-02 
C02 1qa9 A A 4 .1 E-01 1.9E-01 4 .1 E-01 
CD 58 1qa9 8 8 4.7E-01 7.7E-02 4 .6E-01 
vascular endothelial growth factor 1qty A vw 6.6E-01 2.4E-01 9.7E-02 
FMS-Iike tyrosine kinase-1 1qty 8 X 7.5E-01 1.6E-01 9.2E-02 
tumor necrosis factor receptor p55 1tnr A A 5.5E-01 2 .9E-01 1.5E-01 
tumor necrosis factor beta 1tnr 8 R 5.5E-01 3.0E-01 1.5E-01 
nerve growth factor 1www A vw 6.2E-01 2 .3E-01 1.5E-01 
TRKa receptor 1www B XY 6 .7E-01 2 .7E-01 6.8E-02 
229 
pdbid Reso- Protein Average Total interface 
lution mass volume surface area 
Miscellaneous A Daltons N'3 area A"2 A"2 
cyclophilin A 1ak4 A A 1.75 17977 30970 7470 4 .6E+02 
HIV-1 capsid 1ak4 B D 1.75 16073 29560 8551 5.6E+02 
nucleotide exchangefactor GRPE 1dkg A AB 2 .5 33470 62110 17770 9. 7E+02 
molecular chaperone DNAK 1dkg B D 2 .5 39886 69660 16680 9.8E+02 
Fab lgG1 1 igc A LH 2 .1 47259 80670 18760 6 .3E+02 
protein G 1 igc B A 2 .1 6303 12000 3781 6 .8E+02 
transthyretin 1qab A A 2 .9 51097 89910 21010 1.4E+03 
retinol binding protein 1qab B BCD 2 .9 39710 70460 19520 1.5E+03 
pdbid Circularity RMSD Atom Atom 
to plane burial access-
Miscellaneous ibility 
cyclophilin A 1ak4 A A 4 .0E-01 2 .5E+OO 6.8E+OO 1.2E+01 
HIV-1 capsid 1ak4 B D 1.9E-01 1.7E+OO 1.1E+01 1.8E+01 
nucleotide exchangefactor GRPE 1dkg A AB 2 .5E-01 2 .5E+OO 8.9E+OO 1.8E+01 
molecular chaperone DNAK 1dkg B D 2 .1 E-01 2 .5E+OO 9.2E+OO 1.7E+01 
Fab lgG1 1igc A LH 7.4E-01 1.7E+OO 9.0E+OO 1.6E+01 
protein G 1igc B A 7.7E-01 1.7E+OO 9.7E+OO 1.6E+01 
transthyretin 1qab A A 1.7E-01 6 .5E+OO 8.3E+OO 1.5E+01 
retinol binding protein 1qab B BCD 9.4E-02 5.9E+OO 9.3E+OO 1.5E+01 
pdbid Shape Vol. Ratio Vol. Ratio 
compte- infc core/ infc perim/ 
Miscellaneous mentarity prot. core prot. core 
cyclophilin A 1ak4 A A 8.1 E-01 1.1 E+OO 1. 7E+OO 
HIV-1 capsid 1ak4 B D 8.1 E-01 9 .5E-01 1.9E+OO 
nucleotide exchangefactor GRPE 1dkg A AB 6.2E-01 1.1 E+OO 3.0E+OO 
molecular chaperone DNAK 1dkg B D 6.2E-01 1.0E+OO 2 .2E+OO 
Fab lgG1 1igc A LH 6.9E-01 1.2E+OO 2 .0E+OO 
protein G 1 igc B A 6.9E-01 1.2E+OO 2 .0E+OO 
transthyretin 1qab A A 5.3E-01 1.4E+OO 2 .1 E+OO 
retinol binding protein 1qab B BCD 5.3E-01 1.0E+OO 2 .2E+OO 
pdbid Hbonds per 100 Hbonds per 100 
Miscellaneous <3.3 A sq angstro1 <4.0 A sq angstro 
cyclophilin A 1ak4 A A 1.5E+01 3.2E+OO 2 .1 E+01 4 .5E+OO 
HIV-1 capsid 1ak4 B D 1.5E+01 2 .7E+OO 2 .1 E+01 3.8E+OO 
nucleotide exchangefactor GRPE 1dkg A AB 1.0E+OO 1.0E-01 1.0E+OO 1.0E-01 
molecular chaperone DNAK 1dkg B D 1.0E+OO 1.0E-01 1.0E+OO 1.0E-01 
Fab lgG1 1igc A LH 9.0E+OO 1.4E+OO 1.4E+01 2 .2E+OO 
protein G 1igc B A 9.0E+OO 1.3E+OO 1.4E+01 2 .1 E+OO 
transthyretin 1qab A A 1.3E+01 9.2E-01 2 .2E+01 1.6E+OO 
retinol binding protein 1qab B BCD 1.3E+01 8.7E-01 2 .2E+01 1.5E+OO 
Miscellaneous pdbid %non-pola %polar %charged 
cyclophilin A 1ak4 A A 5.7E-01 2.8E-01 1.5E-01 
HIV-1 capsid 1ak4 B D 7.2E-01 2 .8E-01 O.OE+OO 
nucleotide exchangefactor GRPE 1dkg A AB 6.4E-01 1.7E-01 1.9E-01 
molecular chaperone DNAK 1dkg B D 6 .3E-01 1.8E-01 1.9E-01 
Fab lgG1 1igc A LH 6 .2E-01 2.9E-01 9.1 E-02 
protein G 1igc B A 4 .8E-01 4 .7E-01 5.0E-02 
transthyretin 1qab A A 5.6E-01 3.3E-01 1.1E-01 
retinol binding protein 1qab B BCD 7.2E-01 1.9E-01 8.7E-02 
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